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Abstract 
Mitochondria produce 90% of the adenosine triphosphate (ATP) used by eukaryotic cells as 
a source of energy. ATP synthesis is carried out by the oxidative phosphorylation (OXPHOS) 
system whose components are partially-encoded by mitochondrial DNA and translated by 
mitoribosomes found in the organelle itself. The interaction between mitoribosomes and the 
inner mitochondrial membrane (IMM) has been claimed to be important for efficient protein 
synthesis in these organelles, but how this association occurs is still unclear.  
The aim of this study was to investigate the association between mitoribosomes and IMM in 
human mitochondria. My attention focused on MRPL45, a component of the mitoribosome that 
might be a key player of this interaction due to its proximity to the polypeptide exit tunnel and its 
structural similarity to the IMM-interacting proteins TIM44 and Mba1. During the course of this 
study, in order to further investigate the interaction, interest in the IMM protein OXA1L arose. 
The yeast homologue of this protein has been reported to interact with the mitoribosome, 
offering an interacting point between the IMM and the translation machinery.  
I performed depletion studies that confirmed the importance of MRPL45 for the stability of 
the mitoribosomal large subunit (mt-LSU) and mitochondrial translation. With the development 
of a protocol to investigate membrane-interaction, I demonstrated that MRPL45 is able to 
interact directly with the IMM. The addition of a FLAG-tag at the C-terminal of MRPL45 did not 
affect the ability of the protein to interact with the membrane and did not have effects on the 
homeostasis of the cells. Therefore, immunoprecipitation of MRPL45FLAG was performed in 
the absence of assembled mitoribosomal subunits to identify potential IMM binding partners. No 
obvious candidates, however, were detected from mass spectrometry analysis of the 
immunoprecipitated sample. Modifications of MRPL45 based on structural similarities with 
TIM44 and Mba1 were performed to identify the membrane-associating domain of the protein. 
Mutation of charged amino acids on a protruding α-helix of MRPL45 were performed. The 
resultant protein was completely integrated into the mt-LSU in the absence of the endogenous 
counterpart, partially rescuing the phenotype observed upon depletion of MRPL45. Membrane -
interaction studies showed that the modifications did not affect the ability of this mutant to 
interact directly with the membrane. Another attempt to disrupt the interaction between MRPL45 
and the membrane was performed by expressing a mutant protein lacking 117 amino acids at 
the N-terminal, which is predicted to correspond to the putative membrane-interacting domain 
of TIM44. Only a minor proportion of this protein was integrated in the mt-LSU in absence of the 
endogenous MRPL45, although the mutant protein retained the ability to interact directly with 
the membrane. 
The role of another mitochondrial protein, OXA1L, in mitochondrial translation was also 
investigated in this work. This was motivated by the discovery of a paediatric patient with 
mutations in the gene encoding OXA1L. Since the published studies showing OXA1L to interact 
with the mitoribosome were attempted in vitro, I performed immunoprecipitation studies which 
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confirmed the ability of OXA1L to associate with the mitoribosome in intact human cells. In order 
to characterise the role of OXA1L in mitochondrial translation, depletion studies were performed. 
These suggested that OXA1L was important for the stability of both the large and, unexpectedly, 
the small mitoribosomal subunit. Due to this surprising result, extensive studies were performed 
to confirm its robustness, which confirmed the reduction of the steady-state level of the 
mitoribosomal subunits and of OXPHOS components upon depletion of OXA1L.  
To conclude, my studies showed the importance of the mitoribosomal pro tein MRPL45 for 
the stability and the assembly of the large subunit of the mitochondrial translation machinery, as 
well as its ability to interact directly with the IMM. Although it was not possible to identify the 
domain of MRPL45 involved in membrane interaction, insights on the importance of the N-
terminal domain for its integration in the mt-LSU were identified. The ability of OXA1L to interact 
with the mitoribosome in vivo was determined and a role of this protein in the stability and 
assembly of the mitoribosome was demonstrated. 
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Chapter 1: Introduction 
1.1. Mitochondria 
Mitochondria are a distinctive feature of eukaryotic cells. These double-membraned organelles 
are thought to be derived from the phagocytosis of an α-proteobacteria, retained by the pre-
eukaryotic cell for selective advantage (Gray MW, 1999). Mammalian mitochondria contain their 
own small DNA molecule (mtDNA) of approximately 17,000 bases, derived from the reduction of 
the genome of the prokaryotic ancestor. On contrary, plants contain a wider mitochondrial 
genome, which can be composed of up to 2,500,000 bases (Galtier N, 2011). The mammalian 
mtDNA encodes for 13 polypeptides, 2 rRNA and 22 tRNA (Anderson S et al., 1981). All the 
remaining proteins found in mitochondria are encoded by the nuclear genome and imported into 
the organelle (Mokranjac D et al., 2005). 
One of the key functions of mitochondria is ATP production, which is the main source of energy 
used by eukaryotic cells. This is synthesised by the oxidative phosphorylation (OXPHOS) system 
found in the inner mitochondrial membrane (IMM) and accounts for approximately the 90% of the 
energy required by cells. However, it is important to remember that these organelles perform 
several other important functions. These include regulation of apoptosis (Wang C et al., 2009), 
involvement in calcium homeostasis (Rizzuto R et al., 2012) and formation of iron-sulphur clusters 
(Lill R et al., 2005). The β-oxidation of fatty acids also takes place in the mitochondria (Kunau WH 
et al., 1995) and so do crucial stages of the biosynthesis of heme (Ponka P, 1999) and pyrimidine 
(Jones ME, 1980). 
The involvement of mitochondria in several crucial processes highlights their importance for 
the homeostasis of cells. Mutations that change the sequence of mitochondrial proteins are linked 
to a vast and heterogeneous group of pathologies named mitochondrial diseases (reviewed in 
(Lightowlers RN et al., 2015)). These can arise in early childhood or in adulthood and present a 
variety of symptoms that can affect different tissues, from skeletal muscle and heart, to the 
nervous system. Because of the severity and heterogeneity of these pathologies, a complete 
understanding of the mitochondrial biological processes is essential to provide useful information 
to understand the mechanism involved in diseases and help in the development of therapies.  
1.2. The origin and evolution of mitochondria 
According to the endosymbiotic theory, mitochondria originate from the phagocytosis of α -
proteobacteria by ancestral eukaryotic cells (Falkenberg M et al., 2007; Gray MW, 1999). The 
concept of symbiosis (Latin ‘living together’) was developed by the Swiss botanist Simon 
Schwendener in 1867 after discovering that lichens consisted of a fungus and a photosynthesiser 
(Schwendener S, 1867). In the following years, the German botanist Heinrich Anton de Bary 
defined this coexistence of 2 organisms that can result in the formation of a new organism as 
symbiosis (De Bary A, 1878).  
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The phagocytosis of α-proteobacteria is thought to have occurred approximately 1.5 billion 
years ago (Brocks JJ et al., 1999) and resulted in the formation of different mitochondria-like 
organelles. These can be classified as classical mitochondria, mitosomes and hydrogenosomes 
(Embley TM et al., 2003; van der Giezen M et al., 2005). While mitochondria synthesise ATP 
aerobically, hydrogenosomes are anaerobic, do not have respiratory complexes and synthesise 
ATP through fermentation of pyruvate to acetate, CO2 and H2, carried out by pyruvate:ferredoxin 
oxidoreductase. In addition, mitochondria contain their own genome, which is absent in most of 
the hydrogenosomes. DNA is also absent in mitosomes, which are organelles that are not able 
to synthesise ATP but that are important for the assembly of iron-sulphur clusters used as 
cofactors by several enzymes. 
Because most of the nucleated eukaryotic cells contain mitochondria, it is likely that the  α-
proteobacteria was retained because it offered a selective advantage in the environmental 
conditions present at the time of the phagocytosis. This advantage might be related to the 
presence of a high concentration of oxygen, rather than the need for an additional source of 
energy. The ATP/ADP translocases that shuffle ATP and ADP across the membrane appear to 
be acquired by eukaryotic cells throughout evolution and were, therefore, not present in the α -
proteobacteria. As a consequence, at the time of the phagocytosis, the ATP could not be 
transported from the ‘parasite’ to the host (Karlberg O et al., 2000). Instead, the reduction of the 
oxygen tension due to the retained α-proteobacteria (Kurland CG et al., 2000) could have helped 
cells resist the high oxygen levels present in the atmosphere at the time of the phagocytosis (Des 
Marais DJ, 1998). 
Several mitochondrial proteins are related to bacterial forms, further supporting the hypothesis 
of the prokaryotic origin of these organelles. The human mitochondrial proteome is composed of 
over 1,000 proteins (Lotz C et al., 2014), but the human mtDNA encodes for only 13 of these. 
Therefore, during evolution, many genes have been either lost or have migrated to t he nuclear 
genome. 
The presence of mtDNA in modern mitochondria forces the cells to synthesise the thousand 
proteins necessary for mitochondrial gene expression within the cytosol and then import these 
into the organelles. Although this process appears counter-productive, its potential advantages 
have been explained by 2 theories. The ‘hydrophobic theory’, (von Heijne G, 1986) arose from 
the observation that all the mt-encoded proteins are highly hydrophobic components of the 
OXPHOS system. According to this theory, these proteins will be difficult to import into 
mitochondria, and therefore their genes have been retained to be transcribed and translated 
within the organelles. A second theory, known as the ‘colocalisation for redox regulat ion theory’, 
hypothesised that the genes have been retained to allow their expression to be controlled by the 
redox state of the organelle (Allen JF et al., 1996). 
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1.3. Mitochondrial structure 
Mitochondria are composed of an inner matrix, surrounded by a double layer of membranes, 
named inner and outer mitochondrial membranes (OMM and IMM, respectively).  Due to its 
multiple invaginations (cristae), the IMM presents a large surface area and is the site of the ATP 
production. Between the IMM and the OMM is found a compartment named inter membrane 
space (IMS) (Fig. 1.1). 
 
Figure 1.1 Structure of the mitochondrion. 
A) Schematic representation of mitochondria: outer mitochondrial membrane (orange), inner 
mitochondrial membrane (yellow), matrix (light blue). B) Electron-micrograph of a mitochondria. 
Figure from Mathews and val Holde: Biochemistry 2/e 
The mitochondrial matrix contains a high number of proteins and molecules. Amongst these 
are found the components involved in mitochondrial gene expression, as well as β -oxidation of 
fatty acids and the citric acid cycle. 
The OMM is relatively permeable due to the presence of porins that allow small molecules (up 
to approximately 5,000 Da) to pass through it (Benz R, 1994; Mannella CA, 1992). The 
permeability of the IMM, by contrast, is more selective as this membrane is only freely permeable 
for water, carbon dioxide and oxygen. This characteristic is important to maintain the membrane 
potential, essential to harness the H+ gradient generated by the OXPHOS complexes to 
synthesise ATP. 
In addition to this difference in permeability, the OMM and IMM present a different protein 
content, as well as a different phospholipid composition (Horvath SE et al., 2013). The IMM is 
more protein rich with a protein:lipid ratio of 3:1, compared to the 1:1 of the OMM (Gohil VM et 
al., 2009). Several of the phospholipids present in the mitochondrial membranes are common to 
other cellular membranes (phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, 
phosphatidylserine, and phosphatidic acid), while phosphatidylglycerol and cardiolipin, are 
exclusively components of mitochondrial membranes (Colbeau A et al., 1971). A greater amount 
B 
A B 
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of cardiolipin is found in the IMM, when compared to the OMM. Studies reported the importance 
of this phospholipid not only for the structure of the membrane, but also for other functions, such 
as fission and fusion (Frohman MA, 2015; Ortiz A et al., 1999), or the assembly and stability of 
several IMM proteins (reviewed in (Paradies G et al., 2014)). These membranes also exhibit a 
low content of sphingolipids and cholesterols, which are widely represented in the plasma 
membrane. 
More recently, the IMM has been suggested to be divided into cristae membranes (CM) and 
inner boundary membranes (IBM), which is found parallel to the OMM. The former contains the 
OXPHOS complexes, while the latter harbours the protein import machinery and the proteins 
required for the processes of fission/ fusion (Vogel F et al., 2006). CM and IBM are connected by 
cristae junctions, pore-like structures whose formation depends on a complex named MICOS 
(‘mitochondrial contact site and cristae organizing system’) (Kozjak-Pavlovic V, 2016). This 
complex associates with the SAM (‘sorting and assembly’) machinery, creating the ‘mitochondrial 
intermembrane space bridging’ (MIB) complex, which creates the cristae junctions by joining the 
IMM with the OMM (Fig. 1.2). This organisation of the IMM defines a new compartment within the 
IMS, named intracristal space. Due to the presence of the cristae junctions, which limit the 
diffusion of molecules, the composition of the intracristal space is different from the one observed 
in the remaining IMS. An example of the importance of these junctions with respect to the 
concentration of cytochrome c (Scorrano L et al., 2002). This protein is involved in the apoptosis 
cascade (Jiang X et al., 2004) and is able to pass through the OMM when its permeability is 
increased (Gogvadze V et al., 2006). The containment of this protein within the intracristal space 
limits its diffusion in the IMS and its permeation through the OMS, controlling apoptosis.  
 
Figure 1.2 Organisation of the mitochondrial inner membrane. 
Representation of the inner mitochondrial membrane (IMM) of mitochondria and its division 
into inner boundary membrane and cristae membrane. The former contains proteins from 
the membrane import machinery (TOM, translocase of the outer mitochondrial membrane; 
TIM, translocase of the inner mitochondrial membrane), while the latter contains the 
OXPHOS system (complexes I, III, IV, V. Complex II was absent in the original figure). The 
MICOS (mitochondrial contact site and cristae organizing system) and SAM (sorting and 
assembly machinery) associate to create the MIB (mitochondrial intermembrane space 
bridging) complex, responsible of the formation of the cristae junctions. OMM= outer 
mitochondrial membrane, IMS= intermembrane space. 
Figure from Kozjak-Pavlovic V (2016), Licence number 3924681399708. 
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Mitochondria are highly dynamic organelles that move in the cytoplasm along microtubule 
tracks (Morris RL et al., 1995). While moving, mitochondria can encounter and undergo fission 
and fusion (Fig. 1.3), creating the dynamic tubular network characteristic of mitochondria 
(reviewed in (Chan DC, 2006)). In mammals, the fusion machinery is composed of mitofusin 1 
and 2 (Mfn1, Mfn2), which mediate the fusion of the OMM, and optic atrophy 1 (Opa1), whose 
role is to fuse the IMM. Fusion can be either transient, if only soluble proteins are exchanged, or 
complete if the membrane proteins can combine and the mtDNA is mixed between the organelles 
(Liu X et al., 2009). When division of the mitochondrial mass is needed, mitochondria undergo 
fission, mediated by dynamin related protein 1 (Drp1) (Labrousse AM et al., 1999; Shin HW et al., 
1997). This cytosolic protein is recruited to the fission site and creates a spiral around the 
mitochondrial mass, dividing it to create 2 organelles (Smirnova E et al., 2001). 
 
Figure 1.3 Mitochondrial fission and fusion. 
Schematic representation of the processes of fission and fusion. Mfn (mitofusin) on the 
outer mitochondrial membrane and Opa1 (optic atrophy 1) on the inner mitochondrial 
membrane mediate the fusion of 2 individual mitochondria. The division of mitochondrial 
mass is, instead, performed by Drp1 (dynamin related protein 1).  
Figure from van der Bliek AM et al. (2013), © Cold Spring Harbor Laboratory Press 
1.3.1. Nucleoids and RNA granules 
The existence of 2 new compartments within the matrix, named nucleoids and RNA granules, 
has been suggested.  
RNA granules are ribonucleoparticles known to exist within the nucleus and cytoplasm of 
somatic cells, neurons and germ cells. These are not delimited by a membrane and are used to 
compartmentalise certain processes, such as RNA splicing and mRNA degradation (Anderson 
P et al., 2006). RNA granules have also been described within organelles including chloroplasts 
(Uniacke J et al., 2008) and mitochondria (Antonicka H et al., 2013; Jourdain AA et al., 2013). 
These compartments are used in mitochondria to organise the processing of the polycistronic 
RNA transcripts derived by mitochondrial transcription (qv 1.6.2. and 1.8.1.). Several factors for 
RNA modification and processing have been localised within the mitochondrial RNA granules 
(reviewed in (Jourdain AA et al., 2016)). The first proteins identified in these granules were 
GRSF1 and mt-RNaseP, involved in mitochondrial RNA processing and translation (Antonicka 
H et al., 2013; Jourdain AA et al., 2013). Other proteins present in the RNA granules are 
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members of the FASTK family (important for RNA processing and mitoribosome assembly), the 
mitochondria poly(A) polymerase (qv 1.8.1.), RNA helicases, methyltransferases. The complex 
hSuv3-PNPase, involved in degradation of RNA (qv 1.8.4.), was also localised in this 
compartment, together with the 12S and 16S mt-rRNA. Because of the presence of the rRNA, 
it was proposed that, together with RNA processing, this compartment was also involved in the 
assembly of the mitoribosome. 
In close proximity to the RNA granules, are other compartments named nucleoids (reviewed 
in (Hensen F et al., 2014)). Their main functions are to protect the mtDNA from damage and to 
provide a compartment for its replication and transcription. The confirmation of the colocalisa tion 
of proteins and mtDNA came in 2001, when Twinkle, a mtDNA helicase, was shown to colocalise 
with the mitochondrial genome (Spelbrink JN et al., 2001). Since then, several proteins have 
been reported to associate with the nucleoids (Bogenhagen DF, 2012). Due to the use of 
different isolation methods, combined with mass spectrometry analysis, debate is still present 
in the field and a unique list of proteins localised in the nucleoids is not available (Hensen F et 
al., 2014; Kukat C et al., 2015). It is also possible that the factors involved in different steps of 
mtDNA metabolism can be either permanently or transiently associated with the nucleoids, 
suggesting that they should be referred to as nucleoid associated proteins (mt-NAPs). Of the 
proteins most frequently found to be associated with the nucleoids is the transcription factor 
TFAM, the DNA binding proteins mt-SSB and RNA polymerase, POLRMT (Kukat C et al., 2015). 
1.4. Functions of mitochondria 
Despite mitochondria being commonly associated with their ability to efficiently synthesise ATP 
(qv 1.4.1.), these organelles perform several other essential functions, which will be briefly 
described in this section. 
Iron-sulphur (Fe/S) clusters are important for the functions of several proteins, which use them 
as cofactors able to accept and donate electrons. In eukaryotic cells these clusters are found in 
mitochondria, cytosol and nucleus but synthesised in mitochondria before being used as cofactors 
by proteins involved in the tricarboxylic acid cycle (aconitase), electron transport in the OXPHOS 
chain (complexes I, II, III), β-oxidation of fatty acids (ETF-ubiquinone oxidoreductase) and for 
lipoate and biotin biosynthesis (lipoate and biotin synthases) (Rawat S et al., 2011) as well as 
DNA polymerases. Due to the central role of these cofactors in several processes within 
mitochondria, numerous diseases have been connected with defects in their biogenesis (Rouault 
TA, 2012). 
Production of NADH and FADH2 in mitochondrial is essential to donate electrons that will 
contribute to ATP synthesis performed by the OXPHOS system (Berg JM et al., 2002). Pyruvate 
in mitochondria is metabolised to acetyl-CoA, which is used in the tricarboxylic acid (TCA) cycle 
to generate NADH and FADH2 (3 and 1 molecules for every acetyl-CoA oxidised, respectively) 
(Berg JM et al., 2002).  
7 
 
Mitochondria also play a central role in apoptosis. The Bcl2 family members Bax and Bac 
regulate the release from the IMS towards the OMM of proteins that, once in the cytosol, can 
initiate apoptosis (Cory S et al., 2002; Hockenbery D et al., 1990). One of the proteins released 
is cytochrome c (Xuesong L et al., 1996) usually confined within the intercristal space. This protein 
reaches the cytosol where it activates the caspase cascade that will in itiate apoptosis. Omi/HtrA2 
(Suzuki Y et al., 2001) and Smac/DIABLO (Rehm M et al., 2003) are also released from 
mitochondria to induce apoptosis. Both lead to the activation of caspases by removing their 
inhibition performed by components of the IAPs (inhibition of apoptosis protein) family, although 
by a different mechanism. While Omi/HtrA2 mediates the irreversible degradation of IAPs (Yang 
QH et al., 2003), Smac/DIABLO function as an antagonist of these inhibitors (Srinivasula SM et 
al., 2000). Together with caspases activation, apoptosis can also be promoted by degradation of 
nuclear chromatin DNA. The mitochondrial proteins AIF (apoptosis inducing factor) (Susin SA et 
al., 1996) and endonuclease G (Li LY et al., 2001) can activate apoptosis via this second pathway. 
AIF is an IMM protein that can be truncated and migrate to the nucleus. Endonuclease G is located 
in the IMS, but how its release is mediated is still unclear. 
Mitochondria are also the major source of reactive oxygen species (ROS), which are 
generated in the matrix and play an important role in cell signalling (Ray PD et al., 2012).  
In addition to these functions, mitochondria are also involved in calcium handling (Rizzuto R 
et al., 2012), thermogenesis (Ricquier D et al., 2000), β-oxidation of fatty acids (Kunau WH et al., 
1995), and heme (Ponka P, 1999) and pyrimidine (Jones ME, 1980) biosynthesis.  
1.4.1. Oxidative phosphorylation 
The production of ATP is carried out by respiratory chain and ATP synthase through a 
process called oxidative phosphorylation. The first step involves 4 complexes whose purpose is 
to create a proton gradient that is used by ATP synthase to phosphorylate ADP (Fig. 1.4).  
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Figure 1.4 OXPHOS system. 
Representation of the main components of the oxidative phosphorylation system found in 
the IMM. Complex I (blue), complex II (yellow), complex III (violet), complex IV (dark 
green), complex V (red). The movement of protons (H+) and electrons are indicated by 
white and blue arrows, respectively. The electron acceptors ubiquinone (cyan) and 
cytochrome c (green) are also depicted. Reactions occurring in the matrix side at the 
complexes are also reported. 
The formation of the OXPHOS system is dependent both on mitochondrial and nuclear DNA 
(Table 1.1). Therefore mutation in either of these genomes can lead to an alteration of these 
complexes and cause severe diseases (Smeitink J et al., 2001). 
Table 1.1 Composition of the complex of oxidative phosphorylation.  
Complex n-DNA encoded 
subunits 
mtDNA encoded subunits 
I 38 7 
(ND1, ND2, ND3, ND4, ND5, ND6, ND4L) 
II 4 0 
III 10 1 
(CyB) 
IV 10 3 
(COXI, COXII, COXIII) 
V 14 2 
(ATP6, ATP8) 
The first complex (NADH:ubiquinone oxidoreductase) is composed of 45 subunits, of which 
7 are mtDNA encoded. The subunits associate into an L-shape with the hydrophobic part 
integrated into the membrane and the hydrophilic portion directed into the matrix. In order to 
perform its biological activity, this large complex relies on prosthetic groups (1 flavin 
mononucleotide and 8 Fe-S clusters). These cofactors allow the transfer 2 electrons from NADH 
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(nicotinamide adenine dinucleotide) to ubiquinone, creating ubiquinol that can diffuse in the 
membrane. This process also results in the net transfer of 4 protons from the matrix to the 
intermembrane space (Efremov RG et al., 2010). 
Succinate:ubiquinone oxidoreductase is the second complex of the respiratory chain and it 
is the only one completely encoded by the nuclear genome. It is composed of 4 subunits and 
contains a FAD (flavin adenine dinucleotide) group, 3 Fe-S clusters and a heme group. Two of 
the subunits project into the matrix and the other 2 anchor the complex to the membrane. This 
complex converts succinate to fumarate by transferring 2 electrons from the former to FAD. The 
electrons are then conveyed through the Fe-S clusters to ubiquinone, which is reduced to 
ubiquinol. Unlike the complex I, this complex does not act as a proton pump.  
Complex III (ubiquinol:cytochrome c oxidoreductase) is a dimer composed of two 11 
polypeptides monomer. Each monomer contains 4 prosthetic groups: 2 b-type cytochrome (mt-
encoded), a cytochrome c and a Rieske protein (Fe-S cluster). In this stage, ubiquinol is oxidised 
to ubiquinone and protons are pumped into the interspace space increasing the proton gradient. 
Cytochrome c oxidase (complex IV) is the terminal electron acceptor of the respiratory chain.  
It is composed of 13 subunits, of which 3 encoded by mtDNA, and it contains 2 non-covalently 
bound cytochrome and 2 copper centres (Tsukihara T et al., 1996). It reduces oxygen to 2 
molecules of water, resulting in the pumping of 4 protons into the intermembrane space. The 
reduction of oxygen can lead to the formation of ROS that can cause damage to  protein or DNA.  
The proton gradient that is built by the complexes of the respiratory chain is then used by 
ATP synthase to produce ATP. This integral membrane complex is composed of 2 mitochondrial 
encoded subunits and 14 nuclear encoded subunits and is divided into 2 structural domains: F0, 
a proton channel located in the IMM, and F1, which is found in the matrix and that synthesises 
ATP from ADP and phosphate (Jonckheere AI et al., 2012).  
1.5. Mitochondrial diseases 
Due to the involvement of mitochondria in several cellular functions, a wide range of 
pathologies can be related to dysfunction of these organelles. Patients can be affected from the 
early childhood, or be asymptomatic until adulthood. These diseases are characterised by a 
variety of symptoms, which can have a different grade of severity and invo lve single or multiple 
organs. These usually involve tissue with high energy demands, such as the nervous system, 
skeletal muscle and cardiac muscle. A comprehensive summary of the genes involved in 
mitochondrial diseases has been recently published (Lightowlers RN et al., 2015). 
Because functional mitochondria rely on both nuclear and mitochondrial DNA, these diseases 
can arise from mutations of either of these genomes. Mitochondrial DNA has a higher mutation 
rate (Schneider S et al., 1999) when compared to nuclear DNA, partially due to the presence or 
ROS within mitochondria and to the reduced mechanisms available for DNA repair  (Dianov  GL 
et al., 2001; Souza-Pinto N et al., 2009). Although most of the mutations are neutral, to date over 
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250 mutations of mtDNA have been identified. The majority of the point mutations are located in 
genes encoding for mt-tRNA, while the majority of the deletions are found in areas for the control 
of mtDNA replication and transcription (Tuppen HA et al., 2010). Few factors are involved in 
characterising the onset and the severity of mitochondrial diseases related to mtDNA mutations. 
Since mitochondria contain several molecules of mtDNA, it is possible that a mixture of wild -type 
and mutated mtDNA is present within the organelles (heteroplasmy). Biochemial dysfunction, 
which can lead to the development of clinical symphtomps, can arise when the level of mutated 
mtDNA reaches a threshold (Rossignol R et al., 2003). This scenario is further complicated by 
the random segregation of mitochondria that occurs during mitosis and can lead to a different 
level of dysfunctional mitochondria in the daughter cells (Matthews PM et al., 1995). Pathologies 
due to mtDNA mutations include progressive external ophthalmoplegia (PEO) (Dodson RF et al., 
1976), MELAS (mitochondrial encephalopathy, lactic acidosis, stroke-like episodes) (Pavlakis SG 
et al., 1984) or MEERF (myoclonic epilepsy and ragged red fibres).  
Since the majority of the mitochondrial proteome is nuclear encoded, nuclear-DNA mutations 
can also lead to mitochondrial diseases. These mutations will follow the classical Mendelian rules 
and their identification is rapidly increasing thanks to the use of next generation sequencing. 
Several mitochondrial diseases have been related to the mutation of nuclear-encoded genes, for 
example, Alpers syndrome is due to mutation of the mitochondrial DNA polymerase (Davidzon G 
et al., 2005), while Leigh syndrome can arise from mutations of SURF1, a gene important for the 
biogenesis of complex IV (Péquignot MO et al., 2001). Mitochondrial myophaty can also be due 
to mutations of nuclear-encoded genes encoding for the mitochondrial thymidine kinase (Saada 
A et al., 2001). Defects in the assembly of complex III due to mutation of BCS1L gene have been 
reported to lead to GRACILE syndrome (Growth Retardation, Aminoaciduria, Cholestasis, Iron 
overload, Lactacidosis, Early death) (Visapaa I et al., 2002). 
In addition, mitochondrial dysfunction has also been suggested to play a role in other 
pathologies such as Parkinson disease (Schapira AH et al., 1989), Alzheimer disease (Swerdlow 
RH et al., 2010) and cancer (Warburg O, 1956).  
Due to their complexity and variability, few options are currently available to treat mitochondrial 
diseases. It is, therefore, important to fully understand the different functions carried out by 
mitochondria to provide useful information for the diagnosis and development of treatments.  
1.6. Mitochondrial DNA 
The presence of double-stranded circular DNA within mitochondria was discovered in 1963 by 
Nass (Nass MK et al., 1963). The human mitochondrial genome is a 16,569 bases molecule 
encoding 13 polypeptides, 22 tRNAs and 2 rRNAs (Fig. 1.3). The polypeptides encoded by the 
mtDNA are all components of the OXPHOS machinery, the mt-rRNA (12S and 16S) are a part of 
the translation machinery and the mt-tRNAs (1 for each amino acid and 2 each for leucine and 
serine) are involved in translation or in the case of mt-tRNAVal it is also a component of the 
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ribosome (Brown A et al., 2014). All the other proteins found in mitochondria are encoded by the 
nuclear genome and are imported into mitochondria (Mokranjac D & Neupert W, 2005) (qv 1.7.) 
after being synthesised by cytosolic ribosomes. 
The human mitochondrial genome is very different from the nuclear counterpart.  Not only is 
mtDNA is smaller than the nuclear one, but it is also circular, has no introns and contains only 
one non-coding region (displacement-loop or D-loop, Fig. 1.5), which contains important elements 
that regulate replication and transcription. The mitochondrial genome is organised on 2 strands: 
the heavy strand that contains the majority of the coding material (12 open reading frames, both 
the rRNAs and 14 tRNAs), and the light strand that contains just 1 open reading frame (ORF) and 
8 tRNAs. The genes encoded by mtDNA are usually separated by a few bases, but in two cases 
they overlap (ATPase8-ATPase6 and ND4L-ND4). In the D-loop there is one promoter for the 
transcription for the light strand (LSP) and two for the heavy strand (HSP1 and HSP2). The 
presence of two HSPs has been debated in the literature. Replication of mtDNA starts from a site 
named OH, which is located in this fragment too (Gustafsson CM et al., 2016) 
 
Figure 1.5 Structure of human mitochondrial genome.  
The tRNA genes are indicated by red circles and their respective single letter code. The 
rRNA are in violet. The 13 ORF are labelled and colour-coded according to the complex of 
the OXPHOS that they belong to (complex I= blue, complex III= orange, complex IV= 
brown, complex V= green). The non-coding region (D-loop) of the heavy strand is coloured 
with white and red stripes. The origins of replication (OH and OL) as well as the origins of 
transcription (HSP1, HSP2, LSP) are also visualised. 
Figure © 2015, Yusoff AAM, Ahmad F, Idris Z, Jaafar H, Abdullah JM. Originally 
published in ‘Molecular Considerations and Evolving Surgical Management Issues in 
the Treatment of Patients with a Brain Tumor’ under CC BY 3.0 license. Available from: 
DOI: 10.5772/58965 
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The mitochondrial genome is constantly replicated (qv 1.6.1.) and this process is independent 
from the cell cycle (Bogenhagen D et al., 1977). As a consequence, whilst there are only 2 copies 
of the nuclear genome for each cell, there can be thousands of copies of mtDNA. Th e copy 
number has been reported to change dramatically between different cell lines, ranging in human 
from 600 in skin fibroblasts to 1,500,000 in oocytes (Greggains GD et al., 2014). The copies share 
the same sequence (homoplasmy), although the coexistence of molecules with different 
sequence due to polymorphisms or under disease conditions is also possible (heteroplasmy). 
During cell division, the mtDNA molecules are segregated randomly giving rise to mitochondria 
with different mtDNA populations. If the number of pathogenically mutated mtDNA molecules 
passes a threshold level, a respiratory chain deficiency can develop (Smeitink J et al., 2001). 
Another difference between the nuclear and mitochondrial human genomes is found in their 
inheritance pattern. While the nuclear DNA contains information coming from the 2 parents, the 
mitochondrial genome is exclusively maternally inherited. Although documented cases of 
paternally-inherited mitochondria have been reported (Schwartz M et al., 2002), the organelles 
derived from the sperm cell are usually degraded just after fertilisation (Al Rawi S et al., 2011). 
Mitochondrial DNA is not packed into chromosomes, but is instead found in structures called 
nucleoids (qv 1.3.1.) that groups mtDNA together with several proteins required for replication 
and transcription, such as DNA polymerase, DNA binding proteins (mtSSB), DNA helicase 
(twinkle), transcription factors (TFAM), chaperones and proteases (Bogenhagen DF, 2012). 
These structures are also useful to preserve the genome from a high exposure to ROS produced 
by oxidative phosphorylation. 
1.6.1. Replication 
Unlike nuclear DNA, the replication of the mitochondrial genome is independent of the cell 
cycle. Replication can be divided in initiation, elongation and termination (Holt IJ et al., 2012) 
and is performed by a specific machinery encoded in the nucleus. It is composed of DNA 
polymerase γ (POLG), Twinkle (DNA helicase, that unwinds the DNA), topoisomerases (that 
remove supercoils from the DNA molecule) and mtSSB (mitochondria l single strand DNA 
binding protein). While the machinery has been well defined, the process of mtDNA replication 
is still under debate. Although POLG and Twinkle are sufficient to synthesise ssDNA up to 2 kb 
in vitro, mtSSB are necessary to synthesise up to 16 kb (Korhonen JA et al., 2004).  
Initiation begins after the mitochondrial RNA polymerase (POLRMT) synthesises the RNA 
primer necessary for POLG to start the replication. Once the replication machinery is assembled 
then elongation takes place. A number of theories have been proposed for this phase: the 
strand-displacement model (proposed by Clayton (Clayton DA, 1982) and revisited by Holt et 
al. (Holt IJ et al., 2000)), the strand-coupled bidirectional model (Bowmaker M et al., 2003) and 
the RITOLS (RNA Incorporation Through-Out the Lagging Strand) model (Yasukawa T et al., 
2006).  
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According to the strand-displacement model, the H-strand is replicated from OH found within 
the D-loop, using the L-strand as template. The displaced strand is covered by mtSSB, in order 
to protect it from damage, and it is copied only after OL is reached. The L-strand is then 
synthesised in the opposite direction. The strand-coupled bidirectional model, instead, suggests 
that the replication of both strands happened simultaneously, starting from a common origin and 
proceeding bidirectionally. Evidence has been presented for both the models and it is possible 
that both the processes are adopted in vivo (Holt IJ et al., 2000). 
The most recent and controversial theory is the RITOLS (or bootlace) model. According to 
this model, the replication follows the strand-displacement model, but the displaced strand is 
covered with RNA to protect the DNA from damage until the OL is reached and its synthesis can 
begin.  
Once elongation is completed, mtDNA replication is concluded by ligation of the ends (Ligase 
III) and the introduction of supercoils, which allow DNA to compact. Details regarding this stage 
are very sparse. 
1.6.2. Transcription 
The first step of gene expression is transcription, which is the synthesis of RNA molecules 
reading from the genome as template. In mitochondria, this process leads to the formation of 3 
polycistronic species that are then processed to obtain rRNA, tRNA and open reading frames 
(ORFs). Transcription is performed by POLRMT, a monomeric enzyme whose C-terminal part 
resembles the bacteriophage T7 counterpart. The enzyme catalyses the formation of a 
phosphodiester bond between 2 nucleotides, coordinating their phosphate groups with 2 
magnesium cations. In addition to its role in transcription of RNA required for translation, this 
enzyme is also responsible for the synthesis of the RNA fragment necessary to start the mtDNA 
replication (qv 1.6.1.). POLRMT is unable to bind and interact with the promoter sequence on 
the DNA by itself and it needs the help of mitochondrial transcription factor A (TFAM) that bends 
the promoter region and stimulates the recruitment of RNA polymerase and of TFB2M. The 
latter is the mitochondrial transcription factor B2 and its role is to assist the enzyme during the 
melting of mtDNA (Arnold JJ et al., 2012). The RNA polymerase activity has also been reported 
to be modulated by other components, such as mitochondrial transcription elongation factor 
(TEFM) (Minczuk M et al., 2011), mitochondrial transcription termination factors (mTERFs) and 
mitochondrial ribosomal protein L12 (MRPL12) (Wang Z et al., 2007). 
The light strand is transcribed from its only promoter (LSP) and the derived polycistronic 
species contains the ORF for MTND6 and 8 mt-tRNA species. Transcription of the heavy strand, 
instead, is ‘debatably’ controlled by 2 different promo ters and, as a consequence, leads to the 
production of 2 different polycistronic species (Montoya J et al., 1982). The smaller product is 
composed mainly of the 2 rRNAs and it is produced from the promoter HSP1, situated 16 bp 
before tRNAPhe. The larger product corresponds to the entire H-strand and it is created when 
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transcription starts at HSP2, situated slightly before the beginning of the gene encoding for the 
12S rRNA (Fig. 1.6). Transcription of the species containing the 2 rRNA has been reported to 
be performed 50-100 times more than the one of the larger transcript (Gelfand R et al., 1981). 
Among the 3 promoters identified, only one of them (HSP1) has a corresponding termination 
site and factor named mTERF1 (Fernandez-Silva P et al., 1997), which terminate at the tRNALeu 
(Asin-Cayuela J et al., 2005). This factor has also been suggested to be involved in the initiation 
at HSP1 and HSP2, facilitating the recycling of the transcription machinery (Martin M et al., 
2005). The termination site for LSP promoter has still not be identified, while the one for HSP2 
has been located beyond the non-coding region although the binding factors are still unknown 
(Camasamudram V et al., 2003). 
 
 
Figure 1.6 Initiation sites of mitochondrial transcription. 
Representation of the initiation sites of transcription HSP1, HSP2 and LSP. These are 
contained in the D-loop (green). Genes encoding for tRNA are depicted in red and reported 
with the letter corresponding to the amino acid. The rRNA 12S and 16S are in violet. 
Cytochrome b (Cyt b) is in orange, while ND1 is in blue. The content of the transcript 
produced from every initiation site is also reported (ORF= open reading frame).  
The polycistronic RNA species created during transcription need to be processed to lead to 
individual RNA species and then matured to produce functional mRNA, tRNA and rRNA. It is 
important to remember that 2 bicistronic transcript are also present, with overlapping sequences 
(ND4L/ND4 and ATP8/ATP6). The current theory for the cleavage of transcripts is the ‘tRNA 
punctuation model’ (Ojala D et al., 1981). In the human mtDNA, the 22 tRNA genes are 
interspaced between the majority of genes encoding for the 13 polypeptides and the 2 rRNAs 
(Fig. 1.5). This model suggest that the individual RNA fragments are generated by cleavage at 
the 5’ and 3’ ends of tRNA, respectively by RNase P (Doersen CJ et al., 1985) and RNase Z 
(ELAC2) (Brzezniak LK et al., 2011). However, this process does not explain how the transcripts 
corresponding to ATP6 and COXIII are divided because no gene encoding for a tRNA species 
is present between the genes MTATP6 and MTCO3. The transcript cannot be processed via 
the same mechanism, but how this is processed is still unclear. 
1.7. Protein import in mitochondria 
Because over 99% of the mitochondrial proteins are encoded by the nuclear, mitochondria 
developed a system to import several components of its proteome from the cytosol.  
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In order to be targeted to mitochondria, nuclear-encoded proteins need to present either a 
cleavable N-terminal presequence or an internal targeting signal. The cleavable presequence 
usually forms an amphipathic α-helix of 10-30 amino acids and is adopted by proteins destined 
to the matrix as well as by few IMM proteins. The internal signal, instead, is usually used by 
proteins of the OMM, IMS and by some IMM proteins. By interaction with different protein 
complexes, the mitochondrial proteins reach their destination (Fig. 1.7). All the proteins will 
interact with the translocase of the outer mitochondrial membrane (TOM complex). After that, 
OMM proteins will interact with the sorting and assembly machinery (SAM complex), while the 
presequence translocase (TIM23 complex) and its associated import motor (PAM complex)  will 
take care of matrix proteins. Finally, proteins destined to the IMM will be inserted in the membrane 
with the help of the carrier translocase (TIM22 complex). 
 
Figure 1.7 Pathways of protein import in mitochondria. 
The figure (Dudek J et al., 2013) summarised the pathways of import followed by proteins 
of the OMM, IMM, IMS and matrix. Full description is given in the text.  
Licence number: 4003280468275. 
As previously mentioned, the TOM complex (Fig. 1.7, in magenta) is the first gate used by 
nuclear-encoded mitochondrial proteins to enter the OMM. This is composed of 7 subunits, of 
which 4 are receptors (Tom5, Tom20, Tom22, Tom70), 1 forms a channel (Tom40) and the other 
2 are required for the stability of the complex (Tom6, Tom7). After recognition of the targeting 
sequence by Tom20 and Tom22 (Abe Y et al., 2000; Brix J et al., 1997), the preprotein is 
transferred, with the help of Tom5, to the Tom40 translocation channel. The activity and the 
assembly of the TOM complex have been reported to depend on cytosolic protein kinases 
(Schmidt O et al., 2011). In particular phosphorylation of Tom70 by protein kinase A affected its 
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role as a receptor. Another kinase (casein kinase 2) phosphorylate Tom22 and the import protein 
Mim1 (necessary for the assembly of TOM20) (Waizenegger T et al., 2005), promoting the 
assembling of the TOM complex. The OMM proteins with simple topology are inserted in the 
membrane directly by the TOM complex, while more complex proteins (such as Porin, Tom40, 
Sam50 and Mdm10) require the help of the SAM complex to be successfully inserted within the 
OMM. Carrier proteins destined to the IMM (such as ADP/ATP or phosphate carriers) are led to 
the receptor of the TOM complex Tom70 (Brix J et al., 1997) by the molecular chaperones Hsp90 
and Hsp70 (Young JC et al., 2003) and then translocated through Tom40 to the complex Tim9-
Tim10 found in the IMS (Vial S et al., 2002). These IMM proteins are then inserted in the inner 
membrane via the TIM22 complex (Fig. 1.7, in orange). This complex present a pore composed 
of Tim22, and other 3 proteins (Tim12, Tim18, Tim54). In order to insert the preprotein in the pore 
and to laterally release it in the IMM, membrane potential is essential. As previously mentioned, 
some IMM proteins also contain N-terminal presequence. These contain a hydrophobic stop 
signal and their translocation is arrested within the IMM, to allow their lateral movement and 
insertion in the lipid layer of the IMM (Glick BS et al., 1992). This fate is also followed by proteins 
destined to the IMS that contain an N-cleavable presequence, which are released in the IMS by 
cleavage of the IMM portion. IMS proteins containing cysteine residues, instead, rely for their 
import and assembly on the MIA machinery, also found in the IMS. The core of this machinery is 
Mia40, a protein which forms a disulfide bridge with the IMS protein, resulting in oxidation of the 
latter which will then undergo folding in the IMS (Banci L et al., 2010; Banci L et al., 2009; Hofmann 
S et al., 2005). 
After interaction with the TOM complex, matrix proteins reach their destination by interacting 
with the TIM23 complex (Fig. 1.7, in light blue), which is composed of 3 integral membrane 
proteins (Tim50, Tim23, Tim17). After translocation through Tom40 of the TOM complex 
preproteins interact with Tim50, which leads them to the TIM23 complex. As with the translocation 
carried out by TIM22 complex, membrane potential is essential for the process and drives the 
positively-charged presequence towards the matrix side (Martin J et al., 1991). This process is 
also aided by the PAM complex (Fig. 1.7, in pink) that is localised in the matrix. The PAM complex 
is composed of the membrane-interacting protein Tim44 (which binds to the chaperone mtHsp70 
and to the TIM23 complex) and 3 proteins that assist the process (Pam18, Pam16, and Mge1). 
The order of the events involved in this final step of the translocation in the matrix is not yet fully 
understood. 
Once the N-terminal cleavable presequence is no longer needed, it is cleaved by mitochondrial 
processing metalloendopeptidases (Taylor AB et al., 2001). The imported mitochondrial matrix 
proteins are finally assisted by mitochondrial chaperones to complete their folding (Bukau B et 
al., 1998; Hartl FU et al., 2002). 
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1.8. Mitochondrial protein synthesis 
1.8.1. Pre-Translation Events 
The assembly of the mitoribosome, as well as the modifications and stabilisation of mRNA 
and tRNA are important aspects of mitochondrial translation, which are necessary prior to the 
beginning of the process and of which several aspects remains uncharacterised. In the following 
paragraphs, an overview on modifications of mRNA and tRNA, as well as on the assembly of 
the mitoribosome to date will be discussed. 
- mt-mRNA processing and stabilisation 
In human mitochondria, oligo/polyadenylation is necessary for the maturation of mt-mRNA 
transcripts, with the exception of MTND6 (Slomovic S et al., 2005; Tomecki R et al., 2004). 
This process is carried out by a mitochondrial poly(A) polymerase (mtPAP), which introduces 
a poly- or oligo-(A) extension needed to complete the UAA stop codon in 7 transcripts (Ojala 
D et al., 1981). While polyadenylation is generally used in bacteria to promote the degradation 
of the transcripts (Xu F et al., 1995) and in the cytosol of mammalian cells to increase their 
stability ,(Bernstein P et al., 1989), its role on the stability of mammalian mitochondrial 
transcripts is still unclear (Bratic A et al., 2016; Nagaike T et al., 2005; Tomecki R et al., 2004; 
Wilson WC et al., 2014). 
The association of mt-mRNA with mRNA-specific proteins has an influence on their stability. 
The degradation of transcripts encoded by the mtDNA heavy strand is prevented by the 
complex LRPPRC/SLIRP (Sasarman F et al., 2010), whereas MTCO1, MTCO2, MTCO3, 
MTATP6/8, MTCYB and MTND3 are stabilised by FASTKD4 (Wolf AR et al., 2014). The only 
protein coding transcript derived from the light strand, MTND6, interacts with the binding 
protein FASTDK (Jourdain AA et al., 2015) and GRSF1, which is reported to affect its stability 
(Antonicka H et al., 2013; Jourdain AA et al., 2013). 
- Maturation of mt-tRNAs 
Several modifications are needed to promote function and stability of mt -tRNA. A 
comprehensive description of these modifications have been described by Suzuki (Suzuki T, 
2014) and Salinas-Giege et al (Salinas-Giege T et al., 2015). After the mt-tRNAs have been 
modified and the CCA is added to the 3’ terminus (Nagaike T et al., 2001), the transcripts are 
ligated to the appropriate amino acid by the relevant mitochondrial aminoacyl-tRNA synthetase 
(Diodato D et al., 2014). The mt-tRNAs are then competent to participate in mitochondrial 
translation. 
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- Assembly of the mitoribosome 
The mitochondrial translation machinery is, like other ribosomes, composed of 2 subunits. 
Several key players are needed to correctly assemble the rRNA and the ribosomal proteins 
into complete and functional subunits but while this process is well understood for the bacterial 
ribosome (Hage AE et al., 2004), the steps of the biogenesis of the mammalian mitoribosome 
are mainly unknown.  
After transcription, the rRNA molecules are cleaved from the polycistronic transcript and 
are likely to be stabilised and modified prior to its assembly in the subunits. The rRNAs are 
subjected to pseudouridylation, base methylation and 2’-O-ribose methylation at conserved 
sites that are important during translation. The extent of the modification was originally 
assessed on mammalian mitochondria from hamster cells, where 9 modifications were 
detected (Dubin DT et al., 1978). Five were base methylations of 12S mt-rRNA, of which 3 are 
performed by TFB1M (adenine) (Metodiev MD et al., 2009; Seidel-Rogol BL et al., 2002) and 
NSUN4 (cytosine) (Metodiev MD et al., 2014). Three 2’-O-ribose methylation were detected 
on 16S mt-rRNA, performed by methyltransferases (MRM1, MRM2, MRM3) (Lee KW et al., 
2014 ; Rorbach J et al., 2014). The 16S mt-rRNA is also supposed to be pseudouridylated 
(Ofengand J et al., 1997), although this modification was not detected in the study performed 
on hamster. Recently, some mitoribosomal protein have been identified in association with 
unprocessed RNA, suggesting that mitoribosomal assembly proceeds co-transcriptionally 
(Rackham O et al., 2016). 
GTPases and ATP-dependent RNA helicases are required for the formation of 
ribonucleoprotein particles. However, few of these enzymes have been identified in 
mammalian mitochondria (De Silva D et al., 2015). To date, 2 mitochondrial GTPases (Mtg1, 
Mtg2) have been reported to interact with the incomplete mt-LSU (Kotani T et al., 2013), and 
1 (C4orf14, or NOA1) appears to play a role in the assembly of the mt-SSU (He J et al., 2012). 
Different hypotheses have been suggested for the role of GTPases in this process. It is 
possible that the hydrolysis of GTP regulates the association or dissociation of proteins, or that 
this promotes conformational changes. It has also been suggested that these proteins might 
act as place holders for other proteins prior their recruitment in the biogenesis process. Finally, 
the GTPases might act as sensors for GTP/GDP ratio, reducing the assembly of new 
mitoribosomal subunits in conditions of starvation (lower GTP/GDP ratio). ERAL1 is an RNA-
binding GTPase that has been reported to stabilise 12S mt-rRNA (Dennerlein S et al., 2010; 
Uchiumi T et al., 2010). 
ATP-dependent RNA helicases are enzymes that bind and remodel RNA and 
ribonucleoprotein particles. Their roles can involve unwinding RNA (important to initiate 
ribonucleoprotein assembly) or protein displacement from RNA (Linder P et al., 2011). At 
present few have been identified in human mitochondria. DDX28 (Tu YT et al., 2015) and 
DHX30 are both involved in mitoribosome assembly (Antonicka H et al., 2015). In addition, 
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another helicase, SUPV3L1, has been reported to play a role in mt-RNA metabolism (Borowski 
LS et al., 2013). 
Together with GTPases and helicases, only a few other factors involved in the assembly of 
mammalian mitoribosomes have been reported. mTERF3, involved in mitochondrial 
transcription, appears to be able to associate to 16S mt-rRNA and play a role in the biogenesis 
of the mt-LSU (Wredenberg A et al., 2013). FASTKD2 (Fas-activated Serine Threonine 
Kinase) and the helicase DDX28 are also shown to be required for mt -LSU (Antonicka H & 
Shoubridge EA, 2015; Popow J et al., 2015; Tu YT & Barrientos A, 2015). In yeast the 
maturation of MRPL32 is required for its insertion in pre-ribosomal particles and is supported 
by the components of the mAAA-protease system (Nolden M et al., 2005). Another protein, 
C7orf30 (MALSU1), has been reported to interact with MRPL14 and might be involved in the 
assembly of the mt-LSU (Fung S et al., 2013; Rorbach J et al., 2012). Depletion of the IMM-
interacting protein MPV17L2, also known to interact with the mt-LSU, showed a reduction of 
both subunits, suggesting a possible role in their assembly (Dalla Rosa I et al., 2014). Finally, 
mt-SSU assembly has been suggested to be aided by GRSF1 as its depletion leads to 
accumulation of incomplete subunit (Antonicka H et al., 2013; Jourdain AA et al., 2013).  
Concerning the localisation of mitoribosomal assembly, 2 submitochondrial compartments 
have been suggested, the RNA granules and the nucleoids (qv 1.3.1.). Briefly, RNA granules 
are the centre of posttranscriptional RNA processing and maturation, while nucleoids are the 
site for mtDNA maintenance, replication and transcription. Proteins involved in mitoribosomal 
biogenesis have been detected in both nuceloids and RNA granules compartments, together 
with several mitoribosomal proteins (Antonicka H & Shoubridge EA, 2015; Bogenhagen DF et 
al., 2014), suggesting that mitoribosome assembly might begin in the nucleoids and continue 
in the RNA granules. More studies are needed to identify the involvement of these 
compartments in this process, as well as all the steps that lead to fully assembled 
mitoribosomal subunits. 
1.8.2. Molecular Mechanisms of Mitochondrial Translation 
Transcription of human mtDNA leads to the formation of 9 monocistronic and 2 dicistronic 
mRNA species that are translated by the mitoribosome in a process that can be divided in 
initiation, elongation and termination (reviewed in (Christian BE et al., 2012; Mai N et al., 2016; 
Ott M et al., 2016)). While the process does not differ significantly from the one described for 
the other ribosomes, it is important to remember that mitochondrial coding system varies in 
different organism. In mammalian mitochondria, the canonical stop codon UGA is recognised 
as tryptophan, while AUA encodes for methionine, and AGA and AGG are codons not 
recognised by any mt-tRNA or protein (Chrzanowska-Lightowlers ZM et al., 2011; Suzuki T et 
al., 2011). 
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The first step in protein synthesis is initiation (Fig. 1.8). At the beginning of this phase, the 
mt-SSU is bound to the initiation factor mtIF3, which inhibits the early formation of the 
monosome. The complex is joined by the initiation factor mtIF2:GTP and, subsequently, the 
mRNA enters the mRNA tunnel. The recruitment of mRNA has been suggested to be helped by 
a mitoribosomal protein found at the entrance of the mt-mRNA channel of the mitoribosome, 
named MRPS39 (Amunts A et al., 2015; Greber BJ et al., 2015). AUG, AUA, AUU are 
recognised as start codons by a formylated methionyl-tRNA (Tucker EJ et al., 2011), which is 
also recruited by mtIF2:GTP to the mitoribosome. In the case of a positive codon:anticodon 
interaction, a stable complex is created and the interaction with the mt-LSU follows. The 
formation of the monosome causes the hydrolysis of the mtIF2-bound GTP to GDP and the 
release of mtIF2 and mtIF3 from the complex. If the start codon is not present in the P-site or f-
Met-tRNAMet is not available, the inspection fails and the mRNA is released.  
A peculiar feature of human mt-mRNAs is the absence of a 5’ untranslated sequence, used 
by prokaryotes to position the start codon in the ribosome. Of the monocistronic transcripts, only 
3 mt-mRNA present a few nucleotides prior the start codon, while the others have the AUG 
immediately at the 5’ end (Christian BE et al., 2010). The 2 bicistronic transcripts, RNA7 
(MTND4/MTND4L) and RNA14 (MTATP8/MTATP6), present an upstream sequence ahead of 
the second ORF, which corresponds to the upstream sequence. How these start codons are 
correctly localised within the mitoribosome is still unclear. 
 
Figure 1.8 Initiation of mitochondrial translation. 
Diagram of the stages and the key players of mitochondrial translation initiation. A 
complete description of the process can be found in the text.  
mt-SSU: small mitoribosomal subunit; mt-LSU: mitoribosomal large subunit; mtIF2, mtIF3: 
mitochondrial initiation factor 2 and 3; Met: methionine; GTP: guanosine triphosphate; 
GDP: guanosine diphosphate. 
Figure from Mai N et al. (2016). 
After the monosome is formed, the elongation of the nascent chain can start (Fig. 1.9). The 
mitochondrial elongation factor mtEF-Tu, GTP and a charged mt-tRNA form a complex, which 
can enter the A-site, where the codon:anticodon interaction takes place. In the case of a positive 
interaction, the mitoribosome stimulates the hydrolysis of GTP and the subsequent release of 
GDP:mtEF-Tu. The interaction of mtEF-Tu with the nucleotide exchange factor mtEF-Ts 
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restores the GTP:mtEF-Tu complex (Cai YC et al., 2000). After the release of mtEF-Tu, the 
peptidyl transferase centre (PTC) in the mt-LSU catalyses the formation of the peptide bond. As 
a result, a polypeptidyl-tRNA is found in the A-site, while the P-site of the mitoribosome is 
occupied by a deacylated mt-tRNA. The release of the mt-tRNA from the P-site and the 
movement of the peptidyl-tRNA to the same site are mediated by the alteration of the structural 
conformation of the mitoribosome triggered by the elongation factor mtEF-G1 with the 
mitoribosome. The recent publication of the porcine and human structures (Amunts A et al., 
2015; Greber BJ et al., 2015) confirmed the presence of an E-site in mammalian mitoribosome 
where the deacylated mt-tRNA moves to before exiting the monosome. This process is then 
repeated until a stop codon is presented in the A-site. 
 
Figure 1.9 Elongation process in mitochondrial translation. 
Schematic representation of the elongation of the nascent polypeptide chain during 
mitochondrial translation. The description of all the stages and components involved can be 
found in the main text. The mt-SSU is depicted in light blue, while the mt-LSU is in dark blue. 
The red dot represents GTP, while the orange one GDP. 
mt-SSU: small mitoribosomal subunit; mt-LSU: mitoribosomal large subunit; mtEF-Tu, 
mtEF-Ts, mtEF-G1: mitochondrial elongation factor Tu, Ts and G1; GTP: guanosine 
triphosphate; GDP: guanosine diphosphate 
Figure from Mai N et al. (2016). 
The termination of protein synthesis takes place once a stop codon enters the A-site (Fig. 
1.10). In human mitochondria, this codon is recognised by mtRF1a (mitochondrial release factor 
1a), which is believed to be sufficient to terminate the synthesis of all the 13 mt-encoded 
polypeptides (Soleimanpour-Lichaei HR et al., 2007). This factor belongs to class I release 
factors that, unlike class II, is able to recognise specific sequences of the mRNA and has two 
functions. The first is the recognition of a stop codon on the A-site and mediated by its sequence 
recognition domains. The second function, which is dependent on the first, is performed by a 
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conserved GGQ domain that promotes the catalysis of the hydrolysis of the ester bond between 
terminal mt-tRNA in the P-site and the nascent polypeptide (Frolova LY et al., 1999). In the 
presence of GTP, mtRF1a promotes the release of the polypeptide from the mt-LSU (Schmeing 
TM et al., 2005).  
UAA and UAG are used as stop codons in human mitochondria to terminate 9 and 2 ORFs 
respectively. The coding sequence for the remaining 2 ORFs, MTCO1 and MTND6, terminates 
in AGA and AGG respectively. Because no corresponding tRNA was present in the 
mitochondrial genome, these triplets were originally suggested as alternative stop codons 
(Anderson S et al., 1981). Recent studies, however, showed that a classical UAG codon was 
also used by these two species to terminate translation (Temperley R et al., 2010). This was 
explained by the occurrence of a -1 frameshift, which might be due to structured RNA found 
downstream of the termination codons. This mechanism, reasonable for humans, does not lead 
to the creation of a stop codon in all other vertebrates. More recently, ICT1 has been proposed 
to act as a mitochondrial translation release factor and may be involved in the termination of the 
synthesis of COXI and ND6. This protein has an indiscriminate peptidyl-tRNA hydrolase activity 
(Richter R et al., 2010) and might enter the A-site to promote the release of the polypeptide 
chain (Akabane S et al., 2014), as performed by its bacterial homologue ArfB (Gagnon MG et 
al., 2012). In contrast with this hypothesis, ICT1 has been identified as a constitutive component 
of mt-LSU where it is not located in proximity of the A-site (Brown A et al., 2014; Greber BJ et 
al., 2014), having therefore limited access to this site. Despite this, it has been proposed that a 
limited free pool of ICT1 might perform the hydrolase activity. Recent studies on isolated ICT1 
confirmed its ability to hydrolyse peptidyl-tRNA on stalled ribosomes but, intriguingly, not when 
the RNA template extended more than 14 nucleotides past the A-site (Feaga HA et al., 2016). 
As MTCO1 and MTND6 mt-mRNA have 3’ extensions longer than 14 nucleotides, it is unlikely 
that ICT1 might act as a natural translation terminator in vivo.  
Finally, the dissociation of the mitoribosomal subunits is promoted by 2  ribosomal recycling 
factors, mtRRF1 and mtEF-G2, leading to the release of mt-mRNA and deacylated mt-tRNA 
(Rorbach J et al., 2008; Tsuboi M et al., 2009). After the release of the 2 recycling factors the 
translation cycle can reinitiate. 
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Figure 1.10 Termination of mitochondrial protein synthesis and recycling of the 
mitoribosomal subunits. 
The last stages of mitochondrial translation are summed up in this figure. A complete 
description is present in the text. The mt-SSU and mt-LSU are depicted in lighter and 
darker blue, respectively. 
mt-SSU: small mitoribosomal subunit; mt-LSU: mitoribosomal large subunit; mtRF1a: 
mitochondrial release factor 1a; mtRRF1: mitochondrial ribosomal recycling factor 1; mtEF-
G2: mitochondrial elongating factor G2. 
Figure from Mai N et al. (2016). 
1.8.3. Regulation of mitochondrial translation 
The efficient assembly of the OXPHOS complexes relies on the coordination of cytosolic and 
mitochondrial translation. In yeast, translation can be activated by several proteins, which 
associate with the untranslated regions (mainly 5’) of all yeast mt-mRNA species (reviewed in 
(Herrmann JM et al., 2013)). Published data suggested the involvement of these proteins in 
feedback loops, regulating mitochondrial translation depending on the availability of nuclear -
encoded components of the OXPHOS that leads to a successful assembly of the complex.  
The absence of untranslated regions in the majority of human mt-mRNA transcripts indicates 
that any translational activators would have to act via a different mechanism. At present, only 1 
translational activator has been identified in human mitochondria. This was named TACO1 and 
its absence in patients presenting mutations in the encoding gene resulted in the  selective loss 
of translation of MTCO1 (COXI of complex IV) (Weraarpachai W et al., 2009). Translational 
activators bind in most cases to the 5’-UTR of transcripts. Since this is absent in MTCO1, it has 
been suggested that TACO1 might have an effect on the translation of this mRNA by stabilising 
the nascent polypeptide or by promoting the recognition of the start codon. Another hypothesis 
suggests a role of TACO1 in the release of the complete COXI, via interaction with the 
translation termination factor (Weraarpachai W et al., 2009). 
Recent studies suggested that the assembly of the OXPHOS complexes can regulate 
mitochondria translation, helping to maintain the balance with nuclear translation. Studies on 
complex IV assembly identified a complex named MITRAC (MItochondrial TRanslation 
Regulation Assembly intermediate of cytochrome c oxidase (Mick DU et al. 2012)). Two of its 
components, C12orf62 and MITRAC12, appeared to regulate COXI synthesis, as their loss 
affected this process (2012; Weraarpachai W et al., 2012). Recent studies showed that the 
translation of COXI was stalled in absence of the nuclear encoded COXIV, futher suggesting an 
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effect of the assembly of complex IV on mitochondrial translation (Richter-Dennerlein R et al., 
2016 ). Similarly, defects in the assembly of complex III were reported to decrease the 
translation of cytochrome b (Tucker EJ et al., 2013). 
As a result of the mitochondrial levels of ATP, acetyl-CoA and NADH, mitoribosomal proteins 
can be phosphorylated (Miller JL et al., 2009) or acetylated, affecting the interaction between 
the 2 subunits of the machinery. For example, a role in the formation of the monosome might 
be played by the mt-specific protein DAP3 (also known as MRPS29). This protein presents 
phosphorylation sites on its intersubunit face (Miller JL et al., 2008), which might have an impact 
on the formation of the monosome (Miller JL et al., 2009). In addition, DAP3 is bound to GDP in 
the mammalian 55S structures (Amunts A et al., 2015; Greber BJ et al., 2015), and it is possible 
that the hydrolysis of GTP to GDP might play a role in ribosome assembly (Amunts A et al., 
2015). Modifications of other mitoribosomal proteins have been identified at the subunits 
interface or in domains crucial for translation (mRNA channel, the PTC or the PES) and are also 
likely to have a role in regulating the assembly of the monosome (Miller JL et al., 2009). This 
process is also promoted by mTERF4-NSUN4, an mt-SSU-interacting complex that supports 
the recruitment of the mt-LSU (Cámara Y et al., 2011; Metodiev MD et al., 2014). Studies on the 
pentatricopeptide repeat (PPR) domain protein MRPS27 suggested a potential role of this 
protein in regulating mitochondrial translation, although the mechanism is still unknown (Davies 
SM et al., 2012). Recently, the protease CLPP was suggested to regulate translation by 
removing ERAL1 from the 12S rRNA (Szczepanowska K et al., 2016). 
Finally, mitochondrial translation was also reported to be affected by the cellular environment. 
In the cytosol, the interaction of microRNAs with the proteins AGO2 and GW182 creates a 
complex capable of reducing translation of cytosolic mRNAs (Czech B et al., 2011). A complex 
between microRNAs and AGO2 was also observed in mitochondria, where it increased the 
translation of certain transcripts during muscle differentiation (Zhang X et al., 2014). However, 
the presence of miRNAs in mitochondria is still unclear (Mercer TR et al., 2011). 
1.8.4. Post-Translation events 
While the mitoribosomal subunits are recycled at the end of mitochondrial protein synthesis, 
the fate of mt-mRNA is still unclear. The mt-mRNAs species might be protected and translated 
again, thanks to the interaction with RNA chaperones (like LRPPRC/SLIRP, FASTKD2, 
FASTKD4), but it is also possible that these species are degraded. The helicase responsible for 
RNA metabolism has been identified as SUPV3L1 (Minczuk M et al., 2002). It was found to 
interact with the human polynucleotide phosphorylase (PNPase) (Borowski LS et al., 2010), 
which was shown to be important for mitochondrial RNA degradation (Chujo T et al., 2012). 
However, the localisation of this protein within the mitochondrial intermembrane space (Wang 
G et al., 2010) makes unlikely its involvement in RNA degradation in the matrix. An exonuclease, 
named REXO2 was identified both in the cytosol and in mitochondria and might play a role in 
the degradation of RNA species in mitochondria (Bruni F et al., 2013). In addition to REXO2, 
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recent studies identified an endoribonuclease, LACTB2, with mitochondrial localisation. The 
physiological role of this protein is still unclear (Levy S et al., 2016). 
1.9. The mitoribosome 
The existence of a mitochondrial machinery for protein synthesis was discovered in 1958 by 
John R. McLean in rat liver (McLean J et al., 1958) and this was then isolated from the same 
organ in 1967 by Thomas W. O’Brien (O'Brien TW et al., 1967). Like the other ribosomes, 
mitochondrial ribosomes are composed by 2 subunits, large and small, that associate together to 
form a fully functional monosome. Because it has been proposed that mitochondria derive from 
the endosymbiosis of an α-proteobacteria, it was originally thought that their ribosome would 
resemble the bacterial counterpart more than the cytosolic one. However, several differences are 
present between bacterial and mitochondrial ribosomes and, further, differences can be 
highlighted between mammalian and yeast mitoribosomes, suggesting a parallel evolution of 
these 2 machineries from the common bacterial ancestor. The most striking difference between 
these 3 regards the amount of RNA and protein. While the bacterial ribosome and yeast 
mitoribosome are mainly composed of RNA (approximately 70% of its total weight), the 
RNA:protein ratio is reversed to 30:70 in the mammalian mitoribosome, as a consequence of the 
shortening of the rRNA molecules and the presence of additional protein mass (Fig. 1.11), already 
identified in proteomics studies carried out in 2001 (Koc EC et al., 2001; Koc EC et al., 2001). 
The different RNA:protein ratio observed for the mammalian mitoribosome also results in a 
different composition of intersubunit bridges. In bacteria, the two ribosomal subunits interact 
mainly via RNA:RNA bridges (Liu Q et al., 2016), whereas in the mammalian 55S particle there 
is a higher proportion of protein-protein and RNA:protein connections (Amunts A et al., 2015; 
Greber BJ et al., 2015). As opposed to mammalian mitoribosomes, the yeast mt-rRNAs acquired 
new domains (Foury F et al., 1998). Despite this, the yeast mitoribosome present several 
mitochondrial-specific (mt-specific) proteins absent in the bacterial counterpart. 
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Figure 1.11 Distribution of conserved and mitochondrial specific proteins in the human 
mitoribosome. 
Representation of the human mitoribosome. Proteins conserved with bacteria are depicted 
in blue, extensions of homologous proteins in yellow, and mitochondria-specific proteins in 
red. rRNA is shown in grey. 
Figure from Amunts A et al. (2015), License number 3930190789240 
The increase of protein content observed for mitochondrial ribosomes is a result of both the 
extension of homologous proteins and the acquisition of mt-specific proteins. In mammalian 
mitoribosomes, a small proportion of the new protein mass is filling the void due to the shortening 
of rRNAs. The majority of this new mass is, instead, found peripherally (Brown A et al., 2014) and 
has been suggested to protect the mt-rRNA from potential damages due to the presence of high 
ROS levels within the organelle (Lightowlers RN et al., 2014). In addition to ROS protection, some 
of the mt-specific proteins also present a second function. For instance, several DAP3 (Kissil JL 
et al., 1999), MRPL37 (Levshenkova EV et al., 2004), MRPL41 (Yoo YA et al., 2005) and MRPL65 
(previously named MRPS30) (Sun L et al., 1998) have been linked to apoptosis. Another protein, 
MRPL12, seems to play a role in POLRMT function and stability (Nouws J et al., 2016; Surovtseva 
YV et al., 2011). The cryo-EM studies performed on human and porcine samples also confirmed 
the presence of, ICT1, a ribosome-dependent peptidyl-tRNA hydrolase (Richter R et al., 2010) 
has been confirmed as a structural component of the mt-LSU but might also play a role in 
translation as mentioned in the previous paragraph (Akabane S et al., 2014; Feaga HA et al., 
2016). 
Despite all of the differences, the functional core of the mitoribosome is mainly conserved, 
suggesting that the mechanism of protein translation does not differ considerably from the 
bacterial counterpart. This is composed of the mt-mRNA recognition site on the mt-SSU and 
peptidyl transferase centre in the mt-LSU.  
In the last few years, a new nomenclature has been adopted for mitoribosomal proteins, 
according to the presence of homologues of these proteins in bacteria (Ban N et al., 2014). 
However, in this study, the old nomenclature will be reported. If needed, a table reporting new 
and old nomenclature can be found at Appendix 1. 
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1.9.1. Structure of the mammalian mitoribosome 
While the first low resolution cryo-EM structure of the bovine monosome was released in 
2003 (Sharma MR et al., 2003), the structure of the human (Amunts A et al., 2015; Brown A et 
al., 2014) became available after the beginning of this study, together with the high-resolution 
structure of the porcine counterpart (Greber BJ et al., 2015; Greber BJ et al., 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
As previously mentioned, the functional core of the mitoribosome has been conserved 
throughout evolution and, as in most ribosomes, the A, P and E sites can be identified (Wettstein 
FO et al., 1965). The residues of the mt-SSU important for the decoding at the A-site are present, 
and the ability of mt-tRNA to interact with the mt-LSU has also been conserved. Due to the 
shortening of the rRNA, no A-site finger was detected on porcine mitoribosomes. This structure 
might not be necessary as mammalian mt-tRNAs do not show the typical cloverleaf structure 
observed in their bacterial counterparts (Suzuki T et al., 2011). The P-site is well preserved, 
although the presence of a P-site finger introduces a stronger interaction with the T-loop of mt-
tRNAs than those seen in bacteria (Schuwirth BS et al., 2005). This structure might be 
necessary to keep mt-tRNAs in position, because their T-loop is smaller than those of bacterial 
tRNA. Finally, despite most of the contact points between the bacterial ribosome and tRNA on 
the E-site seemed absent on the mammalian mitoribosome until the recent cryo-EM studies 
confirmed its modified presence (Greber BJ et al., 2014). 
- Mitoribosomal small subunit 
The mammalian mt-SSU is composed of 30 proteins (14 mt-specific in human) and a 12S 
mt-rRNA (Amunts A et al., 2015; Greber BJ et al., 2015). Due to the presence of the mt-specific 
proteins, the shape of the subunit differs from the bacterial counterpart and appears more 
elongated.  
The mt-mRNA entrance channel is one of the most divergent areas of the mt-SSU. RPS4 
and the C-terminus of RPS3 (uS3) define the entrance of this channel in the bacterial ribosome 
but are absent in the mt-SSU (Fig. 1.12A). The ring-shaped entrance is, instead, defined by a 
mt-specific extension of MRPS5 (Fig. 1.12B). Another mt-specific protein, MRPS39 (PTCD3) 
is found in close proximity to the entrance site for mRNA. Because this protein belongs to the 
pentatricopeptide repeat containing (PPR) protein family that are able to bind RNA (Filipovska 
A et al., 2013; Lightowlers RN et al., 2013), it is possible that this protein could be involved in 
recruiting the mt-mRNA to the mt-SSU. 
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Figure 1.12 mRNA entrance site for the human mitochondrial and bacterial ribosomes.  
Representation of the proteins defining the entrance site of the mRNA tunnel of human 
mitochondria ribosomes (B, PDB 3J9M (Amunts A et al., 2015)) and the bacterial 
counterpart (A, PDB 4YBB (Noeske J et al., 2015)). The small subunit is in green, whereas 
the large is in blue. The entrance of the tunnel is indicated by an asterisk. Homologues 
protein are depicted in the same colours. Magenta corresponds to S3 in the bacterial 
ribosome, which is the homologue of MRPS24 of the human counterpart. 
Figure modified from Mai N et al. (2016). 
Bacterial ribosomes present an anti Shine-Dalgarno sequence on the rRNA, close to the 
exit of the mRNA exit site. This  domain is absent in the 12S mt-rRNA and reflects the absence 
on mt-mRNAs of the corresponding 5’-untranslated region (Montoya J et al., 1981). The space 
generated by the lack of this rRNA domain is now occupied by the mitochondrial -specific 
protein mS37 that takes on the interaction with the 12S mt-rRNA. In contrast to these structural 
modifications, the central portion of the mRNA channel that is directly involved in the translation 
process, is mostly conserved (Greber BJ et al., 2014). 
- Mitoribosomal large subunit 
The mammalian mt-LSU is composed of 16S mt-rRNA and 52 proteins (53 in humans), of 
which 22 are mt-specific (Brown A et al., 2014; Greber BJ et al., 2014). An additional rRNA 
molecule (5S) is found in the central protuberance of bacteria l LSU (Ban N et al., 2000). No 
additional rRNA is encoded by the mitochondrial genome but, in 2014 a  cryo-EM structure of 
the mammalian mitoribosome revealed the presence of an unidentifiable RNA density similar 
to a domain of bacterial 5S rRNA (Greber BJ et al., 2014). The recent higher-resolution cryo-
EM studies on mt-LSU confirmed the presence of an additional RNA species, identifying a mt-
tRNAPhe for the porcine mitoribosome  (Greber BJ et al., 2014) and mt-tRNAVal for the human 
counterpart (Brown A et al., 2014).  
One of the most altered domain of the mitoribosome is the polypeptide exit site (PES) (Fig. 
1.13). In mammals, a second layer of mt-specific proeins (MRPL39, MRPL44 and MRPL45) 
are found on top of a conserved ring of proteins (MRPL22, MRPL23, MRPL24, MRPL29) that 
define the exit site itself. Because the mitoribosome is specialised in the synthesis of highly 
B 
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hydrophobic proteins, it is possible that the recruitment of these additional proteins might aid 
their synthesis and couple it with their insertion in the IMM. 
 
Figure 1.13 Polypeptide exit site of bacterial and human mitochondrial ribosomes. 
The polypeptide exit site of bacterial (A, PDB 4YBB (Noeske J et al., 2015)) and human 
mitochondrial (B, PDB 3J9M (Amunts A et al., 2015)) ribosomes were visualised in Pymol. 
The SSU are depicted in green, while the LSU in green. The exit site is indicated by an 
asterisk and homologous proteins are reported in the same colour.  
Figure modified from Mai N et al. (2016). 
1.9.2. Interaction of the mitoribosome with the inner mitochondrial 
membrane 
Mitochondrial ribosomes are specialised in the synthesis of highly hydrophobic polypeptides, 
which are all components of the OXPHOS system. In order to avoid their aggregation and 
precipitation in the matrix, their translation is likely to be coupled with their insertion within the 
IMM. This will be aided by the anchoring of the mitoribosome to the membrane so that the 
polypeptide exit site can be aligned with the insertion machinery.   
Studies in yeast identified the IMM-interacting protein Mba1 (Ott M et al., 2006; Pfeffer S et 
al., 2015), the IMM protein Mdm38 (Lupo D et al., 2011) and Oxa1 (Jia L et al., 2003) as able to 
interact with the mitoribosome. Recently, this important interaction was confirmed in yeast by 
cryo-EM tomography (Pfeffer S et al., 2015). This study was able to show mitoribosomes 
anchored to the IMM and to identify Mba1 and rRNA as interacting points.  
These important interactions are still mainly unexplored in mammalian mitoribosomes. 
Studies on the bovine system reported that approximately 50% of mitoribosomes interact with 
the IMM (Liu M et al., 2000). The authors suggested that the interaction might be mediated by 
both electrostatic interactions of the mitoribosome with the membrane, and direct interaction 
between the mitoribosome and IMM proteins. Amongst the IMM proteins, OXA1L (homologue 
of yeast Oxa1) has been cross-linked to components of the mt-LSU, suggesting its involvement 
in the interaction (Haque ME et al., 2010). LetM1, another IMM protein, is the homologue of 
yeast ribosome-interacting protein Mdm38 and has also been reported to interact with the 
mitoribosome (Piao L et al., 2009). Finally, MPV17L2 is a protein that has been recently reported 
A B 
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to interact with both the IMM and the mt-LSU, suggesting that it might be involved in anchoring 
the subunit to the IMM (Dalla Rosa I et al., 2014). 
Amongst the mitoribosomal proteins, MRPL45 is a mt-specific protein found in close 
proximity to the polypeptide exit site, an ideal position for membrane-interaction, a hypothesis 
also suggested by Greber et al. shortly after this study began (Greber BJ et al., 2014). The 
potential involvement of MRPL45 in the interaction with the IMM is also supported by its 
homology with the membrane-interacting yeast protein Mba1 (Ott M et al., 2006; Pfeffer S et al., 
2015) and by its structural homology with another IMM-interacting protein, Tim44 (Handa N et 
al., 2007). 
As the role of the proteins involved in the interaction between mitoribosome and IMM is the 
theme of my thesis, these aspects will be more extensively discussed in the introductions of the 
results chapters. 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
1.10. Aims 
Several aspects of mitochondrial translation still need to be explored. In this study, I decided 
to focus my attention on the interaction between the mitoribosome and the IMM. As stated in the 
introduction, this interaction is important for coupling the synthesis of 13 highly hydrophobic 
components of the OXPHOS system with their insertion into the membrane. Defects in this 
process can lead to problems in the assembly of the OXPHOS complexes, which can lead to a 
reduction of available ATP as source of energy to the cell.  
As discussed earlier, MRPL45 might be one of the mediators of this important interaction, 
because of its similarity with other membrane-interacting proteins and its ideal location. The main 
focus of my project was assessing the involvement of MRPL45 in the interaction with the IMM 
and its role in the stability of the mitoribosome. During the project, interest for OXA1L, another 
candidate player in this important interaction, arose. While the yeast homologue of this protein 
has been widely characterised in yeast, more work is needed on the human homologue to 
understand its role in mitochondrial translation and in the interaction with the mitoribosome. 
Therefore, I decided to also investigate this protein in this study. A patient cell lines with mutations 
in the gene encoding for OXA1L was identified during the course of my project and was therefore 
also characterised in this study. In the Appendix 17, a brief discussion and characterisation of 
another IMM protein, named LetM1, suggested to play a role in the interaction with the 
mitoribosome will be discussed. 
 
In detail, the aims of my project were: 
- Understand the importance of MRPL45 for the stability of the mitoribosome by using siRNA 
technology to deplete levels in human cell lines  
- Develop a protocol to investigate the interaction of proteins with the membrane  
- Study the interaction of the mitoribosome with the IMM and the ability of MRPL45 to directly 
interact with the IMM with the developed protocol 
- Assess the involvement of candidate domains for membrane interaction of MRPL45 by 
generation of site directed mutants 
- Identify the putative binding partners of MRPL45 in the IMM via immunoprecipitation 
experiments 
- Investigate the involvement of the IMM protein OXA1L in the interaction with the 
mitoribosome  
- Characterise the role of OXA1L in mitochondrial translation via siRNA depletion studies 
- Characterise the biochemical and molecular phenotype of patients carrying mutation in 
OXA1L. 
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Chapter 2: Material and methods 
2.1. Tissue culture 
2.1.1. Cell maintenance and propagation 
Different human cell lines were used in this study: 
- HEK293 Flp-In™ T-Rex™ (Invitrogen). This cell line derived from human embryonic 
kidney cells (HEK293). The cells are engineered with the Flp-In™ System, which has 
both the integration into a specific cassette and tetracycline-inducible expression of a 
gene of interest. 
- HeLa. Human cervical cancer carcinoma cells from Henrietta Lacks. 
- U2OS. Human osteosarcoma cell line. 
- U2OS Flp-In™ T-Rex™. Human osteosarcoma cell line engineered with the Flp-In™ 
System. 
- 143B. Human osteosarcoma cells. 
- 143B ρ0. Human osteosarcoma cells lacking of mitochondrial DNA. Maintained in 1mM 
sodium pyruvate, 50 µg/mL of uridine and 200 ng/mL of ethidium bromide. 
- Primary fibroblast. Isolated from patient or control. 
Patient: LetM1 (M2129-21, courtesy of Dr. Carrozzo Rosalba, Ospedale Bambino 
Gesù, Rome) 
Control: M0456-11, M0528-12 
- Immortalised fibroblast. Derived from primary fibroblast. 
Patient: OXA1L (M0686-13) 
Control: M1171-13, M0528-12 
- Tetracycline inducible cell lines. 
HEK293-MRPS27FLAG (Prepared by M. Wydro) 
HEK293-LuciferaseFLAG (Prepared by M. Wydro) 
HEK293-MRPL45  
HEK293-MRPL45FLAG 
HEK293-MRPL45FLsil 
HEK293-MRPL45FLala 
HEK293-MRPL45FLΔ 
U2OS-OXA1L 
HEK293 Flp-In, HeLa, U2OS, U2OS Flp-In and 143B cells were grown in Dulbecco's 
Modified Eagle's medium (DMEM) containing 4500 mg/L glucose and 1 mM pyruvate  
Prepared during the project 
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(Sigma, cat no D6429) supplemented with 10% foetal calf serum (FCS, Gibco, cat no 
10270), 1x of non-essential amino acids (Sigma, cat no M7145) and 50 µg/mL of uridine 
(Sigma, cat no U3003). 143B ρ0 cells were cultured in the same medium supplemented 
with 200 ng/mL of filter-sterilised ethidium bromide (Sigma, cat no E1510). Transfected 
HEK293 Flp-In™ and U2OS Flp-In™ were maintained in media with addition of 10 µg/mL 
BlasticidinS (Melford, cat no B1105) every third feed. 
Cells were grown at 37°C with 5% CO2 in a humidified atmosphere. At 70-80% 
confluence, the media was removed and the cells were harvested with PBS (Sigma, cat no 
P4417) containing 1 mM EDTA (Sigma, cat no E5134). Primary and immortalised fibroblast 
were detached after incubation for 2 minutes at 37°C with 1x Trypsin (Sigma, cat no 
59427C) in PBS. The cells were centrifuged for 4 minutes at 280g, resuspended in fresh 
media and seeded at a density of 1 in 3 for fibroblast and 1 in 5 for HEK293, HeLa and 
U2OS cells.  
All the flasks used were manufactured by Greiner bio-one, whereas the plates were 
manufactured by Corning. 
2.1.2. Cell storage 
Cell lines were stored for later use. For every sample, a confluent 75 cm2 flask was 
harvested and the cell pellet was resuspended in FCS supplemented with 10% dimethyl 
sulfoxide (DMSO, Sigma, cat no D5879) in cryostorage vials. After 24 hours at -80°C in a 
cryo-box, the vial was transferred to the liquid nitrogen dewar for long term storage. 
2.1.3. Cell counting 
When needed, cells were counted with a haemocytometer (depth 0.1 mm, surface 1/400 
mm2). To exclude dead cells from the count, an aliquot of cells (10 µL) was diluted 1:1 with 
trypan blue (Sigma, cat no T8154), which dead cells are unable to pump out, turning them 
dark. The number of live cells per mL was obtained multiplying the number of counted cells 
for 2·104. 
2.1.4. Ethidium bromide treatment 
Depletion of mt-DNA was obtained by growing cells in supplemented media (qv 2.1.1) 
in presence of 250 ng/mL of ethidium bromide for 10 days. 
2.1.5. siRNA transfection 
Cells were transfected with siRNA in 6 well plates (Corning) for 3 days (reverse 
transfection) or 6 days (reverse transfection for 3 days, followed by forward transfection for 
other 3 days). 
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- Reverse transfection 
After pre-warming medium and Opti-MEM I + GlutaMAX-I (Gibco, cat no 51985), a 
mixture composed of 250 µL of Optimem, 2.5 µL of 20 µM siRNA and 2 µL of 
Lipofectamine™ RNAiMAX (Invitrogen, cat no 13778030) was prepared for each well from 
a 6-well plate that needs to be treated. The final siRNA concentration was 33 nM, unless 
differently stated. The mixture was incubated for 25 minutes at room temperature, then 
added to the wells and incubated for further 10 minutes. In the meantime, cells were 
harvested, counted and diluted so that 1.25 mL contained the desired amount of cells per 
well. In particular, 200,000 cells were seeded for every single well of a 6-well plate for a 3 
days transfection, whereas the number was lowered for a 6 days transfection to 100,000 
cells. The plate was then placed at 37°C with 5% CO2 for 3 days. After that, the media was 
removed and the cells were collected for further analysis or transfected again.  
- Forward transfection 
This procedure was used on adherent cells to extend the transfection for further 3 days. 
In an Eppendorf, 2 µL of Lipofectamine™ RNAiMAX were mixed with 15 µL of Optimem 
(for each well of a 6-well plate), and in another Eppendorf, 2.5 µL of 20 µM siRNA were 
mixed with 125 µL of Optimem I (for each well of a 6-well plate). Both the solutions were 
left to incubate for 10 minutes and then were mixed and left to incubate for another 25 
minutes. During this time, the old medium present in the wells was removed and 1.353 mL 
of new warm medium was added to each well. The cells were not detached. After the 
incubation, the solution of siRNA and lipofectamine was added to the well  (144.5 µL each). 
The final siRNA concentration was 33 nM. Everything was mixed by rocking the plate and 
then the cells were grown for other 3 days at 37°C with humidified 5% CO2. At the end the 
cells were harvested to perform further analysis. 
2.1.6. Stable transfection 
Genes of interest were inserted into engineered cells via the Flp-In™ system. Cells were 
plated in a 6-wells plate at approximately 30% confluence. On the following day, when the 
confluence of the cells will be approximately 60%, every well was incubated with 500 µL of 
DMEM lacking supplements (FCS, non-essential amino acids and uridine), but containing 0.8 
µg of pcDNA™5/FRT/TO (carrying the gene of interest) and 1.2 µg of pOG44 premixed with 10 
µL of Superfect (Qiagen, cat no 301305), as per manufacturer’s instructions. As a control for the 
following antibiotic selection, one well was left untreated and incubated with media. After 1 hour 
of incubation at 37°C with 5% CO2, the mixture of plasmids and Superfect was replaced with 
supplemented growth media and the cells were then grown for one day. After that 100 µg/mL 
HygromycinB (Sigma, cat no. H9773) and 10 µg/mL BlasticidinS were added to supplemented 
growth media to every well, in order to select the successfully transfected clones. Once no cells 
36 
 
were left in the control well, individual clones were picked and expanded in a new well. Protein 
overexpression was induced by adding to the media 1 µg/mL tetracycline (Sigma, cat no T7660) 
and then verified via western blot analysis.   
When Viafect (Promega, cat no E4983) was used instead of Superfect to carry out the 
transfection, the cells were left in the mixture containing the two plasmids and the transfecting 
reagent for 24 hours. After that, the media containing the selective antibiotics was added to carry 
out the selection. 
The clones were cultured in supplemented media with addition of 10 µg/mL BlasticidinS every 
third feed. 
2.2. Bacteria culture 
2.2.1. Propagation and storage 
Chemically competent cells (α-select Bioline, cat no BIO-85025) were used in cloning 
experiments. The cells had the following genotype:  
F- deoR endA1 recA1 relA1 gyrA96 hsdR17(rk-,mk+) supE44 thi-1 phoA Δ(lacZYA-
argF)U169 Φ80lacZΔM15 λ-). 
Cells were grown at 37°C in liquid LB media containing the appropriate antibiotic and 
prepared as follows. The pH of the solution was brought 7.5 and then autoclaved before use. 
For plates 3% agar (BD, cat no 214010) was added to the liquid LB media (LB-agar) prior 
autoclaving.  
Table 2.1 LB media components. 
Reagents Final concentration 
Bacto-tryptone (BD, cat no 211705) 
Yeast extract (BD, cat no 212750) 
NaCl (Sigma, cat no S7653) 
NaOH (Sigma, cat no S5881) 
1% w/v 
0.5% w/v 
1% w/v 
Until pH 7.5 
Transformed strains were stored in glycerol stocks. When needed, a small amount of 
frozen glycerol stock was scraped, plated on LB-agar and let grow overnight at 37°C. 
Glycerol stocks were prepared resuspending the cells in LB media supplemented with 
18% glycerol and then stored at -80°C for future use. 
2.2.2. Transformation 
Heat shock was used to transform chemically competent cells (Bioline, cat no BIO-85025) 
with the desired plasmid. Aliquots of competent cells (40 µL) were thawed on ice and then 
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incubated on ice with 4 µL of ligation mixture (qv 2.3.9.) or 10 ng of plasmid DNA for 30 minutes. 
The suspension was then placed at 42°C for 45 seconds and placed on ice for the following 2 
minutes. After the heat-shock, 900 µL of SOC media (Table 2.2A) were added and the cells 
were incubated at 37°C for 1 hour with shaking. At the end of the incubation, the suspension 
was centrifuged at 15,700 g for 1 minute. The pellet of cells was resuspended in 100 µL of fresh 
SOC media, plated on LB agar with the appropriate antibiotic (Table 2.2B) and incubated 
inverted overnight at 37°C. 
Table 2.2 Composition of SOC media used during transformation (A) and 
concentration of antibiotics used during the selection (B). 
Reagents Final concentration 
Bacto tryptone 
Yeast extract 
NaCl 
KCl (VWR, cat no 26764.260) 
MgCl2 (Sigma, cat no M8266) 
Glucose (BDH, cat no 10117) 
NaOH 
2% w/v 
0.5% w/v 
0.05% w/v 
2.5 mM 
10 mM 
20 mM 
Until pH 7.0 
  
Antibiotic Final concentration 
Ampicillin 
Kanamycin 
100 µg/mL 
50 µg/mL 
2.2.3. Isolation of plasmid DNA   
The cells containing the plasmid were plated on LB agar (Table 2.1) with the appropriate 
antibiotic and grown at 37ºC overnight. The following day, single colonies were picked and 
expanded overnight at 37ºC in 5 mL of LB media (Table 2.1) supplemented with  the 
appropriate antibiotic. Cells were pelleted and the plasmid was extracted following the 
protocol of the GeneJET™ Plasmid Miniprep kit (Thermo Scientific).  
2.3. DNA manipulations 
2.3.1. DNA isolation from human cells 
Cells were harvested and resuspended in 400 µL of 10 mM Tris (Sigma, cat no T1503) pH 
7.4 supplemented with 1 mM EDTA. SDS (Sigma, cat no L3771) and proteinase K (Roche, cat 
no 25530) were added at a final concentration of 1% and 20 mg/mL respectively. The sample 
was then incubated overnight at 37ºC. DNA was extracted via phenol extraction and then 
precipitated with ethanol (qv 2.3.5.). 
A 
 
A
) 
B 
 
B
) 
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2.3.2. DNA electrophoresis 
Gel electrophoresis was used throughout the cloning procedure to analyse the quality of 
samples or the success of reactions. Usually, gels were prepared at 1.2% of agarose (Bioline, 
cat no BIO41025), in 1xTAE buffer (Table 2.3A). The solution was warmed until the agarose 
was completely melted and, after the addition of 0.05 µL/mL of ethidium bromide, the gel was 
poured and left to solidify. 
Table 2.3 Composition of 1xTAE buffer (A) and 6x DNA Loading dye (B). 
Reagents Final concentration 
Tris base 
Glacial acetic acid (VWR, cat no 20104.367) 
EDTA 
40 mM 
0.114% v/v 
0.1 mM 
 
Reagents Final concentration 
Glycerol (Sigma, cat no G5516) 
Bromophenol blue (Sigma, cat no B5525) 
Xylene cyanol (Sigma, cat no X4126) 
50% 
0.125% 
0.125% 
The DNA samples to analyse were mixed with loading dye (Table 2.3B, 1x final 
concentration) and then loaded on the agarose gel, together with 3 µL of 1 kb marker ( Invitrogen, 
cat no 15615). The gel was then electrophoresed at 55-60 V (for a 30 mL gel) or 70-80 V (for a 
50 mL gel) for approximately 1 hour, or until the samples were separated as required. After that, 
the bands were visualized using the Chemi Doc™ MP Imaging System (Bio-Rad®). 
2.3.3. DNA amplification via polymerase chain reaction 
Defined DNA regions were amplified using PCR. The technique was mainly used to prepare 
inserts for cloning of genes of interest within plasmids. A complete list of the primers used is 
reported in Appendix 5. The cDNA obtained for reverse transcription from RNA extracted from 
HEK293 WT cells (qv 2.4.2.) was used as a template for the PCRs. The reactions were carried 
out in the PTC200 PCR Thermal Cycler (MJ Research), using 500 µL thin-wall tubes with the 
proof-reading KOD Hotstart DNA Polymerase (Merk Millipore, cat no 71086) in the mixture 
reported in Table 2.4. 
 
 
 
 
 
A 
 
A
) 
B 
 
B
) 
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Table 2.4 PCR reaction mixture. 
Reagents 
Final 
concentration 
Volume for 1 tube 
dH2O 
10x KOD Hotstart Buffer 
25 mM MgSO4 
2 mM dNTPs 
50 µM Sense Primer 
50 µM Anti-sense Primer 
1 U/µL KOD Hotstart DNA polymerase 
cDNA 
/ 
1x 
1 mM 
0.2 mM 
1 µM 
1 µM 
1U 
/ 
 
32 µL 
5 µL 
5 µL 
5 µL 
1 µL 
1 µL 
1 µL 
2 µL 
50 µL total 
The conditions used for the PCR reactions are reported in the following table. The annealing 
temperature used for every reaction took into consideration the melting temperature of the 
primers (reported in Appendix 5). Extension times were dependent upon the length of the 
product. The sequence of denaturation-annealing-extension cycle was repeated 30 times. 
Table 2.5 PCR reaction conditions used for KED Hotstart DNA polymerase 
on PTC200 PCR Thermal Cycler. 
Reaction Temperature Time 
Initial denaturation 
Denaturation 
Annealing 
Extension 
Final extension 
95ºC 
95ºC 
variable * 
70ºC 
72ºC 
3 min 
1 min 
1 min 
1 min 
5 min 
The PCR reaction was resolved on a 1.2% agarose gel (qv 2.3.2.) to confirm the success of 
the reaction. The desired product was isolated by excision of the band and the DNA was 
extracted with the QIAquick® Gel Extraction Kit (Qiagen, cat no 28704) as per manufacturer’s 
instructions. 
2.3.4. Real-time PCR 
The RNA content of cell samples was estimated with real-time PCR. RNA was reverse 
transcribed to cDNA (qv 2.4.2.) and every real-time PCR was prepared as shown in the following 
table. Triplicates for every pair of primers used were prepared. To exclude DNA contaminations, 
a reaction without DNA was also performed. 
 
X 30 
 
X 30 
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Table 2.6 Real time reaction mixture. 
Components 
Volume per 
reaction 
2x FastStart SYBR Green Master (Roche, cat no 04673484001) 
Nuclease-free water 
10 µM Forward primer 
10 µM Reverse primer  
DNA from reverse transcription or from 5 µg/µL stock 
10 µL 
6 µL 
1 µL 
1 µL 
2 µL 
The list of primers used is reported in the Appendix 5. All the primers used were validated 
personally or in the laboratory. The reactions were sun on the LightCycler® Nano (Roche), using 
the following program (set up by Christie Waddington): 
Table 2.7 Conditions of real time reaction. 
Temperature Time Ramp 
95ºC 
95ºC 
60ºC 
72ºC 
65ºC 
95ºC 
10 min 
10 sec 
10 sec 
15 sec 
50 sec 
15 sec 
5 
5 
4 
5 
4 
0.1 
The program will elaborate the data and calculate the Ct (Cycle threshold) value of every 
sample. This number is equivalent to the cycles needed for the fluorescent signal to cross the 
background fluorescence level and correlates to the amount of targeted DNA in the sample. The 
ΔΔCt method was used to analyse the results obtained for RNA species. This method allows 
the upregulation or the downregulation of a species of interest to be evaluated. As a 
consequence, when testing any condition (e.g. overexpression, siRNA knockdown, etc), a 
control condition (e.g. uninduced cells, transfection with NT-siRNA) is needed. For every 
condition, the amount of the ribosomal RNA 18S (‘reference’) was quantified and used to 
normalise the level of the RNA of interest (‘target’). The average of every triplicate was 
calculated and then used in the following calculations: 
ΔCt (Condition) = ΔCt (ConditionTarget) – ΔCt (ConditionReference) 
ΔCt (Control) = ΔCt (ControlTarget) - ΔCt (ControlReference) 
ΔΔCt = ΔCt (Condition) - ΔCt (Control) 
Difference in fold for the target between the condition tested and the control= 2 -ΔΔCt 
The calculations were repeated for every target RNA measured. The values obtained in the 
last calculation were used in a bar graph to represent the data acquired. 
X 45 
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2.3.5. Phenol extraction and ethanol precipitation of DNA 
PCR products, plasmids and whole cell DNA were purified following this protocol. Each 
sample was diluted up to 50 µL with nuclease-free water and an equal volume (50 µL) of buffer 
equilibrated phenol (Sigma, cat no P4557) was added. The sample was vortexed and then 
centrifuged at 15,700 g for 2 minutes at room temperature. The upper aqueous layer was 
retained and mixed with 25 µL of phenol and 25 µL of chloroform (Sigma, cat no C2432). After 
vortexing and centrifugation as in the previous step, the upper aqueous layer was saved. 
Following the addition of 50 µL of chloroform, the sample was vortexed and centrifuged one 
more time. Finally, the resulting upper aqueous layer was diluted with 2 volumes of cold ethanol 
(Fisher Chemicals, cat no BP2818) and 0.1 volumes 3M CH3COONa (BDH, cat no 102355P) at 
pH 5. The sample was frozen at -80°C for 2 hours, and the DNA precipitated was centrifuged 
for 10 minutes at 15,700g. The pellet was air dried and resuspended in 20  µL of nuclease free 
water. 
2.3.6. DNA purification 
In order to buffer-exchange the DNA sample after the gel or phenol-chloroform extraction, 
this was dialysed against a solidified solution composed of 1% agarose and 100 mM glucose  in 
water for 90 minutes on ice. 
2.3.7. DNA digestion 
The plasmid (≈ 3 µg) and the insert (≈ 1 µg) were digested with the appropriate restriction 
enzyme and reaction buffer (Table 2.8). The reaction was incubated at 37ºC for 90 minutes. 
When the plasmid was digested, 1 µL of the solution was analysed on a 1.2% agarose gel to 
verify the success of the digestion. 
Table 2.8 Restriction enzymes relative buffers used to digest DNA samples.  
Restriction enzyme 10x Buffer 
AflII (NEB, cat no R0520) 
BamHI (Roche, cat no BAMHI-RO) 
BssHII (NEB, cat no R0199) 
HindIII (Roche, HINDIII-RO) 
KpnI (Roche, cat no KPNI-RO) 
NotI (NEB, cat no R0189) 
NEB4 
Roche M 
NEB3 
Roche M 
Roche L 
NEB3 
2.3.8. DNA dephosphorylation 
In order to avoid the self-religation of the plasmid, its 5’-ends were dephosphorylated. A 
volume of digested plasmid (20 µL) was mixed with 1 µL of 10% SDS, 3.5 µL of 1 M Tris pH 9 
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and 1 µL of alkaline phosphatase (Sigma, cat no APMB-RO). The reaction was incubated at 
37°C for 30 minutes and then at 50°C for further 30 minutes. 
2.3.9. Ligation 
The insert was ligated into digested and dephosphorylated vector using the Rapid DNA 
Ligation Kit (Thermo Scientific, cat no K1422). The following equation was used to calculate the 
amount of insert to use in the ligation reaction: 
(ng of vector × kb size of insert)
(kb size of vector)
× 3 = ng of insert 
The ligation mixture was prepared as in Table 2.9 and incubated at room temperature for 30 
minutes. At the end of the reaction, the mixture was transformed into competent cells (qv 2.2.2.) 
or frozen for future use. 
Table 2.9 Ligation mixture (Rapid DNA Ligation Kit, Thermo scientific). 
Ligation mixture 
50 ng vector 
x ng insert 
4 µL 5X ligation buffer 
1 µL DNA ligase 
dH2O up to 20 µL 
2.3.10. Colony screening and DNA sequencing 
It is possible that during the ligation step the plasmid will recircularise on itself, without 
integrating the insert. After transformation of competent cells (qv 2.2.2.) it was, therefore, 
fundamental to identify colonies successfully transformed with the plasmid containing the insert.  
For a quick screening of colonies, the cracking-gel technique was used. Individual colonies 
obtained from the transformation were expanded of fresh LB-agar plates overnight at 37°C. Half 
of each colony was then transferred to an Eppendorf and cells were disrupted in 20 µL of 
cracking buffer (Table 2.10). 
Table 2.10 Cracking buffer composition. 
Reagents Final concentration 
NaOH 
SDS 
EDTA 
50 mM 
0.5% 
5 mM 
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The samples were incubated at 55°C for 30 minutes and then vortexed for 1 minute. The 
samples were then mixed with loading dye and analysed via DNA electrophoresis (qv 2.3.2.). 
The gel was then visualised at the ChemiDoc to assess the migration of the plasmid contained 
in each colony. 
As an alternative, the presence of the insert was verified via PCR. Individual colonies were 
spread on LB agar plates and grown overnight at 37°C. After that, half of each colony was 
harvested, dissociated with 40 µL of 10% Triton X-100 (Sigma, cat no T8787) and frozen at           
-20°C for 30 minutes. The cells were then thawed and centrifuged at 15,700 g for 1 minute. The 
resulting supernatant was used as template for a PCR reaction to assess the presence of the 
insert. The plasmid pcDNA5/FRT/TO was used for all the cloning reactions presented in this 
work. To detect the presence of the insert, the multiple cloning site was amplified using primers 
for CMV and BGH sequences, which flank at either side of this site. The reaction was performed 
with DreamTaq™ Polymerase (Thermo Scientific, cat no EP0701) with the following conditions:  
Table 2.11 Components (A) and conditions (B) for the amplification of the multiple cloning 
site of pcDNA5/FRT/TO, to identify the presence of the insert. 
Reagents 
Final 
concentration 
Volume for each 
reaction 
Nuclease-free water 
10x DreamTaq™ Buffer 
10 mM dNTPs 
50 µM CMV primer 
50 µM BGH primer 
5 U/µL DreamTaq Polymerase 
DNA 
/ 
1x 
0.2 mM 
1 µL 
1 µL 
1U 
/ 
19.575 µL 
2.5 µL 
0.5 µL 
0.5 µL 
0.5 µL 
0.125 µL 
1.3 µL 
25 µL tot. 
 
  
  
Reaction Degrees Time 
Initial denaturation 
Denaturation 
Annealing 
Extension 
Final extension 
95ºC 
95ºC 
52ºC 
72ºC 
72ºC 
3 min 
1 min 
1 min 
1 min 
8 min 
The presence of the insert was verified by loading 5 µL of each reaction on a 1.2% agarose 
gel. In presence of the insert, a higher molecular weight band will be detected.  
If a single restriction enzyme was used to prepare a fragment to insert within the plasmid, 
the orientation of the insert post ligation needed to be checked. For this purpose, a diagnostic 
digestion was performed. This technique consists of the digestion of the construct with a 
X 34 
 
X 34 
A 
B 
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restriction enzyme that cuts both the insert and the plasmid once only. Through the analysis of 
the size of the fragments obtained by this digestion, it was possible to verify the orientation of 
the fragment. As a control, the plasmid was also linearized by digestion with a restriction enzyme 
that performs a single cut in the construct. The products of the digestion were analysed on a 
1.2% agarose gel. Details for the diagnostic digestion performed in this study can be found in 
the results sections. 
Once the orientation of the insert was confirmed, the multiple cloning site of the plasmid was 
sequenced to exclude the presence of undesired mutations and to further confirm the identity of 
the insert. For this purpose, the BigDye Terminator v3.1 Cycle Sequencing Kit (Life 
Technologies, cat no 4337455) was used. Two reactions, each containing 450 ng of plasmid, 
were set up. One reaction contained the CMV forward primer, whereas the other contained the 
BGH reverse primer. The reactions and the condition used are reported in the following tables:  
Table 2.12 DNA sequencing reaction (A) and conditions (B) with BigDye Terminator v3.1 
Cycle Sequencing Kit. 
Sequencing reaction mixture    Reaction Degrees Time 
450 ng plasmid 
3 µL 5X sequencing buffer  
3 µL Big Dyes v3.1 
dH2O to 15 µL 
 Initial denaturation 
Denaturation 
Annealing 
Extension 
95ºC 
95ºC 
50ºC 
60ºC 
5 min 
30 sec 
10 sec 
4 min 
At the end of the reaction, the sample was stored at -20°C or sequenced with 3130xl Genetic 
Analyzer (Applied Biosystems). 
The sequence resulting from the analysis was then aligned with the target sequence using 
the online alignment tool BLAST® (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and translated using 
ExPASy (http://web.expasy.org/translate/). 
2.3.11. Preparation of the insert using PCR-script 
When problems in obtaining positive colonies were present, the PCR-script Amp Cloning Kit 
(Stratagene, cat no 211188) was used to prepare the insert.  
The PCR product (insert) was ligated in the pPCRscript Amp SK(+) plasmid incubating the 
mixture in Table 2.13 at room temperature for 1 hour.  
 
 
 
 
 
 
X 30 
 
X 
30 
B A 
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Table 2.13 Reaction mixture for insert ligation in pPCR-script cloning vector.  
Reagents 
Final 
concentration 
Volume for 1 tube  
10 ng/µL pPCR-script cloning vector  
10x PCR-script reaction Buffer 
10 mM rATP 
Insert 
5 U/µL Sfr I restriction enzyme 
4 U/µL T4 DNA ligase 
dH20 
10 ng 
1x 
1 mM 
/ 
5 U 
4 U 
/ 
1 µL 
1 µL 
0.5 µL 
2-4 µL 
1 µL 
1 µL 
Up to 10 µL 
The solution was heated for 10 minutes at 65°C and the mixture was then used to transform 
competent cells (qv 2.2.2.). The colonies obtained were spread on new LB plates containing 
100 μg/mL of ampicillin and screened on a cracking gel (qv 2.3.10.). The positive colonies were 
grown O/N at 37°C in 5 mL of LB media (containing 100 μg/mL of ampicillin) . The corresponding 
plasmids were extracted with GeneJET™ Plasmid Miniprep kit and then digested with the 
appropriate restriction enzyme. The product of the digestion was loaded on an agarose gel and 
the bands corresponding to the insert were then excised for DNA extraction. The product 
obtained was purified (qv 2.3.6.) and then ligated into the vector of interest (qv 2.3.9.). 
2.4. RNA manipulations 
To reduce the risk of degradation, all the solution used in RNA manipulation were prepared 
with water treated with 0.1% DEPC (Sigma, cat no D5758) and then autoclaved. 
2.4.1. RNA extraction 
Cells were harvested and washed in 1.5 mL of cold PBS. The pellet obtained after 5 minutes 
of centrifugation at 400 g at 4ºC was resuspended with 200 µL of TRIzol® reagent ( Thermo 
Scientific, cat no 15596) and incubated at room temperature for 5 minutes. Chloroform (40 µL) 
was added to the sample that was then vortexed for 15 seconds and incubated at room 
temperature for 3 minutes. After that, the sample was centrifuged at 12,000 g for 15 minutes at 
4ºC. The clear top layer contained the RNA and was carefully moved to a clean Eppendorf, 
avoiding contamination of TRIzol® and of the white DNA layer. Isopropanol (100 µL) was added 
to the solution and, after 10 minutes of incubation at room temperature, the sample was 
centrifuged at 12,000 g for 10 minutes at 4ºC. The centrifugation pelleted the RNA that was then 
rinsed in 1 mL of cold 75% ethanol. The ethanol was discarded and the pellet was let to air -dry 
for 10 minutes. The RNA was resuspended in DEPC water. The samples were stored at -80ºC. 
When the RNA to be extracted was from a liquid sample, TRIzol® LS reagent (Thermo 
Scientific, cat no 10296) was used, following the same protocol stated above.  
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When the amount of RNA to extract was very small, this was co-precipitated with 1 µL of 
Glycoblue® (Invitrogen, cat no AM9516) or 10% glycogen (Ambion, cat no AM9510). This was 
added to the clear top layer obtained from the first centrifugation step, prior addition of 
isopropanol. 
2.4.2. Reverse transcription 
The cDNA was obtained by reverse transcription from RNA. The reaction was carried out 
with Superscript®III Reverse Transcriptase kit (Life Technologies). Annealing reaction and 
master mix were prepared as follows: 
Table 2.14 Annealing reaction and Master mix reaction for reverse transcription. 
Annealing reaction Master mix 
5 µg RNA 
50 pmol random hexamers  
(Gibco BRL, cat no 51709) 
DEPC H2O up to 12 µL 
2 µL 10x RT buffer 
2 µL 25 mM MgCl2 
2 µL 0.1 mM DTT (Sigma, cat no D0632) 
1 µL 10 mM dNTP mix (Bioline, cat no BIO-39044) 
The annealing reaction was heated at 70ºC for 10 minutes, and then mixed with the master 
mix. After addition of 1 µL of enzyme, the solution obtained was incubated at 42ºC for 50 
minutes. Finally, the temperature was raised to 70ºC for 15 minutes, to denature the enzyme. 
The samples obtained were used to prepare inserts for cloning or analysed via qPCR. 
2.5. Protein manipulations 
2.5.1. Preparation of cell lysate 
Lysis buffer (15 µL, Table 2.15) was added to each sample for every 5-10 mg of wet weight 
cells to resuspend the sample. The suspension was then vortexed for 30 seconds  and 
centrifuged at 4ºC for 4 minutes at 800g. The supernatant was transferred in a clean Eppendorf 
and after determination of protein concentration, was used for western blot analysis. 
Table 2.15 Cell lysis buffer composition 
Reagents 
Final 
concentration 
Tris pH 7.5  
NaCl  
MgCl2  
PMSF (AppliChem, cat no A0999) 
NP-40 (Sigma, cat no N6507) 
EDTA-free protease inhibitor (Pierce, cat no 88666) 
50 mM 
130 mM 
2 mM 
1 mM 
1% (v/v) 
1 tablet for 10 mL 
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In rare cases, the lysate was viscous, because of the presence of genomic DNA. To solve 
this issue, benzonase, a DNase/RNase (Millipore, cat no 70746) was added after protein 
quantification (qv 2.5.2.). The enzyme was diluted 1/10 and 1 µL was added to the sample and 
the reaction was incubated at 37°C for 20 minutes. 
2.5.2. Protein quantification 
The protein content of samples was assessed using the Bradford assay. A standard curve 
obtained with bovine serum albumin (BSA - Sigma, cat no A2153) was used as a reference and 
was prepared as shown in the following table:  
Table 2.16 Standard curve with BSA for Bradford assay. 
BSA (1 µg/µL) Water 
Bradford reagent 
(Biorad, cat no 500-0006) 
0 µL 
2 µL 
5 µL 
10 µL 
15 µL 
20 µL 
800 µL 
798 µL 
795 µL 
790 µL 
785 µL 
780 µL 
200 µL 
200 µL 
200 µL 
200 µL 
200 µL 
200 µL 
A specific volume of sample (usually 1 or 2 µL) was diluted with water up to 800 µL and then 
mixed with 200 µL of Bradford reagent. Every point of the standard curve and every sample 
were prepared in duplicate. Aliquots of 200 µL of each sample were loaded on a 96 -well plate 
that was analysed at 595 nm using SpectraMax M5 (Molecular devices) to determine the 
absorbance of the samples, from which the concentration was inferred.  
2.5.3. TCA protein precipitation 
When more concentrated samples were needed, proteins were precipitated by addition of an 
equal volume of 20% trichloroacetic acid (TCA) (Sigma, cat no T9159). After 30 minutes of 
incubation on ice, the samples were centrifuged for 15 minutes at 15,700 g and the pellets 
obtained were washed 3 times with 200 µL of cold acetone. The final pellets were resuspended 
in the appropriate buffer and the solubilisation of the sample was aided with the addition of 1% 
SDS, and heating up the solution at 50°C for 30 minutes. 
2.5.4. SDS-PAGE 
Proteins were separated according to their molecular weight on denaturing 12% acrylamide 
resolving gel. Resolving and stacking gels were prepared prior to the analyses as reported in 
Table 2.17 B and C. The resolving gel was poured in between the 2 glass plates. Once this was 
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polymerised, the stacking gel was poured on top and the comb was inserted to create the wells 
for loading the samples. Samples were prepared adding Laemmli sample buffer (Table 2.17A) 
and were denaturated at 95°C for 3 minutes. 
Table 2.17 Composition of 5x Laemmli sample buffer (A), Resolving gel (B) and Stacking 
gel (C) for SDS-page analysis. 
Reagent Final concentration 
Tris pH  
6.8  
Glycerol (Sigma, cat no G3516) 
SDS  
Bromophenol blue (Sigma, cat no B5525) 
DTT  
312.5 mM 
50% 
10% 
0.05% 
 
Added fresh, 100 mM final in the sample  
 
Reagent 
Final 
concentration 
Tris pH 8.5  
30% acrylamide-bisacrylamide 29:1 (NBS Bio Logical, cat no NBS2600-05) 
SDS  
APS (Sigma, cat no A3678) 
Temed (Sigma, cat no T22500) 
380 mM 
12% 
0.1% 
0.1% 
0.1% 
 
Reagent Final concentration 
Tris pH 6.8  
30% acrylamide-bisacrylamide 29:1 
SDS  
APS  
Temed  
125 mM 
3.75% 
0.1% 
0.1% 
0.1% 
The system for the SDS-PAGE was built and 1x running buffer (Table 2.18) was added to 
the tank until the correct level was reached. The samples were carefully loaded on the gel and, 
together with them, 4 µL of Spectra™ Multicolour Broad Range Ladder  (Thermo Scientific, cat 
no 26634) or 1.5 µL of BLUE Wide Range recombinant protein marker  (Clever Scientific, cat no 
CSL-BBL) were also loaded and used as size markers. 
The gel was run initially at 100V, until the samples reached the resolving gel. After that, the 
voltage was incremented to 150V for approximately 1 hour in 1x running in the Mini-PROTEAN® 
Tetra Cell (Biorad). 
 
A 
B 
C 
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Table 2.18 Running buffer (1x) composition. 
Reagent Final concentration 
Tris base  
Glycine (Sigma, cat no G7126) 
SDS 
25 mM 
192 mM 
0.1% 
2.5.5. Western blotting 
After the SDS-PAGE analysis, the proteins were transferred from the acrylamide gel to the 
Immobilon®-P PVDF membrane (Millipore, cat no IPVH00010) using the Mini-PROTEAN® 
Tetra Cell system (Biorad). The membrane was activated in methanol, rinsed in water and 1x 
transfer buffer (Table 2.19A). The transfer unit, containing membrane and gel, was assembled, 
immersed in 1x transfer buffer and exposed to 100V for 1 hour. At the end of the process, the 
membrane was incubated with 20 mL of 5% non-fat dried milk in T-TBS (Table 2.19B) for 1 hour 
(blocking) and then incubated overnight at 4°C with the primary antibody (in 5% milk T -TBS). 
The list of the primary antibodies used is reported in the Appendix 2. 
Table 2.19 Composition of 1x transfer buffer (A) and T-TBS (B). 
Reagent Final concentration 
Tris base 
Glycine 
SDS 
Methanol (Fisher Chemicals, cat no A412) 
25 mM 
192 mM 
0.02% 
15% 
 
Reagent Final concentration 
Tris base 
NaCl 
Tween® 20 (Sigma, cat no P2287) 
 
20 mM 
150 mM 
0.1% 
pH 7.4 
Following ~16 hours incubation, the membrane was washed 3 times in T -TBS for 5 minutes 
and then incubated with the appropriate secondary antibody (Appendix 2) for 1 hour at room 
temperature. 
The membrane was washed 3 times in T-TBS for 5 minutes and then detected with Chemi 
Doc™ MP system after 5 minutes of incubation with ECL prime (GE healthcare biosciences, cat 
no RPN2232) or ECL+ (Thermo Scientific, cat no 32106). If necessary, after an extended wash, 
the membrane was probed again with a different primary antibody, following the same protocol 
just described. The data were collected were analysed with the software Imagelab (Biorad). 
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The molecular weight of the signal detected by every antibody was compared to the protein 
ladder to confirm the identity its correspondence to the molecular weight of the targeted protein. 
The protein ladder will be omitted in the figures presented in this thesis.  
When needed, the quantification of the bands was performed. For every protein detected, a 
box was drawn around the band using the rectangle tool from the ‘Volume tools’ menu. Another 
box of the same size was drawn in an empty part of the blot to subtract the background. The 
values (‘volume’) calculated by the program for every box was found in the ‘Analysis table’  
option. The final value of the band was obtained by difference of the protein signal with the 
background. Once these values were calculated for a housekeeping gene (β -Actin, Porin, 
SDH70, TOM20, etc.), the values obtained for other proteins were normalised according to the 
quality of the loading. The results were shown as percentages of the control condition using bar 
graphs. 
2.5.6. Silver staining 
Protein samples can be visualised with a high sensitivity by silver staining. After the samples 
were resolved via SDS-PAGE (qv 2.5.4.), the polyacrylamide gel was washed for 1 hour in 50% 
methanol. Meanwhile, the staining solution was prepared by adding drops of 0.2 g/mL silver 
nitrate solution (Sigma, cat no S6506) to a conical flask containing water, 0.075% NaOH and 
1.4% NH4OH, until the solution lost its transparency. The gel was incubated with the staining 
solution for 15 minutes at room temperature and then washed with water 3 times for 5 minutes. 
The developer solution (Table 2.20A) was added to the gel until the desired intensity was 
achieved. The solution was then discarded and replaced with the stop solution (Table 2.20B). 
The gel was finally rinsed in water and imaged at the ChemiDoc system. 
Table 2.20 Composition of developer solution (A) and stop solution (B) for silver 
staining. 
Reagents Final concentration 
Citric acid (Sigma, cat no C2404) 
Formaldehyde 
0.005% 
0.05% 
 
Reagents Final concentration 
Methanol 
Acetic acid 
45% 
10% 
2.6. Isolation of mitochondria 
Cells were harvested and resuspended in 1.4 mL of homogenisation buffer (Table 2. 21) 
supplemented with 0.1% of BSA and 1 mM PMSF. All the steps were performed on ice, using 
pre-chilled tubes and centrifuging the samples at 4°C. 
A 
 
A
) 
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Table 2.21 Homogenisation buffer composition. 
Reagents Final concentration 
Tris pH 7.4  
Mannitol (Sigma, cat no M4125) 
EGTA (Sigma, cat no E4378) 
10 mM 
0.6 M 
1 mM 
In order to obtain a mitochondria-enriched fraction, the cells were homogenised and then 
centrifuged at 400 g for 10 minutes. This step was performed 3 times on the same pellet, saving 
the supernatant obtained for every homogenisation. The supernatants were then centrifuged at 
400 g for 5 minutes, in order to remove contamination from the previous pellet. The centrifugation 
of the resulting supernatant at 11,000 g for 10 minutes led to a pellet that represented a fraction  
enriched in mitochondria, and a supernatant contained the cytosolic proteins (which was often 
saved for Western blot analysis).  
The mitochondria-enriched fraction was washed twice with homogenization buffer containing 
1 mM PMSF (but without BSA), and then resuspended in the 100 µL of the same buffer. 
2.7. Mitochondrial sub-fractionation 
Mitochondria were extracted (qv 2.6.) and the protein content was quantified (qv 2.5.2.). A 
sample of 600 µg of proteins was diluted up to 300 µL with homogenization buffer (Ta ble 2.21). 
A volume of this solution (12.5 µL) was used to prepare a sample for western blot analysis, while 
the rest was diluted by adding 2.5 mL of 10 mM Tris/1 mM EDTA. The solution obtained was 
centrifuged at 11,000 g for 10 minutes at 4ºC and then the pellet was resuspended in the same 
volume of the previous Tris buffer. The sample was halved and 1.44 µg of proteinase K was 
added to one half of the suspension. Both halves of the sample were left on ice for 30 minutes.  
After the incubation, 1 mM of PMSF was added and the samples were centrifuged at 11,000 
g for 10 minutes at 4ºC. The pellets were washed twice with 1 mL of 10 mM Tris/1 mM EDTA and 
then resuspended with 137.4 µL of homogenization buffer. A volume of 12.5 µL for each sample 
was saved for a western blot analysis. The sample obtained in absence of proteinase K 
represented mitoplasts, while the one incubated with this enzyme represented the shaved 
mitoplasts. 
The sample digested with proteinase K was washed with 1.262 mL of homogenization buffer. 
The pellet obtained after centrifugation at 12,000 g for 10 minutes at 4ºC was resuspended with 
2.6 mL of 100 mM Na2CO3 (Sigma, cat no S7795) and incubated for 30 minutes on ice. 
Subsequently, the sample was centrifuged in the Optima™ TLX Ultracentrifuge (Beckman) (rotor 
TLA120.2) for 15 minutes at 53,000 rpm (122,000 g) and 4ºC. The supernatant was discarded, 
whereas the pellet was resuspended in 80 µL of homogenization buffer. Finally, 12.5 µL of the 
sample were saved for a western blot analysis. 
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2.8. Isokinetic sucrose gradient 
This technique was used to separate cellular components in different layers according to their 
density and dimension. The experiment was carried out in an ultracentrifuge tube ( Beckman 
Coulter, cat no 343778) containing a gradient with an increasing concentration of sucrose from 
the top to the bottom of the tube. The gradient was prepared mixing the sucrose gradient buffer 
(Table 2.22) with sucrose to obtain a 10% and a 30% sucrose solutions. A syringe was used to 
add first 0.5 mL of 10% sucrose solution at the bottom of the ultracentrifuge tube and then to add 
0.5 mL of 30% sucrose solution at the bottom of the first layer. The gradient was created with the 
107 Gradient Master Ip (BioComp) using the built-in setting ‘TLS55, short sucrose 10%-30%, 55 
seconds’ and then placed in the cold room for 45-60 minutes. 
Table 2.22 Sucrose gradient buffer. 
Reagents Final concentration 
Tris pH 7.2  
MgAcetate (Sigma, cat no M5661) 
NH4Cl (Sigma, cat no A9434) 
KCl  
PMSF 
Chloramphenicol (Duchefa Bioch, cat no C0113.0025) 
50 mM 
10 mM 
40 mM 
100 mM 
1 mM 
50 µg/mL 
Cell lysate (100 µL at 7-8 µg/µL) was carefully added at the top of the gradient and the tube 
was centrifuged in the Optima™ TLX Ultracentrifuge (rotor TLS 55) at 39,000 rpm (100,000 g) for 
2 hours and 15 minutes at 4°C. At the end of the process, 100 µL fractions were collected from 
the top of the gradient and stored at -20°C for further analysis. Generally, 10 µL from each fraction 
were used for Western blot analysis. 
2.9. Immunoprecipitation 
Cells were harvested, mitochondria were extracted (qv 2.6.) and lysed in 500 µL of the 
following buffer for 30 minutes at 4°C on a rotating wheel. 
Table 2.23 Immunoprecipitation lysis buffer composition. 
Reagents Final concentration 
Tris pH 7.4 
NaCl 
EDTA 
Triton X-100 
EDTA-free protease inhibitor 
PMSF 
MgCl2 
RiboSafe (Bioline, cat no BIO-65028) 
50 mM 
150 mM 
1 mM 
1% 
1x 
1 mM 
10 mM 
1.5 µL 
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In the case where a FLAG-tagged protein was immunoprecipitated, the FLAG® 
Immunoprecipitation kit (Sigma, cat no FLAGIPT1-1KT) was used. Packed beads (20 µL) were 
washed 3 times with 500 µL of wash buffer (Table 2.24), pelleting the beads by centrifugation at 
6,000 g for 30 seconds at 4°C, and being careful to not discard the beads. 
Table 2.24 Immunoprecipitation wash buffer. 
Reagents Final concentration 
Tris pH 7.4 
NaCl 
Protease inhibitor 
PMSF 
MgCl2 
RiboSafe  
50 mM 
130 mM 
1x 
1 mM 
10 mM 
2.5 µL 
When the lysis was complete, the suspension was centrifuged at 12,000 g for 10 minutes at  
4°C to eliminate unbroken mitochondria. The protein concentration was checked by Bradford 
assay (qv 2.5.2.). A sample of 15 µg of mitochondria lysate was saved for western blot analysis. 
Up to 3 mg of protein were added to the beads in a final volume of 500 µL. The sample was then 
incubated on the rotating wheel for 2 hours at 4°C. At the end of the incubation, the sample was 
centrifuged at 6,000 g for 30 seconds at 4°C. The supernatant represents the unbound proteins 
and was saved for further analysis.  
Finally, the beads were washed 3 times as previously performed. The bound proteins were 
eluted either with incubation with 110 µL of wash buffer with 250 µg/mL of 3x F LAG peptide 
(Sigma, cat no F4799) for 45 minutes at 4°C with shaking, or incubating the sample with 1x sample 
buffer (Table 2.17A) at 95°C for 3 minutes. 
In case the protein to precipitate did not have a FLAG-tag, the magnetic beads Dynabeads® 
Protein G (Thermo Scientific, cat no 10004D) were used. A volume of 20 µL (≈ 0.6 mg) of beads 
were washed 3 times with 200 µL of IP lysis buffer (Table 2.23). As these beads are magnetic, 
instead of centrifugation, a magnetic stand was used to separate them from supe rnatant. After 
being washed, the beads were coated with the antibody of interest (between 0.6 -6 mg of antibody 
for every mg of beads) and incubated at 4°C with shaking for 45 minutes. After that the beads 
were washed again 3 times with 200 µL of IP lysis buffer and then incubated 300 µL of mitolysate 
at 4°C with shaking up to 2 hours. At the end of the incubation, the beads were washed with IP 
lysis buffer and then the proteins were eluted at 95°C for 3 minutes in 25 µL of IP lysis buffer 
containing 1x sample buffer (Table 2.17A). 
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2.10. Bioinformatic analyses tools 
The bioinformatic tools that were used in this study are listed in the following Table: 
Table 2.25 Bioinformatic tools. 
Name Use  
BLAST 
http://blast.ncbi.nlm.nih.gov/Blast.cgi  
Nucleotide or protein alignments 
for 2 sequences 
JalView Sequence alignments within 
different organisms 
NEBcutter 
http://nc2.neb.com/NEBcutter2/  
Restriction enzyme digestion 
sites 
PyMol 
(Open source) 
Visualisation and analysis of 
protein structures from PDB files 
Phyre2 
http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index  
Secondary and tertiary structure 
predictions from protein 
sequences 
Reverse Complement  
http://www.bioinformatics.org/sms/rev_comp.html  
Transformation of DNA 
sequences into the reverse 
complement 
SeqScanner Analysis of data obtained from 
sequencing 
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Chapter 3: MRPL45 in human mitochondria 
3.1. Introduction 
Amongst the 80 proteins that compose the human mitoribosome, my attention focused on a 
protein named MRPL45. This protein is one of the mitochondria-specific mitoribosomal 
components that lacks a bacterial orthologue. It contains a TIM44-like domain, the importance of 
which is that TIM44, as a component of the translocase inner membrane (IMM) machinery found 
in the matrix, is reported to interact with membranes (Marom M et al., 2009) and so mediate the 
interaction between the core of the translocase machinery and matrix proteins (Voos W et al., 
1996). Due to this similarity of TIM44-like domain, one hypothesis is that MRPL45 is involved in 
the interaction between the mitoribosome and IMM. As discussed in the introduction, this 
interaction is essential for an efficient protein synthesis because all the products of mitochondrial 
translation are highly hydrophobic polypeptides that need to be immediately integrated in the IMM.  
A few months after the beginning of this project, the first high resolution structure of the large 
mitoribosomal subunit was released (Greber BJ et al., 2014). This structural data on the porcine 
subunit, confirmed that MRPL45 is a component of the mitoribosome and that it is localised in 
close proximity to the polypeptide exit site. This location is consistent with an interaction with the 
IMM and supports the hypothesis of MRPL45 playing a role in this interaction, as was postulated 
by the authors. 
Shortly after, the high resolution structure of the human mt-LSU was released (Brown A et al., 
2014) and confirmed the localisation of MRPL45 observed in the porcine counterpart. This 
structure gave further insight into the structure of the protein, which differs from the porcine 
orthologue. The structure of MRPL45 and its similarity to orthologous proteins will be discussed 
in the following chapter. 
Human MRPL45 is encoded by chromosome 17 and is composed of 306 amino acids, giving 
a predicted molecular weight of 36 kDa. Data presented in chapter 6 of this thesis suggested that 
MRPL45 is targeted to mitochondria by a presequence which is cleaved on import into the 
organelle. 
The aim of this chapter was to study the characteristics of MRPL45. SInce at the beginning of 
this project the structure of the human mitoribosome had yet to be published, it was important to 
confirm the localisation of MRPL45 within the mitoribosome. Subsequently, the importance of this 
protein was tested by depleting it from different cell lines using siRNA technology. After initial 
optimisation, the effects of reduced steady-state levels of MRPL45 were assessed. The 
parameters measured included cell growth and morphology, mitochondrial protein synthesis, 
stability of the mitoribosome and stability of the mitochondrial mRNA species. The tools (antibody 
and siRNA) that were to be used throughout these studies were a lso validated in this chapter. 
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3.2. Methods 
3.2.1. Cell cycle analysis using Flow-cytometry 
Cell cycle analysis was performed following propidium iodide staining of nuclear DNA in 
whole cells. This fluorescent dye binds stoichiometrically to the DNA present in the cell.  
Between 200,000 and 500,000 cells were harvested for every sample . In order to retain the 
dye, cells were fixed with 1 mL of ice-cold 70% ethanol that was added dropwise to the cell 
pellet and left to incubate at 4ºC for 30 minutes. After that, the pellet was washed twice in 
phosphate-citrate buffer (Table 3.1 below) and, to ensure that only DNA was stained, it was 
incubated for 20 minutes at 37ºC with 50 µL of 100 µg/mL RNase A. 
Table 3.1 Phosphate-citrate buffer composition.  
Reagents Final concentration 
Na2HPO4 
Citric Acid 
192 mM 
4 mM 
Propidium iodide (200 µL of 50 µg/mL; Sigma, cat no P4170) was added to each sample that 
was then analysed with the FACSCanto II Flow Cytometer (BD Biosciences) with the help of Dr. 
Andrew Filby. FacsDiva8.0 and FlowJo were used to analyse the data collected. The DNA 
histograms obtained were analysed according to the Watson (Pragmatic) model.  
3.3. Results 
3.3.1. Localisation of MRPL45  
At the beginning of this project, the structure of the human mitoribosome was not available. 
Therefore, I aimed to confirm the localisation of MRPL45 within mitochondria and then whether 
it was integrated into the large mitoribosomal subunit. To determine this, mitochondria were 
isolated from HEK293 wild-type cells and subfractionated (qv 2.7.) in order to separate the 
different mitochondrial compartments. The success of the fractionation was assessed via 
western blot with antibodies recognising proteins of the outer membrane (TOM20), inner 
membrane (NDUFB8) and matrix (GDH) (Fig. 3.1).  
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Figure 3.1  Mitochondrial subfractionation to localise MRPL45. 
Western blot analysis of proportional amounts of fractions obtained from mitochondria 
extracted from HEK293 cells. Antibodies targeting TOM20 and NDUFB8 were used as 
markers for, respectively, OMM and IMM. Antibodies targeting GDH was used as a 
marker for the matrix fraction. The subfractionation experiment was performed once. 
MRPL45 was detected in the mitochondrial fraction, as well as in the mitoplast fraction. This 
confirmed that the protein is in mitochondria but not in the intermembrane space since this 
compartment is absent from mitoplasts. The subsequent removal of the OMM, which generated 
the shaved mitoplasts, did not affect the levels of MRPL45 detected in the fraction. However, 
the levels of MRPL45 were lower in the IMM fraction. Taken together these data inferred that 
this protein is mainly found in the mitochondrial matrix. Interestingly, the presence of MRPL45 
in the IMM fraction might suggest its interaction with the inner membrane either directly or as a 
part of a complex. The pattern of MRPL45 was similar to that of GDH, but it is important to 
specify that the weak signal observed for GDH in the IMM fraction is due to the low level of a 
membrane-bound form of GDH as previously reported (Rajas F et al., 1996). The detection of 
MRPL45 showed the presence of an intense signal, corresponding to the predicted size of the 
full length protein (≈36 kDa), and 2 less intense ones corresponding to approximately 30 kDa. 
I aimed to confirm the localisation of MRPL45 within the large mitoribosomal subunit  using 
cell lysate from HEK293 wild-type cells was separated on a linear 10-30% isokinetic sucrose 
gradient (qv 2.8.). During centrifugation, the components of the lysate were separated according 
to their density. Twelve fractions were obtained from the gradient and were analysed via western 
blot (Fig. 3.2).  
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Figure 3.2  Isokinetic sucrose gradient to assess the presence of MRPL45 in the LSU.  
Whole cell lysate (700 µg) from HEK293 cells was loaded on top of a 10-30% isokinetic 
sucrose gradient (qv 2.8.). The 12 fractions obtained after centrifugation were analysed 
via western blot. mt-LSU and mt-SSU were localised using antibodies against, 
respectively, MRPL11 and DAP3. The distribution observed for MRPL45 in the figure is 
representative of 3 biological repeats. 
To determine the relative position of the mitochondrial ribosomal subunits, mt -SSU and mt-
LSU, antibodies were used against DAP3 and MRPL11 respectively. These data indicated that 
the mt-SSU was recovered mainly in fraction 5, whereas the heavier mt-LSU was detected 
mainly in fractions 6 and 7. The lowest sucrose density (fraction 1, lysate with no sucrose) 
represented the protein or small complexes of low molecular weight, whereas fraction 12 
represented the highest sucrose density (30%) and contained heavy complexes or aggregates. 
MRPL45 was detected in fractions 6 and 7, migrating with other mt-LSU proteins and so was 
consistent with the protein being a component of the mt-LSU. The proportion of MRPL45 
recovered in the heaviest fraction of the gradient potentially indicated the presence of 
aggregates or incompletely solubilised extract. Since MRPL45 was also detected in fraction 1, 
it suggested that a proportion is found free or as a part of small complexes. Not all the 
mitoribosomal proteins show a proportion that is found in the least dense fraction of the sucrose 
gradient, as observed for MRPL11, which is absent in fraction 1 (Fig. 3.2).  
A closer inspection of the western blot analysis of the sucrose gradient experiment revealed 
the presence of 2 lower molecular species detected by MRPL45 antibody, also observed in Fig 
3.1. As previously observed, these signals were less intense than the higher molecular weight 
one. Surprisingly, the lower MRPL45 signals were detectable exclusively in fraction 1, even 
though the intensity of the higher molecular weight species was comparable or higher in 
fractions 6 and 7 compared to fraction 1.  
The presence of MRPL45 was also assessed in 143B ρ0 cells. These cells lack mt-DNA and 
are cultured in media containing ethidium bromide, in order to suppress a potential 
subpopulation containing mt-DNA. In the absence of mt-DNA, the mt-ribosomal RNA is not 
available and therefore the mitoribosomal subunits are unable to fully assemble. MRPL45 levels 
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were evaluated in lysate from wild-type parental 143B and 143B ρ0 cells, using the outer 
membrane protein porin as a loading control (Fig 3.3). 
 
  
Figure 3.3  Assessment of the presence of MRPL45 and of other mitoribosomal 
proteins and OXPHOS components in 143B ρ0 cells. 
Western blot analysis was performed on cell lysate (30 µg) from wild-type and ρ0 143B 
cells. Steady state levels of mitoribosomal proteins (MRPL45, MRPL11, MRPL24, 
MRPS27) were assessed. Antibodies against NDUFB8, COXII and ATP5β were also 
visualised. Porin was used to verify the quality of the loading.  The figure is 
representative of 2 biological replicates. 
MRPL45 was still detectable in 143B ρ0 cells, although the steady state level was strongly 
reduced. In contrast, MRPL11 was undetectable in cells lacking mt-DNA. The steady state level 
of MRPL24 was also reduced in 143B ρ0 cells, whereas the level of MRPS27 was unchanged. 
The absence of the mt-encoded COXII and the component of complex I NDUFB8 confirmed that 
143B ρ0 cells lack of mt-DNA. The steady state level of the component of the F1 of complex V 
ATP5β was not affected. The signal obtained from porin confirmed the equality of the loading.  
3.3.2. Optimisation of MRPL45 depletion  
To study the role of MRPL45 in mitochondrial gene expression, the protein was depleted 
from a number of human cell lines and the consequences on cellular and mitochondrial 
metabolism were analysed. Transient transfections of targeted siRNAs (MRPL45 siRNA) were 
used alongside siRNA that was designed not to correspond to any cellular target (NT siRNA).  
Initially, the effects of transfection were tested after 3 days (reverse transfection in solution, 
qv 2.1.5.) with 33 nM siRNA. Reverse transfection was performed in order to increase the 
surface of the cells in contact with the reagents and therefore the efficiency of the transfection. 
Because a stable knockdown was not required, siRNA was preferred as silencing tool as 
opposed to shRNA (short-hairpin RNA). This reagent also avoided the possibly lethal effect due 
to a constitutive knockdown of MRPL45. Delivery of the siRNA was performed using a lipid 
carrier, a technique with less detrimental effects on cells when compared to e lectroporation. 
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Since it is important to eliminate the possibility of off-target effects, individual siRNAs that target 
different regions of the same gene transcript were tested. The depletion was performed using 2 
different siRNA targeting MRPL45 (Appendix 4), to test whether the reagents gave consistent 
data, at least 3 independent repeats of each depletion experiment were performed. To eliminate 
effects due to the use of reagents, cells were also transfected in parallel with 33 nM of NT siRNA, 
as experimental control. 
HEK293 cells were transfected for 3 days by reverse transfection (qv 2.1.5.) with the 2 
MRPL45 siRNA and NT siRNA at the same final concentration of 33 nM. After 3 days, cells were 
harvested and the lysates were analysed via western blot to determine the efficiency of MRPL45 
loss and the effects on other MRPs (Fig. 3.4). 
          
Figure 3.4  Depletion of MRPL45 on HEK293 cells using 2 different siRNA.  
HEK293 cells were transfected with MRPL45, NT siRNA or cultured as an untreated 
control for 3 days. At the end of the incubation, cell lysate (30 µg) was analysed via 
western blotting. The figures shown is representative of the results obtained. Antibodies 
against MRPL45 and COXII were detected on membrane A, while membrane B was 
incubated with components of large (MRPL3) and small (DAP3) mitoribosomal subunits. 
Porin or TOM20 were used to verify the equality of the loading. The figure is 
representative of 2 biological replicates. 
MRPL45 depletion was efficient with both the tested siRNA (Fig. 3.4A, lanes 3 and 4). 
Together with the reduction of steady state level of MRPL45, a reduction in the steady state 
levels of a mitochondrial encoded subunit of complex IV (COXII) was also observed in both the 
siRNA treatments (Fig. 3.4A, lanes 3 and 4). Porin was used to validate loading. With respect 
to the mitoribosomal proteins, a reduction of MRPL3 levels was detected in MRPL45 cells 
depleted using either of the targeted siRNAs, whereas the levels of the mt-SSU protein DAP3 
were unchanged compared to controls (Fig. 3.4B, lanes 3, 4 cf lanes 1, 2). The equality of the 
loading was determined with antibodies targeting TOM20. 
Having established that MRPL45 depletion was successful in HEK293 cells using the 
conditions tested, the depletion studies continued using MRPL45 siRNA02 
(SASI_Hs02_00359740, Appendix 4) at a final concentration of 33 nM. Parallel control 
depletions were performed throughout the study with 33 nM NT-siRNA in order to exclude 
effects related to reagents present in the transfection rather than the targeted depletion. All the 
conditions tested were performed in duplicate for every experimental repeat, unless otherwise 
stated and experimental repeats were performed for all investigations. Although the depletion 
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was efficient after 3 days, the following studies presented in the chapter were performed over 6 
days in order to detect effects due to the depletion of MRPL45 that might not be present after 3 
days. Reverse transfection was performed, after 3 days, the cells were retransfected while 
adherent with the forward transfection method (qv 2.1.5.). 
3.3.3. Effects of MRPL45 depletion on cell growth and morphology 
The effects of 6 day MRPL45 depletion on cell growth and morphology were assessed on 
HEK293, HeLa and U2OS cells. 
The daily visual inspection of HEK293 cells showed the emergence of large clusters of cells 
in the sample depleted of MRPL45, whereas the control sample showed an even distribution of 
cells on the culture surface (Fig. 3.5).  
  
Figure3.5 Effects of MRPL45 depletion on HEK293 cells. 
HEK293 cells were visualised with bright field using the inverted Zeiss Axiovert 200M 
microscope at 10x magnification after 6 days of incubation with NT siRNA (left panel) or 
MRPL45 siRNA (right panel). Scale bar= 100 µm. The figure are representative of 3 
biological replicates. 
Due to the presence of clusters, it was not feasible to estimate cell number using a method 
that depended on calculating the occupied surface area (IncuCyte). Therefore, the growth curve 
for HEK293 cells was obtained by cell counting, which was performed every 48 hours on 
individual wells set up in parallel at the outset of the experiment (Fig. 3.6). Counting was done 
in the presence of Trypan blue to exclude dead cells from the cell counts.  
NT siRNA MRPL45 siRNA 
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Figure 3.6  Effects of MRPL45 on HEK293 cell growth. 
Cell counts were performed in 2 independent experiments on HEK293 cells incubated 
with NT or MRPL45 siRNA, approximately every 48 hours throughout the depletion and 
the data obtained were plotted to monitor cell growth.  
At day 6, the number of living cells that remained after treatment with MRPL45 siRNA was 
approximately half the number of living cells recovered for the control sample.  
In contrast to HEK293 cells, depletion of MRPL45 in U2OS or in HeLa cells did not cause 
the formation of clusters of cells, therefore it was possible to monitor cell growth with the  
IncuCyte® ZOOM System (Fig. 3.7). This instrument can be ‘trained’ to recognise specific cell 
types and so allows the generation of a growth curve based on the occupied space as a 
representation of the confluency of adherent cells but does not count the number of cells present 
in the sample. The number of points that are monitored per well can be selected. For my 
experiments, images at 12 points/well were taken for every well of a 6-well plate every 3 hours 
and the confluency was then calculated by the integrated software. A minimum 2 wells for every 
treatment were prepared and the confluency at every time point was calculated as an average 
of 12 data points obtained in each individual well. The cells from each well were harvested at 
the end of the siRNA treatment so that the efficiency of the depletion could be confirmed by 
western blot analysis (Fig. 3.7; inserts). Depletion in HeLa cells was interrupted at day 5 due to 
acidification of the media and high confluency of the cells. 
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Figure 3.7  U2OS and Hela cell growth was monitored during MRPL45 depletion. 
Cell coverage was evaluated every 3 hours through the IncuCyte system for U2OS (A) 
and HeLa (B) cells during MRPL45 depletion, and NT siRNA control treatment. Data is 
presented as a growth curve of calculated confluency over time. The efficiency of the 
depletion was confirmed via Western blot analysis (inset panels) using antibodies 
against MRPL45. The levels of β-Actin and HSP60 were used as loading controls. The 
figures are representative of 2 biological repeats. 
The western blot analysis confirmed that the depletion of MRPL45 was efficient in both U2OS 
and HeLa cells. At this level of depletion, cell growth did not appear to be strongly impaired in 
U2OS cells, as 100% confluency is reached by the sample depleted of MRPL45 (white circles) 
with minor delay when compared to the control (black circles) (Fig. 3.7A). For HeLa cells, no 
growth defect was detected by IncuCyte monitoring (Fig. 3.7B).  
Cells were also visualised using the IncuCyte system. Images after approximately 6 days are 
shown for U2OS and HeLa cells in Fig. 3.8 A and B. 
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Figure 3.8  U2OS and HeLa cells after 6 days of siRNA treament to deplete MRPL45.  
U2OS (A) and HeLa (B) cells were transfected for 6 days with NT or MRPL45 siRNA 
and visualised 5 days later. Images were obtained from the IncuCyte system. Cells 
containing vacuoles are indicated by black arrows. The figures are representative of 3 
biological repeats. 
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A proportion of U2OS and HeLa cells depleted of MRPL45 looked enlarged, with less defined 
edges and containing vacuoles (Fig. 3.8, indicated by black arrows). These features were less 
common in the control cells. The enlargement of the cells might also  
Interestingly, a major effect on U2OS cell growth could be seen by cell counting when the 
depletion levels of MRPL45 were so low that western blot could not detect any protein. 
Representative results of these experiments are illustrated in Fig. 3.9. The growth curve  was 
obtained by manual cell counting performed approximately every 48 hours throughout the 6 
days of depletion rather than by IncuCyte (Fig. 3.9 A). Cell morphology was evaluated on a daily 
basis using the inverted microscope (Fig. 3.9 B) and the efficiency of the depletion was 
confirmed via Western blotting (Fig. 3.9 C).  
 
  
 
 
Figure 3.9  Effects of MRPL45 knockdown on U2OS cells upon higher efficiency of the 
depletion. 
U2OS were transfected with NT siRNA or MRPL45 siRNA for 6 days. The growth curve was 
obtained by cell counting during 6-days depletion of MRPL45 (A). Cells were visualised using the 
inverted microscope at the end of the treatment (B). Cell lysates (x µg) were analysed via Western 
blotting to confirm the depletion. HSP60 was used as loading control (C). The data are 
representative of 2 biological repeats. 
When the level of MRPL45 was undetectable via western blot (Fig. 3.9 C), a severe growth 
defect (Fig. 3.9 A and B) was observed, whereas a milder growth defect was observed when 
the depletion was less efficient, as shown in Fig. 3.7 A and 3.8 A. Although 2 different methods 
were used to evaluate cell growth (occupied surface in 3.7 A and number of cells in 3.8 A), a 
difference in cell growth can be appreciated in the figures of cells obtained in the two different 
experiments (Fig. 3.8 A and 3.9 B).  These data, combined with those previously observed on 
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U2OS cells depleted of MRPL45, suggest that the effect on cell growth might be finely regulated 
by the efficiency of the depletion.  
As cell growth seemed to be affected, cell cycle analysis was performed on U2OS cells after 
6 days of transfection with MRPL45 and NT siRNA. Cells can be attributed to different phases 
of the cell cycle according to their DNA content. The profile of “healthy” cell growth usually 
results in the majority of the cells in G1 phase, which will contain the normal amount of genomic 
DNA (diploid). A smaller proportion of the cell population will be actively replicating DNA 
(designated S phase) and the remainder will be in late stage of mitosis phase (G2) where the 
chromosomes have been duplicated and so cells contain twice as much DNA as cells in phase 
G1. Some cells stick together and so in the sample they were present as doublets. These could 
be easily identified and excluded from the final analysis. The results (Appendix 7) were analysed 
and the cells were partitioned into the different phases as shown in the following figure (Fig. 
3.10A). The Watson model was preferred to the Dean-Jet-Fox model to analyse the data. The 
former model makes no assumption on the shape of the S phase, which instead is modelled in 
the Dean-Jet-Fox model. A sample for each treatment was retained to confirm the efficiency of 
the knockdown via western blot analysis (Fig. 3.10B). 
 
 
Figure 3.10  Cell cycle analysis of U2OS cells following MRPL45 depletion.  
A) Propidium iodide DNA staining was performed on U2OS cells after incubation for 6 days 
with NT or MRPL45 siRNA. Approximately 100,000 events were collected and the data were 
analysed and the percentage of cells in phases G1 (green), S (yellow) and G2 (blue) was 
calculated (Watson model). B) Western blot analysis to confirm the efficiency of MRPL45 
depletion in the cells used for the cell cycle analysis. SHD70 was used as a loading control.  
The experiment was performed once. 
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The western blot analysis confirmed depletion of MRPL45. The cell cycle analysis indicated 
that when compared to control cells, cells treated with MRPL45 siRNA for 6 days showed an 
increase in proportion of cells in S (+11%) and G2 (+7%) phases, with a relative reduction of 
cells in G1 phase (-16.5%). This result might suggest that the cells are proliferating faster or that 
they are arrested in the middle of duplicating their DNA. In order to discriminate between the 2 
possibilities, it would be possible to analyse the S phase using bromodeoxyuridine (BrdU) 
uptake. This reagent is an analogue of thymidine that is incorporated into DNA during its 
replication. When a BrdU pulse-chase experiment is performed, it is possible to follow the group 
of cells that were actively replicating the DNA during the pulse of BrdU staining as they progress 
through the cell cycle of and understand if the cells were increasing their proliferation or if they 
were arresting in a particular phase. This experiment was not performed as it was considered 
not crucial for the project. 
3.3.4. Effects of MRPL45 depletion on mitochondrial protein synthesis 
and the OXPHOS components 
As MRPL45 was predicted to be a component of the mitochondrial translation machinery, 
the effects of its depletion on mitochondrial translation were assessed. 
The depletion was performed over a 6-days period, combining reverse transfection with 
forward transfection (qv 2.1.5.), to analyse the effects observed due to the prolonged absence 
of the protein. The experiment was performed on different cell lines to determine it this was a 
physiologically relevant effect and to indicate the reproducibility of the findings  in different 
systems. At the end of the transfection period, cells were lysed and the protein content was 
analysed via western blot. Cells transfected with NT-siRNA were used as control (Fig. 3.11). 
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Figure 3.11  Analysis of the steady state level of OXPHOS components following MRPL45 
depletion. 
HEK293 (A;30 µg), U2OS (B;30 µg) and HeLa (C;30 µg) cells depleted of MRPL45 for 6 days 
were analysed by Western blot. The efficiency of the depletion was verified with antibodies against 
the depleted protein. The effects of the depletion on the OXPHOS components were analysed 
using antibodies against the mitochondrial encoded COXII or nuclear encoded components 
(ATPVb, NDUFB8, NDUFA9, SDH70). TOM20, HSP60 and β-Actin were used as loading controls. 
The data shown are representative of 3 biological repeats. 
Data obtained for HEK293 cells showed that, together with the reduction of the steady state 
level of MRPL45, a reduction of the mitochondrial encoded subunit II of complex IV (COXII) was 
observed. Antibody against the OMM protein TOM20 was used to confirm the equality of the 
loading (Fig. 3.11A). The results obtained were recapitulated in U2OS and HeLa cells (Figure 
3.11 B and C). The steady state level of other OXPHOS components were also assessed in 
these 2 cell lines following MRPL45 depletion. Together with the reduction of the mitochondr ial-
encoded protein COXII, a reduction of a nuclear-encoded subunit of complex I (NDUFB8) was 
observed. This protein is also absent in ρ0 cells (Fig. 3.3), probably because the mt-encoded 
components of the complex are needed for its integration within a subcomplex of complex I to 
stabilise it. This indicates that NDUFB8 is a good surrogate marker to interrogate the state of 
mitochondrial translation. Unlike NDUFB8, no reduction was detected in the steady-state level 
of another nuclear encoded component of the same complex, (NDUFA9). No changes were 
detected in the steady-state level of 2 other nuclear encoded components of the OXPHOS 
system, SDH70 (Complex II) and ATPVb (Complex V). This result was also expected as both 
these proteins are present at normal level in ρ0 cells. HSP60 or β-Actin were used as loading 
controls. 
The OXPHOS deficiency highlighted from western blot analysis after MRPL45 down-
regulation was also supported by the acidification of the media observed in the depleted cells 
(Fig. 3.12). 
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Figure 3.12  MRPL45 down-regulation affects the growth media acidity. 
Images of 6-well plates were taken after 6 days of MRPL45 depletion on U2OS cells.  
When compared to the control, the media of cells depleted of MRPL45 was more yellow. 
Phenol red, is a pH indicator that is included as a component of the growth medium. It has a 
range from 6.2 (bright yellow) to 8.4 (pink/purple). This allows for quick visual assessment of the 
metabolic status of the cells in culture. The observed change in colour indicated the acidification 
of the media, probably due to the metabolic switch for ATP production from oxidative 
phosphorylation to glycolysis in MRPL45 depleted cells. In this condition, glucose is transformed 
in pyruvate to generate ATP. Due to the failure of the OXPHOS system, pyruvate cannot be 
further metabolised and is reduced to lactate by the enzyme lactate dehydrogenase, which uses 
the excess of NADH accumulated as a consequence of the malfunction of the OXPHOS. The 
release of lactic acid within the media lowers its pH, which leads to the change in colour of 
phenol red. 
3.3.5. Effects of MRPL45 depletion on the stability of LSU and SSU 
The steady state level of a mitochondrial encoded protein (COXII) was compromised in the 
absence of MRPL45 (Fig. 3.11). This was predicted to be caused by a lack of functional 
mitoribosome, so to investigate if this effect was due to a defect of mitochondrial protein 
synthesis, the stability of the mitoribosome was examined. Cells were, therefore, depleted of 
MRPL45 for 6 days and the steady state level of protein components of the mt-LSU and the mt-
SSU was assessed via western blot analysis (Fig. 3.13). 
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Figure 3.13  Evaluation of the steady state level of proteins of the mt-LSU and mt-SSU in 
MRPL45 depleted cells. 
Western blot analysis was performed after 6 days of MRPL45 depletion in HEK293 (A; 30 µg) 
and U2OS (B; 30 µg) cells. Antibodies against MRPS26 and DAP3 were used as markers for the 
mt-SSU, whereas antibodies against MRPL11 and MRPL3 were used to detect the mt -LSU. 
Quantification of 3 biological repeats is also presented. 
The analysis of the steady state level of components of the LSU following MRPL45 deplet ion 
in HEK293 (Fig. 3.13A, lane 2 and bar graph) and U2OS (Fig. 3.13B, lane 2 and bar graph) cells 
showed a reduction of MRPL11, MRPL3, whereas the SSU proteins tested (MRPS26 and 
DAP3) were not affected. TOM20, porin, HSP60 and β-Actin were used to verify the equality of 
the loading. 
To further confirm the effects on the stability of the 28S and 39S subunits, the steady state 
level of the mitochondrial rRNAs (16S and 12S) were evaluated by qPCR (qv 2.3.4.). Total RNA 
was isolated from U2OS cells after 6 days of MRPL45 depletion or siNT treatment and aliquots 
(500 ng) from each were then reverse transcribed (qv 2.4.1. and 2.4.2.). An equal proportion of 
each cDNA (2 µl) was used to programme the qPCR and the data were analysed as reported in 
2.3.4. The results are reported in Fig. 3.14 and are representative of 3 biological repeats.  
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Figure 3.14 Effects of MRPL45 depletion on mt-rRNA. 
The levels of 12S and 16S rRNA were quantified after 6 days of MRPL45 depletion via q-PCR 
reaction for 3 biological repeats. NT-siRNA was used as a control. The cytosolic 18S rRNA was also 
quantified and used to normalise the data, which were analysed as in 2.3.4.  
The qPCR analysis showed a reduction of 16S rRNA, while 12S rRNA was unaffected. This 
agreed with the western blot data which showed the instability of the mt-LSU, but not of the mt-
SSU after depletion of MRPL45. 
3.4. Discussion 
The results obtained in this chapter have confirmed that MRPL45 is a mitochondrial protein 
mainly if not exclusively found in the matrix and showing a weak association with the IMM. Two  
additional bands were detected for the protein in the figure obtained for the sucrose gradient 
analysis, indicating a possible existence of a cleaved version of this protein. Isokinetic sucrose 
gradient analysis confirmed that MRPL45 is a component of the mt-LSU, as reported in the 
structures of the porcine (Greber BJ et al., 2014) and human (Brown A et al., 2014) mt-LSU 
published after the start of this project. Interestingly, the sucrose gradient analysis also highlighted 
the presence of an important free pool of protein that is not associated with the mitoribosome. Of 
all the mitoribosomal proteins that have been analysed in our laboratory, relatively few are well 
represented in the low density fractions that reflect low molecular weights. Like MRPL45, another 
mitoribosomal protein that shows a biphasic distribution is MRPL12. Published data show the 
existence of a proportion of MRPL12 in the first fraction of the sucrose grad ient (Surovtseva YV 
et al., 2011). The same study also claims that the proportion of MRPL12 that is not bound to the 
mt-LSU is involved in regulation of mitochondrial transcription via interaction with POLRMT. Since 
MRPL45 shows a similar distribution to MRPL12, it is reasonable to speculate a second 
unidentified role of MRPL45 within mitochondria. In addition, the lower molecular weight signals 
detected by MRPL45 antibody were detected only in the first fraction. A recent study by Nouws J 
et al. (2016) identified that the interaction between MRPL12 and POLRMT is mediated by a 
cleaved version of this mitoribosomal protein, that is found in fraction 1 of the sucrose gradient 
analysis of the cited study. It is tempting to speculate the possibility of a second role of cleaved 
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versions of MRPL45 outside the mitoribosome. This hypothesis could be further explored, 
although this aspect is not in the scope or time frame of this project.  
Because of its proximity to the polypeptide exit site and its structural similarities to the IMM 
interacting protein TIM44, the importance of MRPL45 for an efficient translation in mitochondria 
was assessed via siRNA depletion experiments. 
The optimisation of the siRNA transfection was performed using multiple siRNA duplexes 
targeting different regions of the MRPL45 transcript. Since these had similar consequences on 
cell growth, morphology, and mitochondrial homeostasis it suggested specificity and not off -target 
effects. A commercially available antibody was used and validated the depletion. The siRNA was 
therefore selected for further use in my study. 
The use of siRNA allows specific depletion of proteins by selectively targeting the mRNA 
sequence that encodes for the protein of interest. As this approach is not a genetic knockdown, 
the efficiency can be variable and the depletion is usually not complete. In the experiments 
performed in this chapter, it emerged that the amount of MRPL45 remaining after the depletion, 
differently affected the cell growth. Despite there being differences observed in how severe ly cell 
growth was affected, the cell morphology was affected in all the experiments performed. Whereas 
HEK293 cells tended to grow in clusters following loss of MRPL45, U2OS and HeLa cells showed 
a morphology more reminiscent of senescent cells, which could not be clearly confirmed by 
subsequent experiments on U2OS cells. In addition, cell cycle analysis suggested a longer 
doubling time. Altogether, these data highlight the importance of MRPL45 for maintaining cellular 
homeostasis. 
Further evidence of the importance of MRPL45 within mitochondria came from the analysis of 
protein content in the depleted cells. The reduction of the tested mitoribosomal components of 
the mt-LSU observed in the absence of MRPL45 revealed the crucial role of this protein for the  
stability and assembly of the large subunit. This is a striking difference from the yeast homologue 
of MRPL45, Mba1, which is only transiently associated with the mitoribosome and, therefore, not 
required for the stability of the mt-LSU. As a consequence of the absence of the mt-LSU, the fully 
assembled mitoribosome is absent and cannot perform mitochondrial translation. This leads to a 
dramatic reduction of mitochondrial encoded protein as observed in the MRPL45 depletion 
studies here reported. In the absence of mitochondrial-encoded proteins, the OXPHOS 
complexes cannot assemble in functional units, leading to the impossibility to create a proton 
gradient and eventually produce ATP. In these conditions, cells must survive by relying on 
glycolysis for ATP synthesis. 
Unlike the mt-LSU, the mt-SSU did not show instability in the absence of MRPL45, as inferred 
by the unchanged steady state level of the tested components of the subunit, both protein and 
rRNA. This result suggests that the assembly and stability of the mt-SSU does not require the 
presence of the mt-LSU. 
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Since my data demonstrated the importance of MRPL45 for protein synthesis in mitochondria, 
its potential involvement as mediator of the interaction with the IMM, as hypothesised earlier, will 
be investigated in the following chapter.  
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Chapter 4: Analysis of the interaction of mitoribosome and MRPL45 
with the IMM 
4.1. Introduction 
As described earlier in the general introduction, the 13 products of intramitochondrial 
translation are all hydrophobic OXPHOS proteins that are inserted in the IMM upon synthesis by 
the mitoribosome. Due to high hydrophobicity of their products, it is likely that the translating 
mitoribosomes are found in close proximity to the IMM to avoid the aggregation of the newly 
synthesised polypeptides, their unfolding and refolding, and to promote their direct integration into 
the membrane. Previous studies on mammalian mitochondria have reported that approximately 
50% of the mitoribosomes are tightly bound to the IMM (Liu M & Spremulli LL, 2000), but how this 
interaction is mediated is still unclear. As discussed in the general introduction, at present only 
few mammalian proteins (MPV17L2, OXA1L and LetM1) have been suggested to interact with 
both the IMM and the mitoribosome, but extensive studies to confirm and characterise their role 
in this interaction are missing. While the previous chapter was focused on understanding the 
importance of MRPL45 as a structural component of the mitoribosome, this chapter will study the 
possible role of the protein in the interaction between mitoribosome and IMM. The location of this 
protein in close proximity to the polypeptide exit site (as shown in Fig. 1.13, page 29) and its 
structural similarity with an IMM-interacting protein support the hypothesis of a role of MRPL45 in 
the interaction with the IMM.  
The PFAM (Protein FAMily) database search of MRPL45 suggested that this protein contains 
a Tim44-like domain located between residues 119 and 263 (RefSeq NP_115727.5). The Tim44-
like domain corresponds to a region at the C-terminus of TIM44, a peripheral membrane protein 
that binds to the IMM and to the TIM23 complex, allowing the translocation of polypeptides 
through the IMM into the mitochondrial matrix (D’Silva P et al., 2004). The N-terminus of yeast 
Tim44p was suggested to be involved in the interaction with Tim23p (Schiller D et al., 2008), 
whereas in vitro studies on the C-terminus of both the yeast and the mammalian homologues 
highlighted the ability of this domain to interact with membrane-like structures. The crystal 
structures of the C-terminus of both yeast Tim44p (PDB 2FXT (Josyula R et al., 2006)) and human 
TIM44 (PDB 2CW9 (Handa N et al., 2007)) were previously resolved by Josyula R and Sha B 
(2006) and Handa N et al. (2007) respectively. The publication of the human mt-LSU structure in 
2015 (Brown A et al., 2014) included structural details of MRPL45 (PDB 3J7Y (Brown A et al., 
2014), chain d), allowing it to be compared to the structure of human TIM44, shown in Fig. 4.1. 
Although the cryo-EM studies on the human mt-LSU gave nanometer resolution, it did not fully 
resolve MRPL45 (resolved residues: 119-200, 207-252, 255-287). The structure of MRPL45 
within the mt-LSU obtained from this study is shown in Appendix 15. 
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Figure 4.1 Structural comparison of human TIM44 and human MRPL45. 
A) The structures of the C-terminus of human TIM44 (cyan, PDB 2CW9 (Handa N et al., 
2007)) and the human MRPL45 (red, PDB 3J7Y, chain d (Brown A et al., 2014)) were 
visualised on Pymol as cartoons. The structure of MRPL45 obtained from the PDB file was 
not complete and is reported in Appendix 15.  B) Superimposition of the structures of 
TIM44 and MRPL45 visualised in Fig. 4.1A. 
Figure 4.1 shows the structural similarity between the MRPL45 protein and the C-terminus of 
human TIM44. Both the proteins present a similar organisation composed of cystatin-like folding, 
which is defined as helix packed against coiled antiparallel beta-sheet. The 2 proteins share a 
sequence identity of approximately 11%, with a similarity that reaches approximately 21% 
(http://www.ebi.ac.uk/Tools/psa/emboss_needle/).  
The ability of the C-terminus of human and yeast Tim44 to interact with membranes has been 
studied in vitro. With respect to Tim44p, the C-terminus of this protein was shown to interact with 
liposomes containing cardiolipin (Marom M et al., 2009), which is the most highly represented 
acidic phospholipid of the IMM (Comte J et al., 1976). Two hydrophobic regions were detected on 
the C-terminus of Tim44p, of which 1 is found between 2 α-helices and 1 creates a cavity that is 
composed of residues Val306, Gly388, Tyr 398 and Phe422. The specific region of the C-terminus 
of Tim44p involved in the interaction with the membrane was found by studying the interaction of 
truncated versions of the protein with liposomes (Marom M et al., 2009). The interaction with the 
membrane-like structures was lost when helix A1 was absent, despite the presence of the 
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hydrophobic cavity. In the study, the authors claim that the folding of the 2 α-helices A0 and A1 
(Fig. 4.2) is involved in the interaction with the model membrane, and that their relative position 
is important for this interaction. 
 
Figure 4.2  Putative membrane-interacting domain of yeast Tim44p 
PyMol was used to visualise the structure of yeast Tim44p, shown as cartoon (PDB 2FXT 
(Josyula R & Sha B, 2006)). The putative membrane-interacting helices are shown in light 
blue (A0) and blue (A1). The remaining part of the protein is shown in green.  
The crystallisation of the C-terminus of human TIM44 was performed by Handa N et al. (2007) 
using PEG 400 as a precipitant. The resulting structure closely resembles the yeast homologue, 
with the exception of the C-terminal domain, which presents 1 long helix in human, in contrast 
with 2 shorter helices found in yeast (Fig. 4.3, indicated by arrows). These domains also differ in 
the orientation of the helices, with the yeast ones protruding more from the central structure. It 
has been proposed that upon binding with the membrane, these helices undergo a conformational 
change, resembling the long helix (α1) found on the human TIM44 (Josyula R & Sha B, 2006). 
 
Figure 4.3 Structural comparison of human TIM44 and yeast Tim44p. 
Superimposition of human (cyan, PDB 2CW9 (Handa N et al., 2007)) and yeast (green, 
PDB 2FTX (Josyula R & Sha B, 2006)) Tim44 obtained by automatic structure alignment 
on PyMol. 
A0 
A1 
Tim44p 
TIM44 
TIM44p 
A0 
A1
 
α2 
α1 
78 
 
In the crystal structure of human TIM44, 2 molecules of PEG were recovered, indicating 
hydrophobic regions that might act as binding sites with the membrane. One of the PEG 
molecules recovered was bound to the highly conserved loop present between helices α1 and α2 
(Fig. 4.4A, shown in orange, indicating one of the potential membrane binding sites that is very 
well conserved amongst species (Fig. 4.4B). The PEG molecules also identified another 
hydrophobic cavity found in the core of the protein, between helices α3, α4, α5 and two β-sheets. 
 
  
 
 
 
Figure 4.4  Putative membrane interacting domain of the C-terminus of human TIM44 
and its conservation amongst different species. 
A) Crystal structure of the C-terminus of human TIM44 obtained in PyMol using the 
published PDB 2CW9  (Handa N et al., 2007). The residues claimed to interact with 
membrane-like structures (Marom, Safonov et al. 2009) are depicted in orange. B) 
Alignment of Tim44 sequences from different species. The intensity of the blue indicates 
the degree of conservation of the amino acid sequence. The putative membrane-
interacting site is indicated in orange. 
Because of its structural similarity to the membrane interacting protein T IM44, MRPL45 might 
be able to interact with the IMM via the domain corresponding to the one suggested for TIM44 
interaction. 
In addition to the presence of a Tim44-like domain, studies on the yeast MRPL45 homologue 
(named Mba1) further support the hypothesis of a role of MRPL45 in the  interaction with the 
membrane. Unlike the mammalian homologue, Mba1 is not a constitutive component of the 
mitoribosome, but has been suggested to interact tightly with the matrix face of the IMM (Preuss 
M et al., 2001) and to bind the mitoribosome (Ott M et al., 2006). Studies in yeast showed that 
Mba1 could be cross-linked with proteins at the polypeptide exit tunnel of the mitoribosome 
(Gruschke S et al., 2010). Recent studies reported that Mba1 creates a complex with Cox20 to 
support cotranslational maturation of Cox2 (Lorenzi I et al., 2016). Additional evidence of the 
Mba1-mediated bridge between the mitoribosome and IMM came in 2015 by cryo-electron 
tomography studies on yeast that identified 2 contact points between the mitoribosome and the 
membrane (Pfeffer S et al., 2015). Of these, one was mediated by rRNA and the other one by 
Mba1. The superposition of the sub-tomogram of yeast mitoribosome and the structure of 
mammalian mitoribosome presented in the study showed the colocalisation of Mba1 and MRPL45 
(Fig 4.5). 
TIM44 
(C-terminus) B 
A 
α2 
α1 
79 
 
 
Figure 4.5  Colocalisation of Mba1 and MRPL45 shown by superimposition of the 
structures of yeast and mammalian mt-LSU. 
The cartoon structure of mammalian mt-LSU (PDB 4CE4 (Greber BJ et al., 2014), in 
purple) was superimposed on the sub-tomogram of yeast 54S mt-LSU ((Pfeffer S et al., 
2015), taken with permission from Rightslink, license number 3831330401788). The 
position of Mba1 within the tomogram is circled. MRPL45 is depicted in red in the mt -LSU 
structure. 
Little is known about how Mba1 interacts with the IMM in yeast. A physical association of this 
protein with the IMM protein Mdm38 has been reported by (Bauerschmitt H et al., 2010). The 
homologue of Mdm38 in human is LetM1, a protein that will be discussed in Appendix 17. Briefly, 
LetM1 is an IMM protein that has been reported to have a role in the maintenance of mitochondrial 
tubular networks and in the assembly of the supercomplexes of the respiratory chain. This protein  
has a matrix domain suggested by PFAM to contain a ribosome-binding domain. It is possible that 
the interaction between Mba1 and Mdm38 described in yeast is conserved between the two 
respective homologues in human.  
In addition to its role as a receptor for the mitoribosome on the membrane, it has been 
suggested that Mba1 also interacts with mitochondrial translation products, including Cox1, Cox2, 
Cox3 and Cytb. This protein has been also reported as necessary for the insertion of both 
mitochondrial and nuclear encoded proteins into the IMM (Preuss M et al., 2001). This observation 
might support the hypothesis of a second role of MRPL45, as speculated in the previous chapter. 
Altogether, the observations presented above support the hypothesis of a role for MRPL45 in 
anchoring the mitochondrial translation machinery to the IMM, probably aligning the nascent chain 
of the mt-encoded OXPHOS components with insertases and chaperones, to facilitate the 
integration into the membrane. MRPL45 might mediate the interaction by binding directly to the 
IMM (as shown for TIM44) or via the binding with IMM proteins, as suggested for its homologue 
Mba1. 
In the previous chapter, I confirmed the importance of MRPL45 for the stability of the mt -LSU 
and, as a consequence, for an efficient protein synthesis. In this chapter, I aimed to confirm the 
interaction of the mitochondrial translation machinery with the IMM in human mitochondria and to 
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study the possible involvement of MRPL45 in this interaction. For this purpose, a protocol to 
analyse the interaction was developed and applied in the studies that are presented in this 
chapter. In order to study the ability of MRPL45 to directly interact with the IMM, cell lines able to 
inducibly express this protein were prepared. After the characterisation of the phenotype of the 
cell line was obtained, the direct interaction of MRPL45 with the membrane was studied in cells 
induced to express the protein in the absence of the assembled mitoribosome. Once the existence 
of a direct interaction between MRPL45 and the IMM was established, modifications to the protein 
were engineered to investigate the involvement of certain domains in the interaction.  
4.2. Methods 
4.2.1. Generation of stable cell lines able to overexpress MRPL45 
The ORF encoding MRPL45 was cloned into pcDNA5/FRT/TO, a plasmid that is compatible 
with the Flp-In TRex system and that allows the inducible overexpression in HEK293 Flp-In 
TRex cells by addition of tetracycline or doxycycline to the growth media. The multiple cloning 
site of the plasmid contains a BamHI restriction site that was used to insert the sequence 
encoding for MRPL45. A complete map of pcDNA5/FRT/TO can be found in Appendix 3.  
The plasmid was obtained from an E. coli strain previously transformed with the plasmid in 
our laboratory, purified and digested with BamHI (qv 2.3.7.) (Fig. 4.6). 
 
Figure 4.6  pcDNA5/FRT/TO was purified and digested with BamHI. 
The extracted plasmid (Pl) was separated on 1.2% agarose gel prior (A) and following (B) 
digestion with BamHI. M=marker, Pl=pcDNA5/FRT/TO. 
The fragment to be used in the ligation was prepared via PCR using random hexamer primed 
cDNA obtained from HEK293 cells as template. The primers were designed to amplify the 
mature MRPL45 mRNA sequence and to insert BamHI restriction sites on either side of the 
sequence. Three inserts were prepared using different combinations of custom designed 
primers (Frw1, Rev3; Frw2, Rev3; Frw2, Rev2; listed in Appendix 5), targeting a different region 
prior or after the ORF of MRPL45. The products obtained were separated on 1.2% agarose gel 
and after visualisation with UV light, the bands correspondent to the insert size were excised 
(Fig. 4.7). 
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Figure 4.7  Preparation of MRPL45 insert via PCR 
DNA electrophoresis on 1.2% agarose gel of purified MRPL45 fragments 
obtained via PCR reactions. The inserts were obtained with different 
combinations of primers (1= Frw1, Rev3; 2= Frw2, Rev3; 3= Frw2, Rev2, 
see Appendix 5). M=size marker. 
 After digestion with BamHI and purification via gel extraction, insert 2 (1,004 bp) was used 
to perform ligation in pcDNA5/FRT/TO. The product of ligation was used to transform competent 
cells (qv 2.3.9.) that were plated on LB-agar containing 100 µg/mL of ampicillin for the selection 
of the transformed cells. After overnight incubation, single colonies were expanded and 
analysed to verify the presence of the insert within the plasmid. Half of each colony was used in 
a PCR performed with CMV and BGH primers (sequences in Appendix 5) that span the multiple 
cloning site of pcDNA5/FRT/TO (qv 2.3.10.). If MRPL45 was not successfully inserted in the 
plasmid, the fragment obtained from the PCR reaction would have been equal to the distance 
between CMV and BGH sites on the empty plasmid (338 bp), whereas if the insert was present 
the length of the amplified DNA would have been of 1342 bp. The products obtained from the 
PCR were visualised on agarose gels to determine the size of the amplicon (Fig. 4.8). 
 
Figure 4.8  PCR amplification of MRPL45 to identify colonies containing successful 
insertion into pcDNA5/FRT/TO. 
The products obtained from the PCR reactions performed using CMV and BGH 
primers were separated on a 1.2% agarose gel. The arrow indicates the size of the 
fragments that confirm the success of the ligation reaction. M=size marker, Numbers = 
colony designation. 
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The DNA electrophoresis analysis showed that the PCR performed on colonies 10 and 11 
produced a fragment of approximately 1,300 bases, indicating that these colonies contained the 
ORF for MRPL45 ligated into the plasmid. 
Due to the use of the same restriction enzyme on both sides of the insert, the orientation of 
MRPL45 within the plasmid needed to be confirmed. For this, diagnostic digestion was 
performed on plasmids from colonies 10 and 11. Each plasmid (500 ng) was digested with AflII, 
a restriction enzyme that cuts both the plasmid and the insert. If the orientation of MRPL45 is 
correct, the enzyme will cut 116 bases prior to the end of the insert itself, leading to the formation 
of a 877 bp fragment. Whilst, if the insert has been ligated in the wrong orientation, the digestion 
will produce a smaller fragment of 137 bp. In both cases, a bigger fragment (5264 bp and 6004 
bp respectively) containing the majority of the vector will be obtained from the digestion (Fig.  
4.9A). In order to have a positive control, the plasmids were also linearised via digestion with 
KpnI, which performed a single cut on the whole MRPL45- pcDNA5/FRT/TO construct. The 
fragments obtained were analysed on a 1.2% agarose gel (Fig.  4.9B). 
 
Figure 4.9 Identification of the colony containing the MRPL45 ORF in the correct orientation. 
Diagnostic digestion was performed using AflII, which cut the plasmid as represented 
in (A). The plasmid was also linearised with KpnI and the products obtained from the 
digestion were on a 1.2% agarose gel (B). The arrow indicates the size of the fragment  
The diagnostic digestion showed that colony 10 contained MRPL45 inserted with the correct 
orientation into pcDNA5/FRT/TO, as a fragment of approximately 900 bp was obtained by the 
digestion of the construct with AflII. Subsequently, the plasmid from colony 10 was sequenced 
to confirm the identity of the sequence. The result obtained also confirmed the absence of 
mutations in MRPL45 nucleotide sequence cloned in pcDNA5/FRT/TO (Appendix 8). Finally, 
MRPL45-pcDNA5/FRT/TO was used, together with pOG44m to generate HEK293 Flp-In TRex 
cells able to overexpress MRPL45 (qv 2.1.6.). Positive transformants were selected through 
antibiotic resistance and individual clones were expanded and testef fot the ability to 
overexpress the protein upon induction with tetracycline. 
M(bp) 10     11     10      11  
AflII           KpnI 
1,018 
1,635 
516 
3,054 
5,090 
A 
B 
83 
 
4.2.2. Membrane-Soluble Fraction Protocol Optimization 
A reliable protocol to separate membranes from the soluble fraction in mitochondria was 
required in order to study the interaction of the mitoribosome with the IMM.  
The interaction of Mba1 with the IMM had been previously studied in yeast using the 
“membrane flotation assay” (Ott M et al., 2006). In this assay, intact mitochondrial membranes 
are disrupted by 3 cycles of freezing in liquid nitrogen and thawing at 37°C and then the 
membranes are separated from the soluble fraction by centrifugation at high speed using a step 
gradient containing different concentrations of sucrose. The composition of the IMM of human 
mitochondria differs from the yeast counterpart, the protocol cannot be directly transferred to be 
performed on human mitochondria. I, therefore, decided to optimise a method to perform on 
human mitochondria to separate membranes from the soluble fraction.  
After extraction from cells (qv 2.6.), mitochondria were disrupted using different techniques 
and buffers. The separation of membranes and the soluble fraction was then performed via high-
speed centrifugation, of which the duration and g-force needed to be adjusted. The protocol is 
summarised in Fig. 4.10.  
 
Figure 4.10  Protocol to determine the ability of proteins or complexes to interact with the 
mitochondrial membranes. 
Mitochondria were extracted and their membranes were disrupted by sonication. The 
sample was then divided in half and one half was incubated with 1.6% (v:v) Triton X-100 to 
release membrane- and membrane-interacting proteins. After that, the membrane fraction 
was pelleted by high g-force centrifugation. The matrix sample (S) was retained and the 
pelleted membranes (P) were resuspended. The samples obtained were analysed via 
western blot. The blue dots represent membrane and membrane-interacting proteins. 
Mitochondrial disruption was performed in 2 different buffers using either sonication or 
freeze-thaw cycles. Both the methods led to protein degradation when performed on 
mitochondria resuspended in phosphate-based buffer (potassium phosphate pH 7.4 20 mM, 
DTT 5mM, KCl 10 mM, MgCl2 10 mM). Sonication was preferred over freeze-thaw cycles to 
disrupt mitochondria in sucrose-mannitol buffer (MS buffer, Table 4.1) because the latter, 
performed by freezing the samples in liquid nitrogen and thawing them on ice led to degradation 
of proteins. Samples were sonicated on ice for a total time of 1 minute, composed of 10 seconds 
of activity followed by 50 seconds of rest on ice, to allow the dispersion of the heat generated. 
S 
P 
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After sonication, a clearing spin was performed to eliminate unbroken mitochondria. The 
supernatant obtained was expected to be composed of matrix proteins, fragments of 
mitochondrial membranes and membrane vesicles. The membranes needed to be separated 
from the soluble components via high-g force centrifugation (100,000 g, 30 minutes at 4ºC). 
After that, the pellet was resuspended in MS buffer (Table 4.1) and half of it was incubated with 
high salt concentration (500 mM KCl), which should detach the proteins loosely bound to the 
IMM, without extracting the integral IMM proteins. Western blot analyses performed with the 
samples obtained suggested that the salt treatment was not efficient, therefore, another 
approach was developed. 
I thought it was possible to investigate and estimate the interaction of the monosome and its 
subunit with the membrane by comparing the effects on the composition of the membrane and 
soluble fractions obtained by high g-force centrifugation in presence or absence of detergent.  
The signal detected by western blot analysis of the mitoribosomal subunits in the membrane 
fraction (P) will be composed of membrane-interacting subunits (or monosome) together with a 
proportion of the unbound subunits (or monosome) that are pelleted at that g-force due to their 
weight. The incubation of the sample with a non-ionic detergent (Triton X-100) aimed to release 
the integral and peripheral membrane proteins so that they would then be detected in the soluble 
fraction on western blot analysis. The presence of a signal for a protein in the membrane fraction 
upon treatment with Triton X-100 would suggest that this protein is a part of a heavy complex 
that is pelleted at the condition used for the high g-force centrifugation. The detection of an 
integral IMM protein that is not a component of a heavy complex, for example TOM20, was used 
to confirm the efficiency of the incubation with Triton X-100. If the protein of interest, which is 
suspected to interact with the membrane, has a different distribution between P and S fractions 
in the presence or absence of detergent, it is likely that that protein is interacting with the IMM.  
In order to limit the precipitation of heavy soluble complexes present in the matrix, a lower g-
force needed to be found at which only the membranes are pelleted. For this purpose, the 
protocol was repeated centrifuging the samples for 30 minutes at 4 different g -forces (50,000, 
70,000, 100,000 and 150,000). Mitochondria were extracted and the membranes disrupted by 
sonication as previously described. After a clearing spin at 11,000 g for 10 minutes at 4ºC, the 
supernatant was supplemented with 150 mM NaCl and divided into 2 samples of  equal volume. 
One half of each sample was then supplemented Triton X-100 at the final concentration of 1.6% 
and all the samples were incubated for 30 minutes on ice, with gentle vortexing every 10 
minutes. At the end of the treatment, the samples were centrifuged. The pellets obtained from 
the protocol were resuspended in presence of 0.2% SDS (W/V) at 37ºC in half the volume of 
the soluble fraction. A comparable volume of the two samples (15 µL for S, and 7.5 µL for P) 
were analysed via western blot (Fig. 4.11). 
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Figure 4.11 Separation of soluble and membrane components in presence or absence 
of Triton X-100 at 4 different g-force centrifugations. 
Western blot analysis of membrane (P) and soluble (S) proteins obtained after disruption of 
mitochondria with sonication. The initial sample was incubated on ice in the presence or 
absence of 1.6% of Triton X-100 (Tri). Soluble proteins and membrane proteins were 
obtained after centrifugation at different g-forces (150,000 g, 100,000 g, 70,000 g and 
50,000 g) for 30 minutes at 4°C. GDH was used as marker for the matrix, whereas 
NDUFA9 was used to confirm the membrane fractions. 
The western blot analysis showed that at all the tested g-forces, the matrix protein GDH was 
found mainly in the soluble fractions. A weak signal was expected in the membrane fractions in 
absence of detergent because of the ability of one of its isoform to interact with the IMM (Rajas 
F et al., 1996). Triton X-100 should release the remaining, membrane-interacting, GDH that 
should be then detected in the soluble fractions (Fig. 4.11, lanes 4, 8, 12, 16). The IMM protein 
NDUFA9 (a component of respiratory complex I) was predominantly detectable in the 
membrane fractions in absence of detergent (Fig. 4.11, lanes 1, 5, 9, 13). In presence of 
detergent, NDUFA9 was relased and detected in the soluble fractions (Fig. 4.11, lanes 4, 8, 12, 
16) and should be absent or barely detectable in the membrane fractions (Fig. 4.11, lanes 3, 7, 
11, 15). A significant signal for this IMM protein was detected in the membrane fraction when 
the centrifugation was performed at 150,000 g (Fig. 4.11, lane 3), suggesting that NDUFA9 (and 
probably the whole complex I) was pelleted at that speed due to its mass. In addition, GDH was 
also detectable in the same fraction (Fig. 4.11, lane 3), suggesting again that the g-force applied 
was pelleting a heavy complex containing the hexameric complex of the protein. 
At the lower g-force tested (50,000 g) a signal from NDUFA9 was detectable in the soluble 
fraction in absence of detergent (Fig. 4.11, lane 14), indicating that complex I and likely the 
membranes were not completely pelleted at this g-force. 
Because the 70,000 g centrifugation resulted in an efficient separation of membranes from 
soluble components, this g-force was selected to be used for the membrane-interaction studies. 
The final protocol used throughout the study is reported below. 
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General protocol 
Cells were grown in the desired conditions in 75 cm2 flasks until 80% confluent. Cells were 
then harvested, mitochondria were extracted (qv 2.6) and resuspended in Mannitol-Sucrose 
buffer (MS buffer, Table 4.1).  
Table 4.1  MS buffer composition.  
DTT and PMSF were added immediately prior to use to the buffer, due to their lower 
stability in aqueous solution. 
Reagents Final concentration 
Mannitol  
Sucrose 
HEPES, pH 7.8 (Sigma, cat no H3375) 
EDTA  
DTT  
PMSF  
EDTA-free protease inhibitor (Pierce) 
210 mM 
70 mM 
20 mM 
2 mM 
2 mM 
1mM 
1x 
Once fully resuspended, an aliquot of mitochondria was retained for lysis and protein 
concentration was quantified. The suspension was sonicated on ice in a minimum volume of 
800 µL for 1 minute at amplitude 10 with the Soniprep 150 plus (MSE) doing cycles of 10 
seconds of sonication followed by 50 seconds of rest, to avoid overheating of the sample. After 
the membrane disruption, the sample was centrifuged at 11,000 g for 10 minutes at 4ºC to 
eliminate unbroken mitochondria. The resulting supernatant was d ivided into two samples of 
equal volume. Both the samples were supplemented with 150 mM NaCl. In order to solubilise 
the membranes, Triton X-100 was added to one of the samples at a final concentration of 1.6% 
(v:v). The final volume of the two samples was then equalised by addition of MS buffer and the 
samples were incubated on ice for 30 minutes with occasional gentle vortexing. At the end of 
the incubation time, the volume of the samples was measured and then moved to polycarbonate 
tubes (Beckman Coulter, cat no 343778). The untreated membranes were separated from the 
soluble fraction by centrifugation at 70,000g for 30 minutes at 4ºC in the Beckmann 
ultracentrifuge (rotor TLA120.2). The supernatants were saved for western blot analysis, and 
the pellets were washed in MS buffer and centrifuged again using the same conditions. The 
pellet was then resuspended in MS buffer containing 0.2% SDS, in a final volume that was half 
the volume of the sample measured prior to centrifugation. A volume of 15 µL of every  
supernatant (S) and 7.5 µL of every pellet (P) were resolved by SDS-PAGE and analysed via 
western blot. The results were quantified with ImageLab (as in 4.2.2.) for every condition tested 
(presence or absence of detergent) and presented as percentages using the following 
equations: 
Signal P + Signal S= Total signal (corresponds to 100%) 
%Signal P= Signal P * 100/ Total signal 
%Signal S= 100- %Signal P 
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4.3. Analysis of the interaction of the mitoribosome with the IMM 
The protocol developed in the previous section was used to assess the interaction between 
the mitoribosome and the IMM in human organelles, an interaction that was previously reported 
in bovine tissue (Liu M & Spremulli LL, 2000). 
HEK293 cells were grown in 75 cm2 flasks until 80% confluent. Mitochondria were extracted, 
burst by sonication and then the membranes were separated from the soluble fraction as 
explained in 4.2.2. Membranes (P) and soluble (S) fractions obtained in presence or absence 
of Triton X-100 were analysed via western blot (Fig. 4.12A). 
 
 
 
Figure 4.12 Interaction of large and small subunits of the human mitoribosome with the IMM.  
A) Representative figure of membrane (P) and soluble (S) fractions obtained in presence 
or absence of 1.6% Triton X-100 from mitochondria extracted from HEK293 cells (qv 4.2.2) 
and analysed via western blot. The distribution of the mitoribosome between the two 
fractions for each treatment was visualised using antibodies against mt-LSU (MRPL11) and 
mt-SSU (MRPS26) proteins. GDH and NDUFA9 were used as markers for the soluble and 
the membrane fractions respectively. B) Quantification of the western blot results was 
obtained with ImageLab and calculated as reported in 4.2.2. The results summarise 3 
different biological repeats and are shown as percentages. 
The efficiency of the protocol was confirmed by the distribution of GDH and NDUFA9. The 
matrix protein GDH was mainly present in the S fraction for both the conditions tested (Fig. 4.12A, 
lanes 2 and 4). The component of complex I NDUFA9 was predominantly found in the P fraction 
in absence of Triton X-100 (Fig. 4.12A, lane 1), whereas its presence was mainly in the S fraction 
upon solubilisation of the membranes by the detergent (Fig. 4.12A, lane 4).  
The partitioning of the mitoribosomal subunit between membrane and soluble fraction was  
assessed using antibodies against MRPL11 (mt-LSU) and MRPS26 (mt-SSU). The addition of 
detergent led to release of these 2 proteins, although this was not complete. The presence of 
approximately 30% of both MRPL11 and MRPS26 in the P fraction upon solubil isation of the 
membranes with Triton X-100 (Fig. 4.12A, lane 3) suggested that at the g-force used, at least this 
proportion of mt-LSU and mt-SSU pelleted because of their weight. Subtracting the intensity of 
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this residual signal (lane 3) from the signal obtained in the absence of detergent for the P fraction 
(lane 1), it is possible to infer information with respect to the interaction of the subunits with the 
IMM. My data suggest that al least ≈45% of mt-LSU and at least ≈15% of mt-SSU interacted with 
the membrane. This observation indicated that at steady state there is a greater association of 
the mt-LSU with the IMM than there is of the mt-SSU, and that this interaction might happen when 
the mt-LSU is not associated with the mt-SSU. It is important to notice that a proportion of both 
the subunits was found in the supernatant in the absence of detergent (Fig. 4.12, lane 2). This 
suggested that a proportion was not interacting with the membrane.  
4.4. Analysis of the interaction of MRPL45 with the IMM 
In addition to the analysis of the interaction of the mitoribosome with the IMM, the protocol 
developed in 4.2.2. was also used to investigate the specific involvement of MRPL45 in this 
interaction.  
To test the possibility of a direct interaction of MRPL45 with the IMM, this mitoribosomal protein 
needed to be present in mitochondria in the absence of the rest of the mitoribosome. The steady 
state level of the mitoribosome and of the mitoribosomal proteins can be depleted with incubation 
of the cells with ethidium bromide. This reagent intercalates into mt-DNA, inhibiting its replication 
and transcription. As a consequence, the 16S and 12S rRNA encoded by the mitochondria cannot 
be transcribed and be integrated into the subunits of the mitoribosome. In this condition,  the 
mitoribosome cannot fully assemble and mitoribosomal proteins, including MRPL45, become 
depleted. A cell line that can be induced to overexpress MRPL45 can be used in these conditions 
to independently study the interaction of MRPL45 with the IMM. The cell line was generated as 
reported in 4.2.2. Prior the analysis of the interaction of MRPL45 with the IMM, the effects of the 
overexpression of the protein were evaluated. 
4.4.1. Effects of MRPL45 overexpression 
Prior to the use of the MRPL45-HEK293 cell line to test the interaction of MRPL45 with the 
membrane, the effects of the overexpression on the cellular phenotype were studied.  
MRPL45-HEK293 cells were induced for 10 days and cell growth was monitored with the 
IncuCyte system over the overexpression period (Fig. 4.13A). The morphology of the cells after 
6 days of overexpression is shown in Fig. 4.13B. 
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Figure 4.13 Effects of MRPL45 overexpression on cell growth. 
A) Cell confluence was measured with the IncuCyte system every 3 hours over 10 days 
of overexpression of MRPL45 in HEK293 Flp-In TRex cells. The red arrow indicates when 
the media was replaced. B) Cell morphology was visualised after 6 days of MRPL45 in 
HEK293 Flp-In TRex cells. The data are representative of 3 biological repeats. 
A mild growth delay was observed in the cell line overexpressing MRPL45 (Fig. 4.13A). 
Because the overexpression leads to non-physiological levels of this protein, it is possible that 
this condition causes stress and affects cell homeostasis, causing the mild growth retardation. 
A minor drop in the growth was present for both the samples due to replacement of the media 
(Fig. 4.13A, red arrow) caused a minor drop in the growth. No effects were detected on cell 
shape or morphology (Fig. 4.13B). 
The effects on the steady state level of mitochondrial proteins involved in translation were 
also analysed via western blotting of cell lysate after 10 days of continuous induction of MRPL45 
(Fig. 4.14). 
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Figure 4.14  MRPL45 overexpression effects on steady state level of 
mitochondrial proteins involved in mitochondrial translation.  
Western blot analysis was performed on lysate obtained after 10 days of MRPL45 
overexpression (In) in MRPL45- HEK293 Flp-In TRex. Uninduced cells (Un) were 
cultured as a control. Levels of MRPL45 overexpression were detected using an antibody 
targeting the protein. Steady state level of components of mt-SSU (MRPS22, MRPS27, 
MRPS17) and mt-LSU (MRPL11, MRPL3) were evaluated, as well as the mitochondrial 
encoded protein COXII. SDH70 steady state levels were used as loading control. The 
figure is representative of 3 biolgical repeats. 
As expected, the overexpression of MRPL45 had no effect the steady state level of COXII, 
suggesting that protein synthesis in mitochondria was not affected. However, the levels of the 
mitoribosomal proteins evaluated were mildly affected. 
These results suggest that the overexpression of MRPL45 did not cause any major 
deleterious effect on MRPL45-HEK239 cells. 
4.4.2. Analysis of the direct interaction of MRPL45 with the IMM 
After the confirmation of the interaction between the mitoribosome and the IMM in 4.3, the 
ability of MRPL45 to directly interact with the membrane was studied. 
MRPL45-HEK293 Flp-In TRex cell line was cultured in two 75 cm2 flasks using supplemented 
media containing 250 ng/mL of ethidium bromide for 10 days to deplete mitochondrial DNA. In 
the last 4 days of ethidium bromide treatment, MRPL45 was overexpressed, by adding of 1 
µg/mL of tetracycline to the growth media. The length of the ethidium bromide treatment was 
considered sufficient to lead to depletion of the assembled mitoribosome. This needed to be 
confirmed on western blot analysis using antibodies targeting components of mt -SSU and mt-
LSU. COXII steady state levels could also be used to further verify the efficiency of the ethidium 
bromide treatment. 
The treatment with ethidium bromide made the cells very delicate, therefore extra care was 
needed during their growth. Media was replaced every 2 days (or earlier if a change of its colour 
indicated increased acidity), in order to replace the glucose needed throughout the ethidium 
bromide treatment for the glycolytic synthesis of ATP. Attention was also paid to the cell 
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confluence, which was kept below 70%, to avoid cell detachment, which was observed at higher 
confluency. 
At the end of the ethidium bromide treatment, cells were harvested and mitochondria were 
isolated. Membrane and soluble fractions were separated following the protocol optimised in 
4.4.2, with some modification. In particular, the membranes were pelleted at 150,000 g, and no 
incubation with 1.6% Triton X-100 was performed prior to centrifugation. These modifications 
were legitimate because, after incubation with ethidium bromide, the mitoribosome was absent 
and therefore could not sediment during the high speed centrifugation, used to separate 
membranes from the soluble fraction. The same protocol was also performed in parallel on 
HEK293 cells, cultured in normal growth media. The samples obtained were analysed on 
western blot (Fig. 4.15). 
 
Figure 4.15 Distribution of MRPL45 between membranes and soluble 
fractions in wild-type cells or in cells overexpressing MRPL45 and treated 
with ethidium bromide. 
Western blot analysis was performed on membranes (P) and soluble (S) fractions 
obtained from wild type HEK293 cells and HEK293 Flp-In TRex cells overexpressing 
MRPL45 for the final 4 days of 10 days in ethidium bromide. The efficiency of the 
separation was assessed with antibodies against the matrix protein GDH and against the 
membranes protein OXA1L and porin. The success of the overexpression was verified 
using an antibody against MRPL45 and the efficiency of the ethidium bromide treatment 
was confirmed with antibodies against COXII, MRPS26 and MRPL11. The dashed line 
indicated that some lanes have been omitted. The experiment was not replicated. 
MRPS26, MRPL11 and COXII were all detectable in the samples obtained from the HEK293 
wild type cells (Fig. 4.15, lanes 1 and 2), whereas they were undetectable in either of the 
fractions obtained for cells grown in ethidium bromide (Fig. 4.15, lanes 3 and 4), confirming the 
efficiency of the treatment with the intercalating agent. The presence of GDH mainly in the 
soluble fractions and of OXA1L and porin predominantly in the membrane fractions for both the 
cell lines confirmed the successful precipitation of the membranes at the g-force used. As the 
majority of MRPL45 was detected in the membrane fraction in the absence of the assembled 
mitoribosome, it is likely that MRPL45 is able to interact directly with the IMM. 
The overexpression of MRPL45 could potentially cause aggregation of the protein that might 
be pelleted at the g-force used in the previous experiment. In order to discriminate between the 
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presence of MRPL45 in the membrane fraction only because of its aggregation, or as a result 
of its interaction with the IMM, the separation of membrane and soluble fraction was repeated, 
but this time following the optimised protocol given at 4.2.2. MRPL45- HEK293 Flp-In TRex cells 
were grown in the same conditions used for the previous experiment (10 days in ethidium 
bromide with 4 days of MRPL45 overexpression), mitochondria were extracted and the 
membranes and soluble fraction were separated. If MRPL45 was interacting with the IMM, the 
addition of 1.6% Triton X-100 would release the IMM-interacting pool of MRPL45 and the 
distribution of MRPL45 between membranes (P) and soluble fraction (S) should change, 
showing a difference in the presence or absence of the detergent. The fractions obtained were 
analysed by western blot (Fig. 4.16A). 
 
 
 
   Figure 4.16 Distribution of overexpressed MRPL45 between membrane and soluble 
fractions in the presence or absence of detergent. 
Representative figure of western blot analysis (A) performed on mitolysate (Lys), membranes (P) 
and soluble (S) fractions obtained as in 4.2.2. from HEK293 Flp-In TRex cells overexpressing 
MRPL45 for 4 days during ethidium bromide incubation (10 days). Half of the suspension of 
membranes and matrix proteins obtained was incubated with 1.6% Triton X-100 (Tri) prior 
centrifugation. The success of the overexpression was verified using an antibody against 
MRPL45. The efficiency of the protocol was assessed with antibodies against the matrix protein 
GDH and against the membrane protein TOM20. COXII levels were undetectable. Data obtained 
by western blot for 3 biological repeats were quantified with ImageLab as in 4.2.2. and summed 
up in a bar graph (B).  
The matrix protein GDH was present mainly in the S fraction both in the presence and 
absence of detergent. The presence of the outer membrane protein TOM20 in the S fraction 
upon addition of Triton X-100 confirmed the success of membranes solubilisation. No signal for 
either MRPL11 and MRPL26 was detected. The detection of MRPL45 showed that the 
distribution between P and S fractions changed following the incubation with the detergent. 
While the protein appeared to be equally divided between the 2 fractions in the absence of 
detergent (Fig. 4.16A, lanes 2 and 3), the majority of MRPL45 was present in the S fraction upon 
addition of detergent (Fig. 4.16A, lane 5). The addition of Triton X-100 releases the membrane 
proteins, as well as the membrane-interacting ones. As a consequence, the release observed 
for MRPL45 in absence of the assembled mitoribosome suggested that the protein is able to 
0
20
40
60
80
100
GDH TOM20 MRPL45
Triton      -   -   +   +          -    -   +   +         -   -   +   +  
  P  S   P  S            P  S    P  S            P  S   P  S 
          GDH                 TOM20               MRPL45 
A B 
93 
 
interact with the membrane directly. The residual signal for MRPL45 found in the P fraction in 
presence of Triton X-100 might indicate the presence of aggregates. Noticeably, at least the 
50% of MRPL45 was found in the supernatant in the absence of detergent. This suggested that 
a large proportion of MRPL45 was not interacting with the membrane. This could be due either 
to the saturation of the interaction points (since the high steady state level of the protein), or to 
the transient nature of the interaction. The quantification of the data obtained from western blot 
analysis suggested that approximately the 25% of MRPL45 was released by the addition of 
detergent, suggesting that at least this portion of the population was interacting with the IMM 
directly or indirectly. 
4.5. Discussion 
Due to the high hydrophobicity of the products of mitochondrial translation, it is likely that their 
synthesis is coupled with their insertion into the IMM. A protocol was developed in order to 
investigate the interaction between the membrane and the mitoribosome or mitoribosomal 
components. The aim of this protocol was to allow the comparison of the distribution between 
membranes and the soluble fraction of a protein/complex in the presence or absence of detergent. 
The optimised protocol showed efficient separation of membranes and membrane-interacting 
proteins from soluble components as evidenced by the relevant markers (TOM20 or NDUFA9 
and GDH, respectively). The addition of Triton X-100 successfully solubilised the membrane and 
membrane-interacting proteins that were then located in the soluble fraction. From the data 
obtained via western blot analysis, it was possible to hypothesise the existence of an interaction 
of a single protein or a group of proteins with the membranes. The main weakness of the process 
is the absence of a control that can be used to ensure that the membranes and the soluble fraction 
are equally represented on western blot analyses. In order to generate good quality data, extra 
care is needed on analysing representative volumes. In particular, the volume of each of the 
samples needs to be measured prior to high g-force centrifugation and the pellets obtained need 
to be resuspended in half the volume measured before the centrifugation. I decided to resuspend 
the pellet in half a volume in case of needing a more concentrated sample for western blot 
analyses. The volume of supernatant obtained at the end of the protocol does not have to be 
measured. With this precaution, it will be possible to compare the changes in the distribution of 
the analysed protein.  
The protocol performed on wild type HEK293 confirmed the ability of the human mitoribosome 
to interact with the IMM, previously described in bovine organelles by Liu M and Spremulli LL 
(2000). Specifically, my data suggested that under exponential growth conditions approximately 
45% of the mt-LSU interacted with the IMM, since this proportion was released by addition of 
detergent. This data is in agreement with the results published by Liu M and Spremulli LL (2000). 
On the other hand, a smaller proportion of the mt-SSU (≈15%) was found to interact with the 
membrane. It is likely that the interaction of the small subunit with the IMM is mediated by the 
large subunit. Because a higher proportion of mt-LSU was found associated with the membrane, 
94 
 
it is tempting to speculate that the mt-LSU anchors to the membrane first, waiting for the mt-SSU 
to recruit the mRNA and then join to form the monosome. These experiments also showed that a 
proportion of mt-LSU and mt-SSU (≈30% and ≈60%, respectively) were not interacting with the 
membranes. 
The key players in the association between IMM and mitoribosome are not yet fully identified. 
The mitoribosomal protein MRPL45 was suggested to play a role in the interaction because of its 
structural similarity to the membrane interacting protein TIM44 (Handa N et al., 2007; Marom M 
et al., 2009) and because recent mt-LSU structures localised it in close proximity to the 
polypeptide exit site. This position would be ideal to establish membrane-interaction to promote 
the insertion of mitochondrial translation products, however, it was only identified in 2014 by 
Greber et al, after I began this study. Characterisation of the yeast homologue, Mba1, confirmed 
the interaction of this non-mitoribosomal protein with both the IMM and the mitoribosome 
mitoribosome (Ott M et al., 2006). My protocol, which was designed to investigate membrane 
interaction, was performed on cells overexpressing MRPL45 in the absence of fully assembled 
mitoribosomal subunits after incubation with ethidium bromide. It is important to mention that in 
all the cases when the cells were treated with ethidium bromide (both in this and in the following 
chapters), a complete precipitation of TOM20 in the pellet fraction in absence of detergent could 
not be achieved. This effect might be a consequence of the general effect of ethidium bromide on 
mitochondrial physiology. However, the data obtained showed that a proportion of MRPL45 was 
released by addition of detergent and that therefore approximately the 25% of the protein was 
found associated with the membranes, confirming the ability of MRPL45 to d irectly bind the IMM 
and, therefore, a role of this mitoribosomal protein as a mediator of the IMM-mitoribosome 
interaction. A proportion of MRPL45 was not released by the detergent, suggesting the presence 
of aggregates, which might be due to the heat generated during the sonication used to break the 
mitochondrial membranes. In absence of detergent, MRPL45 was not completely interacting with 
the membrane, but approximately 50% was recovered in the free fraction. This suggests that the 
interaction sites might be saturated due to the high steady-state level of the overexpressed 
protein, or that the interaction is only transient. The percentage of MRPL45 suggested to interact 
with the membrane (≈25%) is lower than the one observed for the mt-LSU (≈45%). Because it is 
likely that more than one interaction is contributing to the association of the mitoribosome with the 
IMM, it is predictable that the interaction of MRPL45 might be weaker compared to the one of the 
assembled mt-LSU. 
In the following chapter, the modality of interaction of MRPL45 with the IMM will be discussed. 
  
 
 
95 
 
Chapter 5: Investigation of the mode of interaction of MRPL45 with 
the IMM 
The previous chapter confirmed the ability of MRPL45 to interact directly with the IMM. This 
chapter will investigate the mode of this interaction, which could be mediated by a transmembrane 
domain, by contact with a membrane protein or by interaction with the phospholipid layer. In order 
to identify putative membrane-interacting proteins, immunoprecipitation was performed. This was 
carried out on a cell line that could inducibly overexpress MRPL45FLAG, after proving that the 
addition of the FLAG-tag did not alter the protein’s role. 
5.1. Methods 
5.1.1. Mass spectrometry analysis 
Mass spectrometry was used to identify proteins present in the samples that were obtained 
via immunoprecipitation (qv 2.9.). Extra care was used to prevent contamination of the samples, 
which might impact on the quality of the results obtained in the analysis. Together with attention 
to avoid keratin contamination throughout the protocol, the beads used for the 
immunoprecipitation where washed, prior to elution, 5 times instead of the 3 reported in the 
protocol at 2.9. 
Once eluted, the samples (1/5) were first analysed via western blotting to confirm the success 
of the immunoprecipitation. After that, the remainder of the sample was loaded on a 12% SDS-
PAG and electrophoresed until the samples had migrated 5 mm into the resolving gel. At that 
point the plates containing the SDS-PAGE were wrapped and taken to Dr Achim Treumann for 
proteomic analysis (NUPPA, Newcastle University). 
The samples were digested with the filter-aided sample preparation (FASP) method 
(Winiewski JR et al., 2009). This method allows a wide proteome coverage (including membrane 
proteins) by solubilising the samples in 4% SDS and then replacing the detergent, which is not 
compatible with mass spectrometry analysis, with urea via filtration. This method was also 
demonstrated to be efficient in the detection of membrane proteins via mass spectrometry.  
The data received reported the ID of the protein identified, the sum of raw spectrum identity 
(log(I)), the number of peptides found (rI) and the expectation of finding the protein stochastically 
(log(e)). 
5.1.2. Generation of a cell line able to express MRPL45FLAG 
The addition of a FLAG-tag at the C-terminus of MRPL45 will result in a useful tool to 
investigate the interactome of the protein via immunoprecipitation, as well as to generate 
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mutants that will be easily distinguished from the endogenous MRPL45 via the detect ion with 
an anti-FLAG antibody. 
BamHI was used as restriction site to introduce MRPL45FLAG into pcDNA5/FRT/TO. The 
same plasmid prepared for the previous cloning (Fig. 4.9) was used to introduce the sequence 
encoding for the FLAG-tagged protein. The insert was prepared via PCR starting from cDNA 
from HEK293 cells using the the primers Frw1 and Rev1FLAG (Appendix 5), of which the 
reverse primer contained the nucleotide sequence that encodes the FLAG-sequence (aspartic 
acid - tyrosine - lysine - aspartic acid - aspartic acid - aspartic acid - aspartic acid - lysine). DNA-
electrophoresis of the product obtained PCR showed that the insert was successfully amplified 
(Fig. 5.1). 
 
Figure 5.1  MRPL45FLAG insert was prepared via PCR. 
A purified insert obtained from PCR reaction with Frw1 and Rev1FLAG primers 
was separated in a 1.2% agarose gel to confirm recovery and purity. M=marker, 
Fl=MRPL45FLAG insert. 
After digestion with BamHI, MRPL45FLAG was ligated into pcDNA5/FRT/TO (qv 2.3.9.). Of 
the 36 colonies obtained by transformation, no positive colony was identified using the cracking 
gel technique (qv 2.3.10.). Both ligation and transformation were repeated, but without success.  
One of the possibilities for the failiure in MRPL45FLAG cloning was the incomplete digestion of 
the insert. A successfully digested fragment for insertion was therefore obtained using the PCR-
script Amp Cloning Kit (qv 2.3.11.). This method allows excision of the insert after cloning into a 
pPCR-script vector. After digestion, the insert was gel-purified and used for cloning into the 
plasmid of interest. MRPL45-FLAG obtained from the previous PCR reaction was ligated with 
the pPCRscript Amp SK(+) plasmid and the product was used to transform competent cells. The 
positive colonies were screened using a ‘cracking gel’ and the plasmids extracted from putatively 
positive, which were then digested with BamHI and analysed via DNA electrophoresis (Fig. 5.2).  
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Figure 5.2  Digestion of MRPL45FLAG-pPCRscript Amp SK(+) plasmid 
The plasmids obtained from colonies 4 and 5 were digested with BamHI and the products were 
visualised on 1.2% agarose gel. M=size marker, numbers=PCRscript colonies.  
Two products were obtained from BamHI digested, of which the faster migrating one (≈1000 
bp) corresponded to the insert. The insert obtained from colony 4 was gel-purified and used to 
ligate MRPL45FLAG into pcDNA5/FRT/TO (qv 2.3.9.). The colonies obtained after 
transformation of the competent cells (qv 2.2.2.) were screened to confirm the presence of the 
insert by visualisation of the products obtained for the PCR reaction using CMV and BGH 
primers on agarose gel (Fig. 5.3A) (qv 2.3.10.). The colonies containing the insert were further 
analysed using the diagnostic digestion shown in Fig. 4.12 (page 87), and the products were 
visualised on an agarose gel (Fig. 5.3B). 
  
Figure 5.3  Colony screening to identify colonies positive for MRPL45FLAG 
transformation. 
1.2% agarose gels were used to visualise the products of the PCR performed on colonies 
transformed with MRPL45FLAG-pcDNA5/FRT/TO using BGH and CMV primers (A) and the results 
of diagnostic digestion with AflII  [A] (B) on selected positive colonies from panel A. Plasmids were 
also linearised by digestion with KpnI.[K]  M= size marker, numbers= colonies. 
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All the colonies tested contained the insert, as the analysis indicated by the presence of a 
≈1300 bp fragment, compatible with the presence of the insert (≈1000 bp) between CMV and 
BGH primer sites (344 bp). Colonies 7, 13 and 19 derived from PCRscript fragment 4 were 
further analysed with diagnostic digestion and all presented the correct orientation of 
MRPL45FLAG, as suggested by the ≈900 bp fragment formed after digestion with AflII. The 
plasmid obtained from colony 7 was sequenced using CMV and BGH primers to confirm the 
absence of mutations. While the sequences obtained from the forward primer (CMV) showed 
100% of identity, the one obtained from the reverse primer (BGH) showed a mutation that led 
to an alteration of the encoded amino acid sequence. The altered amino acids was the last one 
found before the FLAG-tag (p.A306T). Due to its close proximity to the end of the protein 
sequence, I made the assumption that this mutation would not cause improper folding of 
MRPL45FLAG.  
HEK293 Flp-In TRex cells were then transfected with the plasmid as explained in 2.1.6. The 
antibiotic-selected clones were expanded and the overexpression verified. Positively-
expressing clones were further expanded to prepare samples for long-term storage in liquid 
nitrogen. 
5.2. Effects of MRPL45-FLAG overexpression 
If the C-terminus of MRPL45 has an essential role in anchoring the mitoribosome to the IMM, 
the introduction of a FLAG-tag at the C-terminus of MRPL45 might disrupt this interaction and 
have effects on mitochondrial translation and cells homeostasis.  
First, the integration of MRPL45FLAG into the assembled mt-LSU needed to be verified. For 
this purpose, an isokinetic sucrose gradient analysis was performed (qv 2.8) on MRPL45FLAG-
HEK293 Flp-In TRex cell lysate after 4 days of overexpression. The 12 fractions obtained were 
analysed via western blotting (Fig. 5.4).  
 
Figure 5.4 Analysis of the integration of MRPL45FLAG into mt-LSU.  
10-30% isokinetic sucrose gradient was performed on MRPL45FLAG- HEK293 Flp-In TRex 
cells (700µg) after 4 days of induction. Aliquots (10 µL) of each of the 12 fractions were resolved on 
a 12% SDS-PAGE and analysed via western blotting. The distribution of the mt-LSU and mt-SSU 
was assessed for the central fractions using antibodies against MRPL11 and MRPS22 
respectively. The distribution of MRPL45FLAG was verified using an antibody targeting the FLAG-
tag. The experiment was not replicated. 
99 
 
The western blot analysis showed that the FLAG-tagged protein was successfully integrated 
in the mt-LSU, as shown by the co-localisation of MRPL11 and FLAG in fractions 7 and 8. A pool 
of MRPL45FLAG was also found in fractions 1 and 2, indicating that it was unassociated (free ), 
this was expected due to the overexpression of the protein. The presence of the protein in the 
bottom fraction of the gradient indicated the presence of high molecular weight particles that are 
likely to be aggregates. The results obtained from this experiment suggested that the FLAG-tag 
on MRPL45 did not prevent either its integration into the mt-LSU or the assembly of the subunit 
itself. Interestingly, a second product was detected with the FLAG antibody, suggesting a possible 
N-cleavage of MRPL45. As observed in the sucrose gradient analysis of wild type HEK293 cells 
(Fig. 3.2, page 58), this second signal was detectable only in the first 2 fractions of the gradient, 
indicating that this form might not be integrated in the mitoribosome. This second signal was also 
detected with MRPL45 antibody in HEK293. The sucrose gradient analysis on wild type HEK293 
showed that the second signal was found in the least dense fraction of the gradient and was not 
detected in the fractions corresponding to the mt-LSU. It is tempting to speculate that this cleaved 
form of MRPL45 might play a second role in mitochondria 
As MRPL45FLAG was shown to be efficiently integrated into the mt-LSU, the effects on cell 
growth and mitochondrial protein content were assessed. MRPL45FLAG- HEK293 Flp-In TRex 
cells were induced for 10 days. Cell confluence was monitored with the IncuCyte system (Fig. 
5.5A) and the correspondent whole cell lysates were analysed via western blotting (Fig. 5.5B). 
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Figure 5.5  Effects of MRPL45FLAG overexpression on HEK293 Flp-In TRex cell growth 
and on components of the mitoribosome. 
MRPL45FLAG- HEK293 Flp-In TRex cells were induced for 10 days and their confluence was 
monitored with the Incucyte system (A). Cell lysates obtained from these uninduced and induced 
cells were resolved on by 12% SDS-PAGE and then analysed via western blotting (B). Antibodies 
against the mt-LSU (MRPL45, MRPL11, MRPL3) and mt-SSU (MRPS22, MRPS27, MRPS17) 
proteins were used. The steady state level of the mitochondrial-encoded protein COXII was also 
evaluated. Nuclear-encoded SDH70 levels were detected to verify the equality of the loading. Cell 
morphology after 6 days of overexpression is also presented (C). The figures are representative of 
3 biological repeats. 
The overexpression of MRPL45FLAG had no effect on cell confluency throughout the 10 days 
of monitoring. A minor drop in the growth was present for both the samples due to replacement 
of the media (Fig. 5.5A, red arrow). The overexpression was successful as shown by the presence 
of an intense signal at a higher molecular weight signal observed after incubation with MRPL45 
antibody. Two lower molecular weight signals were also detected with the FLAG antibody, 
suggesting that the protein was subjected to an N-cleavage. The overexpression had no effects 
of the steady state level of the components of the mt-SSU evaluated, whereas the steady-state 
level of the mt-LSU components seemed mildly upregulated. These results suggested that the 
stability of the subunits was not compromised by the overexpression of MRPL45FLAG. The level 
of COXII was also unaffected, suggesting that the overexpression had no observable effect on 
mitochondrial protein synthesis. 
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These results confirmed that the introduction of a FLAG-tag on MRPL45 has no detectable 
negative effects on the stability of the mt-LSU or mitochondrial translation. 
5.3. Analysis of the direct interaction of MRPL45FLAG with the IMM 
In order to test the ability of MRPL45FLAG to interact directly with the IMM, membranes were 
separated from the soluble fraction following the ethidium bromide treatment optimised in 4.2.2, 
after 10 days of ethidium bromide incubation with overexpression of the tagged protein during the 
last 4 days of the treatment. The mito-lysate and the fractions obtained in the absence and 
presence of 1.6% Triton X-100, were analysed via western blot (Fig. 5.6A). 
 
 
 
 
Figure 5.6 Distribution of MRPL45FLAG between membranes and soluble fraction in 
the absence of assembled mitoribosome. 
A) Representative figure of western blot analysis performed on mito-lysates (Lys), membranes 
(P) and the soluble fractions (S) obtained as in 4.2.2. from HEK293 Flp-In TRex cells overexpressing 
MRPL45FLAG for 4 days during ethidium bromide incubation (10 days). Half of the membranes and 
matrix proteins obtained were incubated with 1.6% Triton X-100 (Tri) prior to centrifugation. The 
success of the overexpression was verified using an antibody against MRPL45. The efficiency of the 
separation protocol was assessed with antibodies against the matrix protein GDH and against the 
membrane protein TOM20. COXII levels were undetectable. B) Quantification of 3 biological repeats 
of the protocol was performed from the western blot analysis using ImageLab as explained in 2.5.5. 
The efficiency of the subfractionation protocol was demonstrated using antibodies against 
GDH and TOM20. The matrix protein GDH was recovered mainly in the supernatant (Fig. 5.6A, 
lanes 3 and 5), whereas the OMM protein TOM20, which is predominantly present in the 
membrane fraction in absence of Triton X-100 (Fig. 5.6A, lane 1), was solubilised after incubation 
with the detergent, ending up in the S fraction (Fig. 5.6A, lane 5). The detection of MRPL45 
showed a change of distribution of MRPL45FLAG upon incubation with Triton X-100, which 
suggested the ability of the protein to maintain its interaction with the IMM despite the presence 
of the FLAG-tag. It is important to notice that a proportion of TOM20 was detected in the S fraction, 
in absence of Triton X-100 (Fig. 5.6A, lane 3). This was observed in every experiment where the 
cells were incubated with ethidium bromide and could indicate that the membrane fraction was 
not completely pelleted. Quantification performed on biological repeats of the experiment (Fig. 
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5.6B) suggested that about 40% of MRPL45FLAG is found in the P fraction in absence of 
detergent and that its addition effected the release from the membrane of at least 20% of the 
protein. A small proportion of MRPL45FLAG was not solubilised by the addition of detergent. This 
could be due to the presence of aggregates. In addition, it is important to notice that approximately 
40% of MRPL45FLAG was present in the soluble fraction in the absence of detergent. As 
previously mentioned for MRPL45 (Fig. 4.16, page 92), it is possible that a proportion of the 
protein in not interacting with the IMM either because of the saturation of the membrane -
interacting points, or because the interaction was transient.  Despite this, the solubilisation of the 
protein after addition of detergent confirmed its ability to interact with the IMM. 
5.4. Characterisation of the interaction of MRPL45 with the IMM 
The interaction between MRPL45 and the IMM might be due to the presence of a 
transmembrane domain, as well as mediated by a direct contact with the phospholipid layer or by 
the interaction with a membrane protein.  
The possibility of the presence of a transmembrane domain was investigated by calculating 
the hydrophobicity of the protein using the Kyte-Doolittle method (Kyte J et al., 1982). Thanks to 
this method it is possible to predict the transmembrane domains in a protein of interest. Every 
amino acid has a hydropathy score that has been experimentally calculated and which depends 
on its characteristics and on the amino acids found in close proximity. The result of the prediction 
is shown in a graph presenting the hydropathy score in function of the window position, which 
correspond to the amino acid sequence. The window size (which is the number of residues 
evaluated at once) needs to be set. When this is set to 19, the presence o f peaks over 1.6 will 
identify putative transmembrane regions and scores above 0 will indicate hydrophobic regions. 
Since the cleavage of the leader sequence of MRPL45 had not been confirmed yet, the prediction 
of the presence of hydrophobic domains was performed on the full -length MRPL45. The 
hydropathy plot is shown in Fig. 5.7. 
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Figure 5.7 Hydrophobicity of MRPL45 calculated with the Kyte -Doolittle method. 
Hydropathy scores were assigned to MRPL45 to highlight the presence of hydrophobic regions and 
transmembrane domains. The window was set at 19. Regions above 0 (blue line) are hydrophobic 
and the ones above the red line (at the score of 1.6) indicate the possible presence of 
transmembrane domains. 
The presence of peaks above 0 (blue line) indicated the presence of only a few hydrophobic 
regions. As no peak reached 1.6 (red line), no transmembrane domains were predicted. 
Because the presence of transmembrane domains of MRPL45 was unlikely, the possibility of 
its interaction with IMM proteins was assessed. For this purpose, the interactome of the protein 
was studied via immunoprecipitation studies on MRPL45FLAG. In order to discriminate between 
IMM proteins interacting with the monosome or directly with MRPL45, cells were incubated with 
ethidium bromide. This reagent made mt-rRNA unavailable, resulting in the lack of assembled 
mitoribosomal subunits. In absence of the ethidium bromide treatment, the whole mitoribosome 
will be co-immunoprecipitated with MRPL45FLAG, together with mitoribosome-interacting (but 
not necessarily MRPL45-interacting) proteins.  
First of all, the efficiency of the immunoprecipitation was verified on HEK293-MRPL45FLAG 
cells cultured in growth media and overexpression of the recombinant protein for 3 days (by 
addition of 1 µg/mL tetracycline). MRPL45FLAG was immunoprecipitated from mitochondria via 
the FLAG-tag following the protocol in 2.9. The removal of the immunoprecipitated proteins from 
the beads was performed at 95°C for 3 minutes in 100 µL of 1x sample buffer (qv 2.5.4). The 
experiment was also performed on HEK293 cells as a negative control. The result of the 
experiment was analysed via silver staining (40 µL of each sample) and western blot analysis (40 
µL of each sample) (Fig. 5.8). 
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Figure 5.8 Immunoprecipitation of MRPL45FLAG 
Silver staining of a 12% SDS-PAGE (A) of samples (40 µL) from FLAG 
immunoprecipitation from HEK293 and HEK293-MRPL45FLAG cells (3 days induction). 
The same samples were also analysed via western blotting (B), using antibodies 
against MRPS26, MRPL11 and OXA1L. Two biological replicates of the experiment 
were performed. 
The samples obtained from FLAG immunoprecipitation from HEK293-MRPL45FLAG 
mitochondria showed the presence of co-immunoprecipitated proteins when compared to the wild 
type cells, suggesting the success of the immunoprecipitation experiment. The signals observed 
at approximately 50 and 25 kDa represent the light and heavy chain of the antibody found on the 
beads and are therefore present in the sample obtained from HEK293 cells. The signal observed 
above 35 kDa for the HEK293-MRPL45FLAG sample might correspond to the FLAG-tagged 
protein. The western blot analysis confirmed the presence of a component of the mt -LSU 
(MRPL11) and a component of the mt-SSU (MRPS26), as well as the presence of OXA1L, an 
IMM protein previously suggested to interact with the mitoribosome (Haque ME et al., 2010). 
Because the immunoprecipitation via the FLAG-tag was successful, the experiment was 
repeated on the same cell line, following ethidium bromide treatment. Wild-type HEK293 cells 
were also incubated with the intercalating agent and used as a control. Each cell line was grown 
in 75 cm2 flasks in presence of 250 ng/mL of ethidium bromide for 10 days. During the last 4 days 
of treatment, 1 µg/mL of tetracycline was added to HEK293-MRPL45FLAG to induce the 
overexpression of the protein. The cells were then harvested, and mitochondria were extracted, 
lysed and used for the immunoprecipitation experiment. A proport ion (15 µg) of mitolysate was 
retained for western blot analysis. The elution of the immunoprecipitated proteins from the beads 
was performed at 95°C for 3 minutes in 50 µL of 1x sample buffer (qv 2.5.5.) as elution with the 
3x FLAG peptide did not efficiently displace the MRPL45FLAG from the beads. The samples (one 
third of the final volume) were analysed via western blot (Fig. 9). HEK293 cell lysate was also 
A 
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loaded as a control for the efficiency of the ethidium bromide treatment.  The sample was also 
analysed via mass spectrometry to identify the proteins that co-immunoprecipitated with 
MRPL45FLAG (Appendix 13). 
 
Figure 5.9 Immunoprecipitation of MRPL45FLAG from ethidium bromide treated cells. 
Western blot analyses performed on mitolysates (15 µg) and FLAG-immunoprecipitated 
samples (25 µL of 50 µL elution volume, IP) from HEK293 (WT) and HEK293-
MRPL45FLAG, both incubated with ethidium bromide for 10 days and with 
overexpression of the FLAG-tagged protein in HEK293-MRPL45FLAG for 4 days. 
Mitolysate from untreated HEK293 cells was also loaded as a control (lane 1). 
Antibodies against FLAG were used to confirm the presence of MRPL45FLAG; 
antibodies against MRPL11 and OXA1L were also used. The dashed line indicates that 
intervening lanes from the same blot have been omitted. Two biological replicates of the 
experiment were performed. 
The FLAG-tagged protein was efficiently expressed (Fig. 5.9, lane 2) and immunoprecipitated 
(Fig. 5.9, lane 4). The steady state level of MRPL11 was reduced in the ethidium bromide treated 
cells (Fig. 5.9, lanes 2 and 3) when compared to the control (Fig. 5.9, lane 1), confirming the 
success of the treatment. MRPL11 was not detectable in the immunoprecipitated sample (Fig. 
5.9, lane 4). No proteins were detected in the sample immunoprecipitated from wild type HEK293 
cells incubated with ethidium bromide (Fig. 5.9, lane 5). A weak signal was detected for OXA1L 
in the sample obtained from immunoprecipitation of MRPL45FLAG (Fig. 5.9, lane 4). 
In order to further identify the proteins that interact with MRPL45FLAG, the sample obtained 
from the immunoprecipitation experiments on HEK293 and HEK293-MRPL45FLAG cells, in 
presence of ethidium bromide, were also analysed via mass spectrometry (qv 5.1.1.) and are 
listed in Appendix 13. For every protein identified, 3 values were reported: the sum of raw spectra 
(log(I)), the number of peptides found (rI) and the expectation of finding the protein stochastically 
(log(e)). The data were sorted according to this last value, setting -2 as cut off point. Protein 
identified with a log(e) major than -2 have a 1 in 100 chance of a stochastic protein assignment. 
The experiment was repeated twice using 2 different controls, either HEK293 cells or induced 
HEK293-MRPS27FLAG cells, each after ethidium bromide treatment. For the biological repeat, 
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the cell line overexpressing MRPS27FLAG was used. This was a better control for the experiment 
since MRPS27 is a mitochondrial protein. 
The proteins identified in the second biological repeat were limited. Several mitochondrial 
proteins were detected the proteomic analysis. Amongst these were chaperones (mt-HSP70, 
HSP60, etc), but these were also identified in the control samples. OXPHOS components were 
present, as well as several matrix proteins. It is likely that several of these proteins were 
interacting non-specifically since several were also detected in the control samples. No IMM 
proteins that might be the membrane partners of MRPL45 were identified. The most interesting 
proteins identified were prohibitin, prohbitin 2 and stomatin-like protein 2. The latter was reported 
to interact with prohibitin and prohibitin 2 (Christie DA et al., 2011), which form a large, multimeric 
ring complex in the IMM (Nijtmans LG et al., 2002). Prohibitin was reported as a component of 
the nucleoids that was able to interact with mtDNA but also with the mitoribosome (He J et al., 
2012). However, prohibitin was also identified in the control sample, with a different ensemble 
identifier. Interestingly, neither LetM1 nor OXA1L were detected.  
The mass spectrometry data obtained from the first biological repeat of the 
immunoprecipitation experiment showed the presence of 2 mitoribosomal proteins in the sample 
obtained from HEK293-MRPL45FLAG. These 2 proteins, MRPL39 and MRPL24, are found in 
close proximity of MRPL45. 
Previously in this chapter, I demonstrated that the addition of a FLAG-tag at the C-terminus of 
MRPL45 did not affect neither protein synthesis nor mitoribosome assembly and that is also did 
not affect the ability of MRPL45 to bind the membrane. In order to confirm that the FLAG-tag was 
not disrupting the interaction of MRPL45 with putative membrane proteins, the 
immunoprecipitation was repeated on cells overexpressing wild type MRPL45.  
First, the ability of MRPL45 antibody to perform the immunoprecipitation was assessed. 
HEK293-MRPL45 cells were induced for 3 days in 75 cm2 flasks. Once 80% confluent, the cells 
were harvested and mitochondria extracted. The immunoprecipitation was performed with 
MRPL45 antibody (5 µg) immobilised on magnetic beads (30 µg) (qv 2.9.) and incubated with the 
lysate after removal of the excess of antibody. Western blot analysis was performed to investigate 
the result of the immunoprecipitation (Fig. 5.10). 
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Figure 5.10 Immunoprecipitation of MRPL45 to identify the presence of 
components of the mitoribosome 
Western blot analyses of cell lysate (≈30 µg) and immunoprecipitated samples (half of 
the final volume) from HEK293-MRPL45 after 3 days of induction. The success of the 
immunoprecipitation was confirmed with antibodies against MRPL45. The blot was 
interrogated with antibodies against MRPL11 and MRPS26 and OXA1L and LetM1.  The 
experiment was performed once. 
The immunoprecipitation of MRPL45 was successful, as shown by the presence of MRPL45 
in the eluted sample. The mitoribosome (represented by MRPL11 and MRPS26) was also 
successfully immunoprecipitated. A major enrichment of the mt-LSU protein MRPL11 was 
detected, when compared to the mt-SSU protein MRPS26, suggesting that a bigger proportion of 
mt-LSU was precipitated when compared to the mt-SSU. The IMM protein OXA1L was well 
represented in the eluted sample, indicating its interaction with the mitoribosome. A weak signal 
was also detected for the IMM protein LetM1.  
Because MRPL45 antibody was efficient in immunoprecipitation of its target, the experiment 
was repeated on HEK293-MRPL45 in the absence of assembled mitoribosome. Cells were grown 
in 75 cm2 flasks for 10 days in ethidium bromide (250 ng/mL), with overexpression of MRPL45 
during the last 4 days. Half of the resulting mitolysate was incubated with magnetic beads coated 
with either antibodies against MRPL45 or MNKI. MNKI is a protein involved in cytosolic translation 
and was used as experimental control. The bound proteins were eluted from the beads in 50 µL 
of 1x sample buffer after incubation at 95°C for 3 minutes. A proportion (1/3) of the eluted volume 
was analysed via western blot, together with 30 µL of whole cell lysate (Fig. 5.11). 
 
Figure 5.11 Immunoprecipitation of MRPL45 in cells incubated with ethidium bromide.  
Western blot analyses performed on HEK293 cell lysate (30 µg, lane 1) and the samples obtained 
from immunoprecipitation of MRPL45 (lane2) or MNK1 (lane 3) from HEK293-MRPL45 cells 
incubated with ethidium bromide for 10 days and with overexpression of MRPL45 for 4 days. 
Antibodies against MRPL45 were used to confirm the success of the immunoprecipitation. 
Antibodies against OXA1L were also used. The figure is representative of 3 biological repeats. 
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The immunoprecipitation of MRPL45 was efficient (Fig. 5.11, lane 2). A weak signal was 
detected for OXA1L in the sample immunoprecipitated with MRPL45 (Fig. 5.11, lane 2), as 
previously observed for MRPL45FLAG immunoprecipitation in presence of ethidium bromide (Fig. 
5.9). No signals for either OXA1L or MRPL45 were detected in the control immunoprecipitation 
(Fig. 5.11, lane 3). Unfortunately, the mass spectrometry analysis that was also performed on the 
samples identified only few proteins for both the biological repeats performed (Appendix 14). 
None of the proteins identified were putative membrane candidates that would be predicted to 
mediate the interaction. 
5.5. Is MRPL45 part of a subcomplex formed during mt-LSU biogenesis? 
The proteomic studies performed on HE293-MRPL45FLAG cells after ethidium bromide 
treatment identified the presence in the immunoprecipitated sample of 2 mitoribosomal proteins 
(Appendix 13). These 2 proteins are MRPL39 and MRPL24, and are found in direct contact of 
MRPL45 (Fig. 5.12). 
 
Figure 5.12 Localisation of MRPL45, MRPL24 and MRPL39 within the mt-LSU. 
The mt-LSU (PDB 3J7Y (Brown A et al., 2014)) is represented on PyMol as surface in 
desaturated blue. MRPL45 (red), MRPL39 (magenta), MRPL24 (yellow) are highlighted. 
The mt-SSU is shown in desaturated green. 
The biological replicate of the experiment failed to identify these proteins. Despite this, since 
the only mitoribosomal proteins identified in the sample are ones that are found on either side on 
MRPL45, it was tempting to speculate that MRPL45, MRPL24 and MRPL39 form a subcomplex 
MRPL45 
MRPL39 MRPL24 
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that might represent one of the steps of mitoribosome biogenesis. To test this hypothesis , the 
level of MRPL24 and MRPL39 were analysed in ethidium bromide treated wild-type HEK293 cells 
and compared to HEK293-MRPL45FLAG cells also treated with ethidium bromide for 10 days, 
with overexpression of the recombinant protein in the last 4 days of e thidium bromide treatment. 
Because MRPL45, MRPL24 and MRPL39 appeared to form a subcomplex, a hypothesis could 
be that the overexpression of MRPL45FLAG in presence of ethidium bromide might lead to 
increased steady state levels of the other 2 mitoribosomal proteins when compared with wild type 
cells also incubated with the intercalating agent. The samples were analysed via western blotting 
(Fig. 5.13). 
 
Figure 5.13 Steady state level of MRPL24 after ethidium bromide 
treatment, in presence or absence of MRPL45FLAG overexpression.  
Western blot analysis was performed on cell lysates (≈30 µg) obtained from uninduced 
HEK293-MRPL45FLAG untreated (lane1) or those incubated with 250 ng/mL of ethidium 
bromide for 10 days with (lane 2) or without (lane 3) induction of MRPL45FLAG during the 
last 3 days of the treatment. The efficiency of the overexpression was confirmed with 
antibodies against FLAG. The quality of the loading was detected with antibodies against 
SDH70. The figure is representative of 2 biological repeats. 
The western blot analysis did not show an increase in the steady state level of MRPL24, 
indicating that the overexpression of MRPL45FLAG does not increase the expression or stability 
of this protein. The success of the overexpression was proved with antibodies against the FLAG-
tag and the equality of the loading was confirmed with antibodies against the IMM protein SDH70 . 
The blot was also interrogated with an antibody for MRPL39, but no signal was detected. 
5.6. Discussion 
The ability of MRPL45 to interact directly with the inner mitochondrial membrane was 
demonstrated in chapter 4. This chapter aimed to clarify the mode of this interaction. For this 
purpose, a cell line able to inducibly overexpress MRPL45FLAG was prepared.  
The FLAG tag was inserted at the C-terminus of the protein. The overexpression of 
MRPL45FLAG did not affect the steady state level of mitochondrial protein, cell morphology or 
growth rate. The sucrose gradient analysis performed after overexpression of the protein showed 
its integration in the mt-LSU, suggesting that the addition of the FLAG did not prevent the protein 
from being assembled in this subunit. Although these results suggest that the homeostasis of the 
cells was not affected, no information of the ability of MRPL45FLAG to interact directly with the 
IMM could be inferred. Because of the importance of a concomitant insertion of the mtDNA 
1        2        3     
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encoded proteins in the IMM with translation, it is likely that more anchoring points cooperate to 
secure the interaction between the IMM and mitoribosome, as previously shown in yeast (Pfeffer 
S et al. 2015). It is therefore possible that the interaction of the whole monosome is maintained 
despite the absence of one (or more) of these anchoring points. The ability of MRPL45FLAG to 
associate directly the IMM was assessed using the protocol developed to study membrane 
interaction, under conditions of overexpression of the tagged protein in absence of the fully 
assembled subunits of the mitoribosome. The data obtained confirmed that the FLAG-tagged 
protein retained the ability to directly bind the IMM.  
The results obtained for MRPL45FLAG suggested that the addition of a FLAG-tag at the C-
terminal of MRPL45 did not affect the role of MRPL45. As a consequence, in the following chapter, 
two MRPL45 constructs presenting a FLAG-tag will be prepared to identify the domain of MRPL45 
involved in the interaction with the IMM. Due to the FLAG-tag, these will be easily discerned from 
the endogenous protein. In chapter 6, immunoprecipitation of MRPL45FLAG (via the FLAG) will 
be used to identify putative membrane proteins that might be interacting directly. 
Concerning the interaction of MRPL45 with the membrane, the prediction of hydrophobic 
domains of MRPL45 did not suggest the presence of transmembrane domains, indicating that the 
interaction was likely to be either with an IMM protein or with the phospholipidic bilayer. The mass 
spectrometry analysis performed on the samples obtained by immunoprecipitation of 
MRPL45FLAG or MRPL45 did not identify any putative interacting membrane proteins, although 
western blot analysis did identify a weak signal for OXA1L in the immunoprecipitated sample . 
This might indicate a non-stoichiometric interaction between MRPL45 and OXA1L. Despite this, 
no convincing evidence was found to substantiate the existence of a IMM protein that could 
mediate the interaction with MRPL45. Therefore, it might be that MRPL45 interacts directly with 
the inner mitochondrial membrane. However, it is important to remember that despite the mass 
spectrometry method used to analyse the immunoprecipitated samples being efficient in detecting 
membrane proteins, it is possible that some proteins were not detectable using this technique.  
Interestingly, of the 80 proteins present in the human mitoribosome, in absence of the 
assembled mt-LSU, only MRPL39 and MRPL24 were co-immunoprecipitated with MRPL45FLAG. 
These 2 proteins are found on either side of MRPL45 and the recent cryo-EM structure of the 
human mt-LSU (Brown A et al., 2014). Unfortunately, it was not possible to replicate this result.  
To date, the steps involved in the assembly process of the mt-LSU are still poorly defined. It 
is possible that MRPL45, MRPL24 and MRPL39 constitute a subcomplex of the large subunit, 
which might be stable in the absence of the 16S rRNA and the other mitoribosomal proteins. If 
this were the case, the overexpression of MRPL45FLAG in the absence of assembled mt-LSU 
would be expected to lead to the increase of the steady state levels of MRPL24 and MRPL39, 
stabilised by complexing with MRPL45FLAG. Because this effect was not observed, it is unlikely 
that these 3 proteins compose a subcomplex of the mt-LSU. The co-immunoprecipitation of 
MRPL39 and MRPL24 with MRPL45 might simply confirm the direct interaction of these proteins. 
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Chapter 6: Investigation of putative membrane-interacting domains 
of MRPL45 
6.1. Identification of the putative membrane-interactive domains and 
their analysis via modification of the protein sequence 
The previous chapter confirmed the ability of MRPL45 to bind directly to the IMM. In order to 
further investigate this interaction, alterations were introduced into the candidate membrane-
binding domains of MRPL45. 
The changes introduced into the first construct were based on the observation that the helix 
α2 (residues 118-129) and the following unstructured sequence (residues 130-136) of MRPL45 
(RefSeq NP_115727.5) were the most protruding domain in the structure of the human 
mitoribosome (Brown A et al., 2014) (Fig. 6.1). 
 
Figure 6.1 Visualisation of the position of MRPL45 within the large subunit of 
the human mitoribosome. 
The figure was obtained using PyMol from the PDB file 3J7Y (Brown A et al., 2014). The 
mt-LSU surface is visualised in grey, whereas MRPL45 is depicted as cartoon in red.  Helix 
α2 is labelled. 
In order to investigate the contribution of this MRPL45 domain in the interaction with the 
membrane, the polar or charged amino acids present were mutated to alanine. This amino acid 
has a methyl group as a side chain, which is not bulky and not reactive, and it is therefore 
commonly used in mutation analyses to evaluate the contribution of specific amino acids. In this 
construct, the mutated residues were Gln 119, Arg 123, Arg 124, Lys 126, Asp 127, Tyr 128 Lys 
133 Lys 135 and Asp136 (Fig. 6.2A, indicated in yellow) and are all found at the beginning of what 
is identified as the ‘Tim44-like’ domain of MRPL45. Asp129 was not mutated into alanine since 
its chain was not protruding towards the outside of the structure and was therefore predicted to 
MRPL45 
mt-LSU 
α2 
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be unlikely to be involved in the membrane interaction. The construct will be identified in this study 
as MRPL45FLala. Although the substitution with alanine should not perturb the formation of the 
helix, the potential effects of these mutations on the secondary structure of the domain were 
predicted using JPred4 (Drozdetskiy A et al., 2015), and the results are shown in Fig 6.2B. 
 
 
 
Figure 6.2 Mutated residues on the most protruding domain of MRPL45 and their effect on 
the secondary structure. 
A) Visualisation of residues mutated (yellow) on MRPL45. The cartoon representation 
was obtained from chain d of the PDB file 3J7Y. B) Prediction of the effects of the 
mutations on the secondary structure with JPred4 (Drozdetskiy A et al., 2015). Jnetpred 
indicates the consensus prediction generated from several methods and its confidence is 
reported at JNETCONF. JNETSOL25, 5 and 0 predict the solvent accessibility, where ‘B’ 
indicates a buried residue. The differences are circled in green. The structure prediction 
was also predicted using the Hidden Markov Model (JNETHMM) and the Position-
Specific Scoring Matrix prediction (JNETPSSM). For the structure prediction models 
used, the red tubes indicate helices. The mutated residues in the MRPL45 sequence are 
indicated by a blue asterisk. 
The mutations performed are not predicted to alter the secondary structure of the domain, but 
might have an effect on the solvent accessibility of some residues, highlighted in green in Fig. 
6.2B. 
To evaluate the importance of the mutated residues, the conservation of the domain subjected 
to mutations was inferred from the alignment of the available sequences of MRPL45 from different 
species (Fig. 6.3). The amino acids mutated in MRPL45FLala are indicated by asterisks. 
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Figure 6.3 Conservation of the mutated area of MRPL45 throughout different species.  
The sequences of MRPL45 available were aligned using Jalview 
(ClustalWS) and the residues were coloured with a different intensity of 
blue according to their conservation. The residues mutated in 
MRPL45FLala are indicated by asterisks. 
The mutations (Fig. 6.3, indicated by asterisks) resulted to be localised in a relatively 
conserved domain of MRPL45, which suggests an importance for the protein stability or function. 
In order to investigate membrane-interaction of MRPL45, a second construct was also 
generated. This was based on the homology with TIM44, but also on the structure of porcine 
MRPL45 available thanks to the cryo-EM structure recently released (Greber BJ et al., 2014). The 
cryo-EM studies on the porcine mt-LSU were able to obtain a better resolution for MRPL45 than 
the one obtained for the human subunit. Porcine MRPL45 highlighted the presence of another 
helix (named α1) N-terminal proximal to the previously discussed helix α2 (Fig. 6.4). 
 
Figure 6.4 Structure of porcine MRPL45. 
The structure of MRPL45 was obtained from the cryo-EM structure of 
porcine mt-LSU and visualised in Pymol as cartoon, from the PDB file 
4V1A (Greber BJ et al., 2014).  
The helix α1 closely resembles the helix α1 found in human TIM44 (Fig. 4.1, page 76). Human 
and porcine MRPL45 are very conserved, therefore the presence of helix α1 in human MRPL45 
is highly likely. Its presence was assessed analysing the amino acid sequence via Phyre2 to 
predict the secondary structure of the full length MRPL45. The prediction program generated a 
PDB file that was then visualised in PyMol (Fig. 6.5).  
α2 
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Figure 6.5 Prediction of the structure of the full length human MRPL45.  
Cartoon representation of the full structure of MRPL45, obtained in PyMol 
using the PDB file generated by the structure prediction of Phyre2 (Kelley 
LA et al., 2015). 
The prediction of the full structure of MRPL45 hypothesised the presence of another helix 
ahead of the helix α2, resolved in the cryo-EM structure. This helix will correspond to the helix α1 
present in the porcine homologue and also present in human TIM44 (as helix α1). 
As mentioned in the introduction of chapter 4, studies on yeast Tim44 suggested that the 
folding of helices A0 and A1 (Fig. 4.2, page 77, corresponding to α1 and α2 in human TIM44 and 
MRPL45) is important for membrane interaction of this protein. In addition, crystallographic 
studies on the C-terminus of human TIM44 highlighted the presence of 2 hydrophobic cavities 
within the structure. In particular, a molecule of PEG was recovered in between helices α1 and 
α2 (residues 289-295, Fig. 4.4A highlighted in orange, page 78). These residues are widely 
conserved in the same protein across species (Fig. 4.4B, page 78) and the corresponding region 
of MRPL45 (Fig. 6.6, green box, residues 104-110) appears to be also relatively conserved across 
different species. 
 
Figure 6.6 Conservation of the putative binding domain of TIM44 across its homologue 
MRPL45 in different species. 
The sequences of MRPL45 available for different organisms were aligned 
using Jalview (ClustalWS) and the residues were coloured with a different 
intensity of blue according to their conservation.  The domain of interest 
is indicated by a green box. 
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A different approach was used to investigate the possible role of this conserved region in the 
interaction with the membrane. Instead of mutations of residues, the domain between 1 and 117 
was deleted. This construct will be referred to as MRPL45FLΔ and will be discussed in 6.4. 
This chapter will focus on the generation of the cell lines expressing MRPL45FLala and 
MRPL45FLΔ, and on the evaluation of the ability of these proteins to be integrated in to the mt-
LSU and to directly interact with the IMM. These experiments aim to identify domains of 
importance for the function of MRPL45. 
6.2. Methods 
6.2.1. Site-directed mutagenesis 
It is possible to quickly generate mutations, insertion or deletions using a technique called 
site-directed mutagenesis. The modifications are inserted by primers that are complementary to 
the template DNA around the region to modify. The mutations were introduced using the 
QuikChange II Site-Directed Mutagenesis Kit (Argilent, cat no 200523). This kit allows to 
introduce the modifications directly on a plasmid, using a PCR-like reaction that will synthesise 
the new mutated plasmid. The reaction was carried out as follows: 
Table 6.1 Composition (A) and conditions (B) of the site directed mutagenesis.  
The reaction was carried out using the QuickChange II Site-Directed Mutagenesis kit 
(Argilent) in ProFlex™ PCR machine (Thermo Scientific). 
Reagents Final concentration/amount 
10x Reaction buffer 
dNTPs mix (from the kit) 
100 µg/µL sense primer 
100 µg/µL anti-sense primer 
Template plasmid 
PfuUltra DNA polymerase (2.5 U/µl) 
DI water 
1x 
2 µL 
125 µg/µL 
125 µg/µL 
50 ng 
1.25 U 
Up to 25 µL 
 
Reaction Temperature Duration 
Initial denaturation 
Denaturation 
Annealing 
Extension 
95ºC 
95ºC 
Dependent on the primers 
68ºC 
30 sec 
1 min 
1 min 
1 min/kb plasmid 
Since the mutated plasmid was generated by the reaction in vitro, newly generated DNA will 
not be methylated, unlike the parental one. This difference in methylation state was used to 
selectively digest the parental plasmid with Dpn1, leaving the newly synthesised plasmid with 
A 
B 
x 20 
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the generated mutations intact. The digestion was performed at 37ºC for 90 minutes by addition 
of 0.5 µL of 10 U/µL DpnI (present in the kit). The product (4 µL) was then used to transform 
supercompetent cells (XL1- Blue cells, Agilent), following the protocol in 2.2.2., and plated on 
LB-agar containing the appropriate antibiotic for selection. The plate was finally grown at 37ºC 
overnight to allow the growth of transformed colonies. 
6.2.2. In vitro transcription 
This protocol was used to prepare mRNA transcripts for in vitro translation. A PCR product 
of the gene of interest was prepared (qv 2.3.3.) using cDNA or previous plasmids as a template 
and the primers listed in Appendix 5. The sense primer used will contain the SP6 promoter (5’-
ATT-TAG-GTG-ACA-CTA-TAG-3’), needed to initiate in vitro transcription. The product obtained 
was purified with the QIAquick PCR Purification Kit (Quiagen, cat no 28104) and then used for 
the in vitro transcription. The reaction was carried out using the AmpliScribe T7 High Yield 
Transcription kit (Epicentre, cat no AS2607), mixing the reagents in the same order shown in 
Table 6.2 with care to avoid RNase contamination. 
Table 6.2 Composition of the in vitro transcription reaction performed with 
AmpliScribe T7 High Yield Transcription kit. 
The reagents were added in the same order as the one listed in this table.  
Reagents Amount 
RNase-free water  
10x SP7 buffer 
100 mM ATP 
100 mM CTP 
100 mM GTP 
100 mM UTP 
100 mM DTT 
RiboSafe 
DNA (from PCR reaction) 
SP6 Enzyme solution 
Up to 20 µL 
2 µL 
1 µL 
1 µL 
1 µL 
1 µL 
2 µL 
0.5 µL 
1 µg 
2 µL 
The mixture was incubated at 37°C for 2 hours. After that, the RNA was precipitated using 
ammonium acetate. After addition of 20 µL of 5 M ammonium acetate, the sample was incubated 
for 15 minutes on ice. The RNA was then pelleted by centrifugation at 10,000 g at 4°C for 15 
minutes. The supernatant was discarded and the pellet was resuspended 200 µL of 75% 
ethanol. The sample was then centrifuged again at 10,000 g at 4°C for 15 minutes. The 
supernatant was discarded again, and the pellet was resuspended in 10 µL of RNase-free water 
with the addition of 1 µL of RNase inhibitor (RiboSafe). The quality of the sample (1/10) was 
checked on 1% denaturing agarose gel (qv 6.2.4.). The sample was stored at -80°C. 
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6.2.3. In vitro translation 
The translation of the RNA transcribed in vitro was performed using the following mixture: 
Table 6.3 Composition of in vitro translation reaction. 
Reagents Amount 
Rabbit reticulocyte lysate 
35S-Met easy tag protein mix 
25 µM Amino acids minus Met 
In vitro transcribed RNA 
RiboSafe 
Nuclease-free water 
10 µL 
3.5 µL (35 µCi) 
0.5 µL 
Up to 5 µL 
0.5 µL 
Up to 20 µL 
 The reaction was incubated at 30°C for 1 hour. Sample buffer was added to every sample, 
which were heated to 95°C for 3 minutes. The samples were resolved on a 12% SDS-PAGE 
gel. The gel was fixed overnight in a solution composed of 30% methanol, 10% acetic acid and 
3% glycerol and then vacuum dried in between filter paper at 65°C for 2 hours. The signals for 
the translated products were detected using the Typhoon FLA 9500 system and ImageQuant 
software (GE Healthcare), after exposition of the gel to a PhosphorImage screen for 1 day. 
6.2.4. Denaturing agarose gel for RNA electrophoresis 
All the equipment to be used for the electrophoresis was soaked in DEPC water and 3% 
H2O2 for 1 hour and then rinsed twice with DEPC water. The samples were prepared as in Table 
6.4A and incubated at 55ºC for 15 minutes. After that, every sample was mixed with 1 µL of 2 
mg/mL ethidium bromide and 2.2 µL of loading dye (Table 6.4B).  
Table 6.4 Preparation of samples for RNA electrophoresis (A) and 10X MOPS 
composition (B). 
Reagents Amount 
10x MOPS  
37% Formaldehyde (Sigma, cat no F1635)  
Formamide (Sigma, cat no F7503)  
RNA  
DEPC H2O  
2 µL 
3 µL 
7 µL 
x µL 
Up to 20 µL 
 
Reagents Final concentration 
MOPS (Sigma, cat no M1254)  
CH3COONa  
EDTA 
400 mM 
100 mM 
10 mM 
A 
B 
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The samples were run on a 1% denaturing agarose gel (Table 6.5) in order to separate RNA 
species of different molecular weight.  
Table 6.5 Denaturing agarose gel (1%) for RNA electrophoresis 
Reagents Final concentration 
Agarose  
DEPC H2O     
1% 
87.5% 
Warmed up until the agarose melts, then added 
10x MOPS  
37% Formaldehyde   
1x 
0.925% 
Once solidified, the samples were loaded and the gel was run at 50-60 V until the needed 
separation of the components was reached. At the end of the electrophoresis, the samples 
quality and migration was checked by imaging the gel with the ChemiDoc system.  
6.3. Investigation of the importance of the α2 helix of MRPL45 
6.3.1. Generation of stable cell lines able to express mutant 
MRPL45FLAG (MRPL45FLala) 
The mutant MRPL45FLAG construct (MRPL45FLala) was personally designed (Appendix 6) 
and then commissioned to the GeneArt service (Thermo Scientific), who synthesised the 
fragment and cloned it into a plasmid carrying kanamycin resistance, named pMK. To allow the 
study of the mutant protein in the absence of the endogenous MRPL45, silent mutations in the 
sequence targeted by siRNA02 (Appendix 4) were introduced so that MRPL45FLala mRNA 
cannot be bound with this siRNA. As MRPL45FLAG was shown to interact with the IMM (Fig. 
5.6, page 101), a FLAG tag at the C-terminus of this construct was also added. This will allow 
to use the anti-FLAG antibody on western blot analysis to easily discriminate the mutant 
MRPL45 from the endogenous counterpart. The sequence of MRPL45FLala designed was 
delimited by 2 BamHI restriction sites, to allow the extraction of the insert from the delivered 
pMK plasmid and it subsequent cloning into pcDNA5/FRT/TO. MRPL45FLala-pcDNA5/FRT/TO 
was used to transfect HEK293 Flp-In cells to express the protein under tetracycline control.  
Because of problems in its production, the construct delivered was not sequence -verified. 
The MRPL45FLala-pMK plasmid (20 ng) was transformed into competent cells (qv 2.2.2.). 
Positive colonies were expanded in LB media containing 50 µg/mL kanamycin and the plasmid 
was extracted. The plasmid obtained (3 mg) was digested with BamHI (qv 2.3.7.) in a final 
volume of 20 µL, and the products of the digestion (1 µL) was resolved on a 1.2% agarose gel 
to assess the efficiency of the reaction (Fig. 6.7). 
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Figure 6.7 Products of MRPL45FLala-pMK digestion with BamHI. 
MRPL45FLala-pMK (3 mg) obtained from GeneArt (Appendix 6) were digested with 
BamHI (20 µL final volume) and 1 µL (Dig) was resolved on a 1.2% agarose gel. The 
undigested plasmid (Pl) was also loaded on the gel. The size of the desired product 
is indicated by the arrow. 
The DNA electrophoresis analysis showed the presence of 3 species after digestion of 
MRPL45FLala-pMK with BamHI. Together with the heaviest species (≈ 2300 bp) that 
corresponded to the pMK empty plasmid, 2 lighter forms were detected. One species at 
approximately 1000 bp matched the size expected for MRPL45FLala insert (984 bp) (Fig. 6.7, 
indicated by the arrow), whereas the smallest band of approximately 500 bp was an unexpected 
product of the digestion. The remaining volume of the reaction was resolved on a new agarose 
gel and the species corresponding to ≈ 1000 bp was excised. After gel extraction, the desired 
insert was ligated into BamHI-digested pcDNA5/FRT/TO and then used to transform competent 
cells as previously described. In order to discriminate colonies successfully transfected with 
MRPL45FLala-pcDNA5/FRT/TO from the ones containing the empty plasmid, half of every 
expanded colony was analysed using the cracking gel technique (qv 2.3.10.) (Fig. 6.8). 
 
Figure 6.8 Identification of colonies positively transformed with MRPL45FLala-
pcDNA5/FRT/TO. 
Cracking gel technique (qv 2.3.10.) was used on expanded colonies obtained from 
the transformation of α-competent cells with MRPL45FLala-pcDNA5/FRT/TO. The 
black arrow identifies the higher products that indicates the colonies containing the 
insert within pcDNA5/FRT/TO. 
MRPL45FLala- pcDNA5/FRT/TO 
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The figure showed that colonies 2, 3 and 5 presented a band corresponding to the plasmid 
that was heavier than other colonies (1, 3, 6, 7). This indicates that colonies 2, 3 and 5 are likely 
to contain a copy of the plasmid with MRPL45FLala successfully inserted in the cloning site.  
Because the same restriction site was used at either side of the insert, diagnostic digestion 
was performed to identify the colonies containing the insert with the correct orientation. At this 
purpose, the plasmid was extracted from colonies 2, 3 and 5 and 500 ng of each plasmid were 
digested either with AflII or simply linearized by digestion with KpnI. AflII will cut the plasmid 21 
bases ahead of BamHI site and the correctly-oriented insert at 848 bases from the insertion site. 
As a consequence, the formation of a heavy fragment of ≈5 kb and one of ≈850 bp upon 
digestion with AflII will identify colonies containing the insert in the wanted orientation. In case 
a fragment of ≈100 bp was present instead of the ≈850 bp, the correspondent colony will contain 
a plasmid with the insert in the wrong orientation. The products of every digestion were analysed 
via DNA electrophoresis (Fig. 6.9). 
 
Figure 6.9 Diagnostic digestion of MRPL45FLala-pcDNA5/FRT/TO. 
MRPL45FLala-pcDNA5/FRT/TO from colonies 2, 3 and 5 was digested with either 
KpnI (K) or AflII (A) to, respectively, linearize the plasmid or investigate the 
orientation of the insert. The samples were resolved on a 1.2% agarose gel together 
with a size marker (M). The presence of a band at ≈ 800 bp will indicate the correct 
orientation of the insert and is indicated by an arrow. 
The digestion of the plasmids obtained from colonies 2 and 5 with AflII produced a fragment 
of approximately 800 bp (Fig. 6.9, lanes 2 and 6, indicated by an arrow), indicating the correct 
orientation of the insert within the plasmids of these colonies. The smaller band detected for the 
same digestion performed on MRPL45FLala-pcDNA5/FRT/TO extracted from colony 3 
suggested that this colony contained the insert with the wrong orientation (Fig. 6.9, lane 4). All 
the plasmids were successfully linearized by KpnI. 
Prior generation of a cell line able to express MRPL45FLala, the sequence of the insert within 
pcDNA5/FRT/TO was verified (qv 2.3.10.). The sequence obtained confirmed the identity of the 
construct designed (Apprendix 10), therefore the plasmid was used to transfect HEK293 Flp-In 
cells (qv 2.1.6.). After antibiotic selection, single colonies were expanded and samples were 
prepared for long term storage in liquid nitrogen. 
MRPL45FLala-pcDNA5/FRT/TO 
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6.3.2. Effects of MRPL45FLala expression 
The ability of HEK293-MRPL45FLala to express the protein was tested. Three different 
clones able to express the mutant protein were tested. Since the data obtained were in 
agreement between the different clones, only one will be represented in the followin g figures. 
Cell growth was monitored as cell confluence for 6 days using the IncuCyte system (Fig. 6.10A). 
Cell lysate obtained after induction with tetracycline for 3 days was analysed via western blotting 
(Fig. 6.10B). The cell morphology after 5 days is shown in Fig. 6.10C.  
 
 
 
 
 
Figure 6.10 Effects of the expression of MRPL45FLala in HEK293 cells on steady state 
level of mitochondrial proteins and on cells growth. 
HEK293-MRPL45FLala cells were induced for 6 days with the addition of 1 µg/mL of 
tetracycline. Uninduced cells were also grown in parallel. Cell growth (A) was monitored by 
confluency estimate every 3 hours throughout the experiment (2 biological repeats).  
Representative figure of western blot analysis (B) performed on lysate (≈30 µg) obtained from 
uninduced and induced HEK293-MRPL45FLala cells after 3 days of induction. Antibodies 
against FLAG were used to detect the expression of the mutant protein. Steady state levels of 
the mitoribosomal protein MRPL24 and of the OXPHOS component COXII were also evaluated. 
SDH70 was used as a loading control. Cell morphology after 5 days of induction is also shown 
(C). The results are representative of 3 biological repeats. 
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 The expression of the FLAG-tagged mutant protein did not affect cell growth over a 6 days’ 
period (Fig. 6.10A). Cell morphology also appeared unaltered (Fig. 6.10C). The expression of 
MRPL45FLala was successful (Fig. 6.10B). The FLAG antibody detected the presence of 2 
species, also previously observed for the detection with the same antibody on cell lysate from 
induced HEK293-MRPL45FLAG cells (Fig. 5.5B, page 100). Since its detection was through the 
FLAG peptide at the C-terminal, this lower Mr species was assumed to be an N-terminal 
cleavage of the protein performed upon or after import. It is important to notice that the detection 
of the FLAG-tagged product required a long exposure of the membrane (≈ 16 seconds), which 
indicate a low steady-state level of the protein. This was also observed comparing the steady 
state level of MRPL45FLala and MRPL45FLAG after 3 days of induction (Fig. 6.27). It is 
possible, indeed, that the mutations generated on MRPL45 affected the stability of the protein, 
although they were not predicted to significantly disturb the secondary structure of the protein 
(Fig. 6.2). The western blot analysis also suggested a mild reduction of the steady state level of 
the mt-LSU components MRPL24 and of the mtDNA-encoded COXII. The equality of the loading 
was confirmed with the detection of SDH70.  
In order to exclude that the low steady-state level of MRPL45FLala observed was due to 
problems in the expression of the correspondent mRNA, qPCR was performed on cDNA 
obtained from reverse transcription of total RNA from uninduced and induced (3 days) HEK293-
MRPL45FLala cells. The level of the transcripts was evaluated with primers targeting MRPL45 
that will, therefore, also measure the endogenous expression of MRPL45 in both the samples. 
The levels of COXII mRNA and 16S rRNA were also measured. The data were normalised on 
the level of 18S rRNA and the result are shown in the following figure.  
 
 
Figure 6.11 Levels of 16S rRNA, COXII mRNA and MRPL45 mRNA upon 
MRPL45FLala induction. 
qPCR was performed on cDNA obtained by HEK239-MRPL45FLala uninduced or induced with 
1 µg/mL of tetracycline for 3 days. The level of MRPL45 were evaluated, together with the levels 
of the 16S mt-LSU rRNA and the mt-encoded COXII mRNA. The results shown were 
normalised to the cytosolic 18S rRNA. The values correspond to 2 biological repeats.  
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The expression of MRPL45FLala caused an increase of approximately 6 folds of the total 
level of MRPL45 mRNA (endogenous + mutated) when compared to the uninduced sample 
(endogenous), indicating that the expression of the mRNA of MRPL45FLala was successful. No 
relevant effects were detected on the levels of 16S and COXII mRNA. This result support s the 
hypothesis of a reduced stability of the mutant protein. 
The low steady-state level of MRPL45FLala might be due to a failure of its targeting to 
mitochondria.  It is important to remember that the length of the targeting sequence of MRPL45 
(as well as its cleavage) has not been confirmed to date. The mutations generated are located 
relatively far from the N-terminal, in particular between residues 119 and 136. To confirm the 
localisation of the mutated protein within mitochondria, cell lysate and mitochondrial lysate were 
prepared from HEK293-MRPL45FLala induced for 3 days. The presence of the mutant protein 
within mitochondria would be confirmed by its enrichment (expected of approximately 5 times) 
in the mitochondrial lysate when compared to the cell lysate. After protein estimation with the 
Bradford assay, the same amount of cell lysate and mitochondrial lysate was resolved on a 12% 
SDS-PAGE gel and analysed via western blotting (Fig. 6.12). 
 
Figure 6.12 Enrichment of MRPL45FLala in mitochondrial lysate.  
Western blot analysis was performed on cell lysate and mitochondrial lysate (both ≈15 and ≈30 
µg) obtained from HEK293-MRPL45FLala after induction for 3 days with 1 µg/mL of tetracycline. 
Antibodies against FLAG were used to detect the expression of the mutant protein.  The steady 
state level of the matrix protein GDH were also evaluated. The experiment was not replicated. 
A distinct enrichment of MRPL45FLala was observed in the mitochondrial lysate (Fig. 6.12, 
lanes 2 and 4) when compared to the same amount of cell lysate (Fig. 6.12, lanes 1 and 3). A 
very similar pattern was observed for the matrix protein GDH, indicating that the FLAG-tagged 
mutant protein is efficiently targeted to mitochondria. 
It is possible that the low steady-state level of MRPL45FLala could be due to a fast 
degradation of the protein. One of the roles of mitochondrial proteases is degrading misfolded 
and damaged proteins. Several mitoproteases have been identified to date (Quirós PM et al., 
2015). From these, Lon protease homologue (LONP) and Clp protease proteolytic subunit 
(CLPP) are 2 of the main proteases suggested to be important for quality-control in the 
mitochondrial matrix. In the attempt to increase the steady state level of MRPL45FLala, 
depletion of either of these 2 proteases was performed. Because of the importance of proteases 
in the homeostasis of cells, the depletion was carried out only for 3 days, both on induced cells, 
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and on induced cells also depleted of MRPL45. The cell lysates obtained at the end of the 
treatment were analysed via western blotting (Fig. 6.13). 
 
Figure 6.13 Depletion of proteases LONP or CLPP in cells overexpressing 
MRPL45FLala, in presence or absence of endogenous MRPL45.  
HEK293-MRPL45FLala were induced for 3 days and then depleted for 6 days of either CLPP 
(lanes 2,3) or LONP (lanes 4,5), with or without concomitant depletion of endogenous MRPL45 
(lanes 3,5 and 2,4 respectively). The expression of MRPL45FLala was continued during the 
depletion. Induced cells were also incubated for 6 days with NT-siRNA as a control (lane 1). The 
cell lysates (≈30 µg) obtained were analysed via western blotting. The level of MRPL45FLala 
were detected with an antibody targeting the FLAG-tag. The efficiency of the depletions was 
assessed with antibodies against CLPP, LONP and MRPL45. The level of the nuclear encoded 
SDH70 were used as a loading control. The experiment was not replicated. 
The western blot analysis showed that the depletion of CLPP and LONP were  efficient (Fig. 
6.13, respectively lanes 2,3 and 4,5). When MRPL45 depletion was present, this was also 
efficient (Fig. 6.13, lanes 3,5). No effects on the steady state level of the FLAG-tagged protein 
were detected. Both in presence or absence of endogenous MRPL45, depletion of the proteases 
CLPP and LONP did not affect the steady state level of MRPL45FLala, indicating  that there are 
not involved in its degradation. 
6.3.3. Integration of MRPL45FLala in the mitochondrial large 
mitoribosomal subunit 
The mutations generated on MRPL45 might affect its ability to be integrated into the mt -LSU 
or to interact with the IMM. To test the first possibility, lysate (700 µg) obtained after 3 days of 
expression of MRPL45FLala was analysed on a 10-30% isokinetic sucrose gradient to separate 
the components according to their molecular weight and, therefore, isolate the mitoribosomal 
subunits. Western blot analysis was performed on 1/10 of each of the 11 fractions collected (Fig. 
6.14). 
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Figure 6.14 Sucrose gradient analysis of HEK293-MRPL45FLala after 3 days of induction. 
Cell lysate (≈700 µg) obtained from HEK293-MRPL45FLala after 3 days of induction with 1 
µg/mL of tetracycline was analysed on a 10-30% isokinetic sucrose gradient. A proportion (1/10) 
of the 11 fractions obtained was analysed via western blot, together with ≈40 µg of lysate from 
uninduced and induced cells. Antibodies against FLAG were used to detect the distribution of 
the mutant protein. Antibodies against MRPL11 and MRPS22 were used to investigate the 
distribution in the different fraction of, respectively, mt-LSU and mt-SSU. The figure is 
representative of 2 biological repeats. 
The mt-LSU was identified mainly in fraction 6, while the small subunit was enriched in 
fractions 4 and 5 (Fig. 6.14). No signal from the FLAG antibody was detected in the fractions 
corresponding to the mt-LSU and MRPL45FLala seemed to localise mainly in fraction 1 and 2. 
It is important to remember that, for the overexpression of MRPL45FLAG (Fig. 5.4, page 98), a 
signal from the fractions corresponding to the mt-LSU was clearly observed when a comparable 
amount of sample (1/10 of a fraction, from 700 µg of cell lysate loaded on the gradient) was 
analysed via western blotting. MRPL11 and MRPS22 were used to localise, respectively, mt -
LSU and mt-SSU along the sucrose gradient. 
Routinely, only 1/10 of every fraction obtained in the sucrose gradient analysis is resolved 
on SDS-PAGE. Because the steady-state level of MRPL45FLala appeared to be low, I thought 
possible that the lack of signal in fraction 6 was due an undetectable amount of protein in the 
sample analysed via western blot. At this purpose, the fractions (from 5 to 8) corresponding to 
the mt-SSU and mt-LSU in Fig. 6.14 were TCA-precipitated (qv 2.5.3.) to further confirm the 
absence of the FLAG-tagged protein. The whole resuspended sample was analysed via western 
blot (Fig. 6.15). 
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Figure 6.15 Sucrose gradient analysis of fractions 5 to 8 from induced 
HEK293-MRPL45FLala after TCA-precipitation. 
Cell lysate (≈700 µg) was obtained from HEK293-MRPL45FLala after 3 days of induction with 1 
µg/mL of tetracycline and analysed on a 10-30% isokinetic sucrose gradient. Fractions 5 to 8 
were TCA precipitated and analysed via western blot. Antibodies against FLAG were used to 
detect the distribution of the mutant protein. Antibodies against MRPL11 and MRPS26 were 
used to investigate the distribution in the different fraction of, respectively, mt -LSU and mt-SSU. 
While MRPL11 and MRPS26 were localised, respectively, mainly in fractions 6 and 5, no 
signal was detected from the FLAG-antibody in any of these fractions (Fig. 6.15), even at high 
exposure times (up to 1 minute). Antibodies against MRPL45 confirmed the presence of the 
endogenous MRPL45 mainly in fraction 6 and 7. 
Despite the failure of MRPL45FLala to integrate in the mt-LSU upon induction, I decided to 
test the possibility of its integration in absence of the endogenous protein. As shown in chapter 
3, MRPL45 is essential for assembled mt-LSU. In the absence of this protein, therefore, 
mitochondria can only assemble mt-LSU by utilising the mutated MRPL45FLala. HEK293-
MRPL45FLala cells were induced for 3 days with 1 µg/mL of tetracycline. Cells were then 
harvested and 1,000,000 cells were seeded in 75 cm2 flasks. MRPL45 depletion was carried 
out with siRNA02 at 33 nM for 6 days (reverse and forward transfection, qv 2.1.5.). The 
expression of the FLAG-tagged mutant protein was continued during the depletion. Because 
silent mutations have been generated in MRPL45FLala in the site targeted by siRNA02 will not 
be targeted by the siRNA and therefore it will still be expressed. At the end of the treatment, 
cells were harvested and 700 µg of cell lysate were analysed on a 10-30% isokinetic sucrose 
gradient. The 11 fractions obtained were TCA-precipitated (qv 2.5.3.) to concentrate the sample 
and facilitate the visualisation of the FLAG-tagged protein and used for a western blot analysis 
(Fig. 6.16A). In parallel HEK293 cells were depleted of MRPL45 for 6 days, as an experimental 
control (Fig. 6.16B). 
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Figure 6.16 Sucrose gradient analysis of HEK293-MRPL45FLala 
A) HEK293-MRPL45FLala cells were induced for 3 days and then depleted of MRPL45 for 6 
days (siRNA02, 33 nM final concentration), continuing the induction. At the end of the treatment, 
cells were harvested and 800 µg of cell lysate were separated on a 10-30% isokinetic sucrose 
gradient. The 11 fractions obtained from the gradient were TCA precipitated and then loaded on 
a 12% SDS-PAGE gel for western blot analysis. Cell lysate (≈40 µg) from uninduced cells and 
from the treated cells were also loaded on the gel. The steady state level of the FLAG-tagged 
protein was detected first. After that, antibodies against MRPL45 and MRPL11 were used to 
localise the mt-LSU, whereas the mt-SSU was localised with antibodies against MRPS17. The 
figure is representative of 2 biological repeats. B) HEK293 cells were depleted for 6 days of 
MRPL45 (siRNA02, 33 nM final concentration) were used as an experimental control for A). Cell 
lysates from untreated HEK293 (WT) and from depleted cells (kd) were analysed via western 
blotting together with the 11 TCA-precipitated fractions obtained from the 10-30% isokinetic 
sucrose gradient analysis. Antibodies against MRPL45 and MPRL24 were used to visualise the 
m-LSU, while antibodies targeting MRPS22 were used to detect the mt-SSU. 
The expression of the protein was successful, as shown by the presence of a signal for the 
FLAG antibody in the lysate from the treated cells (Fig. 6.16A, ‘Ind+kd’). Unlike the previous 
sucrose gradient (Fig. 6.14), a signal from the FLAG-tagged protein was clearly detected in 
fractions 5 and 6 (Fig. 6.16A) and was co-localised with the signal obtained for the mt-LSU 
(MRPL11). It is important to notice that no signal for the FLAG-tagged protein was detected in 
the first fractions of the gradient, suggesting that all the induced protein was completely 
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integrated in the subunit. The incubation of the western blot in Fig. 6.16A with MRPL45 antibody 
will detect both the signal due to the endogenous protein and to the induced MRPL45FLala 
protein. Its detection showed the presence of 3 species. The slowest migrating species, absent 
in the uninduced lysate, corresponds to the mutant protein, while the intermediate species 
correspond to the endogenous protein. The most rapidly migrating species represents the N-
terminal cleaved MRPL45 (see above). The endogenous MRPL45 was mainly present in the 
uninduced lysate and hardly detectable in the induced and depleted lysate. Because the signal 
of the endogenous MRPL45 was weak in the induced and depleted sample, it is possible to 
conclude that the depletion was efficient. Depletion of MRPL45 reduced the level of this protein 
as well as the steady state level of MRPL11, when compared to the uninduced and non-depleted 
sample (Fig. 6.16A, ‘Un’ and ‘In+kd’, respectively) . The mt-SSU protein MRPS22 was mainly 
recovered in fraction 4. The control experiment performed on HEK293 cells depleted of MRPL45 
showed that, despite the reduction of the steady state level of both MRPL24 and MRPL45 upon 
depletion, a proportion of these proteins is still located in the mt-LSU (Fig. 6.16B). In both Fig. 
6.16 A and B, despite the depletion of MPRL45 being successful, the signal detected for 
components of the mt-LSU in the western blot analysis appeared relatively strong. It is, indeed, 
important to remember that every fraction has been concentrated via TCA-precipitation and that 
a large amount of cell lysate (700 µg) was loaded on top of the gradient. 
MRPL45FLala was successfully integrated within the mt-LSU in the absence of the 
endogenous protein, but no information was available from the previous experiment on the 
ability of mt-LSU containing MRPL45FLala to form a translating monosome. This was verified 
on HEK293-MRPL45FLala cells induced for 9 days and depleted of endogenous MRPL45 in the 
last 6 days of induction. Uninduced cells were also incubated with NT-siRNA or MRPL45-siRNA 
for 6 days. At the end of the treatment, cells were visualised at the microscope (Fig. 6.17A) and 
the cell lysate obtained for every sample was analysed via western blot (Fig. 6.17B).   
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Figure 6.17 Effects on MRPL45 depletion on induced HEK293-MRPL45FLala cells. 
MRPL45 depletion was performed using siRNA02 on HEK293-MRPL45FLala uninduced or 
induced with 1 µg/mL of tetracycline. NT-siRNA was used as a control on uninduced cells. Cells 
were visualised at the microscope (A) and cell lysates was analysed via western blot (B). The 
efficiency of the induction was assessed with antibodies targeting the FLAG-tag, while the 
steady-state level of MRPL45 was used to verify the efficiency of the depletion. Antibodies 
against MRPL24 and MRPS17 were also used to assess the effec ts on, respectively, mt-LSU 
and mt-SSU. The steady state level of the mt-encoded COXII was also detected. The IMM 
protein SH70 was used as a loading control. The results are representative of 2 biological 
repeats. 
The depletion of MRPL45 was efficient, as shown in Fig. 6.17B lane 2 by the reduced steady 
state level of MRPL45. Although the expression of MRPL45FLala was efficient (Fig. 6.17B, lanes 
NT-siRNA MRPL45-siRNA Uninduced Induced 
MRPL45-siRNA Uninduced 
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3 and 4), a long exposure was needed to detect the signal, suggesting the low steady state level 
of the protein both in presence and in absence of the endogenous MRPL45. It is important to 
also notice that the steady state level of MRPL45FLala was lower than the level of endogenous 
MRPL45 present in the sample treated with NT-siRNA (Fig. 6.17B, lanes 3, 1 respectively). As 
shown in chapter 3, and confirmed by the results obtained in Fig. 6.17B lane 2, the depletion of 
MRPL45 depletion affects the steady state level of the mt-LSU, leading to an impairment of 
mitochondrial translation. This phenotype was partially rescued by the expression of the mutant 
protein, as shown by the increase of the steady state level of MRPL24 and COXII (Fig. 6.17B 
lane 3), when compared to the sample obtained from the uninduced cell line after depletion of 
the endogenous MRPL45. This result suggests that the mutations generated on MRPL45 are 
not affecting the possibility to generate an actively translating monosomes.  Despite the partial 
rescue observed upon expression of MRPL45FLala, the cells were organised in clumps, as 
observed for MRPL45 depletion on uninduced cells (Fig. 6.17A).  
6.3.4. Rescue of MRPL45 depletion phenotype 
The previous section showed that MRPL45FLala can be integrated in the mt-LSU and that 
its expression is able to partially rescue the phenotype observed upon MRPL45 depletion.  It is 
possible that the full rescue was not obtained because of the low steady state level of this 
protein. To support this hypothesis, a full rescue of the phenotype was attempted by depletion 
of MRPL45 with siRNA02 in cells able to express MRPL45FLAG from mRNA containing silent 
mutations in the region targeted by siRNA02. The silent mutations designed are reported in Fig. 
6.18. This experiment will also further validate the results obtained with the siRNA used in  
chapter 3 of this thesis.  
 
Figure 6.18 Silent mutation generated on MRPL45 at the sequence targeted by siRNA02.  
Silent mutations (red) were introduced in MRPL45 sequence in the region targeted by siRNA02 
(blue). The amino acid sequence correspondent is also reported in bold. 
Silent mutations were generated on MRPL45FLAG-pcDNA5/FRT/TO prepared in chapter 4, 
using site-directed mutagenesis (qv 6.2.1.). The primers used for the reaction were 
MRPL45sisilmutsense and MRPL45sisilmutanti-s (Appendix 5). The annealing temperature 
used was 70ºC, and the extension had a duration of 10 minutes for every cycle. After 
transformation of the product in supercompetent cells, the colonies obtained were expanded on 
a fresh LB-agar plate containing 100 µg/mL of ampicillin and then expanded in liquid LB media 
to perform plasmids extraction. Two of the plasmids obtained were sequenced (qv 2.3.10.) and 
confirmed the presence of the mutations on the sequence targeted by siRNA02 (Appendix 11). 
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MRPL45FLsil-pcDNA5/FRT/TO was used, together with pOG44, to transfect HEK293 Flp-In 
cells and generate a cell line able to overexpress MRPL45FLsil. After antibiotic selection, the 
expanded single colonies obtained were induced for 3 days with 1 µg/mL of tetracycline. The 
results for one of the colonies are shown in the following western blot analysis (Fig. 6.19A). The 
effects of the overexpression on cell growth were monitored over 6 days with the IncuCyte 
system (Fig. 6.19B). The phenotype of the cells after 5 days of expression is showed in Fig. 
6.19C.  
 
 
 
 
 
Figure 6.19 Effects of MRPL45FLsil overexpression on mitochondrial proteins and on cells 
growth. 
Western blot analysis (A) was performed on cell lysates obtained from HEK293-MRPL45FLsil 
cells uninduced or induced for 3 days. Cell growth was monitored (B) during the induction of 
MRPL45FLsil for 6 days (2 biological repeats). The effects on morphology after 5 days of 
overexpression (C) are also reported. The results are representative of 3 biological repeats  
The expression of the protein was very efficient and no effects were observed on the steady 
state level of the mitoribosomal protein MRPL24 or the mt-encoded COXII (Fig. 6.19A). The 
levels of DAP3 appeared slightly reduced in the induced sample. SDH70 confirmed the equality 
of the loading. Cell growth, evaluated as cell confluence, was also unaffected by the 
overexpression of the protein over a period of 6 days (Fig. 6.19B). 
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The levels of overexpression of MRPL45FLsil mRNA were evaluated with qPCR from total 
RNA extracted from HEK293-MRPL45FLsil uninduced and induced for 3 days with 1 µg/mL of 
tetracycline. The levels of 18S rRNA, 16S mt-rRNA, COXII mRNA and MRPL45 mRNA were 
evaluated using the primers in Appendix 5. The data were normalised to 18S rRNA and the 
results are represented in the following bar graph. 
 
Figure 6.20 Levels of 16s mt-rRNA, COXII mRNA and MRPL45 mRNA after 
overexpression of MPL45FLsil. 
qPCR was performed on cDNA obtained from HEK239-MRPL45FLsil uninduced or induced 
for 3 days. The level of MRPL45 were evaluated, together with the levels of the 16S mt -LSU 
rRNA and the mt-encoded COXII mRNA. The results shown were normalised to the cytosolic 
18S rRNA. The values correspond to 2 biological repeats. 
The qPCR showed an overexpression of MRPL45FLsil of more than 5-folds, a value that 
resemble the one observed for MRPL45FLala (Fig. 6.20). 
The ability of MRPL45FLsil to rescue the phenotype observed for MRPL45 depletion was 
tested. HEK293-MRPL45FLsil cells were induced for 3 days and then depleted for 6 days with 
MRPL45 siRNA02, continuing the induction of the FLAG-tagged throughout the depletion. NT-
siRNA was used as an experimental control on uninduced cells. To confirm the efficiency of the 
depletion, uninduced cells were also depleted of MRPL45. At the end of the treatment, cells 
were visualised at the microscope (Fig. 6.21A). Cell lysates were finally analysed via western 
blotting (Fig. 6.21B). 
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Figure 6.21 Effect of MRPL45 depletion in cells overexpressing MRPL45FLsil. 
MRPL45 depletion was performed using siRNA02 on HEK293-MRPL45FLsil uninduced or 
induced with 1 µg/mL of tetracycline. NT-siRNA was used as a control on uninduced cells. 
Cells were visualised at the microscope (A) and cell lysates was analysed via western blot 
(B). Antibodies against FLAG-tag were used to confirm the overexpression. The level of 
MRPL45, MRPL24 and the mt-encoded COXII were also assessed. SDH70 was used as 
loading control. The data shown are representative of 2 biological repeats. Lane1: NT-siRNA 
on uninduced cells, Lane 2: MRPL45-siRNA on induced cells, Lane3: MRPL45-siRNA on 
induced cells. The dashed line indicates the omission of lanes. 
The western blot analysis showed that the overexpression of MRPL45FLsil was efficient. 
Because the FLAG-tagged protein migrates at a higher molecular weight than the endogenous 
one, it was possible to verify the efficiency of MRPL45 depletion using MRPL45 antibody. The 
depletion was efficient as indicated by the weak signal detected for MRPL45 (Fig. 6.21B, lane 
2, 3). When MRPL45 was depleted in uninduced cells (Fig. 6.21B, lane 2), the level of the tested 
NT-siRNA MRPL45-siRNA Uninduced Induced 
MRPL45-siRNA Uninduced 
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mitoribosomal protein and the level of the mt-encoded COXII were also reduced (Fig. 6.21B, 
lane 2), as previously reported in chapter 3. Upon overexpression of MRPL45FLsil both 
mitoribosmal protein and COXII were rescued and their steady state level was increased (Fig. 
6.21B, lane 3) when compared to the depletion alone. SDH70 confirmed the equality of the 
loading. On the other hand, the visualisation of cells at the microscope revealed that the 
overexpression of MRPL45FLsil is not able to completely reverse the effects observed on cells 
morphology upon MRPL45 depletion because in the induced and depleted sample the cell s 
were still associated in clusters (Fig. 6.21A). It is therefore possible to conclude that 
MRPL45FLAG containing silent mutations in the region targeted by siRNA02 was able to rescue 
the phenotype observed for MRPL45, with the exception of the effect observed on cells 
morphology. This result further validated the effects of MRPL45 depletion on mitoribosomal 
protein reported in chapter 3. 
6.3.5. Interaction of MRPL45FLala with the mitochondrial IMM 
Since MRPL45FLala was shown to partially rescue the phenotype of MRPL45 depletion, I 
decided to investigate the ability of the mutated protein to interact with the IMM. For  this, the 
protocol developed in chapter 4 to allow the investigation of membrane interaction was used.  
Because the interaction of the mt-LSU with the IMM might be mediated by other proteins 
than MRPL45, the ability of MRPL45FLala to directly interact with the membrane was also 
assessed. For this, HEK293-MRPL45FLala cells were grown in ethidium bromide for 10 days to 
deplete the assembled mitoribosome. During the last 3 days of treatment, the expression of the 
mutant protein was induced in 1 µg/mL of tetracycline. At the end of the treatment, mitochondria 
were extracted and membrane and soluble fractions were separated following the protocol in 
4.2.2. Soluble (S) and membrane (P) fractions obtained in absence or presence of detergent 
were analysed via western blotting (Fig. 6.22). 
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Figure 6.22 Distribution of MRPL45FLala between soluble and membrane fraction in cells 
incubated with ethidium bromide. 
A) Representative figure of western blot analysis performed on samples from membrane-
soluble fraction protocol (qv 4.2.2.) performed on HEK293-MRPL45FLala cells incubated 
with 250 ng/mL of ethidium bromide for 10 days, with induction of the protein during the last 
3 days of the treatment. Mitochondria from the treated cells (lane 2) and from HEK293 cells 
(lane 1) were analysed via western blot together with the membrane (P, lanes 3, 5) and 
soluble (S, lanes 4, 6) fractions obtained from the protocol in presence or absence of 1.6% 
Triton. Antibodies against GDH and SDH70 were used to confirm the success of the 
protocol. Antibodies against COXII were used to confirm the efficiency of the ethidium 
bromide treatment. The success of the induction and the distribution of MRPL45FLala 
between soluble and membrane fraction were detected with antibodies targeting the FLAG-
tag. B) Quantification of 2 biological repeats of membrane-soluble fraction protocol. 
The absence of COXII in the mitochondria extracted from HEK293-MRPL45FLala cells after 
incubation with ethidium bormide confirmed the efficiency of the treatment (Fig. 6.22A, lane 2). 
The expression of MRPL45FLala was also successful, as confirmed by the presence of a signal 
from the FLAG antibody in the treated mitochondria (Fig. 6.22A, lane 2). The matrix pro tein GDH 
was mainly detected in the soluble fractions (Fig. 6.22A, lanes 4, 6). The IMM protein SDH70 
was mainly found in the pellet in absence of detergent and was solubilised in its presence (Fig. 
6.22A, lanes 3 and 6, respectively). A proportion of SDH70 was detected in the soluble fraction 
in absence of detergent (Fig. 6.22A, lane 4). This was observed in every protocol performed on 
cells treated with ethidium bromide, independently on the marker used to localise the membrane 
fraction. The detection of the FLAG-tagged protein showed a partial solubilisation in presence 
of Triton (approximately 30%), suggesting the ability of MRPL45FLala to interact with the IMM. 
Just above the 20% of MRPL45FLala was detected in the pellet after solubilisation with Triton  
X-100 (Fig. 6.22A, lane 5). This might be due to aggregation resulting from the heat generated 
during sonication, used to disrupt the mitochondrial membranes, or to the presence of the 
protein associating with very large complexes. It is also important to observe that MRPL45FLala 
was also detected in the supernatant in absence of detergent (Fig. 6.22A, lane 4), suggesting 
that a proportion of MRPL45FLala is not interacting with the membrane.  
The ability of the mt-LSU containing MRPL45FLala to interact with the membrane was also 
tested. At this purpose, HEK293-MRPL45FLala cells were grown in 75 cm2 flasks under 
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induction with 1 µg/mL tetracycline for 3 days, before performing MRPL45 depletion with 
siRNA02 for 6 days (forward and reverse transfection, qv 2.1.5.). The induction was carried on 
over the depletion period. At the end of the treatment, cells were harvested, mitochondrial 
extracted and the interaction of the mt-LSU containing MRPL45FLala was investigated with the 
membrane-soluble fraction protocol (qv 4.2.2.). The efficiency of the depletion of MRPL45 and 
of the induction were confirmed by western blot analysis (Fig. 6.23A). A comparable amount of 
membrane (P) and soluble (S) fractions obtained in absence and presence of 1.6% Triton were 
analysed via western blotting (Fig. 6.23B). Because the signal expected from the FLAG-tagged 
protein was expected to be low, twice the usual amount of P and S samples were loaded.  The 
results obtained for different biological repeats were quantified and represented in Fig. 6.23C. 
 
 
Figure 6.23 Distribution of MRPL45FLala between membrane and soluble fraction 
in absence of endogenous MRPL45. 
HEK293-MRPL45FLala cells were induced for 3 days and then depleted of MRPL45 for 6 days, 
continuing the induction. Mitochondria were extracted and membrane and soluble fraction were 
prepared in presence or absence of 1.6% Triton X-100 as in 4.2.2. A) Western blot analysis was 
performed on uninduced and treated cell lysates to confirm the efficiency of the depletion and 
the induction. Antibodies against the FLAG-tag were used, together with antibodies targeting 
MRPL24 and COXII. GDH was used as loading control. B) Representative figure of western blot 
analysis was performed for membrane (P, 15 µL) and soluble (S, 30 µL) fractions obtained from 
the protocol. Mito-lysate (15 µg) was also loaded. The success of the protocol was assessed 
with detection of a matrix protein (GDH) and a OMM protein (TOM20). The signal from 
MRPL45FLala was detected with an antibody targeting the FLAG-tag. C) Quantification of 2 
biological repeats of the membrane-soluble protocol. 
The western blot analysis performed on cell lysates (Fig. 6.23A) confirmed the success of 
the induction, as showed by the presence of a signal for MRPL45FLala. In chapter 3, I reported 
that depletion of MRPL45 leads to reduction of mt-LSU components, affecting mitochondrial 
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translation. Because of the reduction in steady state level of MRPL24 and COXII upon depletion 
of MRPL45 (Fig. 6.23A, ‘In+kd’), I deduced that the depletion was efficient. The western blot 
analysis performed on membrane-soluble fraction protocol (Fig. 6.23B) confirmed the success 
of the protocol. The matrix protein GDH was detected in the S fractions both in absence and in 
presence of detergent (Fig. 6.23B, lanes 3,5). The IMM protein TOM20 was only detected in the 
P fraction in absence of detergent (Fig. 6.23B, lane 2) and was completely solubilised by its 
addition (Fig. 6.23B, lane 4). This shows that the membrane (and membrane -interacting) 
proteins were successfully pelleted at the force applied and that the treatment with 1.6% Triton 
X-100 successfully solubilised the membrane proteins. The signal detected for MRPL45FLala 
was equally divided between P and S both in presence and in absence of detergent, as also 
shown quantification of biological repeats (Fig. 6.23C). This result indicates that no significant 
solubilisation occurred after the addition of Triton X-100. This might be the consequence of 
aggregation due to the heat generated in the sonication used to disrupt mitochondria. The 
detection of a signal for MRPL45FLala in the supernatant in absence of detergent (Fig. 6.23B, 
lane 3) indicates that a considerable amount of the protein (approximately 50%) is not interacting 
with the membrane. 
6.4. Investigation of the importance of the α1 helix of MRPL45 
6.4.1. Generation of stable cell lines able to express truncated 
MRPL45FLAG (MRPL45FLΔ) 
As described in paragraph 5.1, it is likely that human MRPL45 presents helix α1 and it is 
possible that this is involved in the interaction of MRPL45 with the IMM. To test this hypothesis, 
the first 117 amino acids of MRPL45 were deleted. This truncation will remove the targeting 
sequence, therefore the Su9 presequence was added to promote mitochondrial localisation. 
The Su9 presequence is a 69 amino acids presequence of subunit 9 of Neurospora crassa F0-
ATPase. It has been widely used to target proteins to mitochondria and is double-cleaved in the 
mitochondrial matrix. Two alanine were added as a spacer between the Su9 presequence and 
the beginning of the truncated MRPL45. A FLAG-tag was added at the C-terminal of MRPL45, 
since its addition did not show any effect on the ability of the protein to be integrated in the mt-
LSU (Fig. 5.4, page 98) and to interact with the IMM (Fig. 5.6, page 101). This will allow an 
easier discrimination between the endogenous and the mutated protein.  
The Su9 presequence was obtained from a pcDNA5/FRT/TO plasmid containing the insert 
Su9-RelE, previously prepared in our laboratory by Dr. Dennerlein. Digestion of this plasmid 
with BssHII and NotI removed the RelE sequence, that can then be replaced by MRPL45FLΔ. 
The Su9-RelE- pcDNA5/FRT/TO plasmid was extracted from transformed competent cells and 
digested at 37ºC for 1 hour with BssHII and NotI (1 µL each) in a final volume of 20 µL of 1x 
NEB3 buffer. The efficiency of the digestion was verified on DNA gel electrophoresis (Fig.  6.24). 
The insert was prepared in a PCR reaction using the primers in Appendix 5 from HEK293 cDNA. 
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The forward primer (L45trFrw) was used to introduce the restriction site (BssHII) to join the 
truncated MRPL45 to the Su9 presequence and the 2 alanine that  precede the amino acid 118 
of MRPL45. The reverse primer (L45trRev) introduced the FLAG-tag sequence at the end of 
MRPL45 and the second restriction site (NotI), needed for the insertion in the digested Su9-
pcDNA5/FRT/TO. The insert generated was composed of ≈600 bp. The result of the PCR 
reaction was visualised on 1.2% agarose gel electrophoresis (Fig. 6.24). 
 
Figure 6.24 Digestion of Su9-RelE-pcDNA5/FRT/TO and 
preparation of MRPL45FLΔ insert. 
The products obtained from digestion of Su9-RelE-pcDNA5/FRT/TO with NotI and 
BssHI were separated on a 1.2% agarose gel, together with the result of the PCR 
reaction set up to prepare MRPL45FLΔ insert with L45trFrw and L45trRev, using 
MRPL45FLAG-pcDNA5/FRT/TO as template. 
The agarose gel showed the presence of two bands upon digestion of the plasmid. Both the 
bands corresponded to the expected sizes of the RelE insert (lower band, ≈300 bp) and Su9 -
pcDNA5/FRT/TO (higher band, ≈5000 bp). The PCR reaction product showed the presence of 
a band at ≈600 bp, which corresponded to the expected size of the insert. The higher band 
obtained for the digested plasmid and the band derived from the PCR reaction were excised 
and the DNA was extracted. 
The MRPL45FLΔ insert was ligated into Su9-pcDNA5/FRT/TO (qv 2.3.9.), and the product 
was used to transform competent cells, as previously described. Prior generation of a cell line 
able to express MRPL45FLΔ, the insert contained between BGH and CMV was sequenced (qv 
2.3.10.). The sequence obtained confirmed the identity of the construct designed (Apprendix 
12), therefore the plasmid was used together with pOG44 to transfect HEK293 Flp-In cells (qv 
2.1.6.). After antibiotic selection, single colonies were expanded, prepared for long term storage 
in liquid nitrogen and used for the following experiments. 
6.4.2. Effects of the expression of MRPL45FLΔ 
The ability of HEK293-MRPL45FLΔ to express the truncated protein was tested. After 3 days 
of induction, cells were harvested and cell lysate was analysed via western blotting (Fig. 6.25A). 
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Cell growth was also monitored every 3 hours over a 6-days period with the IncuCyte system 
(Fig. 6.25B). Cell morphology after 5 days of induction is also shown in Fig. 6.25C. 
      
 
Figure 6.25 Effects of the expression of MRPL45FLΔ on mitochondrial proteins level and 
cell growth. 
Western blot analysis (A) was performed on HEK293-MRPL45FLΔ cells expressing the 
truncated protein after 3 days. Uninduced cells were used as a control. The efficiency of the 
overexpression was verified using antibody against the FLAG-tag. The steady state level of the 
mt-encoded COXII, as well as of components of the mitoribosome (MRPL45, MRPL24, 
MRPS27) were also evaluated. The nuclear-encoded SDH70 was used as a loading control. 
Cell growth (B) was also monitored as confluency every 3 hours over 6 days of induction of 
MRPL45FLΔ. Cell morphology after 5 days is also shown (C). The results are representative of 
2 biological repeat. 
The expression of the recombinant protein was efficient, although a long exposure needed 
to detect it. This might indicate that, as observed for MRPL45FLala, the steady state level of 
MRPL45FLΔ might be low. The levels of COXII and of the mitoribosomal protein tested 
appeared to be slightly reduced. SDH70 detection showed that the loading was not perfectly 
equal, suggesting that the induced sample was slightly more loaded. Cell growth was unaffected 
upon overexpression of MRPL45FLΔ over a 6-days period (Fig. 6.25B). Cell morphology also 
appeared normal (Fig. 6.25C). 
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Because the targeting sequence of the endogenous MRPL45 was not present in the 
truncated version, but instead the protein was targeted to mitochondria using the Su9 sequence, 
it was necessary to confirm the localisation of the protein in these organelles. At this purpose, 
cell lysate and mitochondrial lysate were prepared from HEK293-MRPL45FLΔ induced for 3 
days, and then loaded on a western blot (Fig. 6.26). 
 
Figure 6.26 Enrichment of MRPL45FLΔ in mitochondria.  
The same amount (30 µg) of cell lysate and mitochondria obtained from HEK293-MRPL45FLΔ 
cells was analysed via western blotting. Antibodies against the FLAG-tag were used to confirm 
the success of the expression of the recombinant protein. The steady state level of the subunit 
of complex V ATP5β was also evaluated. The experiment was not replicated. 
The mitochondrial fractions clearly showed an increase in the signal detected from the FLAG 
antibody when compared to the cell lysate. The same pattern was observed for the mitochondrial 
protein ATP5β, suggesting that the Su9 presequence successfully targets MRPL45FLΔ to the 
organelle. 
The low steady state level detected for MRPL45FLΔ after induction resembles the one 
observed for MRPL45FLala, as shown in the following western blot analysis of cell lysates 
obtained from HEK293-MRPL45FLala, HEK293-MRPL45FLΔ and HEK293-MRPL45FLsil after 
induction for 3 days. Cell lysate from wild-type HEK293 cells was also loaded (Fig. 6.27). 
 
Figure 6.27 Levels of different MRPL45 mutants after 3 days of induction. 
Western blot analysis performed on cell lysates (≈30 µg) from HEK293 cells and from 
induced HEK293-MRPL45FLala, HEK293-MRPL45FLΔ and HEK293-MRPL45FLsil (3 
days, 1 µg/mL tetracycline). The steady state levels of the induced proteins were 
detected with antibodies targeting their FLAG-tag. SDH70 was used as a loading control. 
The detection of the FLAG-tagged proteins confirmed that the level of expression of 
MRPL45FLΔ were similar to the level observed for MRPL45FLala. Both are considerably lower 
than the one obtained for the FLAG-tagged protein only presenting silent mutations 
(MRPL45FLsil). 
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During the detections of the previous western blots, I noticed that the size observed for 
MRPL45FLΔ was of approximately 30 kDa. This molecular weight matches the size predicted 
for Su9-MRPL45FLΔ (30.5 kDa) and is considerably bigger than the one expected after 
cleavage of the Su9 presequence (≈23 kDa). The observed size for MRPL45FLΔ is reported in 
the following figure. 
   
Figure 6.28 Observed molecular weight for MRPL45FLΔ.  
Representative figure of western blot analysis of cell lysate (≈30 µg) from uninduced 
and induced HEK239- MRPL45FLΔ cells. Antibodies against MRPL45 and MRPL24 
were used. A proportion of the protein ladder (M, lane 1) was carefully aligned to the 
western blot to indicate the migration of the species observed. 
* = Molecular weight of the full-length product (unknown length of transit peptide) 
MRPL45FLΔ was present in the cell lysate obtained from induced cells (Fig. 6.28, lane 1 
indicated by the red arrow) and was detected between the endogenous MRPL45 and MRPL24. 
To date, the length of the transit peptide of MRPL45 is unknown, but the full -length protein is of 
approximately 35 kDa. The cleavage of the transit peptide of MRPL24, composed of only 9 
amino acids, lead to a protein of approximately 24 kDa. These observations suggest that 
MRPL45FLΔ should have a molecular weight between 35 and 24 kDa, which will be higher that 
the molecular weight of 23 kDa predicted upon cleavage of the Su9 presequence.  
Although the Su9 has been widely used to target proteins to the mitochondrial matrix, I 
decided to confirm that this presequence is effectively cleaved after the import of the protein. 
Therefore, MRPL45FLΔ was in vitro translated, in order to compare the migration on 12% SDS-
PAGE gel with the migration of the protein expressed in HEK293-MRPL45FLΔ detected with 
the FLAG antibody. The mRNA needed for the in vitro translation was prepared by in vitro 
transcription. Su9-MRPL45FLΔ- pcDNA5/FRT/TO was used as a template in a PCR reaction to 
generate the DNA fragment that was then transcribed to RNA. The forward primer used for the 
PCR (SP6-Su9-L45Frw) contained the SP6 promoter that is used by RNA polymerase to start 
transcription in vitro, while the reverse primer (SP6-Su9-L45trRev) was complementary to the 
FLAG-tag present at the end of the MRPL45FLΔ construct. The primers used were (Appendix 
5). The PCR reaction was carried out as in 2.3.3., using either 65 ºC or 67 ºC as annealing 
temperature. The products obtained were resolved on a 1.2% agarose gel (Fig. 6.29). 
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Figure 6.29 Product of PCR to synthesise SP6-Su9- MRPL45FLΔ. 
MRPL45FLΔ- pcDNA5/FRT/TO was used as a template in a PCR using the primers 
SP6-Su9-L45trFrw and SP6-Su9-L45trRev (Appendix 5). Either 65 ºC (lane 1) or 67 ºC 
(lane 2) were used as annealing temperature. The products obtained were resolved on 
a 1.2% agarose gel and visualised at the ChemiDoc. The desired product is indicated 
by the arrow. 
Both the annealing temperatures tested efficiently produced a single product of the expected 
size (831 bp). The product obtained at 65 ºC was purified and then in vitro transcribed (qv 6.2.2.). 
To confirm the efficiency of the reaction, the product obtained (1 µL) was resolved on a 1% 
agarose denaturing gel (qv 6.2.4.), together with 1 µg and 2 µg of total RNA. The gel was then 
visualised at the ChemiDoc system (Fig. 6.30). 
 
Figure 6.30 Visualisation of the product of in vitro transcription of 
SP6-Su9-MRPL45FLΔ. 
In vitro transcription was performed as in 6.2.2. to obtain SP6-SU9-MRPL45FLΔ. The 
product (1 µL) was resolved on a 1% agarose denaturing gel (qv 6.2.4.) and visualised 
at the ChemiDoc. Total RNA (1 µg and 2 µg) were also loaded on the gel as a reference 
for size and quantity. The desired product is indicated by the arrow. 
The transcription was successful as demonstrated by the presence of a single band in the 
product of the reaction (indicated by an arrow in Fig. 6.30). The 2 bands detec ted for the total 
RNA represented the cytosolic 28S and 18S rRNA, whose approximate sizes are 5 kB and 1.9 
kB, respectively. The band observed in the in vitro transcription product was lower than the 18S 
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band, in agreement with the expected size of Su9-MRPL45FLΔ (831 bp), The intensity of the 
band for Su9-MRPL45FLΔ was comparable with the ones observed for the 2 µg of total RNA, 
suggesting a high amount of RNA in the sample obtained by in vitro transcription. 
The Su9-MRPL45FLΔ RNA was used to perform in vitro translation (qv 6.2.3.). RNA 
encoding for mouse Su9-DHFR was also translated as a control. Cell lysates from HEK293 cells 
and from cells expressing either MRPL45FLAG or MRPL45FLΔ were resolved on a 12% SDS-
PAGE gel, together with samples obtained from in vitro translation. The gel was divided and the 
proportion containing the lysates samples was transferred on a PVDF membrane for western 
blotting, while the remaining part (containing the in vitro translated products) was fixed, vacuum-
dried and exposed for detection of the radioactive products as described in 5.2.3 (Fig. 6.31). 
The migration of the protein visualised were compared to the protein ladder.  
 
Figure 6.31 Migration of MRPL45FLΔ from cell lysate compared to migration of in vitro 
translated Su9-MRPL45FLΔ. 
Cell lysates (≈30 µg) from HEK293, induced HEK293-MRPL45FLΔ and induced 
HEK293-MRPL45FLAG, as well as the product of in vitro translation of Su9-
MRPL45FLΔ (1 µL, lane 10) and Su9-DHFR (2 µL, used as a control, lane 11), were 
resolved via 12% SDS-PAGE. The proportion of the gel containing the lysates was 
transferred on a PVDF membrane for western blot analysis (A). The efficiency of the 
overexpression was detected with antibodies against the FLAG-tag (lanes 2, 3, 4). 
Subsequently, antibodies against MRPL45 were used (lanes 6, 7, 8). The red asterisk 
represents the induced MRPL45FLΔ in lane 5. The experiment was not replicated. 
The proportion of the gel containing the in vitro translated products (lanes 10, 11) was 
fixed overnight and then vacuum-dried. The gel was finally exposed at the 
PhosphorImage screen to visualise the result (B). The size of Su9- MRPL45FLΔ and 
Su9-DHFR is also reported. The protein ladders for both the western blots and the 
radio-labelled detection are also shown (M, lanes 1, 5, 9). Lane 1 was carefully aligned 
with the detection observed for the FLAG-tag antibody. A red line was drawn just below 
the MRPL45FLΔ product observed in the protein lysate. The experiment was not 
replicated. 
MRPL45FLΔ was detected with the FLAG antibody (Fig. 6.31A, lane 2, above the red line) 
and corresponded to a molecular weight of approximately 30 kDa. A signal for MRPL45FLAG 
was also detected with this antibody just below 35 kDa (Fig. 6.31A, lane 4). The following 
incubation of the membrane with MRPL45 antibody showed the endogenous protein at 
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approximately 33 kDa, detected in all the 3 samples (Fig. 6.31A, lanes 6, 7, 8). Upon detection 
of MRPL45, 2 additional bands were detected in lane 8. Of these, one corresponded to the 
endogenous protein, while the other is likely to be a cleaved MRPL45, also observed in the 
previous chapters. The success of the in vitro translation was confirmed by the presence of a 
band above 25 kDa, which corresponded to the expected size of 28 kDa for Su9-DHFR (Fig. 
6.31B, lane 11). Concerning the translation of Su9-MRPL45FLΔ, a single species was detected 
at approximately 34 kDa (Fig. 6.31B, lane 10), when compared to the protein ladder (Fig. 6.31B, 
lane 9). The molecular weight of Su9-MRPL45FLΔ is of approximately 30.5 kDa, lower than the 
one observed. This might suggest an inaccurate migration of the protein ladder. Despite this, 
the migration observed for Su9-MRPL45FLΔ is evidently different for the one observed for the 
protein induced in HEK293-MRPL45FLΔ cells (Fig. 6.31A, lane 2, also indicate by a red line), 
suggesting that the Su9 presequence is efficiently cleaved upon import of the protein.  
The migration observed for the 30.5 kDa Su9-MRPL45FLΔ (Fig. 6.31B, lane 10) is close to 
the one observed for the endogenous MRPL45 (Fig. 6.31A, lane 7). As previously mentioned, 
the exact size of the targeting sequence of MRPL45 is still unknown. Mitoprot II, an online tool 
that calculates the N-terminal protein region that might correspond to the transit peptide (Claros 
MG et al., 1996), predicted a cleavage site for the presequence 42 amino acids from the N-
terminal. This cleavage will lead to a protein of approximately 30 kDa, which appears to be in 
agreement with the migration observed for the endogenous MRPL45 (Fig. 6.31A, lane 7). 
6.4.3. Integration of MRPL45FLΔ in the mitochondrial large 
mitoribosomal subunit 
The ability of MRPL45FLΔ to be integrated in the mt-LSU was verified via isokinetic sucrose 
gradient analysis, as performed for MRPL45FLala. HEK293-MRPL45FLΔ cells were induced for 
3 days and the cell lysate obtained (700 µg) was loaded on top of a 10-30% isokinetic sucrose 
gradient (qv 2.8.). As for MRPL45FLala, the steady state level of MRPL45FLΔ was very low, 
therefore the 11 fractions obtained from the sucrose gradient analysis were TCA-precipitated 
(qv 2.5.3.) and then loaded on a 12% SDS-PAGE and analysed via western blotting (Fig. 6.32). 
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Figure 6.32 Distribution of MRPL45FLΔ on isokinetic sucrose gradient. 
Representative figure of western blot analysis performed on the 10-30% isokinetic sucrose 
gradient analysis of cell lysate (≈700 µg) from induced HEK293-MRPL45FLΔ. The 11 fraction 
collected were TCA-precipitated, resolved on a 12% SDS-PAGE and analysed via western 
blotting. Cell lysate from the induced cells (50 µg) was also loaded on the gel. The efficiency 
of the overexpression was confirmed with antibodies against the FLAG-tag. The distribution of 
mt-LSU was detected with antibodies against MRPL24 and MRPL11, while antibodies against 
MRPS27 were used to localise the mt-SSU. Representative of 2 biological repeats. 
 The western blot analysis showed that the majority of the mutant protein was localised in 
the first fractions of the gradient. These were not corresponding to the fractions containing the 
mt-LSU, identified by MRPL11 mainly in fractions 6 and 7 (Fig. 6.32). The mt-SSU was instead 
localised in fraction 5 by detection of MRPS27. 
In section 6.3.3., MRPL45FLala showed the ability to integrate within the mt-LSU in absence 
of endogenous MRPL45 and to partially rescue the phenotype observed for MRPL45 depletion. 
The possibility of MRPL45FLΔ to follow the same pattern was tested. The integration of 
MRPL45FLΔ within the mt-LSU in absence of the endogenous protein was tested via isokinetic 
sucrose gradient analysis. After 3 days of induction with 1 µg/mL of tetracycline,  1,000,000 
HEK293-MRPL45FLΔ cells were seeded in 75 cm2 flasks and depleted of MRPL45 with 
siRNA02 at 33 nM for 6 days (reverse and forward transfection, qv 2.1.5.), continuing the 
expression of the FLAG-tagged mutant protein. The sequence targeted by MRPL45-siRNA02 is 
localised within the region deleted in MRPL45FLΔ, therefore the siRNA will not target the mutant 
protein. At the end of the treatment, cells were harvested and 700 µg of cell lysate were analysed 
on a 10-30% isokinetic sucrose gradient. The 11 fractions obtained were TCA-precipitated (qv 
2.5.3.) to concentrate the sample and facilitate the visualisation of the FLAG-tagged protein and 
used for a western blot analysis (Fig. 6.33A). A proportion (50 µg) of the cell lysate loaded on 
the gradient was also analysed, together with 50 µg of cell lysate from uninduced HEK393-
MRPL45FLΔ. The same experiment was performed on HEK293 cells, as a control (Fig. 6.33B)  
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Figure 6.33 Distribution of MRPL45FLΔ on isokinetic sucrose gradient in absence of 
endogenous MRPL45. 
A) HEK293-MRPL45FLΔ cells were induced for 3 days and then depleted of MRPL45 for 6 
days (siRNA02, 33 nM final concentration), continuing the induction. At the end of the 
treatment, cells were harvested and 700 µg of cell lysate were separated on a 10-30% 
isokinetic sucrose gradient. The 11 fractions obtained from the gradient were TCA precipitated 
and then loaded on a 12% SDS-PAGE gel for western blot analysis. Cell lysate (≈30 µg) from 
uninduced cells and from the treated cells were also loaded on the gel. The steady state level 
of the FLAG-tagged protein was detected first. After that, antibodies against MRPL45 and 
MRPL24 were used to localise the mt-LSU, whereas the mt-SSU was localised with antibodies 
against MRPS27. SDH70 was used to confirm the equality of the loading of the cell lysates. 
The signal obtained from SDH70 thought the gradient was omitted. The figure is 
representative of 2 biological repeats. B) HEK293 cells were depleted for 6 days of MRPL45 
(siRNA02, 33 nM final concentration) were used as an experimental control for A). Cell lysates 
from untreated HEK293 (WT) and from depleted cells (kd) were analysed via western blotting 
together with the 11 TCA-precipitated fractions obtained from the 10-30% isokinetic sucrose 
gradient analysis. Antibodies against MRPL45 and MPRL24 were used to visualise the m-
LSU, while antibodies targeting MRPS22 were used to detect the mt-SSU. SDH70 was used 
to confirm the equality of the loading of the cell lysates. The signal obtained from SDH70 
thought the gradient was omitted. 
The efficiency of depletion was confirmed by the reduction of the steady state level observed 
for MRPL45 when compared to uninduced and non-depleted cells (Fig. 6.33A). As reported in 
chapter 3, depletion of MRPL45 led to reduction of assembled mt-LSU. In agreement with this, 
a reduction of the steady state level of MRPL24 was observed upon depletion of MRPL45. 
Despite this, a signal form MRPL24 was detected in the sucrose gradient analysis, with an 
A 
B 
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enrichment in fraction 6 and 7, signalling that a proportion of the mt-LSU was still present (Fig. 
6.33A). This can be expected as the depletion of MRPL45 was not complete as a small amount 
of the protein was still present. In fact, detection of MRPL45 also confirmed an enrichment of 
this protein in fraction 6 and 7 (Fig. 6.33A). It is important to remember that the fractions of this 
sucrose gradient have been TCA-precipitated and that, therefore, the signal from detected by 
MRPL24 and MRPL45 appeared very strong despite their depletion. The control experiment 
performed on HEK293 cells confirmed the distribution of MRPL24 and MRPL45 observed 
throughout the gradient upon depletion of MRPL45 (Fig. 6.33B). MRPS27 (Fig. 6.33A), not 
reduced by the depletion, was localised mainly in fractions 4 and 5, identifying the distribution 
of the mt-SSU throughout the 10-30% isokinetic sucrose gradient. Detection of MRPL45FLΔ via 
the FLAG-tag showed that the majority of the protein was localised in fractions 2, 3 and 4 of the 
gradient. A minor fraction of MRPL45FLΔ appeared to be integrated with the mt -LSU since a 
weak signal for the FLAG-tagged protein was observed in fractions 6 and 7 (Fig. 6.33A). The 
presence of the mutant protein in lighter fractions (2, 3, 4) but not in free fraction (1) suggested 
the possibility that this protein is present in complexes. 
The ability of MRPL45FLΔ to rescue the MRPL45 depletion phenotype was also tested. 
HEK293-MRPL45FLΔ cells were induced for 3 days and then depleted of MRPL45, continuing 
the expression of the mutant protein. As control, uninduced cells were also treated with either 
NT- or MRPL45- siRNA for 6 days. At the end of the incubation, cells were visualised at the 
microscope (Fig. 6.34A) and then the cell lysates were analysed via western blotting (Fig. 
6.34B). 
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Figure 6.34 Effects of the expression of MRPL45FLΔ in cells depleted of endogenous 
MRPL45 on cell growth and mitochondrial translation. 
HEK293-MRPL45FLΔ cells were induced for 3 days and then incubated with 33 nM MRPL45-
siRNA for 6 days, continuing the induction of the mutant protein. In parallel, uninduced cells 
were also incubated with either NT- or MRPL45-siRNA for 6 days, as a control. At the end of 
the treatment the cells were visualised (A) and cell lysates were analysed via western blotting 
(B). The efficiency of the overexpression and of the depletion were confirmed with antibodies 
against the FLAG-tag and MRPL45, respectively. The steady-state level of the mitoribosomal 
protein MRPL24 and of the mt-encoded protein COXII were also detected. SDH70 was used 
to confirm the quality of the loading. The results are representative of 2 biological repeats. The 
dashed line indicates the omission of lanes. 
The expression of the mutant protein was confirmed with the detection of a signal from the 
FLAG-tag (Fig. 6.34B, lane 2). The reduction of MRPL45 steady state level observed confirmed 
the efficiency of the depletion (Fig. 6.34B, lane 2, 3). No rescue of MRPL24 or COXII, which 
steady state level was reduced in MRPL45 depleted cells (Fig. 6.34B, lane 3) was observed 
NT-siRNA MRPL45-siRNA 
Uninduced Induced 
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upon overexpression of MRPL45FLΔ. The equality of the loading was confirmed by SDH70. 
This result agrees with a marginal integration of MRPL45FLΔ within the mt-LSU observed upon 
depletion of endogenous MRPL45 (Fig. 6.33). 
6.4.4. Interaction of MRPL45FLΔ with the mitochondrial IMM 
To test if the domain of MRPL45 deleted in MRPL45FLΔ was important for the interaction 
with the membrane, the protocol developed in the previous chapter was performed after 
expression of MRPL45FLΔ in absence of assembled mitoribosomal subunit. HEK293-
MRPL45FLΔ cells were incubated with 250 ng/mL of ethidium bromide for 10 days, with 
induction of the mutant protein during the last 3 days of the incubation. Cell were harvested, 
mitochondria were extracted and membrane and soluble fraction were separated following the 
protocol explained in 4.2.2. Because of the low steady state level of MRPL45FLΔ, twice as much 
material as usually analysed was loaded on a 12% SDS-PAGE for subsequent western blot 
analysis (Fig. 6.35).  
 
 
Figure 6.35 Distribution of MRPL45FLΔ between membrane and soluble fractions after 
treatment of the cells with ethidium bromide. 
HEK293-MRPL45FLΔ cells were incubated with 250 ng/mL ethidium bromide for 10 days, with 
induction of the recombinant protein for the last 3 days. Mitochondria were extracted and 
membrane and soluble fraction were prepared in presence or absence of 1.6% Triton X-100 
as in 4.2.2. A) Western blot analysis was performed on uninduced and treated cell lysates to 
confirm the efficiency of the ethidium bromide treatment as well as the induction. Antibodies 
against the FLAG-tag were used, together with antibodies targeting COXII. SDH70 was used 
as loading control. B) Representative figure of western blot analysis performed for membrane 
(P, 15 µL) and soluble (S, 30 µL) fractions obtained from the protocol. The success of the 
protocol was assessed with detection of a matrix protein (GDH) and the OMM protein TOM20. 
The signal from MRPL45FLala was detected with an antibody targeting the FLAG-tag. C) 
Quantification of 2 biological repeats of the membrane-soluble protocol. 
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The western blot analysis of the cell lysates (Fig. 6.35A) confirmed the induction of 
MRPL45FLΔ. The efficiency of the ethidium bromide treatment was confirmed by the absence 
of COXII in the treated cells. The membrane-soluble protocol was successful. The matrix protein 
GDH was mainly detected in the soluble fractions both in absence and in presence of detergent 
(Fig. 6.35B, lanes 2, 4). The OMM protein TOM20 was used as marker for the membrane 
fraction. This protein was mainly detected in the pellet fraction in absence of Triton X-100 (Fig. 
6.35B, lane 1), although a signal was also detected in the supernatant (Fig. 6.35B, lane 2). This 
was observed for every membrane-soluble fraction experiment performed on cells incubated 
with ethidium bromide. Upon treatment with Triton X-100, the OMM protein was completely 
solubilised (Fig. 6.35B, lane 4). Detection of the FLAG-tagged protein showed a partial 
solubilisation upon treatment with the detergent, quantified as approximately 30% from different 
biological repeats (Fig. 6.35C). This result suggests that, despite the absence of 117 residues 
at the N-terminal, MRPL45 can still interact with the IMM. It is important to notice that 
approximately the 50% of MRPL45FLΔ was detected in the pellet fraction after incubation with 
the detergent. Since SDH70 showed that the solubilisation of the membranes was successful, 
the induced protein might aggregate or be a component of a large complex which is pelleted at 
the g-force used.  In addition, a signal for the mutant protein was detected in the soluble fraction 
in absence of Triton X-100 (Fig. 6.35B, lane 2), suggesting that a small pool of protein 
(approximately 20%) did not interact with the membrane. 
6.5. Discussion 
This chapter focused on the investigation of the domain of MRPL45 putatively involved in the 
interaction with the membrane. For this, 2 different mutants of MRPL45 were generated and 
induced in HEK293 cells. The mutations were proposed according to the structural data available 
on human MRPL45 and on the interaction with the membrane of human and yeast TIM44, which 
share structural homology with MRPL45. 
The first construct, MRPL45FLala, contained mutations in the most protruding domain in the 
structure of human MRPL45 resolved to date (α2  helix). After induction, the steady state level of 
the protein appeared very low. The qPCR analysis confirmed that the mRNA level for MRPL45 
were increased 6 fold upon induction, suggesting that the low level observed was probably due 
to instability of the protein. In an attempt to increase the levels of MRPL45FLala, 2 of the main 
proteases important for quality-control in the mitochondrial matrix (CLPP and LONP) were 
individually depleted. In both cases, no increase of the level of the mutant protein was observed. 
Although CLPP and LONP are 2 of the main proteases suggested to be important for quality-
control in the mitochondrial matrix, it is not possible to exclude that another protease might be 
involved in its degradation within mitochondria. It is also possible that  the mutant proteins could 
be degraded in the cytosol after their synthesis, reducing the amount of these proteins targeted 
to mitochondria. 
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In presence of endogenous MRPL45, MTPL45FLala was not integrated in the mt -LSU and 
was found free or in complexes of small molecular weight. When the endogenous protein was 
depleted, instead, the mutant protein was completely integrated in the mt-LSU. In this scenario, 
a higher steady state level than the one observed for induction in wild type cells was expected for 
MRPL45FLala, since the protein was integrated in the mt-LSU and potentially less accessible to 
degradation from proteases. Instead, no increase in the level of the mutant protein was observed. 
This might have been due either to a relatively fast turnover of the mt-LSU, which did not allow 
the accumulation of the subunit containing the mutated protein, or to the lower stability of the mt-
LSU containing MRPL45FLala. The lack of integration of MRPL45FLala in presence of the 
endogenous protein could be due to a less favourable integration of the mutant protein. This will 
lead to free MRPL45FLala that, consequently, might be quickly degraded, explaining the low 
steady state level observed for the protein. It is also possible that the integration of the mutant 
protein was less probable due to its lower abundancy. It will be possible to discriminate between 
these 2 hypothesis performing a less efficient depletion of MRPL45 (for example by lowering the 
final concentration of siRNA used) and detect the steady state level of COXII via western blot . If 
the steady state level of this OXPHOS protein will be lower than in the control sample, the 
experiment will indicate that a higher amount of MRPL45 will be needed to assemble enough mt -
LSU to assure the synthesis of the ‘normal’ amount of COXII. However, despite this uncertainty, 
the experiments showed that the mutation of charged amino acids to alanine performed in the α2 
helix did not prevent the mutated MRPL45 from its integration in the mt-LSU 
When integrated in the mt-LSU, MRPL45FLala was shown to partially rescue the phenotype 
observed upon depletion of the endogenous protein, suggesting that the mutations generated on 
MRPL45 are not affecting the possibility to generate an actively translating monosome. The 
rescue of MRPL45 depletion phenotype was clear, but not complete. The possibility of a complete 
rescue was confirmed by overexpression of a construct containing silent mutations in the 
sequence targeted by the siRNA used (MRPL45FLsil). This result also validated the phenotype 
obtained for MRPL45 depletion in chapter 3. The partial rescue observed by MRPL45FLala might 
be due to a lower abundancy of mt-LSU available in this condition when compared to wild type 
cells. In chapter 3, I demonstrated that MRPL45 is necessary for the assembly of the mt -LSU. As 
a consequence, it is possible that the amount of MRPL45FLala available upon induction is limiting 
the amount of mt-LSU that can be assembled and that, therefore, not enough mitoribosomes are 
offered to restore the normal level of mitochondrial translation. A partial rescue was also observed 
for MRPL24, supporting the idea that a reduced amount of assembled mt-LSU is present. 
The ability of MRPL45FLala to interact with the membrane was tested after depletion of mtDNA 
and, therefore, of assembled mitoribosomal subunits. In this condition, the expressed 
MRPL45FLala was able to interact directly with the membrane. Solubilisation of the membrane 
fraction obtained with the membrane-soluble fraction protocol developed in chapter 4 suggested 
that at least the 30% of the protein is interacting with the membrane. A small proportion of the 
protein was recovered in the soluble fraction in absence of detergent. This could indicate that the 
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interaction is transient and that therefore not the whole pool of MRPL45FLala was interacting with 
the membrane. From this experiment, it was possible to conclude that the mutation of the helix 
α2 of MRPL45 did not affect the ability of the protein to directly bind the IMM, therefore another 
domain of MRPL45 is mediating the interaction with the membrane of MRPL45FLala. 
The ability of the mt-LSU containing MRPL45FLala to interact with the membrane was also 
tested. No significant interaction was detected and, upon solubilisation of the membranes with 
detergent, approximately the 50% of the MRPL45FLala was detected in the pellet fraction. This 
result suggest that MRPL45FLala is likely to be part of heavy complexes. One possibility is that 
these complexes could be aggregates formed by the heat generated by sonication, performed on 
ice and used to disrupt the mitochondrial membranes. It is also possible that MRPL45FLala could 
be recognised by chaperones while integrated in the mt-LSU, which might associate and increase 
the molecular weight of the subunit. In addition, the presence of a signal for the FLAG-tag in the 
soluble fraction in absence of detergent suggested that approximately 50% of the protein did not 
interact with the membrane, suggesting that the interaction of the mitoribosome might have been 
compromised. Despite this experiment was not able to show an interaction of the mt-LSU 
containing MRPL45FLala, the previous experiment performed on induced cells in absence of 
assembled ribosome clearly confirmed the ability of the mutant protein to interact with the IMM.  
Since MRPL45FLala failed in identifying the domain involved in membrane-interaction, I 
designed a second construct lacking the first 117 amino acids (MRPL45FLΔ). This resulted in the 
deletion of an α-helix and of a following loop predicted to be present on human MRPL45 and 
suggested as an interacting point with the membrane for TIM44. The deletion did not included the 
domain modified in MRPL45FLala. The mitochondria-targeting sequence of MRPL45 was lost 
with the deletion, but the protein was successfully targeted to mitochondria using the Su9 
presequence. The steady state level of MRPL45FLΔ was very low and comparable with the one 
observed for MRPL45FLala.  
During the detection of MRPL45FLΔ I noticed that this migrated at approximately 30 kDa when 
the protein ladder was used as a reference, a molecular  weight which corresponded to the full-
lenght Su9-MRPL45FLΔ. I demonstrated that the product containing the presequence migrates 
at a higher molecular weight, confirming, therefore, that the presequence is efficiently cleaved 
upon import of the protein. Noticeably, the endogenous MRPL45 migrates at a molecular weight 
very close to the one observed for Su9-MRPL45FLΔ. A cleavage site for the 35 kDa full-length 
MRPL45 has not been confirmed to date. This observation suggests that MRPL45 presents a 
transit peptide of approximately 5 kDa, which is cleaved within mitochondria.  This will be in 
agreement with the predicted cleaving site at approximately 40 residues from the N-terminal of 
the protein.  
In the presence of endogenous MRPL45, MRPL45FLΔ was not integrated into the mt-LSU 
and was localised in the low-density fractions of the sucrose gradient analysis, suggesting its 
association within small complexes. Depletion of endogenous MRPL45 in cells overexpressing 
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MRPL45FLΔ did not severely affect the distribution of the mutated protein in the sucrose gradient 
analysis, although a small proportion colocalised with the mt-LSU, indicating a possible 
integration. To support the lack of integration, no rescue of the MRPL45 depletion phenotype was 
observed upon MRPL45FLΔ expression, as opposed to the partial rescue observed by 
MRPL45FLala. Despite a signal was present in the free-fraction of the sucrose gradient analysis, 
the majority of MRPL45FLΔ was recovered in the low density fractions, indicating that the mutant 
protein might be present in a complex. It is possible that this complex corresponds to a partially 
assembled mt-LSU. It will be possible to explore this theory with immunoprecipitation studies on 
HEK293-MRPL45FLΔ cells expressing the protein in absence of endogenous MRPL45. 
Despite no rescue was observed upon induction of MRPL45FLΔ in cells depleted of MRPL45, 
the results obtained from the membrane-soluble fraction protocol suggested that the truncated 
protein retains the ability to interact with the membrane. The protocol, performed on cells 
expressing MRPL45FLΔ in absence of assembled mt-LSU, showed that approximately 30% of 
MRPL45FLΔ is able to interact with the membrane. As for MRPL45FLala, and in the previous 
chapter for MRPL45wt and MRPL45FLAG, MRPL45FLΔ (≈20%) was detected in the soluble 
fraction in absence of detergent, suggesting that a proportion of the protein was not interacting 
with the membrane and that, therefore, the interaction might be transient. In presence of 
detergent, approximately 45% of MRPL45FLΔ was still present in the pellet, suggesting the 
presence of aggregates. 
The results obtained for MRPL45FLΔ suggest that the protein is not integrated in the mt-LSU, 
although a small proportion might be integrated in absence of endogenous MRPL45.  This cannot 
be due to a lack of interaction with the IMM, since MRPL45FLΔ retained the ability to interact with 
the IMM. It is possible that the deleted domain is important to establish interactions crucial for the 
assembly of the mt-LSU. 
Unfortunately, it was not possible to identify the domain of MRPL45 involved in membrane 
interaction since both MRPL45FLala and MRPL45FLΔ maintained their ability to interact with the 
IMM. Comparison of the integration of these 2 proteins within the mt-LSU performed by sucrose 
gradient analysis, suggested that the the domain included in the first 117 amino acids (deleted in 
MRPL45FLΔ) is important for the assembly of the mitoribosomal large subunit.  
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Chapter 7: The role of the inner mitochondrial membrane protein 
OXA1L in mitochondrial translation 
7.1. Introduction 
The inner mitochondrial membrane is one of the most protein-rich membranes in eukaryotic 
cells. It is composed of both nuclear and mitochondrial encoded protein, all of which need to be 
integrated into the membrane itself.  
In bacteria, there are inner membrane proteins (IMP) that are inserted co-translationally. The 
nascent IMP is recognised by a signal recognition particle (SRP) (Keenan RJ et al., 2001), which 
targets the ribosome to the membrane. The IMP can then interact with the SecYEG complex 
(Rapoport TA, 2007) that cooperates with YidC membrane insertase to fold, assemble and insert 
the IMP (du Plessis DJF et al., 2006; Kol S et al., 2009; Scotti PA et al., 2000). It addition to its 
cooperation with SecYEG, YidC is also able to insert several IMPs (Samuelson JC et al., 2000; 
van der Laan M et al., 2004) and has been found associated with the ribosome in bacteria (Kedrov 
A et al., 2013; Kohler R et al., 2009), supporting its role in co-translational insertion. 
Mitochondria lack of both SRP and SecYEG complex (Glick BS et al., 1996), but have 
maintained the ability to insert IMPs in the IMM. In mammals, the only protein known to date to 
be involved in the insertion of nascent proteins from the matrix of IMP is OXA1L (OXidase 
Assembly 1-Like). This protein is a member of the YidC/Alb3/Oxa1 membrane protein insertase 
family (Hennon SW et al., 2015) and it was first identified in yeast as important for the assembly 
of complex IV (Bonnefoy N et al., 1994; Keil M et al., 2012). Subsequently, Oxa1 was also 
reported to be important for the assembly of complex V (Altamura N et al., 1996), helping the 
formation of the transmembrane domain (Jia L et al., 2007). It has been reported that both Oxa1 
and YidC are able to dimerise and form pores in the membrane helping the translocation of IMPs 
(Kohler R et al., 2009; Krüger V et al., 2012). Yeast Oxa1 is suggested to play a role in the 
insertion of the mitochondrial-encoded Atp6, Atp9, Cox1, Cox2, Cox3 and Cyb, but also appears 
to have a role in the insertion of nuclear-encoded IMM proteins (Hell K et al., 1998; Hildenbeutel 
M et al., 2012; Stiller SB et al., 2016). Another member of the YidC/Alb3/Oxa1 family, named 
Cox18, was shown to be important in yeast for the insertion of the C-terminal of Cox2 (Saracco 
SA et al., 2002). Its human homologue, (hCox18) shares 25% identity and 45% similarity with the 
yeast counterpart (Sacconi S et al., 2005) but its role remains unclear. 
Because of the role of Oxa1 in the insertion of mt-encoded proteins, it was suggested that this 
protein is in direct contact with the mitochondrial protein synthesis machinery. This hypothesis 
was validated by the following studies that showed the co-localisation of Oxa1 with the yeast mt-
LSU on sucrose gradients and identified the importance of the C-terminus in this interaction (Jia 
L et al., 2003). Crosslinking experiments were able to identify the presence in close proximity to 
Oxa1 of the yeast mitoribosomal proteins Mrp20 (human MRPL23) (Jia L et al., 2003) and Mrp40 
(human MRPL24) (Jia L et al., 2009), which are found at the polypeptide exit site (PES) of yeast 
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mt-LSU. The interaction with the PES would facilitate a seamless integration of the hydrophobic 
products of mitochondrial translation into the IMM. The ability of Oxa1 to bind the ribosome was 
also confirmed in vitro by Cryo-EM studies that determined the 3D structure of Oxa1 (and YidC) 
bound to bacterial ribosomes (Kohler R et al., 2009). This study showed that the insertases 
interact with the ribosome in the proximity of the ribosomal PES and that the positively charged 
C-terminal domain is involved in this interaction. 
The Cryo-EM studies on Oxa1 and YidC suggested a similarity between the structure and 
function of these proteins. The members of the YidC/Alb3/Oxa1 family are composed of a 
conserved core of 5 transmembrane helices (Hennon SW et al., 2015) and the human OXA1L is 
not an exception. This 48 kDa IMM protein also presents a C-terminal domain found in the matrix, 
which has been cross-linked in vitro to the mitoribosomal proteins MRPL13, MRPL20, MRPL29, 
MRPL48, MRPL49 and MRPL51 (Haque ME et al., 2010). Thanks to the recent release of the 
structure of the mitoribosome, it is now possible to identify the position of these proteins within 
the structure (Fig. 7.1). Of these, only MRPL29 is found in close proximity of the PES, a location 
predicted to be ideal for membrane-interaction. Several of the proteins that form crosslinks are 
not localised on the surface. None of the interactions with MRPL23 and MRPL24 that were 
observed for the yeast Oxa1 (Jia L et al., 2003; Jia L et al., 2009), were reported by Haque et al 
with mammalian mitoribosomes. 
 
Figure 7.1 Positions of the mitoribosomal protein that co-immunoprecipitated with 
human OXA1L. 
Localisation within the mitoribosome of mitoribosomal proteins that co-immunoprecipitate 
with OXA1L as reported by Haque et al (PDB 3J9M). The small subunit is depicted in 
desaturated green, while the large subunit is in blue. Theimmunoprecipitated mitoribosomal 
proteins are highlighted in different colours (MRPL13=red, MRPL20=orange, 
MRPL29=yellow, MRPL48=cyan, MRPL49=green, MRPL51=magenta).  
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Depletion studies of OXA1L in human cell lines suggested the importance of this protein for 
the assembly of complexes I and V (Stiburek L et al., 2007). OXA1L depletion did not affect the 
other partially mt-encoded OXPHOS complexes. If this unexpected result will be confirmed, it will 
suggest that other insertases different from OXA1L must be involved in the insertion of mt -
encoded subunits of complex III and IV. 
Due to the possibility of a central role of OXA1L in the insertion of the mt-encoded proteins in 
the IMM and in the interaction with the mitoribosome, I decided to characterise the effects of the 
depletion of this protein in human mitochondria and to investigate its importance for mitochondrial 
translation. 
7.1.1. OXA1L structure 
A better understanding of the structure of OXA1L can be useful to give insight on its function 
or to infer the importance of particular domains and residues. 
Human OXA1L, yeast Oxa1 and bacterial YidC were aligned using Clustal Omega. Oxa1 
and OXA1L share 31.44% identity, whereas Oxa1 or OXA1L and YidC share 17.14% and 
18.48% identity respectively. It is important to mention that several non-identical residues have 
maintained a certain degree of conservation of the physical proprieties. 
OXA1L is composed of 5 transmembrane helices and a C-terminal domain that protrudes in 
the matrix and has been reported to be important for the interaction with the ribosome (Table 
7.1). Because 3 isoforms of OXA1L have been identified due to alternative splicing, the longer 
isoform identified as Q15070-1 (435 aa) will be used as a reference. 
Table 7.1 Topology of OXA1L. 
The analysis was based on the information predicted for the longer isoform of the protein 
(Q15070-1) by Uniprot. 
Residues From – To (aa seq) Structure/Localisation 
1 – 113 MAMG – SFAE Intermembrane space 
114 – 134 LGLG – FMHV Transmembrane helix (α1) 
135 – 139 DLGLP Matrix 
140 – 160 WWGA – PLTV Transmembrane helix (α2) 
161 – 212 TGQR – HGIK Intermembrane space 
213 – 233 LYKP – FFIA Transmembrane helix (α3) 
234 – 260 LREM – TVSD Matrix 
261 – 281 PIYI – ELGA Transmembrane helix (α4) 
282 – 299 ETGV – VIRM Intermembrane space 
300 – 320 MPLI – MYWL Transmembrane helix (α5) 
321 – 435 SSNL – DTLG Matrix 
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At present, no structure is available for either mammalian OXA1L or yeast Oxa1. The 
structure of human OXA1L was predicted Phyre2, and the result is shown in Fig. 7.2. 
 
Figure 7.2 Predicted secondary structure of human OXA1L. 
The structure of OXA1L was predicted using Phyre2 on the full length isoform of OXA1L 
(435 aa) and visualised as cartoon on Pymol. High confidence was obtained in the 
structure between residues 101 and 331 (blue), due to the similarity with the bacterial 
protein YidC. 
 The prediction of the structure of OXA1L between residues 101 and 331 had 100% 
confidence (Fig. 7.2, blue) and was based on several YidC crystal structures available 
(Kumazaki K et al., 2014; Kumazaki K et al., 2014; Wickles S et al., 2014). This domain of 
OXA1L represents ≈25% identity with the YidC sequence. The confidence represents the 
probability that the match between the sequences analysed and the template is a homology, 
and does not represent the accuracy of the model. The high-confidence structure corresponds 
to the transmembrane domain of the protein. Unfortunately, a good prediction could not be 
obtained for the matrix domain of the protein. 
7.2. OXA1L and the interaction with the mitoribosome 
As discussed in the introduction of this chapter, the C-terminus of OXA1L protrudes in the 
matrix and has been crosslinked in vitro to a number of mt-LSU proteins. As previously mentioned, 
all the proteins suggested to interact with OXA1L (Haque ME et al., 2010), with the exception of 
MRPL29, are distributed at a distance from each other throughout the mt-LSU and not always 
easily accessible from the solvent. Since this study was performed in vitro, I decided to confirm 
the interaction with mitoribosomal proteins via immunoprecipitation from HEK293 cells. HEK293-
MRPL45FLAG cells (qv 5.2) and HEK293 cells with a FLAG tagged MRP protein from the mt-
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LSU, ICT1FLAG, were grown in 75 cm2 flasks and induced for 3 days. At the end of the induction, 
mitochondria were extracted and the immunoprecipitation was performed via the FLAG-tag (qv 
2.9). The elution samples (1/3 of the total volume eluted) were analysed via western blotting (Fig. 
7.3). The FLAG-immunoprecipitation was also performed on wild type HEK293 as an 
experimental control. 
 
Figure 7.3  Immunoprecipitation of ICT1FLAG and MRPL45FLAG to investigate 
the potential interaction with OXA1L. 
Western blot analysis of the eluted protein (1/3 of the total sample) from FLAG-
immunoprecipitation from HEK293 (lane 1), HEK293-ICT1FLAG (lane 3) and HEK293-
MRPL45FLAG (lane 2, 4) cells, after 3 days of induction. Wild type HE293 cells were 
used as a control (lane 1). The presence of the mitoribosome was assessed with 
antibodies targeting MRPS26 and MRPL11. The steady state levels of OXA1L was also 
investigated. The figure is representative of 2 biological repeats. 
The mitoribosome was efficiently immunoprecipitated both via ICT1FLAG and MRPL45FLAG, 
as indicated by the presence of MRPL11 and MRPS26. OXA1L was also detected in both 
samples, confirming its interaction with the mitoribosome. The specificity of the IP was confirmed 
since no signal was detected from the sample obtained from wild type HEK293 cells (Fig. 7.3, 
lane 1). 
7.3. Effects of OXA1L depletion 
OXA1L depletion was performed using siRNA using the lipofectamine technology as for 
depletion of MRPL45. The siRNA used was a SmartPool composed of a mixture of 4 siRNA 
(Dharmacon, cat no M-012696-00, Appendix 4), in which each siRNA was designed to reduce off 
target complementarity. To further reduce these effects, the SmartPool mix was used at a final 
total concentration of 33 nM. Because it is composed by 4 siRNA, each individual siRNA is at the 
lower concentration (≈8 nM), further reducing the chances of off target effects. The consequences 
of 6 days OXA1L depletion on U2OS cell growth and morphology was monitored with the IncuCyte 
system (Fig. 7.4). NT-siRNA was used as an experimental control. 
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Figure 7.4 Effect on cells growth of OXA1L depletion.  
Cell growth was monitored over 6 days of OXA1L depletion by SmartPool siRNA. A) 
Growth was measured as a consequence of cell confluency, calculated by the IncuCyte 
system. The time of restransfection is indicated by a red arrow. B) Cells were visualised 
6 days after incubation with NT-siRNA or OXA1L siRNA. The images are representative 
of 3 biological repeats. 
OXA1L depletion severely affected cell growth. After  2 days, the cell confluency was 
decreasing, suggesting cells death (Fig. 7.4A). The severe effect on cells growth was also 
noticeable from visual inspection of cells (Fig. 7.4B). The steady state level of mitochondrial 
proteins was then analysed by western blotting (Fig. 7.5). 
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Figure 7.5 Effects of OXA1L depletion on steady state level of 
mitochondrial protein using SmartPool siRNA. 
Representative figure of western blot analysis performed on cell lysate (≈30 µg) after 6 
days of incubation with either NT-siRNA or OXA1L SmartPool siRNA. The steady state 
level of OXA1L and of components of the mt-LSU (MRPL45, MRPL11) and mt-SSU 
(MRPS26, MRPS22) were evaluated, as well as the steady state level of the mtDNA-
encoded protein COXII. Antibodies against SDH70 were used as loading controls.  Three 
biological repeats of the experiment were performed.  
The western blot analysis showed a very efficient depletion of OXA1L (Fig. 7.5). This depletion 
appeared to reduce the steady state levels of mitoribosomal components of both the mt-LSU and 
mt-SSU, suggesting an instability of the mitoribosome in absence of OXA1L and therefore its 
possible involvement in the biogenesis of both subunits. As a consequence, mitochondrial 
translation was affected, as confirmed by the reduced steady state levels of the mt-encoded 
COXII. The quality of the loading was verified with antibodies targeting the IMM protein SDH70.  
Due to the unexpected reduction of the steady state level of both the mitoribosomal subunits  
observed upon OXA1L depletion, and to disprove the hypothesis of an off target effect, I decided 
to test the effect of the individual siRNAs present in the SmartPool (Appendix 4). Each siRNA was 
tested at a final concentration of 33 nM, which is routinely used in our laboratory. U2OS cells were 
incubated with OXAsi01, OXAsi02, OXAsi03 or OXAsi04 for 6 days (reverse and then forward 
transfection at day 3). NT-siRNA was used as experimental control. The effects of the depletion 
on cell morphology and their confluency was monitored over the time course (Fig. 7.6). 
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Figure 7.6 Effects on cell growth and morphology of individual OXA1L SmartPool-siRNAs. 
Representative figure (2 biological repeats) of U2OS cells depleted of OXA1L for 6 days 
using 4 different siRNA at the final concentration of 33 nM and visualised at the inverted 
microscope on day 6. 
Examination at the microscope of depleted cells showed a reduction of cell growth for all the 
tested siRNA, with the most dramatic effect observed for OXAsi02. Cells incubated with OXAsi02 
were smaller and round when compared to the one incubated with NT-siRNA. 
Since cell growth was affected by OXA1L depletion with all the siRNAs tested, the effects of 
OXA1L depletion on mitochondrial protein content was analysed via western blotting (Fig. 7.7). 
The sample obtained from cells treated with OXAsi02 was not enough to allow its analysis with 
this technique. 
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Figure 7.7 Effects of 6 days OXA1L depletion using 3 different siRNAs. 
Cell lysates (≈30 µg) following incubation with 3 different siRNAs (33 nM) targeting OXA1L 
were analysed via western blotting. A representative image of 2 biological repeats is 
shown. NT-siRNA was used as a control (lane 1). The efficiency of the depletion was 
verified with antibodies against OXA1L. The effect on the steady state level of the 
mitoribosomal proteins MRPS26, MRPL11 and MRPL45 was also determined. On a 
different western blot, the effects of the depletion of OXA1L on ATP5β and COXII levels 
were detected for cells treated with OXAsi03 and 04. β-Actin was used as a loading control 
for both the membranes. The dashed line indicates that some lanes were excised from the 
figure. 
A weak signal for OXA1L was detectable in samples obtained from cells treated with OXAsi03 
and OXAsi04 (Fig. 7.7, lanes 3, 4), while a strong signal, comparable to the one observed for the 
NT siRNA was detected for the sample depleted with OXAsi01 (Fig. 7.7, lane 1 vs 2), suggesting 
the inefficacy of this siRNA. The siRNAs 1, 3 and 4 had a similar effect on the mitoribosomal 
proteins tested, with a reduction of steady-state level of MRPS26, MRPL11 and MRPL45. Due to 
the inefficacy of OXAsi01 in depleting OXA1L, it is likely that the reduction of the steady state 
level observed for mitoribosomal protein with this siRNA (Fig. 7.7, lane 2) was due to an off target 
effect. OXAsi03 and OXAsi04 also reduced the steady state level of ATP5β, a component of the 
F1 of complex V. 
The off target effects are usually when the complementarity between the siRNA and the target 
RNA is lower than 100%. Therefore, the off target effects tend to be reduced at lower siRNA 
concentration. Since the sequence of the siRNAs found in the SmartPool became available after 
their purchase, the sequences of OXAsi01, 02, 03 and 04  were analysed using BLAST to identify 
other possible targets different from OXA1L (http://blast.ncbi.nlm.nih.gov/). 
OXAsi01 was not successfully depleting OXA1L but showed a reduction of mitoribosomal 
proteins. The 73% of its sequence also matched DDX46 and FBXO38, involved in splicing and 
ubiquitination, respectively. In the match obtained, 73% of OXAsi02 showed a 100% identity to 
HLF, which encodes for a protein that regulates a complex involved in upregulation of anti -
apoptotic genes and downregulation of pro-apoptotic ones. It is possible that the effect observed 
on cell growth upon depletion with OXAsi02 was due to the unwanted targeting of the transcript 
encoding for this protein. OXAsi03 targets PANK1 mRNA with 73% of query coverage and 100% 
identity. This protein is involved in the first step of coenzyme A synthesis, important for the 
metabolism of fatty acids and the oxidation of pyruvate in the citric acid cycle. This siRNA also 
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targets with 68% of query coverage and 100% identity 2 transcripts encoding proteins that have 
been suggested to act as transcription activators (ZNF711 and SIX4), although their role is still 
not confirmed. Finally OXAsi04 had 73% query coverage of DMRTA1, which encodes for a protein 
suggested act as a transcription factor. 
To investigate the possibility of off target effects for OXAsi03 and OXAsi04, the depletion of 
OXA1L was performed at different concentration of siRNA (33 nM, 16 nM and 8 nM) on U2OS cells 
for 6 days, to identify the lowest siRNA concentration that successfully depletes OXA1L and detect 
the effects on mitoribosomal protein steady state levels at the different concentrations. Cell growth 
was monitored via the IncuCyte system (Fig. 7.8A) and, at the end of the depletion, cells were 
collected and analysed via western blotting (Fig. 7.8B). 
    
  
Figure 7.8 Effects of OXA1L depletion using different concentrations OXAsi03 or OXAsi04. 
U2OS cells were independently incubated for 6 days with 2 different siRNA targeting 
OXA1L (OXAsi03, OXAsi04), each at 3 different final concentrations (33 nM, 16 nM and 8 
nM). A) Cell growth was monitored by cell confluency using the IncuCyte. The 
retransfection time is indicated by red arrows. B) Western blot analysis was performed on 
cell lysate (≈30 µg). The efficiency of the depletion was assessed with antibodies targeting 
OXA1L. Steady state levels of the mt-encoded protein COXII as well as mitoribosomal 
proteins MRPL45 and MRPS26 were also visualised. The equality of the loading was 
controlled using antibodies targeting β-Actin. The figures are representative of 2 biological 
repeats. The dashed line indicates that some lanes were omitted from the figure.    
Cell growth was mildly delayed by both OXAsi03 and OXAsi04, independent of the siRNA 
concentration used to perform the depletion (Fig. 7.8A). However, western blot analysis 
highlighted a different efficiency of OXA1L depletion for the concentrations of the 2 siRNA tested. 
OXAsi03 was very efficient in depleting OXA1L at 33 nM (Fig. 7.8B, lane 2), but the depletion was 
B 
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lower at 16 nM (Fig. 7.8B, lane 3) and lower still at 8 nM (Fig. 7.8B, lane 4), showing a graded 
effect. The same trend was observed for the steady state level of COXII, MRPL45 and MRPS26. 
A higher steady-state level of COXII, MRPL45 and MRPS26 was observed when at 8 nM OXAsi03 
(Fig. 7.8B, lane 3) when compared to 16 nM (Fig. 7.8B, lane 4), and the steady state level of the 
protein tested in the latter was higher than the same protein detected after depletion with  33 nM 
OXAsi03 (Fig. 7.8B, lane 2). This result suggest that the effect observed on the mitoribosomal 
protein was related to the efficiency of the depletion of OXA1L, implying that an off target effect 
with the use of OXAsi03 was unlikely. Concerning OXAsi04, a similar level of depletion and a 
similar effect on the steady state level of COXII, MRPL45 and MRPS26 was observed at all the 
concentration tested (Fig. 7.8B, lanes 5,6,7). In particular, COXII was severely reduced, and 
MRPL45 and MRPS26 were also reduced. Because the use of lower concentrations of siRNA will 
reduce the chances of off target effects (Caffrey DR et al., 2011), it is unlikely that the effects 
observed on the mitoribosomal proteins are off target. 
Because OXAsi04 was still very efficient at the final concentration of 8 nM, lower 
concentrations (4 and 2 nM) were also tested. U2OS cells were depleted of OXA1L for 6 days 
using OXAsi04 at 16, 8, 4 and 2 nM. The results were analysed via western blot (Fig. 7.9). 
 
Figure 7.9 OXA1L depletion with OXAsi04 at different concentrations. 
Western blot analysis of cell lysate (≈ 30 µg) obtained from U2OS cells incubated for 6 
days with OXAsi04 at 16, 8, 4 or 2 nM (final concentration). NT siRNA was used as control. 
The efficiency of the depletion was assessed with antibodies against OXA1L. The steady 
state level of the mt-encoded COXII and of the mitoribosomal protein MRPL45 and MRPl11 
was also assessed. β-Actin was used as a loading control. The dashed line indicates that 
some lanes were omitted from the figure. The experiment was not replicated. 
The signal detected for β-Actin (Fig. 7.9) suggested that the loading of lane 5 was lower 
compared to the other lanes. The western blot analysis confirmed the efficiency of OXA1L 
depletion obtained with OXAsi04 at 8 nM (Fig. 7.9, lane 3). OXA1L was still depleted at the final 
concentrations of 4 (Fig. 7.9, lane 4) and 2 (Fig. 7.9, lane 5) nM, although the efficiency was lower. 
As observed for OXAsi03 in Fig. 7.8B, at lower efficiency of depletion (4 and 2 nM, Fig. 7.9, lanes 
4,5) a more intense signal for COXII, MRPL45 and MRPL11 was observed, when compared to 
16 or 8 nM of OXAsi04 (Fig. 7.9, lanes 2, 3). This result supported the direct correlation between 
the steady state level of the protein detected and OXA1L, suggesting that the result observed is 
not due to an off target of the siRNA. 
Stiburek et al suggested that OXA1L was important for the assembly of complex I and V 
(Stiburek L et al., 2007), proposing that the impaired biogenesis of the F1-ATP synthase as a 
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result of OXA1L knockdown in HEK293 could derive form the impaired assembly or membrane 
integration of the nuclear-encoded subunit c of F0. In order to investigate this possibility, OXA1L 
depletion was performed in 143B ρ0 cells. If the reduction observed for ATP5β was due to a lack 
of integration of subunit c, a reduction of the steady state level of this component of complex V 
would be detected in 143B ρ0 cells. 
These cells lack mtDNA but have no growth defect or altered morphology. Their mitochondrial 
membrane potential is lower than the parental 143B cells and it is maintained main ly by an 
incomplete F0F1-ATP synthase (Appleby RD et al., 1999; Buchet K et al., 1998), by the adenosine 
carrier (Buchet K & Godinot C, 1998) and by mitochondrial chloride intracellular channel (Arnould 
T et al., 2003). If any of these components is inhibited, the membrane potential drops. The 
complete F0F1-ATP synthase is absent in ρ0 cells as a consequence of the absence of the mt-
encoded subunit ATP6 and ATP8, but the F1 complex is intact in ρ0 and is present at the same 
level observed for 143B cells (qv Fig. 3.3, page 59). In ρ0 cells, about half of the F1 is associated 
with the IMM, probably through the nuclear-encoded subunit c of F0 (Carrozzo R et al., 2006; 
García JJ et al., 2000).  
OXA1L was depleted in 143B ρ0 cells for 6 days using OXAsi03 or 04 at the final concentration 
of 33 nM. Cell growth was monitored during the depletion and the lysate obtained was analysed 
via western blotting (Fig. 7.10). The reduction in the steady state level of the F1 complex was 
detected by western blot analysis, although, since the importance of this component to maintain 
the membrane potential of this cell line, a reduction in its level will affect cell growth.                   
 
 
 
 
 
 
Figure 7.10  Effects of OXA1L depletion in 143B ρ0 cells. 
143B ρ0 cells were transfected for 6 days with NT-siRNA or OXAsi03/04 at the final concentration 
of 33 nM. A) Representative figure of cell growth, monitored during the depletion as cell confluence 
using the IncuCyte system. The retransfection time is indicated by a red arrow. B) Representative 
figure (2 biological repeats) of western blot analysis performed on cell lysates (≈30µg) obtained 
after incubation with targeting and non-targeting siRNAs. The efficiency of the depletion was 
evaluated with antibodies against OXA1L. The steady state level of mitoribosomal proteins 
(MRPS26, MRP27, MRPL11) was also tested. Antibodies against ATP5β were used to assess the 
steady state level of the F1 subunit of complex V. SDH70 was used as a loading control. 
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No effects on cell growth were observed for ρ0 cells depleted of OXA1L (Fig. 7.10A). The 
western blot analysis performed on the samples confirmed that the level of OXA1L were 
dramatically reduced for both the OXA1L siRNA tested (Fig. 7.10B). Depletion of OXA1L did not 
affect the steady-state level of ATP5β, suggesting that the stability and assembly of the F1 of 
complex V is not dependent on the insertion by OXA1L of nuclear -encoded components of the 
F0.  
The steady-state level of several mitochondrial ribosomal proteins in ρ0 cells is lower than the 
one observed in the parental cell line (qv Fig. 3.3, page 59). Despite this, no reduction in the 
steady state level of mitoribosomal proteins was observed upon depletion of OXA1L when 
compared to the NT control. This observation further disproved the possibility that the effect 
observed on mitoribosomal proteins for OXA1L depletion in U2OS cells was due to an off target 
effect. 
7.4. Confirmation of the absence of off targets effects from OXA1L siRNAs 
OXA1L depletion unexpectedly affected both the large and small subunits of the mitoribosome. 
The previous paragraph suggested that the results observed were not likely to be due to off target 
effects. In order to confirm the robustness of the results obtained with OXAsi03 and 04, I decided 
to perform rescue experiments on U2OS cells. If the reduction of the level of mt-LSU and mt-SSU 
was due to OXA1L depletion, the transfection with OXAsi03 or 04 on cells overexpressing OXA1L 
should not affect the steady state level of mitoribosomal proteins. 
To perform this experiment, OXA1L containing silent mutations at the target sites for the 
siRNAs (OXA1Lsilmut) needed to be cloned into pcDNA5/FRT/TO, which was then used to 
perform a stable transfection in U2OS Flp-In cells.  
7.4.1. Cloning and overexpression of OXA1L 
The OXA1Lsilmut construct was designed personally and synthesised by GeneArt (Thermo 
Scientific) (Appendix 6). Silent mutations were performed at the targets for all the 4 siRNAs 
present in the SmartPool and HindIII restriction sites were added at either site of the construct 
to allow its cloning into pcDNA5/FRT/TO. 
OXA1L-pMK-RQ (10 ng) was transformed into bacterial competent cells (qv 2.2.2.) and 
single colonies were expanded in LB media containing 50 µg/mL of kanamycin. The plasmid 
was extracted and 2 µg were digested with HindIII (qv 2.3.7.) to obtain the OXA1L insert (≈ 1.3 
Kb) (Fig. 7.11A). pcDNA5/FRT/TO was also digested with HindIII, and then dephosphorylated. 
The success of the digestion was verified via DNA electrophoresis on 1.2% agarose gel (Fig. 
7.11B). 
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Figure 7.11 Digestion of OXA1L-pMK-RQ and pcDNA5/FRT/TO with HindIII. 
A) OXA1L-pMK-RQ (2 µg) was digested with HindIII at 37°C for 1 hour and then run on 
a 1.2% agarose gel, together with an undigested sample as control. The lower signal (≈ 
1.3 Kb) corresponds to the insert, successfully digested by the restriction enzyme. B) 
pcDNA5/FRT/TO was digested for 1 hour at 37°C. The linearisation of the plasmid was 
verified on 1.2% agarose gel. 
The band corresponded to OXA1L was excised from the gel and the DNA was extracted 
using the Qiagen kit. The insert and the plasmid were then ligated (qv 2.3.9.) and transformed 
into competent cells (qv 2.2.2.). Single colonies were amplified on a new LB-agar plate and 
analysed on a cracking gel (qv 2.3.10.) to distinguish colonies containing the plasmid with 
inserted OXA1L from colonies containing the empty plasmid (Fig. 7.12). 
 
Figure 7.12 Identification of colonies containing OXA1L within pcDNA5/FRT/TO. 
Cracking gel technique was performed (qv 2.3.10.) on colonies obtained after 
transformation of competent cells with OXA1L- pcDNA5/FRT/TO. The gel was 
visualised to identify colonies containing OXA1L- pcDNA5/FRT/TO plasmid (indicated 
by the arrow) from colony containing the empty plasmid. 
The cracking gel analysis showed the presence of a higher molecular weight species for 
colonies 1, 3, 5, 6, 7, indicating a larger plasmid likely to contain OXA1L (Fig. 7.12, indicated by 
an arrow). Since the same restriction enzyme on both sides of the insert a diagnostic digestion 
was performed to identify colonies containing the insert in the correct orientation. Plasmids 
extracted from colonies containing the OXA1L insert were digested with BamHI. In the case of 
correct orientation of the insert, the restriction enzyme would digest the insert 523 bases from 
its beginning, and the plasmid 17 bases from HindIII, generating 2 fragments of 842 bp and 
approximately 5.6 kbp. If the insert was present in the wrong orientation, the digestion would 
result in 2 fragments of 540 bp and approximately 5.9 kbp (Fig. 7.13). 
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Figure 7.13 Diagnostic digestion of OXA1L-pcDNA5/FRT/TO. 
Plasmids (500 ng) extracted from colonies presenting OXA1L insert within 
pcDNA5/FRT/TO were digested with BamHI to identify the colonies containing the insert 
in the right orientation. The products of each digestion (2 µL) were resolved on a 1.2% 
agarose gel. The arrow indicates the expected size of the fragment obtained by the 
digestion of OXA1L-pcDNA5/FRT/TO containing the insert in the correct orientation.  
Because the OXA1L insert, commissioned to Geneart (Thermo Scientific), was sequence 
verified by the company, the plasmid was directly used to transfect U2OS-FlpIn cells, together 
with pOG44 (qv 2.1.6.). After selection in hygromycinB and kanamycin, colonies were isolated 
and tested for the ability to overexpress OXA1L. After 3 days of overexpression, cells were lysed 
and the protein content analysed via western blotting (Fig. 7.14A). Cell growth upon 
overexpression of OXA1L was also monitored for 6 days (Fig. 7.14B) . 
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Figure 7.14 Effects on mitochondrial protein of OXA1L overexpression in U2OS cells.  
A) Western blot analysis performed on U2OS-OXA1L cell lysate after 3 days of 
overexpression of OXA1L. Cell lysate from uninduced cells was also analysed. 
Antibodies against OXA1L were used to confirm the induction. The steady state level of 
the OXPHOS components COXII and NDUFB8 was also detected, as well as the level 
of the mitoribosomal protein MRPL45. Porin and SDH70 were used as a loading control. 
The bar graph shows the quantification obtained from 3 biological repeats. B) Cell 
growth of uninduced or induced U2OS –OXA1L. Cell growth was represented as 
confluence, measured over 6 days every 3 hours by the IncuCyte system. The data 
presented are representative of 3 biological repeats. 
The detection of OXA1L confirmed the efficiency of the overexpression (Fig. 7.14A). The 
induced sample presented a reduction of the levels of COXII and NDUFB8 when compared to 
the uninduced control. The steady-state level of MRPL45 was unaffected by the overexpression. 
Porin and SDH70 were used as loading controls. No effects of OXA1L overexpression were 
observed on cell growth (Fig. 7.14B). 
7.4.2. Rescue experiments on OXA1L siRNA depletion 
The U2OS cell line able to overexpress OXA1L upon tetracycline induction , prepared as in 
the previous paragraph, was used to confirm that the effect observed on the steady state level 
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of mitoribosomal proteins was due to the absence of OXA1L upon transfection with OXAsi03 
and OXAsi04. 
U2OS-OXA1L cells were induced for 3 days and then depleted of OXA1L for 6 days either 
with OXAsi03 (33 nM final concentration) or OXAsi04 (16 nM final concentration). In parallel 
wild-type U2OS were also depleted of OXA1L. These cells were used instead of the uninduced 
U2OS-OXA1L to exclude the possibility of a less efficient depletion due to leaky expression of 
OXA1L. The induction was continued during the depletion. At the end of the experiment, cells 
lysates were analysed via western blotting (Fig. 7.15). 
 
Figure 7.15 Rescue of OXA1L depletion phenotype by overexpression of 
modified OXA1L immune to the siRNA. 
Western blot analysis was performed on cell lysates from U2OS-OXA1L cells induced 
for 3 days and then depleted of OXA1L for 6 days, whilst continuing the induction. In 
parallel U2OS cells were incubated with either non-targeting siRNA, OXAsi03 (33 nM) 
or OXAsi04 (16 nM) for 6 days. The efficiency of the depletion was detected with 
antibodies against OXA1L. The level of the mitoribosomal proteins MRPL24, MRPL45 
and MRPS22 was also measured. The level of the OXPHOS proteins COXII and ATP5β 
was also detected. SDH70 and TOM20 were used as loading controls.  The experiment 
was not replicated. 
The western blot analysis confirmed the efficiency of the depletion of OXA1L (Fig. 7.15, lanes 
2 and 4) as well as its rescue (Fig. 7.15, lanes 3 and 5) with both the siRNA used. As observed 
in the previous experiments, depletion of OXA1L caused reduction of the steady state level of 
mitoribosomal proteins and OXPHOS components. Upon overexpression of OXA1L (Fig. 7.15, 
lanes 3 and 5), a clear rescue of the level of ATP5β was observed. Full rescue was also 
observed for the levels of MRPS22. A partial rescue of MRPL45 and MRPL24, instead, was 
observed, especially using OXAsi04. No significant rescue was observed for COXII. This might 
be due to the partial rescue of the mitoribosomal protein, which might limit the amount of 
assembled mt-LSU and, therefore, not restoring completely mitochondrial translation. The 
quality of the loading was detected with antibodies against SDH70 and TOM20.  
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7.5. A role for OXA1L in human disease? 
7.5.1. Characterisation of mitochondrial defects in OXA1L patient 
During the course of my studies, the laboratory of Professor Rob Taylor identified a patient 
with mitochondrial disease and biallelic variants in the OXA1L gene. 
The patient was a 5-year-old boy born to unrelated parents. He had other 4 unaffected 
siblings as well as a sister who died at 12 months of unknown causes. His main clinical 
symptoms included severe encephalopathy, hypotonia, developmental delay (both motor and 
cognitive) and motor axonal neuropathy. He also presented with iron deficiency anaemia and 
obesity. The patient died in hospital due to complications related to his condition. Sequential 
COX/SDH reactions identified COX-deficient fibres (Fig. 7.16), whilst assessment of respiratory 
chain complex activities in Newcastle showed a decrease in complex IV activity in isolation. 
 
Figure 7.16 COX and COX/SDH reactions in muscle from a patient with 
mutations in OXA1L. 
Transverse sections of muscle tissue (10µm) were reacted to assess the activity 
complex IV (COX) and complex II (SDH). The figures from the individual COX reaction 
(left) and COX/SDH reaction (right) are represented, highlighting decreased activity. 
Courtesy of Professor Rob Taylor 
A complete screen of his mitochondrial genome (studies performed in Newcastle and 
Zaragoza) failed to identify causative mutations, as did a diagnostic screen of several nuclear 
genes known to be implicated in isolated COX-deficiency. Whole exome sequencing identified 
two novel variants in OXA1L (RefSeq Gene NG_051068.1) (c. 500_507dup (p. S170Qfs*18) 
and c. 620G>T (p. C207F) which segregated with disease in the family and were predicted to 
be pathogenic by a range of in silico tools (Sift, http://genetics.bwh.harvard.edu/pph2/) and were 
absent in the exome data set present in ExAC (http://exac.broadinstitute.org/). 
According to the topography of OXA1L presented in Table 7.1, the identified mutations 
affected an intermembrane space domain found between the transmembrane helices α2 and 
α3. This might affect the stability of the protein. The steady state levels of mitochondrial proteins 
in the patient fibroblast were analysed via western blotting (Fig. 7.17). 
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Figure 7.17 Steady state level of mitochondrial proteins in immortalised 
fibroblast from a patient carrying mutations in OXA1L gene. 
Western blot analysis was performed from control (M0528-12) and OXA1L patient 
immortalised fibroblasts. The steady state level of OXA1L was assessed as were the 
steady state levels of components of the OXPHOS system (NDUFB8, COXII and 
ATP5β). On a separate western blot, the levels of the mitoribosomal proteins MRPL3, 
MRPL45, MRPL11 and MRPS26 were detected. For both the membranes, β-Actin was 
used as loading control. The dashed line indicates that some lanes were omitted from 
the figure. 
The western blot analysis showed a reduced steady-state level of OXA1L, indicating that the 
mutations, occurring in an intermembrane domain, are affecting the stability of the protein. 
Despite that, approximately 40% of OXA1L was detected in the patient fibroblasts. Lower steady 
state levels of NDUFB8, COXII and ATP5β suggested decreased levels of complex I, IV and V, 
respectively. The levels of the mitoribosomal proteins were not affected. These data were 
confirmed by western blots performed by Dr Kyle Thompson on the same cell lines.  
7.6. Discussion 
While several published works investigated the role of yeast Oxa1, few data are available on 
the human homologue. This chapter focused on improving our understanding of the role of this 
protein in mitochondrial translation. 
Yeast Oxa1 is reported to interact with the mitoribosome (Jia L et al., 2003; Jia L et al., 2009). 
The main data reporting an interaction between OXA1L and the mitoribosome comes from in 
vitro studies reported by Haque et al, who crosslinked OXA1L to several components of the mt-
LSU. I confirmed the ability of OXA1L to interact with the mitoribosome in vivo via 
immunoprecipitation of 2 different mt-LSU components. Identifying the mitoribosomal partner of 
the interaction was not possible by immunoprecipitation. In case of a successful 
immunopreciptation of OXA1L, it is likely that the whole mt-LSU, and not only the mitoribosomal 
proteins directly interacting with OXA1L, will co-immunoprecipitate, making it impossible to 
identify direct interactions with this protein. The identification of the binding site of OXA1L on t he 
mitoribosome in vivo might be achievable with the the use of high-resolution microscopy which 
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will allow the visualisation of the interaction and the identification of the mt -LSU proteins is in 
direct contract with OXA1L. 
Oxa1 was named after the discovery of its role in complex IV assembly in yeast (Bonnefoy 
N et al., 1994; Keil M et al., 2012). Since then, Oxa1 has been reported to be involved in the 
insertion of both mitochondrial and nuclear encoded proteins (Hell K et al., 1998; Hildenbeutel 
M et al., 2012; Stiller SB et al., 2016). Depletion of human OXA1L was reported  to affect the 
assembly of complex I and V, while the other OXPHOS complexes appeared unaffected 
(Stiburek L et al., 2007). Due to this unexpected observation and to the the role of OXA1L in 
anchoring the mitoribosome to the IMM, I decided to investigate the effects of its depletion.  
First, a pool of 4 siRNA (SmartPool) targeting different positions in the OXA1L mRNA 
sequence was used to deplete the protein. Every siRNA present in the pool was selected and 
optimised by Dharmacon to increase the specificity and reduce the off target effects (Anderson 
EM et al., 2008; Birmingham A et al., 2006; Jackson AL et al., 2006). The final concentration of 
siRNA routinely used in our laboratory is 33 nM. The use of this final concentration of SmartPool 
allowed to use a lower concentration (8.25 nM) for every individual siRNA found in the mix. 
Since most the off target effects are due a partial complementarily of the siRNA with an 
unintended target, the use of a lower concentration of reagent will further reduce the chances 
of off target effects (Jackson AL et al., 2010). The depletion of OXA1L performed with the 
SmartPool severely affected cell growth. At the protein level, reduction of components of the 
large and, unexpectedly, small subunits of the mitoribosome were detected . COXII was 
undetectable. The depletion of mitoribosomal proteins suggested that OXA1L could play a role 
in the assembly of the large, but also of the small subunit of the mitochondrial translation 
machinery. Further confirmation of this surprising result were needed in order to exclude that 
the phenotype observed was due to off targets. To this purpose the 4 siRNA present in the 
SmartPool were individually tested. While OXAsi01 was not efficiently depleting OXA1L, 
OXAsi02 was lethal. OXAsi01 also led to the reduction of the steady state levels of 
mitoribosomal proteins, despite its inefficiency in depleting OXA1L. This result suggested that 
the depletion of the mitoribosomal proteins observed with the SmartPool might be due to an off 
target effect of OXAsi01. However, depletion with OXAsi03 and 04 led to an efficient depletion 
of OXA1L and showed reduction in the steady state level of both mt-SSU and mt-LSU proteins. 
This result might indicate that OXA1L causes depletion of mitoribosomal proteins, since this  
result was observed for both OXAsi03 and OXAsi04. Interestingly, a depletion of the complex V 
protein ATP5β was also observed, in agreement with the data published by Stiburek et al. Cell 
growth was only marginally delayed by OXAsi03 and 04, suggesting that the negative effect on 
growth observed with the use of the SmartPool siRNA was probably due to OXAsiA02.  
The sequences of OXAsi02, 03 and 04 were analysed with BLAST to identify possible targets 
different from OXA1L. The analysis suggested that OXAsi02 might lead to cell death because 
73% of its sequence aligns to mRNA encoding for HLF, involved in the regulation of apoptosis. 
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OXAsi03 and 04 showed a possible off target on transcriptions factors, which could have an 
impact on cells homeostasis. 
Further confirmation of the results observed with OXAsi03 and OXAsi04 were needed, 
therefore these siRNA were tested at lower concentrations. OXAsi03 was less efficient at 16 
nM. In this condition, the reduction observed for mitoribosomal proteins, and COXII, was a lso 
less pronounced, reflecting the lower efficiency of the depletion. At a final concentration of 8 nM 
of OXAsi03, only a partial depletion of OXA1L was observed, with a steady state level of COXII 
and mitoribosomal proteins tested that was higher than the one observed for depletion at 16 
nM. The efficiency of OXAsi04 was almost unchanged at 33 nM, 16 nM or 8 nM and at all these 
concentrations, a similar depletion of COXII and mitoribosomal proteins was detected. Lower 
concentrations of OXAsi04 (4 and 2 nM) showed a less efficient depletion of OXA1L, with less 
reduction of the levels of mitoribosomal proteins and COXII, as observed for OXAsi03. These 
experiments highlighted a relationship between the efficiency of OXA1L depletion and levels of 
COXII and the mitoribsomal components tested, suggesting a relationship between the two 
effects and the unlikeliness of off target effects. To further validate the data obtained from the 
depletion experiments, a cell line able to overexpress OXA1L upon tetracycline induction was 
prepared, in the attempt to rescue the phenotype observed by the depletion. The protein was 
successfully overexpressed but, unfortunately, the overexpression had an effect on the steady 
state level of OXPHOS components, which appeared reduced. The rescue experiment was 
perfomend, but a full rescue of the levels of mitoribosomal proteins and ATP5β was not obtained. 
This might be due to the negative effects of OXA1L overexpression observed. Interstingly, no 
rescue of COXII depletion was observed. Further considerations on this are found later in this 
discussion. 
As observed by Stiburek et al, the depletion of OXA1L reported in this chapter showed a 
reduction of the steady state level of ATP5β. This protein is a component of the F1 of complex 
V found in the matrix and which associates with F0 of the same complex via subunit c. F1 is 
completely nuclear-encoded and assembled independently from F0 (Tzagoloff A, 1969). A 
downregulation of F1 is rarely observed in cases of impaired mitochondrial translation. Stiburek 
et al suggested that the reduction of ATP5β observed upon OXA1L depletion could be due to 
the lack of insertion of subunit c of the F0, since yeast Oxa1 has been reported to mediate the 
insertion of Atp9 (homologue of human subunit c). If the reduced stability of F1 was due to this, 
a reduction of ATP5β should be observed in OXA1L depletion performed on 143B ρ0 cells. 
These cells lack of mtDNA but maintain the membrane potential also thanks to a partially 
assembled complex V (Appleby RD et al., 1999; Buchet K & Godinot C, 1998). In these cells, 
F1 is intact and approximately half of it is reported to interact with the membrane via subunit c 
(Carrozzo R et al., 2006; García JJ et al., 2000). If the reduction of ATP5β observed upon 
depletion of OXA1L is due to impairment of subunit c insertion into the membrane, the depletion 
of OXA1L in cells should also reduce the level of ATP5β, affecting the membrane potential of 
the mitochondria and therefore the homeostasis of the cell. Upon depletion of OXA1L, no effects 
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on 143B ρ0 cell growth was observed and the steady state level of ATP5β was unchanged. 
Although this result gave no information on the membrane insertion of subunit c, it suggested 
that the instability observed for ATP5β by Stiburek et al (and also in this thesis) cannot be due 
to an improper integration of subunit c into the inner mitochondrial membrane. In support of this, 
published data reported that depletion of subunit c did not affect the steady state level of another 
F1 subunit (ATP5α), confirming that subunit c is not important for the stability of the F1 (Bonora 
M et al., 2013). The mechanism underlying the reduction of ATP5β levels upon depletion in cells 
containing mtDNA is not clear. Interestingly, despite the steady state level of most of the 
mitoribosomal components being lower 143B ρ0 cells, no further reductions were observed upon 
depletion of OXA1L, supporting the idea that their reduction in U2OS is linked to the depletion 
of OXA1L. 
While performing the OXA1L depletion studies, I became aware of a patient with 
mitochondrial disease and biallelic variants in the gene encoding this protein. The patient was 
compound heterozygous for two OXA1L variants, with both the mutations affecting one of the 
intermembrane domains inbetween 2 transmembrane helices. Muscle histochemistry 
highlighted COX-deficiency, supporting the hypothesis derived from the depletion studies 
performed on U2OS cells that OXA1L plays a role of in complex IV assembly. Fibroblasts 
presented a minor OXPHOS defect, which was compensated by an increase of glycolysis. 
Western blot analysis performed on immortalised patient fibroblasts indicated a reduct ion of the 
steady state level of OXA1L to approximately 40% of the control cell line. A reduction of the 
steady state level of components of complex I, IV and V was detected. Reduction of complex I 
and V was in agreement with the observations of Stiburek et al. for OXA1L depletion on HEK293 
cells. Depletion of complex V (ATP5β) was also reported upon depletion of OXA1L in this 
chapter. The effects of the depletion on components of complex I were not tested. In agreement 
with the depletion experiments reported in this chapter, complex IV (COXII) was also reduced 
in the patient cell line, supporting the idea of a role of OXA1L in the assembly of this complex. 
The steady state levels of the mitoribosomal proteins was not reduced in the OXA1L patient 
fibroblasts. It is important to specify that, when the depletion experiments were perfomed with 
siRNA (lower concentrations) that led to a steady state level of OXA1L comparable with the 
levels detected in the patient, there was no significant effect on the steady state levels of 
mitoribosomal proteins. This result is in agreement with the phenotype observed in the patient 
fibroblasts. Work on the OXA1L patient is currently continuing (Dr Kyle Thompson and Professor 
Rob Taylor, unpublished case). 
Interestingly, rescue of the OXA1L patient phenotype was attempted by colleagues, without 
success and is currently being repeated by Dr Kyle Thompson. This, together with the data 
obtained for depletion or overexpression of OXA1L, suggests that there is a narrow range at 
which there is an optimal level of this protein, and it might be important to maintain this for correct 
cellular homeostasis.  
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Although the rescue experiment of the OXA1L depletion phenotype on U2OS cells did not 
successfully increase the level of COXII, the reduction in the steady state level of this protein 
with both the siRNAs tested, and the presence of COX deficiency in the patient fibroblasts and 
muscle, support the role of OXA1L in the assembly of complex IV. 
The reduction of mitoribosomal components observed with OXA1L depletion suggests that 
this protein might be involved in the assembly of both the large and the small mitoribosomal 
subunit. OXA1L might be directly involved in the assembly or might be important for membrane 
insertion of other unknown proteins that might have a key role mitoribosomal assembly. 
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Chapter 8: Concluding  remarks 
The work presented in this thesis focused on the characterisation of the role of 2 mitochondrial 
proteins, MRPL45 and OXA1L, in mitochondrial translation. The main focus was human MRPL45, 
a constituent of the mitochondrial ribosome that was suggested to be involved in the important 
interaction of the mitoribosome with the inner mitochondria membrane. Data generated during my 
project made a connection with and led into work on the IMM protein OXA1L, which in yeast is 
defined as a mitoribosome-interacting protein and as an insertase that contributes to the assembly 
of some OXPHOS components. 
The data obtained for the 2 proteins are summarised in the sections below.  
8.1. MRPL45 
Studies presented here demonstrated the importance of the mitoribosomal protein MRPL45 
for the homeostasis of cells. Depletion of this protein highlighted its central role in the stability and 
the assembly of the mt-LSU. In the absence of MRPL45, the mt-LSU failed to assemble, 
suggesting an involvement of MRPL45 in the first steps of the its assembly process. As a 
consequence of the reduced levels of mt-LSU, mitochondrial translation was impaired and an 
increase in the glycolytic activity, necessary to provide the ATP for the cell to survive, was 
observed.  
Once the importance of MRPL45 was established, I focused my attention on investigating the 
ability of this protein to interact with the membrane. At the beginning of this study, the only 
information available on the possibility of membrane-interaction of this protein was its structural 
homology with the membrane-interacting protein TIM44. However, relatively soon after, the first 
structure of the mammalian mt-LSU was released and localised MRPL45 in close proximity of the 
polypeptide exit site (Greber BJ et al., 2014), further supporting its potential role in the association 
of the mt-LSU with the membrane. In order to study membrane-association, I developed a 
protocol that was used to test membrane-interaction. First, this protocol was used to confirm the 
ability of human mt-LSU to interact with the IMM, as previously suggested by Liu M and Spremulli 
LL (2000). Through the application of the developed protocol on cells overexpressing MRPL45, I 
demonstrated the ability of MRPL45 to interact directly with the membrane in the absence of pre-
assembled mitoribosomal subunits. 
Cell lines able to inducibly overexpress MRPL45FLAG were prepared in order to study the 
interactome of the protein. The addition of the FLAG-tag at the C-terminus of the protein did not 
affect its integration in the mt-LSU and did not inhibit the ability of the protein to directly interact 
with the IMM. The overexpression of another MRPL45FLAG construct, carrying silent mutations 
in the sequences targeted by the siRNA used to deplete the endogenous protein, con firmed the 
ability to obtain a full rescue of the depletion phenotype. This result further confirmed that the 
addition of the FLAG-tag did not affect the function of MRPL45 and validated the phenotype 
observed upon depletion of the endogenous protein. 
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No transmembrane domains were predicted within the MRPL45 protein sequence, and the 
mass spectrometry analysis of the sample obtained from the immunoprecipitation of 
MRPL45FLAG in absence of assembled mt-LSU failed to identify any membrane proteins that 
might interact with MRPL45 to mediate the interaction. A parallel experiment performed on 
untagged overexpressed MRPL45 also did not identify any strong candidate interacting proteins. 
In contrast, samples from both immunoprecipitations analysed by western blot prior to the mass 
spectrometry analysis, detected a weak signal from OXA1L. This might suggest a non -
stoichiometric interaction with MRPL45, but using a sensitive technique the protein would be 
expected to be detected by mass spectrometry, which it was not. The lack of consistent and 
convincing data on the existence of a partner membrane protein for the interaction with MRPL45 
suggests the probability that the interaction of MRPL45 is direct with the phospholipid layer.  
In this study, I also investigated the domain of MRPL45 that is putatively involved in the 
interaction with the membrane. Examining the information available on the structure of human 
MRPL45 I decided to express a version of the protein containing mutations of the charged amino 
acids present in the most protruding domain of the protein (α2-helix) by changing these to alanine 
(MRPL45FLala). Although the steady state level of the protein was very low, it was efficiently 
targeted to mitochondria. Isokinetic sucrose gradient analyses showed that upon expression 
MRPL45FLala was not integrated into the mt-LSU, but that it could be used as a component of 
the subunit only when the endogenous MRPL45 was absent. Consistent with this, the expression 
of the mutant protein in the absence of the endogenous MRPL45, by siRNA depletion, showed a 
partial rescue of the phenotype. This was probably because the relatively low levels of available 
MRPL45FLala was limiting the assembly of the mt-LSU. However, since MRPL45FLala was able 
to interact with the membrane, it suggested that the mutated domain was not involved in the direct 
interaction of the protein with the IMM. 
Since the first MRPL45 mutant examined did not identify the domain involved in membrane 
interaction, I designed a new construct, based on the structural homology with the membrane-
interacting protein TIM44. The new mutant (MRPL45FLΔ) lacked the first 117 amino acids (N-
terminal of the α2-helix) and was efficiently targeted to mitochondria by addition of the Su9 
presequence, which I demonstrated to be efficiently and accurately cleaved upon import. 
Unfortunately, the steady state of this protein was also very low. Unlike the previous mutant 
studies, MRPL45FLΔ was not efficiently integrated within the mt-LSU, even when the 
endogenous protein was absent. Unexpectedly, this protein maintained the ability to interact with 
the mitochondrial membrane. Although the studies that I performed on mutant variants of MRPL45 
did not successfully identify the domain of MRPL45 involved in membrane interaction, 
investigation of MRPL45FLΔ suggested that the deleted domain is important for the assembly of 
the protein within the mt-LSU. 
Since it was not possible to identify the domain of MRPL45 responsible for membrane -
interaction, different MRPL45 mutants could be prepared to analyse their ability to interact with 
the membrane, using the protocol developed during this project.  
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In addition, the improvement of electron microscopy techniques might allow the visualisation 
of the membrane-bound mitoribosomes and the identification of other components that might be 
involved in this important interaction. 
The data presented in this project suggested a central role of MRPL45 in the assembly of the 
mitoribosome, a process is still undefined. Once the components of the assembly machiner y will 
be identified, it will be possible to study the mechanism of the assembly of the mitoribosome by 
replicating it in vitro. 
8.2. OXA1L 
The data presented in this thesis showed for the first time in vivo that the IMM protein OXA1L 
interacts with the mitoribosome, since this was successfully co-immunoprecipitated with 2 
different mitoribosomal proteins. This interaction had been already confirmed in yeast, but it was 
previously reported in human only by in vitro studies (Haque ME et al., 2010). 
Subsequently, depletion of OXA1L was performed to study its involvement in mitochondrial 
translation. This was performed with a pool of 4 siRNA and resulted, unexpectedly, in a reduction 
of the steady state level of components of both the mt-LSU and the mt-SSU. The result was 
confirmed by independently using 2 of the siRNA present in the pool, suggesting tha t the observed 
effect was genuine. In addition, the reduction of the mitoribosomal components observed upon 
depletion of OXA1L could be rescued upon overexpression of the protein, further confirming the 
robustness of these results. From my studies it was not clear if the OXA1L has a direct role in the 
assembly of the subunits or if this effect was due to the failure in the insertion or the import of 
other mitochondrial proteins that play a role in the process of mitoribosome biogenesis. Due to 
the reduction of the steady state levels of mitoribosomal subunits following OXA1L depletion, it 
was not possible to investigate the effects on the interaction of the mitoribosome in absence of 
this IMM protein. 
Depletion of OXA1L also led to a reduction of on the steady state levels of both complex IV 
and V. Depletion of complex IV could be related to an impairment of mitochondrial translation 
following the reduction of mitoribosomal proteins. Reduction of the steady state levels of complex 
V was also observed by Stiburek et al, who, in contrast to my data, did not find any effect on 
complex IV. A reduction in the steady state levels of COXII was shown in my study upon depletion 
with 2 different siRNA, although its levels were not restored by the overexpression of the p rotein. 
In parallel with these studies, the characterisation of the phenotype of a patient carrying a 
compound heterozygous mutation for OXA1L were performed. These also identified a deficiency 
in this complex IV, suggesting the involvement of OXA1L in the assembly and stability of complex 
IV. COX/SDH staining performed on skeletal muscle samples highlighted the presence of COX 
negative fibres, and a reduction of the steady state levels of the COXII component of complex IV 
was detected in immortalised fibroblasts samples by western blot. This analysis also showed that 
the steady state level of OXA1L was reduced to approximately 40% in the patient immortalised 
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fibroblasts, as well as a reduction of the steady state levels of NDUFB8 (Complex I) and ATP5β 
(Complex V). No reduction of mitoribosomal proteins was detected. These results suggest that 
OXA1L plays a role in the assembly of complexes I, IV and V, and that when a proportion of 
OXA1L is present, there are no effects on the assembly of the mitoribosomal subunits. Further 
biochemical characterisation of the patient’s phenotype is currently under investigation.  
In this study, it was not possible to identify the mitoribosomal proteins that are directly 
interacting with OXA1L, since a successful immunoprecipitation of OXA1L will lead to the co -
precipitation of the whole mitoribosome. The proteins in direct contact with OXA1L could be 
identified in the future with the use of advanced electron microscopy techniques that might be 
able to visualise the interaction. Another method that could be used to identify binding partners 
of OXA1L is the proximity labelling combined to affinity purification and mass spectrometry 
analysis. For example, if a fusion protein composed of OXA1L and biotin protein ligase can be 
expressed in human cells without affecting the role of OXA1L, biotinylation of  neighbour proteins 
can be obtained in vivo. These biotinylated proteins can then be collected by affinity purification 
and identified via mass spectrometry. This method could potentially also contribute to the 
identification of the role of OXA1L in the assembly of complexes I, IV and V. In  addition, it will be 
interesting to identify the mechanism by which OXA1L is directly or indirectly involved in the 
assembly of the mitoribosomal subunits. In order to understand OXA1L role in this process, more 
information on this is needed.  
 
 The data presented in this thesis has provided new information on MRPL45 and OXA1L and 
their role in post-transcriptional mitochondrial gene expression. Although this has improved our 
understanding of this process that is crucial for cell viability, a deeper knowledge of mitochondrial 
biology is essential to understand the molecular mechanisms underlying mitochondrial dysfunction. 
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Appendices 
Appendix 1: Nomenclature of mitoribosomal proteins 
The new nomenclature (Greber BJ et al., 2016) contains a letter before the number which identifies 
universal (‘u’), bacterial-homologue (‘b’) and mitochondrial-specific (‘m’) proteins. In case of the 
universal and bacterial-homologue proteins, the number is followed by the letter ‘m’ to refer to the 
mitochondrial protein.  
mt-SSU  mt-LSU 
Old name New name  Old name New name 
MRPS2 uS2m  MRPL1 uL1m 
MRPS5 uS5m  MRPL2 uL2m 
MRPS6 uS6m  MRPL3 uL3m 
MRPS7 uS7m  MRPL4 uL4m 
MRPS10 uS10m  MRPL9 bL9m 
MRPS11 uS11m  MRPL10 uL10m 
MRPS12 uS12m  MRPL11 uL11m 
MRPS14 uS14m  MRPL12 bL12m 
MRPS15 uS15m  MRPL13 uL13m 
MRPS16 bS16m  MRPL14 uL14m 
MRPS17 uS17m  MRPL15 uL15m 
MRPS18b mS40  MRPL16 uL16m 
MRPS18c bS18m  MRPL17 bL17m 
MRPS21 bS21m  MRPL18 uL18m 
MRPS22 mS22  MRPL19 bL19m 
MRPS23 mS23  MRPL20 bL20m 
MRPS24 uS3m  MRPL21 bL2m 
MRPS25 mS25  MRPL22 uL22m 
MRPS26 mS26  MRPL23 uL23m 
MRPS27 mS27  MRPL24 uL24m 
MRPS28 bS1m  MRPL27 bL27m 
MRPS29 (DAP3) mS29  MRPL28 bL28m 
MRPS31 mS31  MRPL30 uL30m 
MRPS33 mS33  MRPL32 bL32m 
MRPS34 mS34  MRPL33 bL33m 
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MRPS35 mS35  MRPL34 bL34m 
MRPS37 (CHCHD1) mS37  MRPL35 bL35m 
MRPS38 (AURKAIP1) mS38  MRPL36 bL36m 
MRPS39 (PTCD3) mS39  MRPL37 mL37 
   MRPL38 mL38 
   MRPL39 mL39 
   MRPL40 mL40 
   MRPL41 mL41 
   MRPL42 mL42 
   MRPL43 mL43 
   MRPL44 mL44 
   MRPL45 mL45 
   MRPL46 mL46 
   MRPL47 uL29m 
   MRPL48 mL48 
   MRPL49 mL49 
   MRPL50 mL50 
   MRPL51 mL51 
   MRPL52 mL52 
   MRPL53 mL53 
   MRPL54 mL54 
   MRPL55 bL31m 
   MRPL57 mL63 
   MRPL58 (ICT1) mL62 
   MRPL59 (CRIF1) mL64 
   MRPS30 (PDCD9) mL65 
   MRPS18a mL66 
   / mL57 
   / mL58 
   / mL59 
   / mL60 
   / mL61 
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Appendix 2: Antibodies 
The primary and secondary antibodies used in this study are listed in the following tables:  
Primary antibodies Dilution Company, Cat. No 
α-FLAG 1:2,000 Sigma, F1804 
ATP5b 1:1,000 Abcam, Ab14730 
β-actin 1:10,000 Sigma, A1978 
CLPP 1:1,000 Abcam, Ab124822 
COXII 1:1,000 Eugene, A6404 
DAP3 1:1,000 Abcam, Ab11328 
GDH 1:500 Custom synthesised 
HSP60 1:5,000 BD biosciences, 611562 
ICT1 1:1,000 Proteintech group, 10403-1-AP 
LetM1 1:2,000 Proteintech group, 16024-1-AP 
LONP 1:1,000 Sigma, HPA002192 
MRPL3 1:1,000 Abcam, Ab39268 
MRPL11 1:1,000 Cell signalling techn., D68F2 
MRPL24 1:1,000 Proteintech group, 16224-1-AP 
MRPL45 1:1,000 Proteintech group, 15682-1-AP 
MRPS17 1:1,000 Proteintech group, 18881-1-AP 
MRPS22 1:1,000 Proteintech group, 10984-1-AP 
MRPS26 1:1,000 Proteintech group, 15989-1-AP 
MRPS27 1:1,000 Proteintech group, 17280-1-AP 
NDUFA9 1:1,000 Abcam, Ab14713 
NDUFB8 1:1,000 
1:1,000 
Invitrogen, A31857 
Abcam, Ab110242 
OXA1L 1:1,000 Proteintech group, 21055-1-AP 
Porin 1:10,000 Abcam, Ab 14734 
TOM20 1:1,000 Santa Cruz, Sc-11415 
SDH70 1:1,000 Abcam, Ab14715 
 
Secondary antibodies Dilution Company, Cat. no 
Rabbit 1:3,000 Dako, P0399 
Goat 1:2,000 Dako, P0260 
Mouse 1:2,000 Dako, P0449 
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Appendix 3: Plasmids 
The following plasmids were used in this study: 
- pcDNA™5/FRT/TO (Invitrogen). Vector designed for use in Flp-In™ systems. It contains a 
multiple cloning site under tetracycline control. It also contains ampicillin and hygromycin B 
resistance genes. used to select clones respectively in bacteria and human cell lines.  
 
- pOG44 (Invitrogen). Flp-recombinase expression vector designed for use in Flp-In™ 
System in co-transfection with pcDNA™5/FRT/TO. It encodes ampicillin resistance for 
selection of positive transformed bacteria. 
 
- pMK-RQ (Thermo Scientific). Vector containing the custom synthesised gene from GeneArt 
(Thermo Scientific). It encodes kanamycin resistance. 
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Appendix 4: Small interfering RNA 
Protein knockdown was obtained using the following small interfering RNA (siRNA):  
Target Company Catalogue no Referred to 
as 
Sequence sense fragment (5’-
3’) 
MRPL45 Sigma-
Aldrich 
SASI_Hs02_00359740 
SASI_Hs01_00089760 
siRNA02 
siRNA01 
GACUGAUAGAGAGAACUGA 
GAGUAUGUUGUAUUCGAAA 
OXA1L Dharmacon M-012696-01 
M-012696-02 
M-012696-03 
M-012696-04 
Smartpool M-012696-00 
OXAsi01 
OXAsi02 
OXAsi03 
OXAsi04 
SmartPool 
UAACGUGGCUUUACAGAUU 
GGAAACCGCUGACCACACG 
CAGGAGACCAUAUUGAGUA 
CAAGUAUCCUGUCUCCGGA 
Mixture of M-012696-01.   
M-012696-02. M-012696-0. 
M-012696-04 
CLPP Qiagen SI00083650 CLPP siRNA CGAUGCAGUACAUCCUCAATT 
LONP Qiagen SI00068488 LONP siRNA CGCGCUUUAUCAAGAUUAUTT 
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Appendix 5: DNA oligonucleotides 
The following DNA-oligonucleotides were used for PCR reactions. They were personally designed 
and then synthesised by Eurogentec. 
Product Use DNA oligonucleotide 5’- 3’ 
MRPL45 
and mutants 
PCR, preparation 
of inserts for 
cloning. 
 
 
 
 
 
Frw1   CTC-TAT-GGA-TCC-ATG-GCA-GCC-CCC-ATA-CC 
Frw2   CTC-TAT-GGA-TCC-CTT-TGC-GGG-AAC-AAG-ATG-G 
Rev1FLAG   CTC-TAT-GGA-TCC-CTA-CTT-ATC-GTC-GTC-ATC-
CTT-GTA-ATC-GGC-TAG-CTG-AGG-CTT-CTG-G 
Rev2   CTC-TAT-GGA-TCC-CTA-GGC-TAG-CTG-AGG-CTT-CTG-G 
Rev3   CTC-TAT-GGA-TCC-GAG-ACT-TCA-AAG-CTT-CCA-GC 
L45trFrw   CAC-ACA-GCG-CGC-CGC-AGC-TGC-ATC-ACA-AGT-
GTC-AAT-CCG-G 
L45trRev   ACA-CAC-GCG-GCC-GCC-AAG-AAG-CCT-CAC-TTG-
TCG-TCA-TCG-TCT-TTG-TAG-TCG-GCT-AGC-TGA-GGC-TTC-TGG 
MRPL45FLsil Site-directed 
mutagenesis 
MRPL45sisilmutsense   CAA-AGG-AGG-GTT-TAA-TCG-AAA-GAA-
CTG-AAC-G 
MRPL45sisilmutanti-s CGT-TCA-GTT-CTT-TCG-ATT-AAA-CCC-
TCC-TTT-G 
MRPL45 qPCR L45qP1Frw   CTC-AGT-CCG-CAG-CTA-TAG-TTC 
L45qP1Rev   GAA-ACA-TAG-GCA-TCA-AAT-ATA-CCA-G 
MRPL45FLΔ In vitro 
transcription 
SP6-Su9-L45Frw   ATT-TAG-GTG-ACA-CTA-TAG-CAC-ACC-TCG-
AGA-CCA-TGG 
SP6-Su9-L45Rev   AAG-CCT-CAC-TTG-TCG-TCA-TCG-TCT-T 
Other DNA oligonucleotides, already in use in our laboratory, were also used in this study: 
Product Use DNA oligonucleotide 5’- 3’ 
18S qPCR Frw    GTA-ACC-CGT-TGA-ACC-CCA-TT 
Rev    CCA-TCC-AAT-CGG-TAG-TAG-CG 
12S qPCR Frw    ACA-CTA-CGA-GCC-ACA-G 
Rev    ACC-TTG-ACC-TAA-CGT-C 
16S qPCR Frw    CCA-ATT-AAG-AAA-GCG-TTC-AAG 
Rev    CAT-GCC-TGT-GTT-GGG-TTG-ACA 
COXII qPCR Frw    CTT-AGA-ACC-AGG-CGA-C 
Rev    GTC-GTG-TAG-CGG-TGA-A 
BGH PCR 
Colony 
screening 
Rev    TGA-AAG-GCA-CAG-TGC-AGG 
CMV PCR 
Colony 
screening  
Frw    CGC-AAA-TGG-GCG-GTA-GGC-GTG  
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Appendix 6: Synthetic genes 
Two construct were synthesised from GeneArt™ (Thermo Scientific) and were used for the cloning 
of mutated OXA1L (A) and MRPL45FLala (B). Both the genes were integrated in pMK-RQ form 
Thermo Scientific. Two restriction site were included at both ends of each gene to allow its isolation 
from pMK-RQ and its cloning into pcDNA™5/FRT/TO. 
 
 
 
 
 
 
 
A 
B 
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 Legend: FLAG tag; siRNA target; Restriction site; Start/Stop codon; Changes to wild type 
 
 
Gene Sequence 
OXA1Lsilmut AAGCTTCCTCTTCCGGGCAAAATGGCGATGGGACTAATGTGCGGACGCCGG
GAGCTTCTGCGCTTGCTACAGTCCGGGCGTCGGGTCCACAGCGTCGCAGGG
CCCTCGCAATGGCTTGGGAAGCCACTTACTACCCGGCTCCTATTCCCAGCAG
CCCCGTGCTGCTGTCGCCCACACTACCTCTTCCTTGCGGCTTCCGGCCCCC
GCAGCCTCAGTACCTCTGCTATCTCTTTTGCAGAAGTCCAGGTTCAGGCCCC
TCCTGTTGTTGCTGCAACTCCCTCACCCACAGCAGTACCTGAGGTGGCTTCT
GGAGAGACTGCAGATGTAGTCCAAACTGCTGCAGAGCAGAGCTTCGCTGAA
CTGGGGCTGGGGTCATACACCCCAGTGGGACTGATCCAGAATTTACTGGAAT
TTATGCATGTTGATCTGGGCCTACCTTGGTGGGGGGCCATTGCTGCATGTAC
AGTCTTTGCCCGCTGCCTGATTTTTCCTCTCATCGTGACGGGCCAGCGAGAG
GCAGCCAGGATCCACAATCACTTGCCAGAGATCCAGAAGTTTTCCAGTCGAA
TCAGAGAGGCCAAGTTAGCAGGGGATCACATCGAATATTACAAGGCTTCCTC
GGAGATGGCACTTTACCAGAAAAAACATGGTATTAAACTCTATAAACCTCTCA
TTCTCCCTGTGACTCAGGCCCCAATCTTCATCTCCTTCTTCATTGCTTTGAGA
GAGATGGCCAACCTTCCTGTGCCCAGCCTGCAGACAGGTGGCCTCTGGTGG
TTCCAGGATCTCACGGTATCCGATCCCATCTACATATTACCACTGGCAGTCAC
TGCTACAATGTGGGCTGTTCTTGAGCTAGGTGCTGAGACAGGTGTGCAAAGT
TCTGACCTTCAGTGGATGAGAAA TGTCATCAGAATGATGCCCCTGATAACCTT
GCCCATAACCATGCATTTCCCCACGGCAGTGTTTATGTACTGGCTCTCCTCC
AATTTGTTTTCCCTGGTCCAGGTGTCTTGCCTTCGGATTCCAGCAGTACGCA
CTGTACTTAAAATCCCCCAGCGTGTTGTACATGACCTGGACAAATTACCTCCA
CGGGAAGGCTTCCTAGAGAGCTTCAAAAAAGGCTGGAAAAATGCTGAAATGA
CGCGTCAGCTGCGAGAGCGTGAACAACGCATGCGGAATCAGTTGGAGCTAG
CAGCCAGGGGTCCTTTACGACAGACCTTTACCCACAACCCTCTCCTACAACC
TGGAAAGGATAACCCTCCCAATATCCCTAGCAGCAGCAGCAAACCAAAGTCA
AAGTATCCCTGGCACGACACACTTGGCTGACTTATATTCAAGCTT 
MRPL45FLala GGATCCTTGCGGGAACAAGATGGCAGCCCCCATACCTCAAGGGTTCTCTTGT
TTATCGAGGTTTTTGGGCTGGTGGTCTCGGCAGCCAGTTCTGGTGACTCAGT
CCGCAGCTATAGTTCCAGTAAGAACTAAAAAACGTTTCACACCTCCTATTTAT
CAACCTAAATTTAAAACAGAAAAGGAGTTTATGCAACATGCCCGGAAAGCAG
GATTGGTTATTCCTCCAGAAAAATCGGACCGTTCCATACATCTGGCCTGTACA
GCTGGTATATTTGATGCCTATGTTCCTCCTGAGGGTGATGCACGCATATCATC
TCTTTCAAAGGAGGGCCTTATTGAAAGGACCGAACGAATGAAGAAGACTATG
GCATCAGCAGTGTCAATCGCCGCUATAGCAGCCGCUGATGCCAACTTTGCU
ATAGCAGCCTTCCCTGAAAAAGCTAAGGATATCTTTATTGAAGCTCACCTTTG
TCTAAATAACTCAGACCATGACCGGCTTCATACCTTGGTAACTGAACACTGTT
TTCCAGACATGACTTGGGACATCAAATATAAGACCGTCCGCTGGAGCTTTGT
GGAATCTTTAGAGCCCTCTCATGTTGTTCAAGTTCGCTGTTCAAGTATGATGA
ACCAGGGCAACGTGTACGGCCAGATCACCGTACGCATGCACACCCGGCAGA
CTCTGGCCATCTATGACCGGTTTGGCCGGTTGATGTATGGACAGGAAGATGT
ACCCAAGGATGTCCTGGAGTATGTTGTATTCGAAAAGCAGTTGACAAACCCC
TATGGAAGCTGGAGAATGCATACCAAGATCGTTCCCCCATGGGCACCCCCTA
AGCAGCCCATCCTTAAGACGGTGATGATCCCTGGCCCTCAGCTGAAACCAGA
AGAAGAATATGAAGAGGCACAAGGAGAGGCCCAGAAGCCTCAGCTAGCCGA
CTACAAAGACGATGACGACAAGTGATGACAAAAATGACTGGATCC 
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Appendix 7: Flow Cytometry analysis of MRPL45 depletion on HEK293 
 
 
Figure a18 Cell cycle analysis with propidium iodide of U2OS cells incubate with NT-siRNA. 
Forward (FSC-A) and side (SSC-A) scatter (A) were used to identify the cells (area P1), while 
pulse shape analysis (B) was used to identify clumps and doublets. Single cells were circled in the 
area P2. The percentage of cells in each phase of the cell cycle were quantified by the program 
(C). 488 585/42 indicates the wavelength and the filter used.  
 
 
Figure a19  Cell cycle analysis with propidium iodide of U2OS cells incubate with MRPL45-
siRNA. 
Forward (FSC-A) and side (SSC-A) scatter (A) were used to identify the cells (area P1), while 
pulse shape analysis (B) was used to identify clumps and doublets. Single cells were circled in 
the area P2. The percentage of cells in each phase of the cell cycle were quantified by the 
program (C). 488 585/42 indicates the wavelength and the filter used. 
A 
A B 
C 
A B 
C 
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Appendix 8: MRPL45WT clone sequencing 
The following figures represent the sequences obtained for the forward (CMV) and reverse (BGH) 
primers used to confirm the identity of the cloned sequence. The output was analysed with 
SeqScanner. 
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Appendix 9: MRPL45FLAG clone sequencing 
The following figures represent the sequences obtained for the forward (CMV) and reverse (BGH) 
primers used to confirm the identity of the cloned sequence. The output was analysed with 
SeqScanner. 
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Appendix 10: MRPL45FLala clone sequencing 
The following figures represent the sequences obtained for the forward (CMV) and reverse (BGH) 
primers used to confirm the identity of the cloned sequence. The output was analysed with 
SeqScanner. 
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Appendix 11: MRPL45FLAGsil clone sequencing 
The following figures represent the sequences obtained for the forward (CMV) and reverse (BGH) 
primers used to confirm the identity of the cloned sequence. The output was analysed with 
SeqScanner. 
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Appendix 12: MRPL45FLΔ clone sequencing 
The following figures represent the sequences obtained for the forward (CMV) and reverse (BGH) 
primers used to confirm the identity of the cloned sequence. The output was analysed with 
SeqScanner. 
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Appendix 13: FLAG immunoprecipitation on induced HEK293-
MRPL45FLAG cells in presence of ethidium bromide 
Only the mitochondrial protein identified in the samples are listed. The following data obtained from 
the mass spectrometry analysis are reported: 
- log(I) = Sum of raw spectra 
- rI = Number of peptides found 
- log(e) = Expectation of finding the protein stochastically. A cut-off of −2 was chosen for this 
score, which corresponds to a 1 in 100 chance of a stochastic protein assignment. 
Biological repeat n. 1 
Samples 
MRPL45FLAG: FLAG-immunoprecipitation from mitochondria of ethidium bromide treated and 
induced HEK293-MRPL45FLAG cells 
Control: FLAG-immunoprecipitation from mitochondria of ethidium bromide treated HEK293 cells  
Sample Identifier Protein log(I) rI  log(e) 
MRPL45FLAG ENSP00000308901 MRPL45 8.24 170 -426.0 
MRPL45FLAG ENSP00000297185 mt-HSP70 7.83 106 -360.0 
MRPL45FLAG ENSP00000373620 HSP60 7.38 42 -253.0 
MRPL45FLAG ENSP00000381736 ATP5α 7.35 27 -213.0 
MRPL45FLAG ENSP00000262030 ATP5β 7.28 27 -187.0 
MRPL45FLAG ENSP00000360671 ADP/ATP translocase 2 7.15 19 -130.0 
MRPL45FLAG ENSP00000300408 Prohibitin 7.21 13 -96.0 
MRPL45FLAG ENSP00000441875 Prohibitin2 7.01 14 -87.9 
MRPL45FLAG ENSP00000370808 ADP/ATP translocase 3 6.84 13 -86.8 
MRPL45FLAG ENSP00000265333 VDAC1 6.68 10 -69.5 
MRPL45FLAG ENSP00000322439 mt-EF-Tu 6.72 8 -63.0 
MRPL45FLAG ENSP00000246957 HSP75 6.52 6 -59.7 
MRPL45FLAG ENSP00000265838 Acetyl-CoA acetyltransferase 6.73 9 -56.6 
MRPL45FLAG ENSP00000368031 ATPase family AAA domain-
containing protein 3A 
6.52 7 -51.3 
MRPL45FLAG ENSP00000298468 VDAC2 6.75 8 -49.2 
MRPL45FLAG ENSP00000280346 Pyruvate dehydrogenase 
complex component E2 
6.49 6 -36.9 
MRPL45FLAG ENSP00000307241 Pyruvate dehydrogenase E1 
component subunit β 
6.24 6 -36.6 
MRPL45FLAG ENSP00000298510 Thioredoxin-dependent 
peroxide reductase 
6.50 5 -36.5 
MRPL45FLAG ENSP00000349142 ATP5γ 6.50 5 -35.2 
MRPL45FLAG ENSP00000290299  ATP5O 6.38 5 -34.9 
MRPL45FLAG ENSP00000263774 Complex I-30kD 6.23 4 -34.3 
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MRPL45FLAG ENSP00000356290 Formyltetrahydrofolate 
synthetase 
6.39 4 -32.8 
MRPL45FLAG ENSP00000277865 GDH 1 6.21 4 -32.3 
MRPL45FLAG ENSP00000265631 Mitochondrial aspartate 
glutamate carrier 2 
6.16 5 -31.6 
MRPL45FLAG ENSP00000394382 Pyruvate dehydrogenase, 
subunit α 
6.17 3 -28.2 
MRPL45FLAG ENSP00000315122 Apoptosis-inducing factor 1 6.05 3 -27.9 
MRPL45FLAG ENSP00000225665 Mitochondrial 2-
oxoglutarate/malate carrier 
protein 
6.05 3 -27.2 
MRPL45FLAG ENSP00000317159 Cytochrome c1 6.16 3 -24.7 
MRPL45FLAG ENSP00000428845 VDAC3 6.26 4 -23.1 
MRPL45FLAG ENSP00000383898 Phosphate carrier protein 6.37 6 -22.6 
MRPL45FLAG ENSP00000360268 Gamma-glutamyl kinase 6.10 3 -21.7 
MRPL45FLAG ENSP00000261413 MRPS27 6.01 3 -21.0 
MRPL45FLAG ENSP00000420961 Sideroflexin-1 5.98 2 -12.6 
MRPL45FLAG ENSP00000294053 CLPB 5.82 2 -12.4 
MRPL45FLAG ENSP00000359151 Dihydrolipoamide branched 
chain transacylase 
5.97 2 -12.3 
MRPL45FLAG ENSP00000284967 MRPL39 5.80 2 -11.3 
MRPL45FLAG ENSP00000387262 Mitofilin 6.14 3 -11.3 
MRPL45FLAG ENSP00000262570 CHCHD3 5.74 2 -11.0 
MRPL45FLAG ENSP00000370023 Trifunctional enzyme subunit α 5.81 2 -10.7 
MRPL45FLAG ENSP00000216121 NipSnap1 5.84 2 -10.4 
MRPL45FLAG ENSP00000318115 TIM50 6.08 3 -9.9 
MRPL45FLAG ENSP00000357838 Ornithine aminotransferase 5.55 1 -9.6 
MRPL45FLAG ENSP00000358737 ATP5b 5.82 2 -9.2 
MRPL45FLAG ENSP00000378812 CHCHD2 6.02 4 -9.2 
MRPL45FLAG ENSP00000333667 Serine 
hydroxymethyltransferase 
5.62 1 -8.6 
MRPL45FLAG ENSP00000249269 Mitochondrial-processing 
peptidase, subunit β 
5.85 2 -8.5 
MRPL45FLAG ENSP00000354525 MRPL24 5.63 1 -7.0 
MRPL45FLAG ENSP00000457733 Mitochondrial ATP-Mg/Pi carrier 
protein 1 
5.67 1 -6.0 
MRPL45FLAG ENSP00000348886 Stomatin-like protein 2 5.50 1 -4.9 
MRPL45FLAG ENSP00000317379 L-glutamine amidohydrolase 5.30 1 -4.0 
MRPL45FLAG ENSP00000327070 Malate dehydrogenase 5.64 1 -3.9 
MRPL45FLAG ENSP00000437996 ATP5d 5.23 1 -3.9 
MRPL45FLAG ENSP00000321070 Malic enzyme 2 5.34 1 -3.7 
MRPL45FLAG ENSP00000168216 Mitochondrial RNase P protein 
2 
5.80 2 -3.5 
MRPL45FLAG ENSP00000260665 LRPPRC 5.66 1 -3.5 
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MRPL45FLAG ENSP00000245206 Aspartate aminotransferase 5.46 1 -3.1 
MRPL45FLAG ENSP00000400646 PNPase 1 5.54 1 -3.1 
MRPL45FLAG ENSP00000269143 Paraplegin-like protein 5.40 1 -3.0 
MRPL45FLAG ENSP00000446779 Citrate synthase 5.45 1 -2.8 
MRPL45FLAG ENSP00000264954 GrpE protein homolog 1 5.84 1 -2.4 
MRPL45FLAG ENSP00000253577 ATP-binding cassette 
transporter 7 
5.27 1 -2.2 
MRPL45FLAG ENSP00000439565 MRPL12 5.44 1 -1.3 
MRPL45FLAG ENSP00000321971 MIRO-2 5.53 1 -1.2 
MRPL45FLAG ENSP00000215882 Citrate transport protein 5.75 1 -1.1 
MRPL45FLAG ENSP00000270538 TIM44 5.73 1 -1.1 
MRPL45FLAG ENSP00000350191 Succinate-semialdehyde 
dehydrogenase 
5.98 1 -1.1 
      
Control ENSP00000381736 ATP5α 7.10 14 -130.0 
Control ENSP00000262030 ATP5β 6.70 12 -79.4 
Control ENSP00000360671 ADP/ATP translocase 2 6.70 10 -75.0 
Control ENSP00000265838 Acetyl-CoA acetyltransferase 6.68 9 -65.6 
Control ENSP00000297185 mt-HSP70 6.60 9 -56.1 
Control ENSP00000300408 Prohibitin 6.87 7 -54.1 
Control ENSP00000322439 mtEF-Tu 6.38 5 -47.7 
Control ENSP00000370808 ADP/ATP translocase 3 6.48 7 -39.6 
Control ENSP00000298468 VDAC2 6.33 4 -36.0 
Control ENSP00000373620 HSP60 6.32 5 -30.9 
Control ENSP00000298510 Peroxiredoxin-3 6.22 3 -21.7 
Control ENSP00000349142 ATP5γ 6.09 3 -21.7 
Control ENSP00000393496 ATP5O 5.96 3 -21.0 
Control ENSP00000265333 VDAC1 6.19 3 -20.6 
Control ENSP00000317159 Cytochrome C1 5.84 2 -12.4 
Control ENSP00000356290 Formyltetrahydrofolate 
synthetase 
6.11 2 -11.4 
Control ENSP00000261413 MRPS27 5.92 2 -9.4 
Control ENSP00000457733 Mitochondrial ATP-Mg/Pi carrier 
protein 1 
5.29 1 -5.2 
Control ENSP00000348886 Stomatin-like protein 2 5.35 1 -4.5 
Control ENSP00000383898 Phosphate carrier protein 5.64 2 -3.2 
Control ENSP00000388658 Mitochondrial aspartate 
glutamate carrier 1 
5.40 1 -3.1 
Control ENSP00000168216 Mitochondrial RNase P protein 
2 
5.19 1 -2.8 
Control ENSP00000215882 Citrate transport protein 5.70 1 -1.7 
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Biological repeat n. 2 
Samples 
MRPL45FLAG: FLAG-immunoprecipitation from mitochondria of ethidium bromide treated and 
induced HEK293-MRPL45FLAG cells 
Control: FLAG-immunoprecipitation from mitochondria of ethidium bromide treated and induced 
HEK293-MRPS27FLAG cells 
Sample Identifier Protein log(I) rI log(e) 
MRPL45FLAG ENSP00000308901 MRPL45 3.17 23 -89.9 
MRPL45FLAG ENSP00000297185 mt-HSP70 2.6 16 -89.8 
MRPL45FLAG ENSP00000262030 ATP5β 2.36 12 -56.9 
MRPL45FLAG ENSP00000300408 Prohibitin 1.66 6 -28.5 
MRPL45FLAG ENSP00000373620 HSP60 1.86 4 -18.3 
MRPL45FLAG ENSP00000370023 Trifunctional enzyme subunit α 1.24 2 -10.5 
MRPL45FLAG ENSP00000356290 Formyltetrahydrofolate synthetase 0.82 2 -10.2 
MRPL45FLAG ENSP00000419038 mtEF-G1 1.21 2 -9.9 
MRPL45FLAG ENSP00000260665 LRPPRC 1.41 2 -9.3 
MRPL45FLAG ENSP00000360268 Gamma-glutamyl kinase 0.99 2 -8.8 
MRPL45FLAG ENSP00000381736 ATP5α 1.69 2 -7.4 
MRPL45FLAG ENSP00000311766 ATPase family AAA domain-
containing protein 3B 
1.41 2 -4.3 
MRPL45FLAG ENSP00000360671 ADP/ATP translocase 2 1.23 1 -4.2 
MRPL45FLAG ENSP00000392451 tRNA pseudouridine synthase A 0.45 1 -2.5 
MRPL45FLAG ENSP00000431040 MRPL22 0.49 1 -1.9 
MRPL45FLAG ENSP00000265333 VDAC1 1.06 1 -1.9 
MRPL45FLAG ENSP00000287025 mTERF3 0.82 1 -1.4 
MRPL45FLAG ENSP00000451320 Bcl-2-like protein 2 0.53 1 -1.3 
MRPL45FLAG ENSP00000281456 ADP/ATP translocase 1 0.83 1 -1.3 
MRPL45FLAG ENSP00000244571 Alanine-tRNA ligase 0.57 1 -1.1 
MRPL45FLAG ENSP00000402535 Apoptosis-inducing factor 1 0.79 1 -1.1 
      
Control ENSP00000261413 MRPS27 3.75 91 -316 
Control ENSP00000297185 mt-HSP70 2.42 17 -70.6 
Control ENSP00000262030 ATP5β 2.37 14 -60.2 
Control ENSP00000418008 MRPS22 2.04 8 -48.7 
Control ENSP00000373620 mt-HSP60 2 6 -37.7 
Control ENSP00000300408 Prohibitin 1.97 7 -31 
Control ENSP00000260665 LRPPRC 1.53 4 -23.6 
Control ENSP00000322439 mtEF-Tu 1.76 4 -22 
Control ENSP00000356290 Formyltetrahydrofolate synthetase 1.03 3 -17.8 
Control ENSP00000360671 ADP/ATP translocase 2 2.27 5 -16.9 
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Control ENSP00000369682 MRPS26 1.67 6 -13 
Control ENSP00000259873 MRPS18b 1.7 6 -11.9 
Control ENSP00000370023 Trifunctional enzyme subunit α 1.04 2 -10.1 
Control ENSP00000402535 Apoptosis-inducing factor 1 1.04 2 -8.8 
Control ENSP00000281456 ADP/ATP translocase 1 2.13 2 -8.4 
Control ENSP00000177742 MRPS34 1.85 3 -8.2 
Control ENSP00000225665 Mitochondrial 2-
oxoglutarate/malate carrier protein 
0.74 2 -7.9 
Control ENSP00000311766 ATPase family AAA domain-
containing protein 3B 
1.34 2 -4.3 
Control ENSP00000265838 Acetyl-CoA acetyltransferase 1.25 2 -3.8 
Control ENSP00000452762 Electron transfer flavoprotein 
subunit α 
0.44 1 -2.7 
Control ENSP00000246957 HSP75 1.41 2 -2 
Control ENSP00000244571 Alanine-tRNA ligase 0.48 1 -1.9 
Control ENSP00000254636 Mitofilin 1.05 2 -1.4 
Control ENSP00000249269 Mitochondrial-processing 
peptidase. subunit β 
0.93 1 -1.4 
Control ENSP00000355741 Chaperone-ABC1-like 0.78 1 -1.1 
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Appendix 14: MRPL45 immunoprecipitation on induced HEK293-MRPL45 
cells in presence of ethidium bromide 
Only the mitochondrial protein identified in the samples are listed. The following data obtained from 
the mass spectrometry analysis are reported: 
- log(I) = Sum of raw spectra 
- rI = Number of peptides found 
- log(e) = Expectation of finding the protein stochastically. A cut-off of −2 was chosen for this 
score, which corresponds to a 1 in 100 chance of a stochastic protein assignment. 
Samples 
MRPL45: MRPL45-immunoprecipitation from mitochondria of ethidium bromide treated and 
induced HEK293-MRPL45FLAG cells. 
Control: MNKI-immunoprecipitation from mitochondria of ethidium bromide treated HEK293 cells. 
Biological repeat n. 1 
Sample Identifier Protein log(I) rI log(e) 
MRPL45 ENSP00000308901 MRPL45 2.79 23 -45.3 
MRPL45 ENSP00000297185 mt-HSP70 2.04 6 -24.3 
MRPL45 ENSP00000373620 HSP60 1.10 1 -1.5 
MRPL45 ENSP00000281456 ADP/ATP translocase 1 1.16 1 -1.5 
      
Control ENSP00000281456 ADP/ATP translocase 1 1,04 1 -1,1 
 
Biological repeat n. 2 
Sample Identifier Protein log(I) rI log(e) 
MRPL45 ENSP00000308901 MRPL45 2,7 17 -55 
MRPL45 ENSP00000297185 mt-HSP70 1,03 4 -22,1 
MRPL45 ENSP00000262030 ATP5β 0,67 1 -2,2 
MRPL45 ENSP00000440846 Monoamine oxidase type A 0,53 1 -1,5 
      
Control ENSP00000262030 ATP5β 1,48 3 -10,6 
Control ENSP00000381736 ATP5α 1,06 1 -1,8 
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Appendix 15: Resolved structure of human MRPL45 to date 
The following figure represent the resolved structure of human MRPL45 to date (Brown A et al., 
2014). The DSSP legend is found at the bottom of the figure. 
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Appendix 16: Alignment of human MRPL45, yeast TIM44 and human TIM44 
The alignment was performed using ClustalOmega. 
 
MRPL45          -------------------------MAAPIPQGFSCLSRFLGWWFRQPVLVTQSAAI--- 
TIM44yeast      ----MHRSTFIRTS----GTSSRTL-------TARYRSQYT-GLLVARVLFSTSTTRAQG 
TIM44human      MAAAALRSGWCRCPRRCLGSGIQFLSSHNLPHGSTYQMRRPGGELPL-------SKSYSS 
                                                      :     :         :      
 
MRPL45          ------------------------------------------------------------ 
TIM44yeast      GNPRSPLQIFRDTFKKEWEKSQELQENIKTLQDASGKLGESEAYKKAREAYLKAQRGST- 
TIM44human      GNRKGFLSGLLDNVKQELAKNKEMKESIKKFRDEARRLEESDVLQEARRKYKTIESETVR 
                                                                             
 
MRPL45          ------------------------------------------------------VPVRT- 
TIM44yeast      ---IVGKTLKKTGETMEHIATKAWESELGKNTRKAAAATAKKLDESF-------EPVRQT 
TIM44human      TSEVLRKKLGELTGTVKESLHEVSKSDLGRKIKEGVEEAAKTAKQSAESVSKGGEKLGRT 
                                                                        :    
 
MRPL45          ---------------------KKRFTPPIY--QPKFKTEKEFMQHARKAGLVIPPEKSDR 
TIM44yeast      KIYKEV-------SEVIDDGESSRYGGFITKEQRRLKRERDLASGKR--HRAVKSNEDAG 
TIM44human      AAFRALSQGVESVKKEIDDSVLGQTGPYRR--PQRLRKRTEFAGDKFKEEKVFEPNEEA- 
                                       :          ::: . ::         ..  ::.   
 
MRPL45          SIHLACTA-----------------GIFDAYVP------PEGDARIS----------SLS 
TIM44yeast      TAVVATNIESKESFGKKVEDFKEKTVVGRSIQSLKNKLWDESENPLIVVM----RKITNK 
TIM44human      ---LGVVLHKDSKWYQQWKDFKENNVVFNRFFEMK-MKYDESDNAFIRASRALTDKVTDL 
                   :.                     :             *.:  :           :   
 
MRPL45          KEGLIERTERMKKTMASQVSIRRIKDYDANFKIKDFPEKAKDIFIEAHL-CLNNSDHDRL 
TIM44yeast      VGGFFAETES-------SRVYSQFKLMDPTFSNESFTRHLREYIVPEILEAYVKGDVKVL 
TIM44human      LGGLFSKTEM-------SEVLTEILRVDPAFDKDRFLKQCENDIIPNVLEAMISGELDIL 
                  *:: .**        .    .:   *  *. . * .: .: ::   * .  ..: . * 
 
MRPL45          HTLVTEHCFPDMTWDIK-YKTVRWSFVESLEPSHVVQVRCSSMMNQGNVYGQITVRMHTR 
TIM44yeast      KKWFSEAPFNVYAAQQKIFKEQDVYADGRILDIRGVEIVSAKLLAPQDIPVLVVGCRAQE 
TIM44human      KDWCYEATYSQLAHPIQQAKALGLQFHSRILDIDNVDLAMGKMMEQG--PVLIITFQAQL 
                :    *  :   :   :  *         :     *::  ..::        :        
 
MRPL45          QTLAIYDRFGRLMYGQEDVPKDVLEYVVF----EKQLTNPYGSWRMHTKIVPPWAPPKQP 
TIM44yeast      INLYRKKKTGEIAAGDEANILMSSYAMVFTRDPEQIDDDETEGWKILEFVRGGS----RQ 
TIM44human      VM-VVRNPKGEVVEGDPDKVLRMLYVWALCRDQDEL--NPYAAWRLLDISASST----EQ 
                      .  *.:  *:           .:    ::   :   .*::            .  
 
MRPL45          ILKTVMIPGPQLKPEEEYEEAQGEAQKPQLA 
TIM44yeast      FT----------------------------- 
TIM44human      IL----------------------------- 
                :                               
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Appendix 17: mRNA sequences targeted by OXA1L siRNA 
The sequences of OXAsi02, OXAsi03 and OXAsi04 were analysed to identify targets using BLAST 
(http://blast.ncbi.nlm.nih.gov/). The targets and the percentage of their query cover and identity are 
reported in the following table. 
siRNA Target Query cover Identity 
OXAsi01 OXA1L 100% 100% 
  MIP, Major intrinsic protein of lens fiber  78% 100% 
 DDX46, DEAD-box helicase 46 73% 100% 
 FBXO38, F-box protein 38 73% 100% 
 RHOU, Ras homolog family member U 73% 100% 
OXAsi02 OXA1L 100% 100% 
 HLF, Hepatic leukemia factor 73% 100% 
 MYL12A, Myosin regulatory light chain 12A 68% 100% 
 SPG7, Paraplegin 68% 100% 
 REG3G, Regenerating islet-derived protein 3-
gamma 
68% 100% 
 CELSR3, Epidermal growth factor-like protein 1 68% 100% 
 KRT4, Cytokeratin-4 68% 100% 
 PLEKHF1, Pleckstrin homology domain-
containing family F member 1 
68% 100% 
 SFXN5, Sideroflexin-5 68% 100% 
OXAsi03 OXA1L 100% 100% 
 PANK1, Pantothenate kinase 1 73% 100% 
 DIS3, Exosome complex exonuclease RRP44 68% 100% 
 SIX4, SIX homeobox 4 68% 100% 
 GLANT4, Polypeptide N-
acetylgalactosaminyltransferase 4 
68% 100% 
 GNRH1, Progonadoliberin-1 68% 100% 
 ZNF711, Zinc finger protein 711 68% 100% 
OXAsi04 OXA1L 100% 100% 
 C5orf63, Glutaredoxin-like protein C5orf63 73% 100% 
 MEIG1, Meiosis/spermiogenesis associated 1 73% 100% 
 DMRTA1, Doublesex- and mab-3-related 
transcription factor A1 
73% 100% 
 CDHR4, Cadherin-related family member 4 68% 100% 
 DNAH11, Dynein heavy chain 11, axonemal 68% 100% 
 SLC22A16, Solute carrier family 22 member 16 68% 100% 
 RNF165,  68% 100% 
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Appendix 18: The role of LetM1 in the interaction between mitoribosome 
and IMM 
Introduction 
As previously stated throughout this work, mitochondrial translation is likely to be localised in 
close proximity to the IMM in order to allow the rapid insertion of the highly hydrophobic OXPHOS 
components synthesised within the organelle itself. In yeast, together with Oxa1, another IMM 
protein has been suggested to mediate this interaction. This protein, named Mdm38, is conserved 
amongst eukaryotes and its homologue in human is named LetM1 (leucine zipper EF -hand-
containing transmembrane protein 1). 
Mdm38 (RefSeq. NP_014615.1) was found to interact with the large mitoribosomal subunit via 
a ribosome binding domain (RBD, between residues 182 and 404) located on the matrix side 
(Frazier AE et al., 2006). This domain has been confirmed to bind the mitoribosome in vitro, and 
structural studies assigned a 14-3-3-like structure to this domain (Lupo D et al., 2011). This 
structure is canonically consists of 9 antiparallel α-helices arranged in a U-like conformation and 
creates a cavity that allows the interaction with other proteins (Aitken A, 2006). The cavity allows 
the interaction with phosphorylated proteins via a conserved triad arginine -arginine-tyrosine 
(Rittinger K et al., 1999), but also with hydrophobic proteins via the side chain of a conserved 
leucine (Ottmann C et al., 2007). A large hydrophobic cavity was observed for the RBD of Mdm38. 
This cavity presented 2 leucine residues (387 and 390, Fig. a3 in red) that correspond to the 
conserved leucine residues found in other 14-3-3-like proteins. These observations suggested 
that this cavity might mediate the interaction of Mdm38 with the mitoribosome.  
           
Figure a3 Structure of Mdm38 C-terminal domain. 
The structure of the C-terminal of Mdm38 was visualised as cartoon (A) and as surface (B) 
using Pymol, from the available PDB file 3SKQ (Lupo D et al., 2011). This domain corresponds 
to the soluble domain of the protein, and the first 5 amino acids resolved were depicted in green 
and docked on the transmembrane domain, represented by a green box. The leucine residues 
present in the hydrophobic cavity are depicted in red. 
A B 
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The role of Mdm38 in yeast was further investigated upon deletion of Mdm38. A growth defect, 
impairment in the transport of proteins from the matrix and an altered morphology of mitochondria 
were observed upon Mdm38 deletion.  
This protein was also suggested to play a role in the assembly of some OXPHOS complexes, 
although its effects on mitochondrial protein synthesis are still under debate. According to Frazier 
et al, deletion of Mdm38 caused an impairment of mitochondrial translation and defects in the 
insertion of Atp6 and cytochrome b (Frazier AE et al., 2006). A different effect on mitochondrial 
translation was observed by Bauerschmitt et al and by Nowikovsky et al, whose deletion 
experiments in yeast showed that this process was not severely affected by the absence of Mdm38 
(Bauerschmitt H et al., 2010; Nowikovsky K et al., 2007). An effect on mitochondrial translation was 
observed by Bauerschmitt et al for Mdm38 and Mba1 double mutants, particularly for COXI and 
CYTB mRNA (Bauerschmitt H et al., 2010). 
The growth defect observed for mdm38-deleted mutants was efficiently recovered by 
overexpression of LetM1, suggesting a similar function to the yeast protein for the mammalian 
homologue (Nowikovsky K et al., 2004). LetM1 is an IMM protein that was found to be present in 
high molecular weight complexes of approximately 300 kDa and 500-600 kDa (Dimmer KS et al., 
2008; Tamai S et al., 2008). This protein is important for mitochondrial morphology, with its 
depletion causing swelling and loss of cristae structure (Tamai S et al., 2008). In the absence of 
LetM1, the assembly of complexes I, III and IV was compromised, although the steady state levels 
of the tested subunits did not seem to be affected. The authors suggested the possibility that the 
effects observed might be related to the loss of cristae and not directly to a role of LetM1 in the 
assembly of the OXPHOS complexes (Tamai S et al., 2008). The importance of this protein was 
further confirmed by the lethality in the early stages of embryogenesis of LetM1 knockout in mice 
(Jiang D et al., 2013). 
In addition to its role in mitochondrial gene expression, Mdm38 has been suggested to play a 
role in H+/K+ exchange (Nowikovsky K et al., 2004; Nowikovsky K et al., 2007). Swelling of 
mitochondria was observed upon deletion of Mdm38, and this effect can be explained by osmosis 
due to the increase of K+ concentration after impairment of ion exchange. The role of LetM1 in 
cation transport is under investigation. The swelling of mitochondria observed for LetM1 depletion 
was reversed by nigericin, which catalyses the electroneutral change of H+ with K+, and was 
phenocopied by addition of valinomycin, a ionophore that catalyses the electrophoretic flux of K+. 
Because of these pieces of data, it was suggested that the increase in the mitochondrial volume 
might be due to K+ accumulation. On the other hand, a genome-wide siRNA screen in Drosophila 
identified a reduction of Ca2+ influx in the absence of LetM1 (Jiang D et al., 2013), suggesting a 
role for this protein as a Ca2+/H+ antiporter. The same effect was observed for LetM1 knockdown 
in HEK293 cells (Jiang D et al., 2013). Whether LetM1 has a role in the transport of K+ or Ca2+ is 
still under debate in the field (Nowikovsky K et al., 2014).  
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As previously mentioned, Mdm38 was shown to interact with the mitoribosomal large subunit. 
In absence of the mitoribosome, it was demonstrated an interaction of this protein with Mba1 
(homologue of MRPL45 in yeast) (Bauerschmitt H et al., 2010). Because of the conservations of 
these 2 proteins in eukaryotes, it is possible that their interaction is still retained in mammals. The 
only study on LetM1 and its interaction with the mitoribosome is based on immunoprecipitation 
experiments on cell line overexpressing either LetM1, MRPL36 or both the proteins. These 
experiments suggested a direct interaction of these 2 proteins (Piao L et al., 2009).  
LetM1 was also demonstrated to directly interact with BCS1L (Tamai S et al., 2008), a 
chaperone necessary for the assemble of complex III (de Lonlay P et al., 2001) and for the 
formation of LetM1 complexes.  
Mutations in LetM1 have also been linked to pathologies. The gene encoding this protein is one 
of the genes deleted in the Wolf-Hirschhorn syndrome (Endele S et al., 1999), where the severity 
of the disease is related to the size of the deletion. The main symptoms are mental retardation, 
seizures, hypertonia and characteristic facial features (Bergemann AD et al., 2005). It is thought 
that LetM1 might play a role in the onset of seizures, due to its possible role in regulating the levels 
of calcium and potassium (Rauch A et al., 2001; South ST et al., 2007). An altered level of LetM1 
has also been found in cancerous tissue, which appear to contain a higher amount of this protein 
(Hwang SK et al., 2010; Li N et al., 2015; Piao L et al., 2009). 
Since only one study attempted to confirm the interaction of LetM1 with the mitoribosome, I 
decided to further confirm it. In addition, the collaboration of Prof Taylor with Dr Carrozzo in Rome, 
allowed me to study the phenotype of a patient carrying mutations on LetM1, which will be 
discussed in this chapter. 
Prediction of the LetM1 structure 
A crystal structure for LetM1 (RefSeq NP_036450.1) was still not available, therefore inferences 
on its structure were made from information available on its domains (Fig. a3) and from a structural 
prediction obtained using Phyre2 (Fig. a4). 
 
Figure a4 Domains predicted for LetM1. 
Summary of the domain information available for LetM1 (RefSeq NP_036450.1). The 
presequence (gray) was predicted by TargetP 1.1 to be between residues 1 and 116 . The 
transmembrane domain (TM, green) was assigned by TM pred to lie between residues 202 
and 229, whereas the ribosome binding domain (RBD, red) was predicted to be between 
residues 252 and 537. After this domain, a leucine-zipper domain (Leu-z, turquois) was 
identified between residues 548 and 590. Finally, the EF-hand domain (EF-h, yellow) was 
assigned between residues 667 and 695. 
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As a nuclear-encoded mitochondrial protein, LetM1 possesses a presequence that targets the 
protein to mitochondria. TargetP 1.1 (Emanuelsson O et al., 2000) predicted this transit peptide to 
target the protein to mitochondria and to be cleaved between the residues 115 and 116. LetM1 is 
an IMM protein and its analysis with TM pred (Hofmann K et al., 1993) identified residues 202 and 
228 as a possible transmembrane domain from the inside (IMS) to the outside (matrix) (Fig. a4, in 
green). The presence of a transmembrane domain in the same part of the sequence was also 
confirmed by the analysis of the hydrophobicity of the protein obtained with the Kyte-Doolittle 
method (Fig. a5). Uniprot suggested that a ribosome binding domain (RBD, Fig. a4, in red) is 
present between residues 252 and 537, followed by a leucine-zipper domain (residues 548-590, 
Fig. a4, in turquoise). Finally, despite 2 EF-hand domains having been identified in LetM1 (Endele 
S et al., 1999), the first, located in the leucine-zipper motif, is likely to have lost its function due to 
alteration of its structure from the canonical EF-hand structure (Kawasaki H et al., 1994). On the 
other hand, the second identified between residues 667 and 695 may still retain the ability to bind 
Ca2+ (Fig. a4, in yellow).  
 
Figure a5 Prediction of a transmembrane domain within LetM1 using the Kyte -Doolittle plot. 
Kyte-Doolittle hydropathy analysis was performed on LetM1. The window was set at 19 and 
the result is shown in a plot with the hydropathy score in function of the window position. A 
score higher than 1.8 (red horizontal line) indicates the presence of possible 
transmembrane (TM) domains. 
The same colour code used for the analysis of the domains present on LetM1 was also used to 
colour the Phyre2 prediction of the protein. The full prediction obtained is shown in Fig. a6. 
TM 
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Figure a6 Prediction of LetM1 structure. 
LetM1 structure was predicted using Phyre2. The result is shown as a cartoon and 
coloured according to different domains reported to be present in LetM1 
(Presequence=gray, Transmembrane domain=green, Ribosome binding domain=red, 
Leucine-zipper=turquoise, EF-hand=yellow). The ribosome binding domain was aligned 
with high confidence (99.9%) and identity (37%) to Mdm38. 
The prediction aligned residues 252-444 with the structure available of Mdm38 (PDB 3SKQ), 
with a confidence of 99.9%, and a sequence identity of 37% and corresponds to the ribosome 
binding domain (Fig. a6, red). This result suggests that LetM1 might have conserved the function 
observed for Mdm38. The remaining structure was not aligned with high confidence or sequence 
identity with any other known structure. 
Interaction of LetM1 with the mitoribosome 
The LetM1 yeast homologue, Mdm38, has been reported to interact with the mitoribosome. 
Because the analysis of LetM1 structure suggested a high homology with the yeast counterpart, 
the possibility of LetM1 to interact with the IMM was explored. 
In case of any interaction with the mt-LSU, LetM1 might co-localise with mt-LSU in an isokinetic 
sucrose gradient analysis. To test this, a cell lysate (800 µg) from HEK293 cells was loaded on a 
10-30% isokinetic sucrose gradient and its components were separated within the gradient upon 
centrifugation (qv 2.8.). The 11 fractions obtained were TCA-precipitated (qv 2.5.3.) and then 
analysed by western blot (Fig. a7). 
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Figure a7 Distribution of LetM1 on isokinetic sucrose gradients. 
HEK293 cells were lysed and ≈800 µg of protein were loaded at the top of a 10 -30% 
sucrose gradient (qv 2.8.). After centrifugation, 11 fractions were obtained, TCA-
precipitated (qv 2.5.3.) and analysed via western blotting. An aliquot of the cell lysate ‘load’ 
(Lys; ≈40 µg) was also loaded on the gel. Antibodies against MRPL11 localised the position 
of the mt-LSU, and antibodies targeting LetM1 identified its distribution. The figure is 
representative of 2 biological repeats. 
The sucrose gradient analysis showed that the major ity of LetM1 was present in the first 
fractions, while a weaker signal was obtained in the fractions corresponding to the mt -LSU.  
Since the sucrose gradient analysis could not confirm the ability of LetM1 to interact with the 
mitoribosome, this hypothesis was investigated via immunoprecipitation of LetM1 from 
mitochondria extracted from HEK293 cells. Magnetic beads were coated with 5 µg of LetM1 
antibody and the experiment was carried out as in 2.9. The 8 µL of eluted sample (25 µL total) were 
analysed via western blotting to determine the presence of mitoribosomal proteins (Fig. a8). 
 
Figure a8 Immunoprecipitation of LetM1. 
Western blot analysis was performed on mitolysate (15 µL) and eluted sample (1/3 of the 
volume) from immunoprecipitation of LetM1 in HEK293 cells. The efficiency of the 
immunoprecipitation was detected with antibodies targeting LetM1. The presence of 
mitoribosomal proteins MRPL45 and MRPS26, as well as the IMM protein OXA1L, were 
also detected. The experiment was not repeated. 
The immunoprecipitation was very efficient, as shown by the presence of large amounts of 
LetM1 present in the eluted fraction (Fig. a8). Despite this, cross reacting material was obtained in 
the western blot analysis for the mitoribosomal proteins tested (MRPL45, MRPL26), of which a 
distinct signal could not be detected. LetM1 immunoprecipitation also showed the presence of a 
weak signal for OXA1L. 
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Phenotype of a patient with mutations in LetM1 
As mentioned in the introduction, deletions of LETM1 gene have been widely associated with 
the Wolf-Hirschhorn syndrome. After starting to work on LetM1, I discovered the existence of a 
patient with mutation in this gene. This is the first case of missense mutations in LetM1. Thanks to 
the help of Prof Taylor, I got in touch with Dr Carrozzo who was studying the phenotype of the 
patient, that kindly agreed to send me primary fibroblast to investigate the potential effect of this 
mutation on the ability of LetM1 to bind the mitoribosome. 
Dr Carrozzo reported that the patient presented with encephalopathy, hypertrophic 
cardiomyopathy and cataract. Increased lactate, α-ketoacids and Krebs intermediate products were 
also observed. Muscle hystochemistry showed the reduction or the absence of COX in several 
fibres. Muscle also showed a reduction of the activity of complex I and IV of the 40% each. The 
search for a mutation identified a homozygous mutation for LETM1. The mutation (c.898C>T) 
caused the proline at position 300 to be translated as serine. Due to the presence of a nitrogen-
containing ring, proline is constrained in its folding as compared to the majority of the other 
residues. As a consequence, proline often introduces tight turns in protein structures or kinks into 
α-helices. Serine is also able to fold in a conformation that allows tight turns. The hydroxyl oxygen 
on the side chain of this small amino acid is able to form a hydrogen bond with the protein 
backbone, mimicking proline. As a consequence, it is possible that this mutation will not severely 
damage the stability of the function of the protein. Despite this, PolyPhen (Adzhubei IA et al., 2010) 
scored the mutation as probably damaging, assigning it the highest score of 1. This program 
predicts the effects of the mutation taking into consideration not only the change of the volume of 
the side chain or of the accessibility to the solvent, but also the contacts that the residue might do 
with other amino acids. It is therefore possible that, despite serine can mock proline, this mutation 
within the sequence of LetM1 is causing a deleterious effect on its structure or function. 
The fibroblast of the LetM1 patient were cultured and the steady state level of OXPHOS 
components and mitoribosomal proteins was analysed via western blot (Fig. a9). 
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Figure a9 Steady state levels of mitochondrial proteins in a patient with mutation 
in LetM1 gene. 
Cell lysate (≈50 µg) from primary fibroblasts of 2 controls (C) and a LetM1 patient (P) were 
separated by 12% SDS-PAGE, and analysed via western blot. The steady state level of 
LetM1 was assessed, as well as the level of OXPHOS components (COXII, NDUFB8, 
NDUFA9, ATP5β). A second western blot was used to detect the levels of the 
mitoribosomal proteins MRPL11 and MRPL45. The equality of the loading was verified 
using antibodies against β-Actin. The figure is representative of 3 biological repeats. 
The phenotype observed for LetM1 patient fibroblast was not very strong. The mutations 
affected the steady state level of LetM1, which was reduced by approximately 30% when compa red 
to the control, and might indicate a mild effect of the mutation on the protein’s stability. While the 
level of complex IV did not seem affected, a reduction of the nuclear encoded components of 
complex I NDUFA9 and NDUFB8 was observed. No effect on the F1 component of complex V was 
observed. Regarding the mitoribosomal proteins, a marginal effect on the steady state levels of 
both MRPL45 and MRPL11 was found using western blot analysis.  
The phenotype observed in the fibroblast was very mild when compared to the information 
obtained in muscle by Dr Carrozzo. Therefore, no further analyses were possible on the phenotype 
of the patient using this cell line. 
Conclusions 
Despite several studies on yeast Mdm38 that support its importance for mitochondria and cell 
homeostasis, the mammalian homologue is still not well understood. While its role in ion transport 
is still contradictory, its role in mitochondrial translation has not been widely explored to date.  
LetM1 depletion has been reported to compromise the assembly of complexes I, III and IV, 
without affecting the steady state levels of the tested subunits (Tamai S et al., 2008). It is important 
to notice that all the subunits tested by the authors were nuclear encoded and, therefore, this result 
gave no information on the effects of the depletion on mitochondrial translation. Because of the 
effects on complex assembly, it is however tempting to infer that the effects observed on complex 
assembly might be caused by the lack of availability of mt-encoded subunits due to defects in 
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mitochondrial protein synthesis. The authors also suggested that this effect could be linked to the 
loss of cristae observed in LetM1 depletion. I believe that this hypothesis is unlikely as, in these 
circumstances an effect on complexes II and V (unaffected according to the authors) should be 
detected. 
Ideally I would repeat the depletion experiment and investigate the effects of the depletion on 
mitochondrial translation. However, due to the limited time frame of my project, I decided to focus 
on the possibility of an interaction between LetM1 and the mitoribosome. As stated in the 
introduction of this chapter, yeast Mdm38 has been reported to interact with the mitoribosome and, 
in particular, with Mba1 (MRPL45 homologue in yeast). LetM1 has been reported to interact with 
MRPL36 (Piao L et al., 2009). The authors studied the interaction of these 2 proteins in HeLa cells 
based on the data published by Ott et al on the interaction with Mdm38 with the yeast mitoribosome 
(Bauerschmitt H et al., 2010). This was a misinterpretation of the work by Ott et al, where MRPL36 
antibody was used as a marker to detect the presence of the mitoribosome as a whole and was, 
therefore, not indicating a direct interaction of Mdm38 with this mitoribosomal protein. 
The sucrose gradient analysis performed on HEK293 cells in this chapter failed to demonstrate 
colocalisation of the IMM protein with the mitoribosome. The immunoprecipitation of LetM1 from 
the same cell line did not lead to the co-precipitation of the mitoribosome. Altogether these data 
suggested that LetM1 does not interact with the mitoribosome. 
Deletion of LetM1 has been widely connected to Wolf-Hirschhorn syndrome. For the first time, 
a patient with a mutation in this gene has been identified and studied by Dr. Carrozzo, I was kindly 
given access to the primary fibroblast cell line from this patient to test the effects of the mutation 
on the stability of the mitoribosome. The mutation mildly affected the steady sta te level of LetM1, 
which caused a mild reduction of the levels of component of complexes I and IV. This effect could 
be due to a minor defect of mitochondrial translation, as well as to a defect in membrane insertion. 
The steady state levels of the mitoribosomal proteins detected appeared to be mildly reduced. 
Unfortunately, because the phenotype shown by the fibroblasts was not very pronounced, it was 
not possible to clearly assess the effects of this mutation on the mitoribosome or on mitochondrial 
translation. The muscle sample analysed by Dr. Carrozzo showed a more marked phenotype 
(Carozzo, personal communication). The difference in severity between fibroblasts, a low requiring 
energy tissue, and muscle, a high requiring tissue, is very frequently observed and it is problematic 
for investigating the role of mutated mitochondrial proteins in diseases.  
Due to the lack of more convincing data on the role of LetM1 and to its involvement in diseases, 
I believe it is important to further study this protein to understand its role both in the Wolf-Hirschhorn 
syndrome and in the patient studied by Dr. Carrozzo. 
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